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Second hepatic resection for recurrent
hepatocellular carcinoma
S. ROAYAIE, MD, D. BASSI, S. HIOTIS, MD,
D. LABOW, MD and M. SCHWARTZ, MD
Mount Sinai Hospital, New York, NY, USA
While several Asian studies have shown promising results
for second resection for recurrent hepatocellular carci-
noma (HCC), there are no Western series on this topic.
The purpose of this study was to determine the outcome
of patients undergoing a second hepatic resection for
recurrent HCC at a Western center and to identify
prognostic variables.
Methods: A retrospective review of all patients under-
going hepatic resection for HCC from 1/1990 to 1/2008
was conducted. Patients underwent second resection if
they had a single tumor on imaging, Child’s A liver
function, platelets > 100 000 and no extrahepatic dis-
ease.
Results: During this period, 487 patients underwent
resection with 221 having documented recurrence. Of
these, 30 underwent second resection. Underlying liver
disease included HBV (n = 18), HCV (n = 6), none
(n = 4), and other (n = 2). Mean tumor size was 9.6 cm
at ﬁrst resection and 4.0 cm at second resection. Median
interval between ﬁrst resection and recurrence was
15.5 months. There were no perioperative mortalities and
1, 3, and 5 years survivals were 88%, 65%, and 65%.
Recurrence rate at 3 year was 80%. Univariate predic-
tors of survival included < 1year interval from ﬁrst
resection to recurrence, gross vascular invasion at second
resection, tumor > 5cm at second resection, and blood
transfusion at second resection. Multivariate analysis
found gross vascular invasion at second resection as the
only independent predictor of mortality (HR 76.9,
P = 0.002). Patients without gross vascular invasion at
2nd resection had median survival of 76.8 months and
5 year survival of 74%.
Conclusions: Second resection for recurrent HCC has
excellent outcomes in well selected patients. Gross
vascular invasion is the only independent predictor of
outcome after second resection.
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Incorporating an HPB fellowship does not
diminish surgical residents’ HPB experience in a
high-volume training program
N. J. ZYROMSKI, MD, L. TORBECK, PHD,
D. F. CANAL, MD, K. D. LILLEMOE, MD and
H. A. PITT, MD
Indiana University, Indianapolis, IN, USA
Background: A major paradigm shift in surgical educa-
tion has recently been instituted by the American Board
of Surgery and the Surgical Council on Resident Edu-
cation (SCORE). Speciﬁc surgical procedures have been
deﬁned as ESSENTIAL (Common/Uncommon – speciﬁc
procedural competency required by the end of training)
and COMPLEX (generic competence required, but not
competence in individual procedures). Importantly, vir-
tually all elective HPB procedures fall into the SCORE
‘COMPLEX’ category. Trainees who wish to practice
HPB surgery will therefore be required to obtain
advanced training. As this training paradigm evolves, it is
equally crucial that incorporation of an HPB fellowship
into an established surgical residency program does not
diminish surgical residents’ exposure to complex HPB
procedures. We hypothesized that incorporation of an
HPB fellowship into a high volume clinical training
program would not detract from residents’ HPB experi-
ence.
Methods: Our institution incorporated an HPB training
program in 2005–2006. Resident operative case logs
(provided by the American Council of Graduate Medical
Education) and HPB fellow case logs were reviewed.
Resident exposure to complex HPB procedures for
3 years prior to and 3 years after fellowship incorpo-
ration were compared. Student’s t-test was applied
where appropriate; P < 0.05 was accepted as statistically
signiﬁcant.
Results: The ACGME requires graduating residents’
exposure to a minimum of three pancreas and four
liver cases (complex biliary cases are not subdivided
from the category ‘alimentary’). In 2007, the national
average exposure of graduating chief residents was:
pancreas – 11; liver – 9; biliary – 5. The International
Hepatopancreatobiliary Association (IHPBA) guidelines
for HPB fellowship training call for exposure to:
pancreas – 30; liver – 25; and biliary – 20. Our institu-
tional resident and fellow HPB experience is shown in
the Table 1.
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Table 1. Resident and fellow HPB experience 2002–2008.
Pancreas Liver Complex Biliary
Resident Fellow Resident Fellow Resident Fellow
2002–2003 20 – 13 – 8 –
2003–2004 25 – 22 – 11 –
2004–2005 27 – 15 – 9 –
2005–2006 23 100 14 40 4 38
2006–2007 23 109 14 42 8 44
2007–2008 19 114 13 40 ** 56
P value 0.39 0.34 0.17
**Data will be available 12/2008.
Conclusions: These data show that an HPB fellowship
program can be incorporated into a high volume clinical
training program without detracting from resident HPB
experience. Prior to initiating an HPB fellowship pro-
gram, individual training programs must carefully assess
their capability to provide an adequate clinical experience
for fellows without diminishing resident exposure to
complex HPB procedures.
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Improved survival with aggressive resection of
hilar cholangiocarcinoma
Y. L. CHEAH, MD, M. AKOAD, MD, K. VAKILI,
MD, J. J. POMPOSELLI, MD, PHD, E. A. POMFRET,
MD, PHD, W. D. LEWIS, MD and R. L. JENKINS,
MD
Lahey Clinic, Burlington, MA, USA
Background: Complete surgical resection with negative
histologic margins is a major determinant of long-term
survival for patients with hilar cholangiocarcinoma. As
our experience with surgical resection for hilar cholan-
giocarcinoma evolved, we adopted a more radical surgi-
cal approach with the addition of hepatectomy and
complex vascular reconstruction to achieve negative
surgical margins. In this study we sought to examine the
results of this aggressive surgical approach and its impact
on patient survival.
Methods: All patients with the diagnosis of hilar cho-
langiocarcinoma evaluated and treated by a single team
of surgeons between 1986 and 2007 were identiﬁed from
our computerized database. A total of 120 patients
underwent resection with curative intent; 65 patients
between 1986 and 1998 at the former New England
Deaconess Hospital (period 1), and 55 patients between
1999 and 2007 at the Lahey Clinic (period 2). Patient
demographics, extent of surgical resection and outcomes
were retrospectively analyzed and compared between
periods 1 and 2. Survival is calculated using the Kaplan–
Meir method and curves were compared using the log
rank test.
Results: The overall 1, 3, and 5-year survival rates of
patients with R0 resection were 85.5%, 63.7% and
35.5% compared to 56.6%, 8.2% and 0% for R1 resec-
tion (P < 0.001). Patients in period 2 received more
extensive surgical resections; hilar combined with hepatic
resection was performed in 69.1% of patients in period 2
compared to 48.6% in period 1. Concomitant vascular
resection was performed in 17 patients (three in period
1 and 14 in period 2), with portal vein resection in 13
patients, hepatic artery resection in two patients, and
both hepatic artery and portal vein resection in two
patients. Negative margins were achieved in 81.8%
in period 2 compared to 50.0% in period 1 (P < 0.05).
The perioperative mortality rate improved from 6% in
period 1 to 1% in period 2. The 1, 3 and 5 year survival
in period 1 was 67.1%, 39.4%, and 18.5% compared to
79.6%, 48.4%, and 31.1% in period 2 (P < 0.05). Post-
operative complications occurred in 22 (40%) patients
in period 2; the most common complication was bile leak
in eight patients.
Conclusion: Aggressive surgery with the addition of
partial hepatectomy and vascular resection in treating
hilar cholangiocarcinoma improves patient survival with
acceptable morbidity and mortality.
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Validation of a predictive algorithm to maxi-
mize resectability of pancreatic adenocarcinoma
P. BAO, MD, D. POTTER, PHD, J. YOUNG,
D. EISENBERG, MD, D. LENZNER, MS, K. LEE,
MD, H. ZEH, MD, M. SANDERS, MD, S. HUGHES,
MD and A. J. MOSER, MD
University of Pittsburgh, Pittsburgh, PA, USA; UPCI
Biostatistics Facility, Pittsburgh, PA, USA
Introduction: The surgeon’s major contribution to
patients with localized pancreatic cancer is a margin
negative resection. We hypothesized that a prediction
algorithm based on preoperative computed tomography
(CT) and endoscopic ultrasound (EUS) could maximize
the rate of R0 resection while reducing the risk of non-
therapeutic surgery.
Methods: 197 patients with biopsy-proven pancreatic
adenocarcinoma (157 head; 40 body/tail) underwent
exploration with intent to resect from 2002 to 2007. All
patients had staging helical CT and 143 had EUS. A
prediction model was developed from the imaging data of
65 patients during 2002–2005. This algorithm classiﬁed
patients as high or low risk for noncurative surgery. It
was validated in a subsequent cohort of 78 patients
between 2005 and 2007. Model performance was eva-
luated using contingency table and survival analysis.
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Results: Predictors of resectability in the development
cohort were: any evidence of vascular involvement on CT
scan, EUS stage IIB by AJCC criteria, and EUS tumor
size greater than 2.6 cm. The resectability rate in the
validation cohort was 77% with a 58% R0 resection rate.
Compared to these outcomes, selecting operative patients
classiﬁed by the model as favorable for curative surgery
would have increased the resectability rate from 77% to
92% (P = 0.03) and the R0 resection rate from 58% to
73% (P = 0.08). The model was 71% accurate with 78%
sensitivity and 61% speciﬁcity for R0 resection. There
was a 40% difference in R0 resectability between high
risk and low risk patients (P = 0.001). High risk classi-
ﬁcation was associated with unresectable locally-ad-
vanced disease (P = 0.007), metastasis (P = 0.012), and
the need for mesenteric vein resection (P = 0.012).
Compared to patients at low risk, those at high predicted
risk had a 67% rate of noncurative surgery and experi-
enced signiﬁcantly shorter median survival (12.3 vs.
20.6 months, P = 0.022).
Conclusion: This validated prediction algorithm uses
standard CT and EUS criteria to identify patients most
likely to beneﬁt from resection for pancreatic adenocar-
cinoma. The model signiﬁcantly increased the R0 resec-
tion rate and reduced the rate of nontherapeutic surgery.
Prediction models may be used to classify patients
entering neoadjuvant therapy trials.
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Serial molecular analysis of EUS guided FNA
aspiration of pancreatic cysts: quantitative
molecular evidence detects neoplastic cyst
progression, stability or regression
D. MALLAT, MD, J. P. TAZELAAR, C. SPENCE,
PHD, E. M. ELDER, SCD and S. D. FINKELSTEIN,
MD
Baylor University, Dallas, TX, USA; RedPath Integrated
Pathology, Pittsburgh, PA, USA
Introduction: The biological behavior of pancreatic
cystic neoplasms, particularly those of mucinous origin,
is difﬁcult to predict. Progression rates of 30% and
higher have been reported in mucinous cystic processes
leading to recommended surgical excision in all cases.
Regression of mucinous cysts over time is suspected
to occur, however objective support has been lacking.
Molecular analysis of aspirated pancreatic cyst ﬂuid
(point mutation, loss of heterozygosity) is used here to
evaluate the presence and rate of that mutational change
over time.
Design: The ﬂuid from 52 patients with EUS-FNA
pancreatic cysts underwent molecular analysis con-
sisting of measurement of 1) DNA quantity, 2) DNA
quality (extent of degradation), 3) Kras point mutation,
4) allelic imbalance (loss of heterozygosity determina-
tion [LOH]) for a panel of 16 markers and 5) degree of
clonal expansion of DNA alterations when present
(PathFinderTG). In each patient, serial aspirations
were available (40-two serial, 8-three, 4-four) totaling 120
separate cyst ﬂuid genotyping reactions. The interval
between serial analyses ranged from 3 to 36 months.
Mucinous cysts were deﬁned as cysts containing gross or
microscopically visible mucin, elevated CEA, Kras point
mutation and/or multiple LOH alterations. Cysts not
meeting these criteria were classiﬁed as serous/reactive
processes.
Results: Forty-two of 52 patients had cysts meeting the
criteria for mucinous etiology. 20 (48%) manifested
neoplastic regression by reduction in DNA amount, shift
from good to poor quality, elimination of some or all of
the point mutations/LOH change present previously and/
or lowering in the degree of clonality. The mucinous cysts
of 19 patients (45%) remained essentially stable while
three patients (7%) manifested molecular evidence of
progression at 6, 8 and 10 months. All 10 non-mucinous
cyst ﬂuids showed stable indolent molecular features (low
DNA, poor quality, 0–2 low clonality alterations).
Mucinous cysts with indolent molecular features did not
manifest neoplastic progression.
Conclusions: Molecular analysis provides a useful ancil-
lary tool with which to characterize aspirated pancreatic
ﬂuid. The vast majority of mucinous cysts did not
manifest neoplastic progression for up to 36-month
follow-up. Only 7% of mucinous cysts showed mole-
cular progression which was predicted in the initial
sample by aggressive molecular changes. The results
support integrated molecular pathology risk stratiﬁcation
of patients with pancreatic cysts including mucinous
cystic lesions.
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A simple risk score predicts inpatient mortality
after liver resection for hepatocellular
carcinoma
J. P. SIMONS, MD, S. C. NG, MS, J. S. HILL, MD,
S. A. SHAH, MD, Z. ZHOU, MD, PHD and
J. F. TSENG, MD, MPH
University of Massachusetts Medical School, Worcester,
MA, USA
Objective: To develop an integer-based risk score based
on national data to estimate the risk of in-hospital
mortality in patients undergoing procedures for hepato-
cellular carcinoma.
Background: There is a wide spectrum of disease burden
in hepatocellular carcinoma accompanied by several
options for surgical management. However, the associ-
ated mortality of such procedures is not well-deﬁned.
Accurate predictions of patients’ perioperative risk
would be helpful to guide decision-making.
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Methods: The Nationwide Inpatient Sample, the largest
all-payer discharge database in the U.S., was queried
from 1998 to 2005. A cohort of patient-discharges for
hepatic procedures with a diagnosis of primary liver
neoplasm was assembled. Procedures were categorized as
hepatic lobectomy, wedge resection, or enucleation/
ablation. Logistic regression and bootstrap methods were
used to create an integer risk score for estimating the risk
of in-hospital mortality using procedure type, patient
demographics, comorbidities, and hospital type. A ran-
domly selected sample of 80% (n = 2274) of the cohort
was used to create the risk score with validation of the
score conducted in the remaining 20% (n = 560).
Results: A total of 2834 patient-dischargeswere identiﬁed.
Overall in-hospital mortality was 6.53%. Factors included
in the ﬁnal model were age, gender, Charlson comorbidity
score, procedure type, and teaching hospital status. Inte-
ger values were assigned to these characteristics, and then
used for calculating an additive score (Figure, right panel).
Four clinically relevant score groups were then assembled
to stratify risk of in-hospital mortality, with a 13-fold
gradient of mortality ranging from 1.6 to 21.5% (Figure,
left panel; P < 0.0001). In the derivation set, as in
the validation set, the score discriminated well, with a
c-statistic of 0.74 and 0.72, respectively.
Conclusion: An integer-based risk score can be used to
predict in-hospital mortality after surgical procedure for
hepatocellular carcinoma, and may be useful for preop-
erative risk stratiﬁcation and patient counseling.
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SNPs in RecQL predict survival in pancreatic
adenocarcinoma
M.-C. GINGRAS, PHD, D. LI, PHD, S. E. HODGES,
R. A. GIBBS, PHD, F. C. BRUNICARDI, MD and
W. E. FISHER, MD
Baylor College of Medicine, Houston, TX, USA; M. D.
Anderson Cancer Center, Houston, TX, USA
Introduction: RecQL is a DNA helicase involved in DNA
mismatch repair. The RecQL 3’UTR A159C genotype
has previously been associated with overall survival of
patients with pancreatic cancer. However, the functional
signiﬁcance of this SNP remains unknown.
Hypothesis: The RecQL A159C SNP is in linkage
disequilibrium with other functional SNPs of the gene.
Somatic mutations of the RecQL gene in tumors may
inﬂuence the clinical outcome of pancreatic cancer.
Methods: We sequenced the entire coding regions of the
RecQL gene in paired blood and tumor DNA of 35
patients with resectable pancreatic cancer treated with
surgery and adjuvant chemoradiation. DNA was isolated
from blood using the PAXgene Blood DNA kit (Pre-
AnalytiX) and from matched tumors using the QIAamp
DNA Mini kit (Qiagen). Primer sets were designed to
cover the 15 RecQL exons with their surrounding
intronic regions. Sequencing was performed on ABI 3700
DNA Sequencers. SNPs and somatic mutations were
validated with Biotage pyrosequencing. SNPs that
showed signiﬁcant association with overall survival were
furthered tested in blood DNA samples of 120 patients
with resectable pancreatic adenocarcinoma who received
neoadjuvant chemoradiation. Univariate analysis of the
effect of genotype on time to recurrence and overall
survival was performed using the Cox proportional
hazards models.
Results: Several previously reported and newly identiﬁed
SNPs but no nonsynonymous SNPs were found in
this study. In addition to the RecQL A159C SNP
(rs13035), 2 SNPs, located in introns 2 and 11
(rs10841834, rs2159943) showed a signiﬁcant association
with overall survival. The three SNPs are part of the
same haplotype block (linkage disequilibrium). The var-
iant allele of each SNP had a similar effect on overall
survival of patients receiving either adjuvant or neoad-
juvant therapy. No mutations were detected in the
tumors in the exonic regions of the RecQL gene.
Conclusion: The SNPs from the 3’UTR and intronic 2
and 11 regions (CC, TT, and AA genotypes) of RecQL
are associated with improved overall survival of patients
with resectable pancreatic cancer. The functional signi-
ﬁcance of these SNPs warrants further investigation.
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Biliary complications including a single donor
mortality: experience of 207 adult-to-adult
living donor liver transplantation
M. A. EL-METEINI, MD, A. F. HAMZA, MD,
A. A. ABDALAAL, MD, M. F. FATHY, MD,
M. BAHAA, MD, A. MOKHTAR, MD,
F. ABOUELFETOUH, MD, I. MOSTAFA, MD and
A. EL-DORRY, MD
Ain-Shams University, Cairo, Egypt; Wady ElNeel
Hospital, Cairo, Egypt
Introduction: Donor safety is crucial in Living donor
liver transplantation (LDLT) with ‘do no harm’
aphorism printed in the transplant team mind. Biliary
anomalies are more common in right liver compared to
left liver grafts. Biliary complication is the main cause of
morbidity following right lobe donation. Mortality
following right lobe donation has been estimated to be
less than 0.5%.
Patients and methods: Between November 2001 to date,
207 adult-to-adult LDLT has been done using right lobe
grafts. The donors included 173 men and 34 women with
mean age 28.4 ± 5.2 years. Siblings were144 (69.6%)
cases while unrelated donors were 63 (30.4%) with a
mean body mass index 25.2 ± 2.4. Liver biopsy is
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routinely done and steatosis less than 15% is accepted.
Single and multiple right bile duct (RBD) were present in
82 (39.6%) and 125 (60.3%) donor, respectively. Multi-
ple RBD included 2 or 3 RBD in 116 (56%) and 9 (4.3%)
cases, respectively. The mean operative time was
360 ± 50 min. with an estimated blood loss around
950 ± 450 mL and returned cell-saver amount of
450 ± 334 mL. Two donors (0.9%), each received two
blood bank units. Donor remnant liver volumes (RLV)
were 33.5 ± 3.2%. Mean ICU stay was 3 ± 0.7 days
and mean hospital stay was 14 ± 3.5 days.
Results: The overall biliary complications occurred in 27
(13.04%) cases. Following modiﬁed Clavien classiﬁca-
tion, biliary complications were graded as grade I
(n = 10), grade II (n = 2), grade III (n = 14) and grade
V (n = 1). Grade I and II (n = 12) biliary complications
were successfully managed conservatively. Grade III
cases were treated by ultrasound guided aspiration,
ERCP and surgery in 10, 2 and 2 donors, respectively.
The later 2 donors were treated by t-tube insertion in one
case and duct-to-duct anastomosis following transaction
of the CBD in the other case. The later case needed
ultrasound guided dilatation and 10F stent insertion
twice with normal liver proﬁle thereafter. Single donor
mortality (Grade V) (0.4%) occurred following biliary
leakage from RBD stump followed by peritonitis that
necessitated exploration on day 11, re-exploration on
day 31 and ERCP with stent insertion on day 38 and
the donor succumbed on day 43 due to uncontrolled
sepsis.
Conclusion: Donor biliary complications accounts for up
to 43% of all complications. The majority of biliary
complications is minor and could be managed conser-
vatively. However, uncontrolled biliary leakage is a
serious morbidity that should be avoided as it could lead
to a mortality.
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Surgical downstaging and neo-adjuvant therapy
in metastatic colorectal carcinoma with irino-
tecan drug eluting beads: a multi-institutional
study
M. BOWER, MD, K. ROBBINS, MD, D. TOMALTY,
MD, C. R. SCOGGINS, MD, K. M. MCMASTERS,
MD, PHD and R. C. MARTIN, MD
University of Louisville, Louisville, KY, USA; Baptist
Health, Little Rock, AR, USA; Huntsville Hospital,
Huntsville, AL, USA
Background: Neoadjuvant chemotherapy for potentially
resectable metastatic colorectal cancer (MCC) is becom-
ing a more common treatment algorithm. However, with
the ever increasing hepatic toxicity with systemic che-
motherapy a more target approach with maximum
response and minimal hepatic toxicity is needed. The aim
of this study was to evaluate the efﬁcacy of precision
hepatic arterial Irinotecan therapy in potentially resect-
able MCC.
Methods: An open-label, multi-center, multi-national
single arm study of MCC patients, who received
hepatic arterial Irinotecan. Primary endpoints were
safety, tolerance and metastatic tumour resection.
Results: Fifty-ﬁve patients with metastatic colorectal to
the liver underwent a total of 90 hepatic arterial
Irinotecan treatments. Thirty (55%) Women, 25 (45%)
Men, 39 (71%) Caucasian, with a median age of
52 years (range 42–75) were treated. The extent of
liver involvement was 41 (75%) of patients had
< 25% Tumor Replacement, 15% (< 26–50% tumor
replacement), 10% (> 50% replacement), with median
number of hepatic lesions being 4 (range 1–20), total
size of all target lesions being 9 cm (range 5.5–28 cm),
and 50% of patients having bilobar tumor distribution.
Median number of irinotecan treatments were two
(range: 1–5), median treatment dose was 100 mg (range
100–200), with total hepatic treatment of 200 mg
(range 200–650), with 86% of treatments being per-
formed in a lobar infusion treatment, and 30% of
patients treated with concurrent simultaneous
chemotherapy. Eleven (20%) patients demonstrated
signiﬁcant response and downstage of their disease or
demonstrated stable disease without extra-hepatic
disease progression that they under went resection,
ablation, or resection and ablation. There were no
deaths with morbidity occurring in 20% of
patients, with none of them being hepatic related.
Non-tumorous liver resected demonstrated no evi-
dence of steatohepatitis from the Irinotecan arterial
infusion.
Conclusions: Hepatic arterial infusion with Irinotecan
was safe and effective in the treatment of MCC as
demonstrated by a minimal infusion complication rate,
acceptable tumor response and sustained disease
stabilization. Hepatic arterial infusion is an acceptable
therapy for evaluating the biology of metastatic colo-
rectal to the live prior to planned hepatic resection.
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Exsanguination protocol improves survival after
major hepatic trauma
V. ZAYDFUDIM, MD, W. D. DUTTON, MD, I. D.
FEURER, PHD, B. K. AU, B.SC., C. W. PINSON,
MD, MBA and B. A. COTTON, MD
Vanderbilt University Medical Center, Nashville, TN,
USA
Background: Hepatic injury remains an important cause
of exsanguination after major trauma. Recent studies
have noted a dramatic reduction in mortality among
severely injured patients when trauma exsanguinations
protocols (TEP) are employed. We hypothesized that
utilization of our institution’s TEP at the initiation of
hospital resuscitation would improve survival in patients
with signiﬁcant hepatic trauma.
Methods: TEP, which involves immediate and sustained
release of blood products to the hemodynamically
unstable trauma patients in the operating room in
pre-deﬁned ratios, was initiated in February 2006. All
patients who (1) underwent immediate operative inter-
vention, (2) sustained intra-abdominal hemorrhage with
Grade 3–5 hepatic injury, and (3) received the TEP
between February 2006 and January 2008 were pro-
spectively identiﬁed. A pre-TEP cohort was retrospec-
tively identiﬁed from among all trauma patients admitted
between February 2004 and January 2006 who (1)
received immediate operative intervention, (2) were
treated for major intra-abdominal hemorrhage with a
Grade 3-5 hepatic injury, and (3) received more than 10
units packed red blood cells in the ﬁrst 24 h. Univariate
and multivariate analyses were used to examine the ef-
fects of TEP on blood product use during the ﬁrst 24 h of
resuscitation and evaluated the effects of demographic
and clinical covariates on survival.
Results: Seventy-ﬁve patients were included in the anal-
ysis: 39 constituted the pre-TEP cohort (31% 30-day
survival) and 36 were treated with the TEP protocol
(53% 30-day survival). There were no differences in age,
gender, mechanism, grade of injury, lobar involvement,
or injury to major hepatic vasculature between the two
cohorts (all P > 0.25). However, patients treated with
TEP had higher injury severity scores (P < 0.01). While
24-hour use of blood products did not differ between
cohorts, TEP patients received more FFP and platelets
during operative intervention and signiﬁcantly less crys-
talloid (all P < 0.01). After adjusting for age, gender,
mechanism, and injury severity score; Grade 5 injury and
involvement of major hepatic vasculature had signiﬁcant
negative effects on survival (both P £ 0.02), while utili-
zation of TEP improved the odds of 30-day survival by
78% (OR = 0.22, CI: 0.06–0.81, P = 0.02).
Conclusions: An exsanguination protocol allows for
more effective utilization of FFP and platelets during
intra-operative management of major hepatic injury.
TEP was associated with a signiﬁcant improvement in
30-day survival among patients treated for intra-
abdominal hemorrhage associated with signiﬁcant
hepatic trauma.
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Evaluation of perioperative chemotherapy using
a prognostic nomogram for survival following
resection of colorectal liver metastases
S. K. REDDY, MD, M. W. KATTAN, PHD, C. YU,
PHD, E. P. CEPPA, MD, S. G. DE LA FUENTE, MD,
Y. FONG, MD, B. M. CLARY, MD and R. R. WHITE,
MD
Duke University Medical Center, Durham, NC, USA;
Cleveland Clinic, Cleveland, OH, USA; Memorial Sloan
Kettering Cancer Center, New York, NY, USA
Introduction: Nomograms are statistical tools designed
to predict outcomes and risk stratify patients for clinical
trials and multi-modality therapy. The aim of this study
was to evaluate the effects of perioperative chemotherapy
on disease-speciﬁc survival (DSS) after resection of
colorectal liver metastases (CLM) using a prognostic
nomogram incorporating demographic and clinicopath-
ologic variables established at Memorial-Sloan Kettering
Cancer Center (MSKCC).
Methods: An external cohort comprised of 203 consec-
utive patients who underwent resection of CLM between
1996 and 2006 at Duke University Medical Center was
used to validate the nomogram and to evaluate the effects
of perioperative chemotherapy on DSS after resection.
Results: Similar to the MSKCC population, the external
cohort included patients with node-positive primary
disease (61.1%), rectal primary tumors (22.2%), disease-
free interval <12 months (63.5%), size greater than 5 cm
(30.0%), multiple CLM (39.4%), bilobar disease
(26.1%), and age greater than 70 (20.7%). After a med-
ian follow-up of 30.4 months (range 0.33–150), Kaplan–
Meier (KM) estimates for 3, 5, and 8-year post-resection
DSS were 56%, 41%, and 32%; similar to nomogram
predicted probabilities for DSS. The nomogram con-
cordance index was higher (0.602) than the concordance
index for the Fong colorectal risk score (CRS; 0.533).
KM DSS was longer for the 50 patients treated with at
least six months of peri-operative irinotecan and/or
oxaliplatin (iri/oxal) based chemotherapy regimens
compared to patients who were not (median 66 vs.
40 months, P = 0.06). KM DSS was greater than
nomogram predicted DSS for treated patients (P = 0.32,
Figure 1).
Conclusions: The CLM nomogram was validated by an
external cohort and more accurately predicted
post-resection survival than the commonly used CRS.
Peri-operative contemporary chemotherapy treatment
may improve outcomes beyond that predicted by the
nomogram.
12
Hepatectomy after neoadjuvant chemotherapy
for initially unresectable liver metastases from
colorectal cancer
J. RACCUIA, MD, J. STEELE, MD and
I. NICHIPORENKO, MD
Saint Vincent’s Hospital Manhattan, New York, NY, USA
Hypothesis: Multiple, bilateral and synchronous disease
is not an absolute contraindications to hepatectomy and
neoadjuvant chemotherapy followed by hepatectomy
could provide signiﬁcant survival in those not previously
considered for cure.
Results: From 1996 to 2008 75 patients had 102 hepa-
tectomies for colorectal liver metastases with 55 (73.3%)
not initially considered for cure based upon the number,
location and size of these lesions. They were only of-
fered palliative chemotherapy by other institutions.
Despite previous opinions, 33 (44.0%) patients had
primary hepatectomy (PH) while the 42 (56.0%) others
received neoadjuvant chemotherapy (NCH) prior to li-
ver resection. A major response occurred in 26/42
(61.9%) patients, partial and total tumor necrosis in 14/
42 (33.3%) and 4/42 (9.5%) others respectively on ﬁnal
pathology. Major hepatectomy was performed in 46
(61.3%) patients and minor in 29 (38.7%) including
discontiguous bilateral hepatectomy in 34 (45.3%) pa-
tients. Morbidity was 31.1% with mortality of 1.4%. 5
and 10-year survival was 41.4% and 25.3% respectively
for the series. With 5 and 10-year survival of 51.2% and
42.7% for PH and 34.2% and 17.1% for the NCH
groups respectively. Disease-free survival at 5 and
10 years was 39.7% and 24.3% that was 45.8% and
38.2% for PH and 24.5% and 12.3% for the NCH
group. The difference in survival was not statistically
signiﬁcant for overall (P = 0.40) and disease-free sur-
vival (P = 0.18). At the last follow-up 33 (44.6%) were
alive with a mean survival of 5.9 ± 0.5 years (range
0.8–11.4 years) 41 (55.4%) were dead, 24 (32.4%) were
disease-free with a mean survival of 5.0 + 0.6 years
(range 0.8–11.1 years) and 9 (12.2%) were alive with
disease with a mean survival of 3.6 ± 1.3 years (range
1.2–4.8 years).
Conclusions: Initially resectable patients can undergo
PH with good survival while others are down-staged
with neoadjuvant chemotherapy prior to liver resection.
Removing all disease can produce long-term survival in
patients deemed initially unresectable for cure. Multiple
and bilateral tumors from colorectal metastases beneﬁt
from neoadjuvant chemotherapy before hepatectomy.
Survival beneﬁt was statistically similar in both the
PH and NHC groups. Salvage of these patients for
cure is encouraging when the only other alternatives
are locoregional and palliative chemotherapy where
the likelihood of obtaining a long-term survival is
hopeless.
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sented.
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Resection of colorectal cancer (CRC) liver
metastases: What is an adequate margin?
R. T. PADBURY, MD, PHD, D. VANDEWEYER,
MBBS, G. J. MADDERN, MD, PHD and J. W. CHEN,
MD, PHD
Flinders Medical Centre, Adelaide, Australia; The Queen
Elizabeth Hospital, Adelaide, Australia.
Traditionally a 1cm margin has been accepted as the goal
when resecting CRC liver metastases. Evidence is emerg-
ing that a lesser margin may provide good outcomes, but
a critical margin, below which recurrence is higher and
survival poorer, has not been universally agreed. In a
recent publication1 we reported peri-operative morbidity
and clear margin as the two independent prognostic
factors. In this study we deﬁned a clear margin as an
absence of tumor cells within 1 mm of the transected
surface. The aim of the current study is to further analyse
the effect of the width of the surgical margin on patient
survival to determine whether a margin of 1 mm is
adequate.
Methods: Two hundred and sixty-one consecutive pri-
mary liver resections for CRC mets from 1992 to 2007
were analysed (including 197 patients from1). 163
(62.5%) were male. The median age was 64 (22–92) years.
The 30 day (inhospital) mortality was 1.5%. The primary
CRC Duke staging include 11 As, 70 Bs, 110 Cs and 70
Ds. Initial analysis was performed on ﬁve groups
according to the resection margins; involved, minimal
margin (0–1mm), > 1–4mm, > 4 to < 10mm and
‡10mm. Subsequent analysis was based on two groups:
margin £ 1mm and > 1mm.
Results: With a median follow-up of 4.7 years, the
overall 5 year patient & disease free survival (DFS) were
38% & 22% respectively. The 5 year patient and DFS
was signiﬁcantly better in patients with ‡ 10mm resection
margin compared with those of involved margin (43.4%
vs. 19.4% P < 0.03; 28.7% vs. 16.9% P < 0.02 respec-
tively). There was no signiﬁcant difference in patient or
DFS between the three groups with margin > 1mm. The
5-year patient survivals in these groups were similar.
When a comparison is made between patient with either
involved or £ 1mm margin with patients with > 1mm
margin, there is a signiﬁcant 5 year patient survival dif-
ference of 25% versus 43% (P < 0.04). The DFS dif-
ference however did not reach statistical signiﬁcance
(P = 0.14)
Conclusions: In this cohort with a medium follow-up of
5 years, we can demonstrate that a margin of > 1 mm is
associated with signiﬁcant better 5 year survival. The
possible beneﬁcial effect of greater margin beyond 1mm
could not be clearly demonstrated in this cohort.
Reference:
1. Scheisser M, Chen JW, Maddern GJ, Padbury RT.
Perioperative morbidity affects long term survival in
patients following liver resection for colorectal metas-
tases. J Gastrointestinal Surg 2008; 12: 1054–60.
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Locally advanced intrahepatic cholangiocarci-
noma: survival beneﬁt with aggressive hepatic
resection
S. H. TEH, MD, D. CUSATI, MD, J. GRAMS, MD,
E. ABOIAN, MD, L. CHANG, MD, S. CHA, PHD,
L. BURGART, MD and D. M. NAGORNEY, MD
Sacred Heart Medical Center, Eugene, OR, USA; Mayo
Clinic, Rochester, MN, USA; Mayo Clinic, Rochester,
MN, USA
Introduction: Intrahepatic cholangiocarcinoma (ICC) is
rare and often presents as locally advanced disease. We
hypothesized that aggressive major hepatic resection may
improve the survival of patients with ICC.
Methods: All consecutive patients who underwent
hepatic resection for ICC from Jan 1993 to Jan 2003 were
retrospectively reviewed. All pathological specimens were
re-examined by two independent pathologists.
Results: There were 100 patients (male = 40, female =
60) with a mean age of 63 years old. Eighty-six patients
had major hepatic resections, of which 30 were extended
hepatic resections and eleven involved resection and
reconstruction of an extrahepatic structure (vena cava =
7, main portal vein = 2, and common bile duct = 2).
The mean tumor size was 7.7 cm; multifocal disease was
present in 27 and regional invasion in 17. There were 89
R0 resections and eight R1 resections despite an extended
hepatic resection. Perioperative morbidity and mortality
were 37% and 3%, respectively. Mean hospitalization
was 9 days. Multivariate analysis demonstrated that the
factors signiﬁcantly predicting survival were R0 resection
(P < 0.0001, HR 3.92), tumor size (P = 0.0001, HR
3.74), metastasis to lymph node(s) (P = 0.0001, HR
3.241), older age (P = 0.002, HR 3.11), and tumor
multiplicity (P = 0.02, HR 1.78). The median survival
rate for R0 and R1 resections was 4.97 years vs.
8.9 months, respectively. Overall 1-, 3-, and 5- year sur-
vival rates for R0 and R1 resection were 84% vs. 45%,
57% vs. 18% and 49% vs. 0%, respectively. Disease
recurred in 59% of patients after a mean follow up of
4 years (hepatic recurrence = 53%, extrahepatic =
47%).
Conclusions: Multivariate analysis demonstrated both
tumor and patient factors as critical predictors of long
term outcome in the management of locally advanced
ICC. However, the most signiﬁcant factor predicting
survival was ability to achieve an R0 resection. Effec-
tive preoperative multimodality therapy is needed to
downstage tumors, and patients should undergo
aggressive major hepatic resection with the goal of R0
resection.
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Long-term outcome following sequential
resections of liver and lung metastases from
colorectal carcinoma
R. MARUDANAYAGAM, MS,
R. KRISHNAMOORTHY, MS, V. SHANMUGAM,
MS, C. COLDHAM, NONE, S. BRAMHALL, MD,
MBBS, D. MAYER, MD, MBBS, J. BUCKELS, MD,
MBBS and D. MIRZA, MS
Queen Elizabeth Hospital, Birmingham, UK
Background: Surgical resection of colorectal liver
metastases (CLM) is an established form of treatment.
Limited data exists on the value of sequential hepatic and
pulmonary metastatectomy. We analysed patients who
underwent sequential liver and lung resections for CLM.
Methods: A total of 910 patients who underwent liver
resection for CLM between January 2000 and December
2007, were analysed to identify patients with resectable
pulmonary metastases (n = 43; 4.7%). Patient demo-
graphics, overall survival and survival difference between
synchronous and metachronous pulmonary metastatec-
tomy group and between ‘liver and lung resection’ group
and matched ‘liver resection only’ group without pul-
monary metastases (matched for age, primary disease
stage, interval to liver resection, and liver disease stage)
were analysed.
Results: Forty-three patients underwent sequential liver
and lung resections. The median age was 62 years. The
median number of liver lesion detected was three and the
most commonly performed procedure was right hemi-
hepatectomy (41.9%). Right upper lobe was the pre-
dominant site of lung metastasis (51%). Ten patients had
synchronous lung metastasis. The median interval be-
tween liver and lung metastatectomy was 25 months. The
1-, 3- and 5-year overall survival rates after ﬁrst metas-
tatectomy were 100%, 87.1% and 53.9% respectively
with a median survival of 42 months. Metachronous
pulmonary metastatectomy group had better 1-, 3- and
5-year survival rates than the synchronous group (100%,
88.9% and 60.9% vs. 100%, 75% and 0% respec-
tively).There was no signiﬁcant survival difference
between the ‘liver and lung resection’ and the ‘liver
resection only’ groups.
Conclusion: Sequential liver and lung resections for
metastases from colorectal carcinoma have good long-
term survival for selected patients. Presence of synchro-
nous lung and liver metastases was not associated with
long term survival.
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Predictors of blood transfusion requirement in
elective liver resection
A. J. COCKBAIN, MBBS, T. MASUDI, MBBS,
G. J. TOOGOOD, MD, J. P. LODGE, MD and
K. RAJ PRASAD, MD
St James’ University Hospital, Leeds, UK
Background: Liver resection for primary and secondary
malignancy remains major surgery frequently requiring
intra-operative blood transfusion. The balance between
safer surgical techniques and more extensive resections
has direct implications on blood transfusion require-
ments. In addition to increasing shortage of blood stocks,
and the cost and side effects of blood transfusion, there is
concern that perioperative blood transfusion has an
immunomodulatory effect which adversely affects
tumour recurrence and prognosis.
Aim: To identify predictors of perioperative blood
transfusion.
Methods: A retrospective review of a prospectively col-
lected database of all elective hepatic resections under-
taken in a tertiary referral centre over a 4-year period was
performed. Data analysed included patient demograph-
ics, comorbidities, underlying liver disease, haematolog-
ical parameters, preoperative radiological intervention,
chemoradiotherapy, previous liver resection, number of
tumours, extent and method of resection, use of hae-
mostatic agents and histological diagnosis and grade.
Number of units of blood crossmatched and transfused
were collected from the hospital’s blood bank database.
Multivariate regression analysis was performed on sig-
niﬁcant factors on univariate analysis to determine
independent predictors of blood transfusion in the
immediate perioperative period (48 h).
Results: 599 patients were identiﬁed with a median age of
64 years and a male: female ratio of 8:5. In the periop-
erative period patients were crossmatched a median of
10 units blood. Ratio of units crossmatched: units
transfused was 13:1. Fifteen percent of patients received a
blood transfusion with a median transfusion of two units.
Transfusion requirement varied by operation from 12%
of patients undergoing hemihepatectomy or metastecto-
my to 48% of patients undergoing trisectionectomy.
Multivariate regression analysis identiﬁed seven inde-
pendent factors predictive of transfusion requirement
(Table 1).
Table 1. Independent predictors of blood transfusion
requirement.
Predictor P-value
Odds
ratio 95% CI
Coronary artery disease 0.009 2.769 1.287–5.960
Preoperative biliary drainage < 0.001 6.120 2.276–16.452
Previous liver resection 0.001 4.450 1.830–10.824
Preoperative platelet count 0.002 1.005 1.002–1.008
No. of segments
resected: 3–4
0.507 1.300a 0.599–2.824
a) compared to 1–2 segments resected
No. of segments resected: 5+ < 0.001 4.182a 1.874–9.328
Hepatocellular carcinoma 0.03 2.443 1.092–5.464
Preoperative haemoglobin
< 10 g/dL
0.021 6.556b 1.325–32.440
b) compared to Hb > 12.5 g/dL
Preoperative haemoglobin
10–12.5 g/dL
0.041 2.019b 1.030–3.958
Conclusions: Results from this single centre study suggest
that major liver surgery may be safely performed with
fewer crossmatched units of blood. Here we have iden-
tiﬁed seven independent predictors of transfusion
requirement. These factors could be used as criteria for
cross matching of blood, with group and save being a
safe and more cost effective measure in certain groups of
patients.
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Targeting focal adhesion kinase inhibits
pancreatic cancer growth and metastasis
J. B. STOKES, MD, R. W. TILGHMAN, PHD,
E. DAN HERSHEY, MS, J. K. SLACK-DAVIS, PHD,
J. THOMAS PARSONS, PHD and T. W. BAUER, MD
University of Virginia, Charlottesville, VA, USA
Background: Focal adhesion kinase (FAK) is a cyto-
plasmic protein tyrosine kinase involved in the regulation
of cellular signaling, migration, apoptosis, and cell cycle
progression. FAK has been shown to activate prolifera-
tion and inhibit apoptosis in cancer; however, its role in
pancreatic cancer is not well understood. We analyzed
the effects of PF-562,271, an inhibitor of FAK, on pan-
creatic cancer growth, invasion and metastasis.
Methods: The human pancreatic adenocarcinoma cell
lines L3.6pl and MPanc 96 were investigated in vitro,
while MPanc 96 was used for in vivo investigation. FAK
phosphorylation was assessed by Western blot analysis.
Transwell migration assays were used to evaluate the role
of FAK inhibition in pancreatic cancer cell migration
and invasion after stimulation with growth factors and
extracellular matrix proteins. To evaluate the effects of
FAK inhibition in vivo, we used an orthotopic mouse
model in which 33 mg/kg of PF-562,271 was adminis-
tered twice daily by gastric lavage. Tumor volume was
evaluated by magnetic resonance imaging (MRI) and
tumor size, retroperitoneal invasion, and metastasis were
evaluated at necropsy. PF-562,271 was generously pro-
vided by Pﬁzer Inc.
Results: In pancreatic cancer cell lines FAK phosphor-
ylation was signiﬁcantly reduced by PF-562 271 admin-
istration exhibiting an IC50 of 0.1 uM. Stimulation by
IGF-I resulted in a 7-fold increase (P < 0.05) in cell
migration which was inhibited 94% by pretreatment with
PF-562 271. Coating of transwell migration chamber
membranes with collagen-I increased migration 6-fold
and this was inhibited 32% by PF-562 271. In mice
bearing orthotopic pancreatic tumors, PF-562,271 ther-
apy (vs. control) signiﬁcantly inhibited tumor growth by
MRI volumetric analysis (58.75 mm3 vs. 127 mm3,
P < 0.05) and by pathologic examination (325 mm3 vs.
816 mm3, P < 0.05). Treatment with PF-562,271 also
yielded signiﬁcantly fewer abdominal metastases (29%
vs.100%, P < 0.05), less retroperitoneal invasion
(0% vs. 83%, P < 0.05), and showed a trend towards
fewer liver metastasis (0% vs. 50%, P = 0.06), compared
to control.
Conclusions: Our study demonstrates the important role
of FAK in pancreatic cancer growth, invasion and
metastasis. These ﬁndings support FAK as a potential
target for therapy in patients with pancreatic cancer.
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The molecular mechanism of HIF-1independent
VEGF expression in hepatocellular carcinoma
cell line
S. B. CHOI, MD, J. B. PARK, PHD, K. S. KIM, MD,
PHD and T. J. SONG, MD, PHD
Yonsei University College of Medicine, Seoul, Republic of
Korea;Research Institute and Hospital, National Cancer
Center, Ilsan, Republic of Korea; Korea University College
of Medicine, Ansan, Republic of Korea
Purpose: Hypoxia-inducible factor-1 (HIF-1) is a master
transcription factor that plays a central role in hypoxic
expression of various genes. The aim of this study was to
provide molecular pathway of vascular endothelial
growth factor (VEGF) expression of HIF-1 independent
pathway in hepatocellular carcinoma cell line (Hep3B).
Methods: HIF-1a, HIF-2a dominant negative lentiviral
vector was introduced to decrease the expression of HIF
in Hep3B cell line. Cells were incubated at 37C under
normoxic and hypoxic condition. We performed VEGF
ELISA using supernatant, and Western Blotting to
demonstrate the difference of protein expression in
normoxic or hypoxic condition. To validate the HIF-1
dependent or HIF-1 independent pathway, we treated the
cells with PI3K inhibitor and Erk kinase inhibitor.
Results: VEGF level was increased under the hypoxic
condition. HIF-1a protein expression was induced in
Hep3B cell line after 24 h of exposure of hypoxia. We
used siHIF-1a and siHIF-2a transfected Hep3B cell line
which was incubated in the normoxic or hypoxic condi-
tion. The production of the VEGF was done by the
HIF-1 pathway. However signiﬁcant portion of the
VEGF was produced by HIF-1 independent pathway.
We treated the vector, siHIF-1a and siHIF-2a transfected
cells with ERK inhibitor before incubating normoxic or
hypoxic condition. The VEGF expression was not dif-
ferent in each cell lines in hypoxic condition. Therefore
the regulation of VEGF expression was not inﬂuenced by
ERK pathway. We treated the vector, siHIF-1a and
siHIF-2a transfected cells with PI3K inhibitor before
incubating normoxic or hypoxic condition. The PI3K
inhibitor decreased VEGF expression in the siHIF-1a
transfected cells in the hypoxic condition. We treated the
vector, siHIF-1a and siHIF-2a transfected cells with
siSP1 transient transfection before incubating normoxic
or hypoxic condition. The siSP1 transient transfection
decreased VEGF expression in the siHIF-1a transfected
cells in the hypoxic condition. Therefore the VEGF
regulation of Hep3B cell line was mainly controlled by
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Akt/PI3K and SP1 pathway which was independent on
HIF-1 in hypoxic condition.
Conclusions: Under the hypoxic condition, VEGF
expression was controlled by HIF-1. However the VEGF
expression by Akt/PI3K and SP1 pathway is not medi-
ated by HIF-1 in the Hep3B cell line.
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Proteasome inhibition in combination therapy of
experimental pancreatic cancer: in vitro and
in vivo evaluation
N. AWASTHI, PHD, M. A. SCHWARZ, MD and
R. E. SCHWARZ, MD
UT Southwestern Medical Center, Dallas, TX, USA
Background: Use of targeted therapy to enhance clinical
beneﬁts of cytotoxic chemotherapy has failed to improve
responses in pancreatic ductal adenocarcinoma (PDAC).
Proteasome inhibition (PI) with agents such as bortezo-
mib (B, Velcade) has shown anticancer beneﬁts through
increase in proapoptotic mechanisms and cell cycle-re-
lated antiproliferative effects. This and the possibility for
an increased biologic activity of other agents after PI
provide the rationale for PI combination therapy. We
have previously shown that endothelial monocyte acti-
vating polypeptide II (EMAP II, E), an antiangiogenic
cytokine, enhances combination treatment effects in
experimental PDAC through VEGF and integrin-related
mechanisms. Testing E and B for combination beneﬁts
in vivo and in vitro was the purpose of this study.
Methods: In vitro studies used WST-1 proliferation
assays with three human PDAC lines and HUVECs
endothelial cells (ECs) in a dose escalation matrix.
Human ASPC PDAC cells were used in a murine xeno-
graft survival model. Twelve days after i.p. or s.c. injec-
tion of 7.5x10E5 tumor cells, animals underwent
treatment with various combinations of E (80 ug/kg i.p.
daily), B (0.8 mg/kg i.p. twice weekly), or gemcitabine
(G, 100 mg/kg i.p. twice weekly) for maximally 30 days.
The resulting group survival (n = 6/group) was
compared via logrank statistic.
Results: In 48-h. assays, B showed strong activity against
various PDAC cells (IC50 range: 0.5-50 uM) and ECs
(25 nM). In a 72-h. combination assay, IC50s against
ASPC (in uM) were: B = 0.1, G = 10, E=not reached at
> 50; addition of G and/or E to B at various doses did not
affect proliferation differently. In a 48-hr. combination
assay, IC50s against ECs (in uM) were: B = 0.025,
G = 5, E = 10; addition of G or E (at their IC20)
increased B toxicity by 20%, and the triple combination by
42%, suggesting someadditive effects. After initiation of in
vivo PDAC therapy, median group survival (d) was: con-
trol = 19, B = 18, E = 20, G = 28; of all three mono-
therapy groups, only G had a signiﬁcant survival impact
(P = 0.02). All combination groups except B+E led to
extended survival compared to monotherapies or control
(P = 0.003). However, addition of B to E,G, or E+Gdid
not enhance survival (p=NS for all three comparisons).
Conclusions: PI with bortezomib mediates strong anti-
proliferative effects against PDACs and ECs in vitro, but
fails to enhance survival. Although combinations are
more effective than monotherapies, the in vivo synergistic
potential is limited. The ﬁndings highlight both beneﬁts
and challenges of combination therapy approaches, while
suggesting limitations of cancer cell in vitro assay efﬁcacy
predictions.
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Anti-inﬂammatory effects of the nigella sativa
seed extract, thymoquinone, in pancreatic
cancer cells
H. A. ARAFAT, MD, PHD, N. CHEHL, B.SC.,
G. CHIPITSYNA, PHD, Q. GONG, MD and
C. J. YEO, MD
Thomas Jefferson University, Philadelphia, PA, USA
Background: Both hereditary and sporadic forms of
chronic pancreatitis are associated with an increased risk
of developing pancreatic ductal adenocarcinoma (PDA).
Inﬂammation has been identiﬁed as a signiﬁcant factor in
the development of solid tumor malignancies. Thymo-
quinone (Tq), the major constituent of the Nigella sativa
oil extract induces apoptosis and inhibits PDA cell pro-
liferation. Tq also increases p21WAF1 expression, inhibits
histone deacetylase (HDAC) activity, and induces his-
tone hyperacetylation. HDAC inhibitors have been
shown to ameliorate inﬂammation-associated cancer in
several animal models.
Objective: To evaluate the anti-inﬂammatory potential
of Tq in PDA cells in comparison to a speciﬁc HDAC
inhibitor, trichostatin A (TSA).
Methods: PDA cells (AsPC-1, HS766T; MiaPaca) were
cultured and treated with or without Tq (25–75 lM),
with or without pre-treatment of TNF- a (30 nM). The
effect of Tq on the expression of different proinﬂamma-
tory cytokines and chemokines was analyzed by real time
PCR. Luciferase-labeled promoter studies evaluated the
effect of Tq on the transcription of monocyte chemo-
attractant protein-1 (MCP-1) and nuclear factor-jB
(NF-jB). The effect of Tq on the endogenous and TNF-a
-induced activation and nuclear translocation of NF-jB
was examined by ELISA and immunohistochemistry.
Results: Within 6 h, Tq signiﬁcantly and dose-depen-
dently reduced PDA cell production of TNF-a (P <
0.02), interleukin (IL-1b) (P < 0.02), IL-8 (P < 0.05),
Cox-2 (P < 0.002), and MCP-1 (P < 0.005). There was
no reduction in interferon-c (IFN-c) in the same cultures.
Within the same time period, TSA reduced the produc-
tion of Cox-2 (P < 0.02) and MCP-1 (P < 0.05), but
had no effect on TNF-a, IL-8, or IL-1b. Tq, but not
TSA, signiﬁcantly and dose-dependently reduced the
intrinsic activity of the MCP-1 promoter. Tq also
inhibited the intrinsic and the TNF-a-mediated activa-
tion of NF-jB in PDA cells and reduced the transport of
NF-jB from the cytosol to the nucleus.
Conclusions: Our data demonstrate previously unde-
scribed anti-inﬂammatory activities of Tq in PDA cells,
which are paralleled by inhibition of NF-jB. Tq as a
novel inhibitor of proinﬂammatory pathways provides a
promising strategy that combines anti-inﬂammatory and
proapoptotic modes of action.
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A proteomic based platform for marker
discovery in cholangiocarcinoma
G. K. BONNEY, R. CRAVEN, A. MELCHER,
P. SELBY, R. BANKS and R. PRASAD
St James’ University Hospital, Leeds, UK
Cholangiocarcinoma (CCA) is the second commonest
primary malignancy of the liver with a rising incidence
worldwide and a dismal prognosis. There remains a lack
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of sensitive and speciﬁc biomarkers for this disease
particularly in distinguishing it from patients with benign
and predisposing diseases such as Primary Sclerosing
Cholangitis.
Bile, directly draining the liver, may contain higher
concentrations of biomarkers than those found in the
general circulation, as these may be tumour derived, shed
or secreted proteins. The proteomic analysis of bile in
disease pathogenesis (i.e. malignancy and gallstone dis-
ease), drug metabolism and biomarker discovery has
received recent interest. We have developed a reproduc-
ible and accurate method of quantifying, desalting and
delipidating bile prior to proteomic analysis. Using this
method we ran two parallel proteomic based approaches,
with the aim of marker discover in CCA.
The ﬁrst, using Differential In Gel Electrophoresis
(DIGE), was a study comparing bile from 4 groups of
patients: healthy liver donors (n = 5), benign obstruc-
tion (n = 5), Primary Sclerosing Cholangitis (n = 3)
and CCA (n = 5). This study resulted in six proteins that
were signiﬁcantly differentially expressed between groups
(downregulated n = 5, upregulated n = 1) which were
then identiﬁed by mass spectrometry. Downstream
validation of the upregulated protein was performed by
Western blotting, which conﬁrmed a signiﬁcant differ-
ence in abundance of this protein between the four
groups.
The second method used a Shotgun based approach,
namely GeLC-MS/MS. For this, a sample of bile from a
patient with CCA was analysed and over 1200 proteins
identiﬁed. In validations studies, by Western blotting,
two of these biliary proteins were differentially upregu-
lated in CCA when compared to other disease groups.
Using a proteomic based approach we have identiﬁed 3
differentially expressed proteins in the bile of patients
with CCA compared to normal, benign and predisposed
patient groups.
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Microenvironment-induced gene expression
changes in breast cancer liver metastases
S. TABARIE`S, PHD, Z. DONG, MD, F. PE´PIN,
M. HALLETT, PHD, A. OMERGLU, MD,
M. HASSANAIN, MD, P. METRAKOS, MD and
P. M. SIEGEL, PHD
McGill University, Montreal, QC, Canada
Introduction: Breast cancer is the most common cancer
affecting Canadian women and is the second leading
cause of cancer related deaths in these patients. The
acquisition of metastatic abilities by breast cancer cells is
the most deadly aspect of the disease. Upon dissemina-
tion from the primary tumor, breast cancer cells display
preferences for speciﬁc metastatic sites. The liver repre-
sents the third most frequent site for breast cancer
metastasis, following bones and lungs. Despite the evi-
dence that hepatic metastases are associated with poor
clinical outcome in breast cancer patients, little is known
about the molecular mechanisms governing the spread
and growth of breast cancer cells within the liver.
Methods: We have employed 4T1 murine mammary
carcinoma cells that were subjected to three rounds of
splenic injection, which permitted the isolation of breast
cancer cells that aggressively grow in the liver. Laser
Capture Microdissection (LCM) was used to identify
gene expression changes within breast cancer liver
metastatic cells that occur in situ in response to the liver
microenvironment.4T1 breast cancer cells located at the
margin and the centre of several metastatic lesions have
been individually sampled by LCM and the recovered
RNA subjected to linear ampliﬁcation, labeling and
hybridization to Agilent microarrays. To date, we have
analyzed four matched sets of margin vs. core liver
metastases samples. Moreover, we have complemented
the analyses of 4T1-derived lesions with LCM experi-
ments performed on liver metastases isolated from breast
cancer patients.
Results: Among several candidate genes that were dif-
ferentially expressed between the margin and core of the
liver metastases, the gene encoding for the leptin receptor
appeared to be up-regulated in the margin. The Leptin/
LEPR axis has gained considerable attention as an
important regulator of breast cancer progression. Indeed,
Leptin and LEPR are over-expressed in breast cancers
compared to normal breast epithelium and Leptin has
been shown to stimulate the proliferation of breast cancer
cells. We have validated LEPR expression in the
4T1-derived liver lesions, and more importantly, observe
LEPR positivity in multiple liver metastases obtained
from breast cancer patients.
Conclusion: The identiﬁcation and functional validation
of candidate genes important for the ability of breast
cancer cells will provide basic insights into the pathways
required for breast cancer cells to metastasize to the liver.
Our results suggest that the LEPR may play an impor-
tant role in enabling breast cancer cells to metastasize to
the liver.
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Validation of a novel, physiologic model of
experimental acute pancreatitis in the mouse
N. J. ZYROMSKI, MD, T. E. WADE, MD,
H. A. PITT, MD, S. WANG, MD and
D. A. SWARTZ-BASILE, PHD
Indiana University, Indianapolis, IN, USA
Background: Acute pancreatitis is a devastating disease
that affects 240 000 Americans each year. No speciﬁc
treatment for acute pancreatitis currently exists, largely
because its precise pathophysiology is poorly understood.
Murine experimental models are attractive, as complete
knowledge of the mouse genome permits precise genetic
manipulation. Unfortunately, current methods used to
induce acute pancreatitis in the mouse (cerulein hyper-
stimulation, intravascular bile salt infusion, supraphysi-
ologic arginine administration) are of questionable
clinical relevance. Therefore, the aim of the current study
was to validate a recently reported murine model of acute
pancreatitis that is more representative of the human
disease process.
Methods: Twenty C57BL/6J and 11 CF-1 mice were
studied. Under general anesthesia, transduodenal cann-
ulation of the pancreatic duct was accomplished with a
30-gauge catheter, and 50 lL of 5% Sodium Taurocho-
late (NaT) or 0.9 normal Sodium Chloride (NaCl) was
infused. Mice were euthanized 24 h later. Three observers
rated pancreatitis severity by light microscopic evalua-
tion of H&E sections. A validated scale incorporating
degree of edema, vacuolization, and inﬂammatory cell
inﬁltrate comprise the total pancreatitis score. Pancreatic
tissue concentration of the chemoattractant molecule
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monocyte chemoattractant protein-1 (MCP-1) and the
proinﬂammatory cytokine interleukin-6 (IL-6) were
determined by ELISA. ANOVA and Student’s t-test were
applied where appropriate; P value < 0.05 was accepted
as statistically signiﬁcant.
Results: Thirteen mice (NaCl – 6; NaT – 7) survived for
24 h. The total pancreatitis score was signiﬁcantly greater
in mice undergoing retrograde pancreatic duct infusion
of NaT (Table 1). Pancreata of mice infused with NaT
demonstrated signiﬁcant necrosis, consistent with severe
acute pancreatitis. Pancreatic concentrations of MCP-1
and IL-6 are shown in the Table 1.
Table 1. Pancreatic concentrations of MCP-1 and IL-6.
Pancreatitis
score
MCP-1
(pg/mg)
IL-6
(pg/mg)
NaCl
(n = 6)
1.2 ± 0.4 2350 ± 1386 452 ± 269
NaT
(n = 7)
6.3 ± 1.2* 3633 ± 1853 2028 ± 1612*
*P < 0.05 vs. NaCl
Conclusions: Retrograde pancreatic duct infusion of
Sodium Taurocholate induces severe acute pancreatitis in
the mouse. Though associated with a discrete learning
curve, this model is likely more representative human
pancreatitis pathophysiology, and therefore provides a
powerful tool with which to elucidate clinically important
basic mechanisms underlying the pathogenesis of acute
pancreatitis.
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The expression of interferon receptor alpha/beta
in human pancreatic cancer in nude mice is
essential for tumor response to interferon alpha
treatment
R. F. SAIDI, MD, A. W. AHAD, MD,
I. NALBANTOGLU, MD and M. J. JACOBS, MD
Massachusetts General Hospital, Boston, MA,
USA;Providence Hospital, Southﬁeld, MI,
USA;Department of Pathology, St John Hospital, Detroit,
MI, USA; Department of Surgery, Providence Hospital,
Southﬁeld, MI, USA
Introduction: Adjuvant interferon (IFN) therapy and
chemoradiation status post pancreaticoduodenectomy
for patients with pancreatic cancer have rendered
promising results.The aim of this study was to evaluate
the in vivo effect of interferon alpha on human pan-
creatic carcinoma implanted orthotopically into nude
mice.
Material and methods: Human pancreatic cancer cell
lines MiaPaCa-2 and Panc-1 were used. MiaPaCa-2 is
known to express the interferon alpha/beta receptor and
Panc-1 cells do not. The cells were implanted into the
pancreas of nude mice and treatment was initiated seven
days later. Regimen I consisted of intraperitoneal single-
agent gemcitabine (125-mg/kg biweekly) and Regimen II
consisted of IFN-alpha (10 000-units daily, subcutane-
ously) and gemcitabine biweekly for 30 days. Animals
were sacriﬁced after 30 days or if they became moribund.
Body weight was determined and the primary tumors in
the pancreas were excised, measured, and weighed. Visi-
ble metastases or adjacent organ invasion were counted
and processed for H&E staining. All macroscopically
enlarged regional (celiac and para-aortal) lymph nodes
were harvested and the presence of metastatic disease was
conﬁrmed by histology.
Results: The mice that were implanted with MiaPaCa-2
cells showed a more dramatic response to Regimen II
when compared to Panc-1 implanted mice. The Mia-
PaCa-2 group that was treated with Regimen II showed
an 87% reduction in tumor volume compared to 50% in
the Panc-1 group treated with the same regimen
(P < 0.001). Mice implanted with MiaPaCa-2 and
treated with Regimen II showed less metastasis, less local
invasion, and a longer survival compared to mice
implanted with Panc-1 treated with same regimen.
Regimen II was more effective on MiaPaCa-2 compared
to Regimen I (p<.001). There were no differences be-
tween regimen I and II in the Panc-1 group.
Table 1. Tumor reduction after treatment based on
regimen.
Regimen/cells
implanted
Regimen 1
(n = 7), %
Regimen 2
(n = 7), %
MiaPaca - 2 48 87
Panc- 1 40 50
Conclusions: Treatment of human pancreatic cancer in
nude mice with interferon alpha and gemcitabine was
associated with a reduction in tumor volume. This pro-
cess occurs in those cells that express the appropriate
interferon receptors.
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Is the use of donors with high donor risk indices
cost-effective in liver transplantation?
D. E. MOORE, MD, MPH, I. FEURER, PHD and
C. W. PINSON, MD, MBA
Vanderbilt University, Nashville, TN, USA
Background: The ever widening gap between the avail-
ability of donor organs and the number of liver trans-
plant candidates requires the maximal use of all
available grafts, including those with high donor risk
indices (DRI). High DRI organs are classiﬁed as those
having DRIs greater than 2.0, while low DRI organs
have DRIs less than 2.0. Organs with a DRI above 2.0
account for about 10% of the donor pool. Recipients
receiving high DRI organs have been shown to have
twice the length of stay and a two fold increase in
hospital costs when compared to recipients of low
DRI organs. Unless these grafts are used judiciously,
outcomes and transplant resource utilization will be
negatively affected. The aim of this study was to eval-
uate the cost-effectiveness of an organ allocation scheme
using high and low DRI organs compared to an allo-
cation scheme using only low DRI organs. Additionally,
the impact of these schemes on wait list mortality will be
evaluated.
Methods: A Markov-based decision analytic model was
created to simulate outcomes for liver transplantation in
recipients of organs from low and high DRI donors
versus recipients of organs from low DRI donors. A
second model was created to simulate outcomes that re-
ﬂect alterations in wait list mortality under both organ
allocation schemes. Baseline values and ranges were
determined from the UNOS database (19 000 recipients
transplanted between 2002 and 2007) and Medicare cost
data. Sensitivity analyses were conducted to test model
strength and parameter variability.
Results: Recipients of organs from low DRI donors had
a three year survival of 75% versus 65% for recipients of
organs from high DRI donors. After transplantation,
recipients of high DRI organs gained 5.1 QALYs
(Quality Adjusted Life Years) at a cost of $75,000/QALY
versus 5.9 QALYs at a cost of $52 000/QALY for
recipients of low DRI organs. However, the allocation
scheme in which both low and high DRI organs were
used together proved more cost-effective when compared
to the scheme in which only low DRI organs were used
and there was a 25% increase in wait list mortality; 5.8
QALYs at a cost of $54 000/QALY versus 5.6 QALYs at
a cost of $59 000/QALY.
Conclusions: High DRI donors provide a signiﬁcant
number of grafts. While these grafts may represent an
increased cost per individual transplant, the overall
contribution of these grafts to the donor pool and a
subsequent reduction in wait list mortality make them
cost-effective.
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The development of a classiﬁcation system for
biliary complications following orthotopic liver
transplantation
A. NEVILLE, MD, M. BOUTROS, MD and
J. BARKUN, MD
Royal Victoria Hospital, McGill University, Montreal,
QC, Canada
Introduction: Biliary tract complications remain a sig-
niﬁcant source of morbidity and mortality following
orthotopic liver transplantation (OLTx). Even though
these occur with an estimated incidence of 10–40% and
may lead to graft failure, there exists no universally
accepted classiﬁcation system. As such, descriptions of
biliary complications in the literature often lack consis-
tency and clarity which limits evaluation and comparison
of post-transplantation outcomes. We propose a struc-
tured classiﬁcation system for biliary complications fol-
lowing choledocho-choledochal anastomosis (CCA) at
OLTx. The classiﬁcation is based on four major com-
ponents: leaks (anastomotic or cystic duct, anastomotic
disruption), ﬁlling defects (stones/sludge/casts in the
intrahepatic, recipient or donor common ducts), stric-
tures (unilateral intrahepatic, common hepatic or anas-
tomotic) and development of sclerosing cholangitis.
Complications are identiﬁed and classiﬁed based on their
appearance on a contrast cholangiogram, mostly endo-
scopic cholangiopancreatography (ERCP). The goal of
this initial report is to ensure that the proposed classiﬁ-
cation is consistent and reliable.
Methods: Patients having undergone OLTx with CCA at
the McGill University Health Center from 2004 to 2007
and who had at least one contrast cholangiogram post-
operatively were candidates for the study. ERCP ﬁlms
were assessed by two independent reviewers to determine
inter-rater reliability and the kappa coefﬁcient of agree-
ment of classiﬁcation of the complication.
Results: One hundred and eight ERCP ﬁlms were
reviewed. Overall inter-rater reliability (percent agree-
ment) among the reviewers was 88.5%. Agreement on
speciﬁc elements of the classiﬁcation scheme (leak, stric-
ture, ﬁlling defect) was similarly high. Agreement among
study reviewers was greater than agreement between
study reviewers and the ofﬁcial radiographic report
(77.9%), although this was not statistically signiﬁcant.
The kappa coefﬁcient was 0.87 (95% conﬁdence interval
0.79-0.94).
Conclusion: The proposed classiﬁcation system demon-
strates high reliability and would allow for consistent
interpretation and reporting of biliary complications
following OLTx. Validation of this classiﬁcation system
is ongoing through correlation of complications with the
end-points of patient survival, graft survival, number of
additional interventions required, length of hospital stay
and number of readmissions.
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Regionalization of liver transplantation to high
volume centers is associated with diminished
volume-outcomes relationship and underutiliza-
tion of high volume centers by minority patients
E. T. TRACY, MD, E. M. AVIKI, T. N. PAPPAS, MD,
B. H. COLLINS, MD, J. E. TUTTLE-NEWHALL,
MD, C. E. MARROQUIN, MD, P. C. KUO, MD and
J. E. SCARBOROUGH, MD
Duke University, Durham, NC, USA
Introduction: Our purpose was to determine the temporal
trends in liver transplant center volume as well as the
effect of those trends on both the volume-outcomes
relationship and the utilization of high volume centers by
minority patients.
Methods: We performed a retrospective analysis of
35 374 adult orthotopic liver transplant procedures
included in the Scientiﬁc Registry of Transplant Recipi-
ents (SRTR) for three consecutive 30-month time periods
between 1999 and 2006. Transplant centers were divided
into ﬁve categories based on annual volume (very low-
volume < 36 procedures per year, low volume = 37–55,
moderate-volume 56–79, high-volume group = 80–129,
very high volume > 130). One-month and 1-year
observed-to-expected patient death ratios (provided by
the SRTR), were calculated for each time period.
Comparisons between volume groups in each time period
were made using chi square analysis. Trends in the
demographic characteristics were also assessed.
Results: The percentage of liver transplants performed at
lower volume centers decreased signiﬁcantly from 51% in
Period 1 to 33% in Period 3 (P < 0.0001), while those
performed at higher volume centers increased signiﬁ-
cantly from 27% in Period 1 to 44% in Period 3
(P < 0.0001). In Period 1, the 1-month and 1-year O:E
patient death ratios at very low-volume centers (1-month
ratio 1.33, 1-year ratio 1.18) were signiﬁcantly higher
than the ratios at very high volume centers (1-month
ratio 0.89, 1-year 0.93, P < 0.0001 at both 1-month and
1-year). By Period 3, the disparity between very low and
very high volume centers was no longer statistically sig-
niﬁcant at either 1 month or 1 year. Meanwhile, in
Period 1 the percentage of Black or Hispanic patients at
very high-volume centers (28.4%) was signiﬁcantly
greater than at very low-volume centers (20.6%,
P < 0.0001). By Period 3, the percentage of Black or
Hispanic patients at very high volume centers had
become signiﬁcantly lower (18.1%) than at low volume
centers (22.7%, P = 0.0004).
Conclusions: As the percentage of liver transplants per-
formed at higher volume centers has increased over time,
the volume-outcomes relationship has become less
prominent. However, regionalization of liver transplan-
tation does appear to be associated with a growing
underutilization of high volume centers by minority
patients.
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Is magnetic resonance imaging superior to
computed tomography for preoperative
evaluation of cystic lesions of the pancreas?
C. K. CHU, MD, A. E. MAZO, B.SC., C. A. STALEY,
MD, J. M. SARMIENTO, MD, D. R. MARTIN, MD,
W. E. TORRES, MD, N. V. ADSAY, MD and
D. A. KOOBY, MD
Emory University School of Medicine, Atlanta, GA, USA
Purpose: Cystic lesions of the pancreas (CLP) represent a
diverse range of pathologies. Appropriate management
depends on accurate diagnostic imaging. Although
magnetic resonance imaging (MRI) provides a theoreti-
cal advantage in improved soft-tissue contrast, no
deﬁnitive superiority in its diagnostic capability has been
established over computed tomography (CT) in evalua-
tion of CLP.
Methods: Database review identiﬁed patients undergoing
surgical management at our institution between 1/1/00
and 12/31/07 for CLP as conﬁrmed by postoperative
pathologic analysis. Records of patients who also
underwent same-institution preoperative CT and/or MRI
were selected for study. Diagnostic accuracy and conﬁ-
dence were rated on a 5-point scale (Table 1) for each
radiologic study as compared with histologic review.
Mann-Whitney U and Chi-square tests were used to
compare scores for CT and MRI.
Results: One hundred and forty-eight patients received
operative interventions for CLP. Of these, 96 (65%)
underwent preoperative CT and/or MRI (43 CT only,
41 MRI only, 12 both) at our institution with a total of
108 radiologic studies. Histologically, 24 patients (25%)
had serous cystadenomas; 23 (24%), intraductal papil-
lary mucinous neoplasms (IPMN); 20 (21%), mucinous
cystadenoma/adenocarcinomas; 19 (20%), pseudocysts; 7
(7%), solid pseudopapillary tumors; 2 (2%), simples
cysts; and 1 (1%), lymphoepithelial cyst. No signiﬁcant
difference between diagnostic scores of CT and MRI was
detected (median 3 vs. 2, P = 0.14). However, only
43.6% of CT studies received scores of 1 or 2, while
62.3% of MRI studies achieved the same (P = 0.05).
There was a trend towards improved preoperative iden-
tiﬁcation of IPMN using MRI as evidenced by percent of
score 1 (50% by MRI vs. 13% by CT, P = 0.075). No
such trend was observed among cystadenomas.
Conclusions: MRI may provide greater diagnostic accu-
racy and conﬁdence in preoperative evaluation of cystic
lesions of the pancreas. MRI is prudent when uncertainty
regarding diagnosis and management of CT-visualized
lesions arise. Additionally, cystic lesions suspicious for
IPMN may be better evaluated for ductal involvement
with MRI than CT.
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Table 1. Diagnostic scoring system used for CT and
MRI.
Score
Degree of accuracy and conﬁdence of radiologic
report results in comparison to surgical
pathology results
1 Deﬁnitive: correct answer proposed as single or
top diagnosis
2 Suggestive: mentions correct answer within a
narrow range (3 or less) possible diagnoses of
equal likelihood
3 Somewhat suggestive: mentions correct answer
within a wide range (greater than 3) of possible
diagnoses
4 Vague: does not mention possibility of correct
diagnosis anywhere within report
5 Contradictory: correct diagnosis not proposed
as possibility, and top proposed diagnosis
inaccurate or contradictory to correct diagnosis
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Comparative performance of staging systems
for early hepatocellular carcinoma
H. NATHAN, G. MENTHA, H. P. MARQUES,
L. CAPUSSOTTI, P. MAJNO, L. ALDRIGHETTI,
C. PULITANO, L. RUBBIA-BRANDT,
N. RUSSOLILLO, B. PHILOSOPHE, E. BARROSO,
A. FERRERO, M. A. CHOTI and T. M. PAWLIK
The Johns Hopkins University, Baltimore, MD, USA
Introduction: While several staging systems for hepato-
cellular carcinoma (HCC) have been proposed for pa-
tients (pts) with a wide spectrum of HCC disease, most
surgical candidates in fact have early HCC. The ability of
staging systems to discriminate prognosis after surgery
for early HCC is unknown. We sought to assess the
performance of major HCC staging systems in a large
cohort of pts with early HCC.
Methods: Data on pts undergoing liver resection (LR) or
transplantation (LT) for early HCC (£ 5 cm, N0M0, no
major vascular invasion) with well-compensated cirrhosis
were collected from an international group of seven
hepatobiliary centers. We evaluated ﬁve staging systems:
American Joint Committee on Cancer (AJCC), Interna-
tional Hepato-Pancreato-Biliary Assoc. (IHPBA), Japa-
nese Integrated Staging (JIS), Cancer of the Liver Italian
Program (CLIP), and Okuda. A previously proposed
scoring system for early HCC was also evaluated; this
system allots 1 point each for size > 2 cm, multifocality,
and microscopic vascular invasion (mVI). The discrimi-
native abilities of the systems were quantiﬁed via boot-
strap-corrected concordance indices (c).
Results: Of 366 eligible pts, 236 underwentLRand 130LT.
Overall survival was 74% at 3 years and 53% at 5 years
(median 63 months). While most pts had size > 2 cm
(n = 278, 76%), a minority had multifocality (n = 47,
13%)ormVI (n = 76, 21%).Thedistributionofpts among
stages was: AJCC: T1 (n = 250), T2 (n = 116); IHPBA:
T1 (n = 67), T2 (n = 273), T3 (n = 26); JIS 0 (n = 51),
1 (n = 249), 2 (n = 54), 3 (n = 12); CLIP: 0 (n = 206),
1 (n = 81), 2 (n = 19), 3 (n = 2); Okuda: A (n = 69), B
(n = 219), C (n = 3); early HCC scoring system: 0
(n = 58), 1 (n = 219), ‡ 2 (n = 89). Except for the AJCC
system, all established staging systems performed poorly as
judged by the c-statistics (Table 1). The proposed scoring
system for early HCC demonstrated the best prognostic
discrimination of all the evaluated systems (Table 1).
Table 1. Survival by stage for ﬁve existing staging systems
and a proposed scoring system for early HCC.
5-year survival, by stage/score (%)
AJCC IHPBA JIS CLIP Okuda
Early HCC
Scoring
System
T1/Score 0/B 59 59 64 52 45 67
T2/Score 1/B 40 52 50 47 53 55
Score 2/C No pts. 51 57 50 67 39
Score 3 No pts. No pts. 47 100 No pts. No pts.
c-Statistics 0.585 0.518 0.502 0.510 0.508 0.592
Conclusions: Most staging systems perform poorly when
used for prognostic stratiﬁcation of pts with early HCC.
Although the AJCC staging provides moderate discrim-
inative ability, it only includes two groupings (T1 and T2)
that constitute early HCC. A simple scoring system for
early HCC provides superior discriminative power than
existing staging systems.
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Liver retransplantation – a 25-year experience
V. SHANMUGAM, C. BHATI, R.
MARUTHANAYAGAM, J. BUCKELS, D. F. MIRZA
and S. R. BRAMHALL
Queen Elizabeth Hospital, Birmingham, UK
Retransplantation (re-LT) is the only viable option for
irreversible graft failure after primary transplantation.
Due to the growing disparity between the number of
people listed for primary Liver transplantation and
organs available and its inferior outcomes when com-
pared to primary transplantation, re-LT is certainly
controversial. The aim of this study was to analyse the
indications and outcomes of re-LT since the beginning of
our programme.
Methods: The clinical and demographic data for this
retrospective study from 1982 to 2007 was collected from
our dedicated transplant database. During this period a
total of 2420 adult transplants were performed at our
centre.
Results: A total of 196 re-LT patients underwent 225
transplantations (8.09%). The mean age was 42.99 years
(SEM±0.09) with the median age of 44.85 years (16.4–
68.3). The number of retransplants has gone down stea-
dily due to the better techniques and newer immune
suppression. Out of 196 re-LT, 23 had second re-LT
(0.95%) and 6 had their fourth re-LT grafts
(0.24%).More then 1/3 in our study (37.6%) required
regrafting within the 6 months of primary transplant.
The most common indication was Hepatic artery
thrombosis (31.5%), followed by chronic rejection
(22.6%) and recurrent disease (14.2%). The patient sur-
vival and graft survival are as shown in Table 1.
Early retransplants (< 7 days) of the primary trans-
plant had a worse outcome than late retransplants
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(P = 0.001). Patient survival after retransplantation in
patient with PNF and Haemorrhagic necrosis had poor
outcome in comparison to others (P = 0.008). MELD
did not have any impact on patient survival (P = 0.2)
Conclusion: Long terms graft as well as patient survival
in patients with regraft populations is signiﬁcantly lower
then patients with primary grafts. Patient survival de-
pends on the indication for retransplantation. Retrans-
plants within 7 days had a poor outcome than the late
transplants. Higher MELD did not have any impact on
patient’s survival. Retransplantation is necessary but the
clinical selection of recipient remains of paramount
importance.
Table 1. Patient (PS) and graft survival (PS).
First Re
LTx
PS GS
Second Re
LTx
PS GS
Third Re
LTx
PS GS
30 days 83% 82% 64% 59% 67% 60%
90 days 73% 72% 59% 59% 24% 40%
1 year 66% 65% 45% 45% 24% 20%
3 years 61% 59% 40% 36% 0%
5 years 57% 54% 40% 32% 0%
10 years 47% 43% 25% 24% 0%
Total no
of patients
196 23 6
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Initial experience using Hepatitis C positive
renal allografts in elderly Hepatitis C negative
recipients
T. R. FLOHR, MD, D. KEITH, MD, P. I. LOBO, MD,
B. R. SWENSON, MD, H. BONATTI, MD,
T. M. SCHMITT, MD, R. G. SAWYER, MD,
T. L. PRUETT, MD and K. L. BRAYMAN, MD, PHD
University of Virginia, Charlottesville, VA, USA
Introduction: First year mortality for elderly end stage
renal disease (ESRD) patients is 1.62–2.53 fold higher as
compared to younger ESRD patients. Renal transplan-
tation is an option that provides improved survival,
however, the lack of suitable organs, longer wait-times
and worsening co-morbidities are great impedances for
the elderly. Considering these difﬁculties, the use of
kidneys from donors with serology positive for Hepatitis
C virus (HCV) has been explored. We report our expe-
rience with nine HCV negative elderly patients whom
underwent renal transplantation receiving an HCV
positive allograft.
Methods: At the University of Virginia Health System,
542 patients underwent renal transplantation between
January 2003 and September 2008. The number of
patients ‡ 60 years transplanted was 137, including 9
HCV negative patients receiving allografts from HCV
positive donors (D+/R-) and 123 HCV negative patients
receiving allografts from HCV negative donors. This
study retrospectively reviewed those recipients’ clinical
course, graft function, HCV status, liver function and
outcome.
Results: The average age of the nine D+/R- patients was
69.67 ± 5.96 years. The average age of the 123 D-/R-
patients was 65.65 ± 4.24 years. All D+/R- transplants
were from cadaveric donors while D-/R- transplants were
divided into 54% cadaveric, 28% living related donors
and 18% living unrelated donors. Follow-up ranged
between 3 months and two years. Three D+/R- patients
(30%) died during the follow-up period: one from causes
unrelated to transplantation, two from sepsis. Nineteen
of 123 D-/R- patients (15%) died during the follow-up
period. The two D+/R- patients who died from sepsis
had the only graft function loss and were both treated for
rejection (one cellular, treated with high dose steroids
and one humoral, treated with plasmapheresis, intrave-
nous immunoglobulin and rituximab). Four D+/R-
patients were diagnosed with HCV by HCV-RNA
reverse transcriptase polymerase chain reaction.
Recipient HCV serology in patients with detectable viral
loads was negative for all patients tested. Two D+/R-
patients had overt signs of liver disease; one died with
transaminitis and one is alive with cirrhosis and portal
hypertension.
Conclusions: Undoubtedly, elderly patients can achieve
improved outcomes with renal transplantation as com-
pared to dialysis. This study size was small and obser-
vational only. However, the effect of using allografts
from HCV positive donors to reduce wait-time and im-
prove survival may put elderly patients at greater risk for
morbidity.
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Repair of laparoscopic bile duct injuries: timing
of surgical repair does not inﬂuence success rate
L. STEWART, MD and L. W. WAY, MD
UCSF, San Francisco, CA, USA
Purpose: Many factors contribute to the success of
biliary reconstruction following laparoscopic bile duct
injury. We previously reported that control of intra-
abdominal infection, complete preoperative cholangio-
graphy, surgical technique, and surgical experience
affected the result. There is no consensus, however, on
whether timing of the operation is important.
Methods: We examined factors inﬂuencing the success of
the ﬁrst repair of 307 major bile duct injuries following
laparoscopic cholecystectomy. The inﬂuence of timing
of the reconstruction was assessed for cases initially
repaired by the primary surgeon or a biliary surgeon.
Bivariate and multivariate analysis were used to deter-
mine the inﬂuence of the factors just mentioned.
Results: One hundred and thirty-seven injuries were
initially repaired by a biliary surgeon, 163 injuries were
initially repaired by the primary surgeon, and seven
were managed non-surgically. The repairs by primary
surgeons were done earlier than those by biliary surgeons
(11 vs. 68 days, P < 0.0001). Bivariate analysis of the
entire cohort suggested that later repairs might have been
more successful than earlier ones (17 vs. 57 days,
P = 0.003). Multivariate analysis, however, showed that
timing of the repair was not important (P = 0.931).
Instead, success correlated with: eradication of intra-
abdominal infection (P = 0.0001), complete preoperative
cholangiography (P = 0.002), correct surgical technique
(P = 0.0001), and repair by a biliary surgeon (P =
0.0001). Separate multivariate analyses of outcomes for
primary and biliary surgeons, revealed that timing was
unrelated to success in either case (see Table 1); although
there was a trend towards signiﬁcance for primary
surgeons (P = 0.103) but not biliary surgeons.
Table 1. Separate multivariate analysis of outcomes for
primary and biliary surgeons.
Time of
repair
Biliary surgeon Primary surgeon
Success
Success
with
dilitation
Bivariate
P value Success
Success
with
dilitation
Bivariate
P-value
OP
repair
- - - - 10% 13% 0.103
< 1
week
93% 96% 0.854 21% 29%
< 1
month
90% 93% 20% 31%
£ 6
weeks
91% 93% 18% 28%
>6
weeks
88% 95% 0% 33%
Conclusion: Thus, the success of biliary reconstruction
for iatrogenic bile duct injuries depended on complete
eradication of abdominal infection, complete cholangi-
ography, correct surgical technique, and repair by an
experienced biliary surgeon. If these objectives were
achieved, the repair could be performed at any time
with the expectation of an excellent outcome. We see no
reason to delay the repair for some arbitrary period in
hopes that the operation will become easier and the
outcome better. The operation is difﬁcult at any time, but
the results are good when it is performed by a biliary
surgeon.
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Role of preoperative biliary drainage of liver
remnant prior to extended liver resection for
hilar cholangiocarcinoma
T. J. KENNEDY, MD, A. YOPP, MD,
L. SCHWARTZ, MD, Y. QIN, MS, P. GUO, MD,
B. ZAO, SCD, M. D’ANGELICA, MD, Y. FONG,
MD, P. ALLEN, MD, R. DEMATTEO, MD,
L. H. BLUMGART, MD and W. R. JARNAGIN, MD
Memorial Sloan Kettering Cancer Center, New York, NY,
USA
Background: In patients with hilar cholangiocarcinoma
(HCCA), concomitant hepatic resection improves sur-
vival but is associated with increased morbidity. Preop-
erative biliary drainage (BD) of the future liver remnant
(FLR) and contralateral portal vein embolization (PVE)
may improve perioperative outcome, but their routine
use is controversial. This study analyzes the impact of
FLR volume and preoperative BD on postoperative
hepatic insufﬁciency and death.
Methods: Patients with HCCA who underwent hepatic
resection and had adequate imaging available for FLR
calculation were identiﬁed retrospectively. Patient
demographic, operative and perioperative data were
recorded and analyzed. The FLR was calculated based
on the total liver volume and the volume of the resection
performed using semi-automated contouring of the liver
on preoperative helical acquired scans. Hepatic insufﬁ-
ciency was deﬁned as a postoperative increase in bilirubin
of > 5mg/dl that persisted for longer than 5 days.
Operative mortality was deﬁned as death related to the
operation, whenever it occurred.
Results: Between 1997 and 2007, 60 patients with HCCA
were identiﬁed who underwent hepatic resection and had
imaging available for analysis. Preoperative BD of the
FLR was used selectively and PVE was used in only
1 patient. The median LOS was 14 days and the overall
morbidity and mortality was 53% and 10%. Preoperative
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FLR volume was a predictor of hepatic insufﬁciency and
death (P = 0.012). 65% of patients had an FLR ‡ 30%
(39/60). No patient in this group had hepatic insufﬁ-
ciency, but there were two operative deaths (5%) in
patients who had preoperative BD (Figure). By contrast,
in the group with FLR < 30% (21/60, 35%), hepatic
insufﬁciency was seen in ﬁve patients and operative
mortality in four patients (Figure) which was strongly
associated with a lack of preoperative BD of the FLR
(P = 0.009).
Conclusions: In patients undergoing liver resection for
HCCA, FLR volume < 30% is associated with
increased risk of hepatic insufﬁciency and death. Preop-
erative BD of the FLR appears to improve outcome if the
predicted FLR is < 30%. However in patients with FLR
‡ 30%, preoperative BD and PVE do not appear to
improve perioperative outcome.
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Elevated CA 19-9 portends poor prognosis
despite surgical resection of biliary malignancies
I. HATZARAS, MD, C. R. SCHMIDT, MD,
P. MUSCARELLA, MD, W. S. MELVIN, MD,
E. C. ELLISON, MD and M. BLOOMSTON, MD
Ohio State University, Columbus, OH, USA
Background: Biliary tree malignancies are aggressive
cancers with a high disease-speciﬁc mortality despite
resection. We sought to evaluate our experience and
identify predictors of survival following resection.
Methods: We reviewed the records of all patients
that underwent radical resection of biliary tree malig-
nancy including extrahepatic, intrahepatic cholangio-
carcinomas and gallbladder cancers. Demographics,
treatment and outcome data were collected and
compared by tumor location. Kaplan–Meier survival
curves were created and compared by log-rank analysis.
Multivariate analysis was undertaken using Cox
proportional hazards.
Results: Ninety-one patients with biliary malignancies
underwent surgical resection between 1992 and 2007.
There were 46 extrahepatic cholangiocarcinomas,
23 intrahepatic cholangiocarcinomas, and 22 gall-
bladder cancers. All 3 groups were similar in terms of
age, gender, preopertive CA 19-9 level, completeness of
resection and tumor histology (Table 1). Gallbladder
cancer histology correlated with the shortest median
survival (14.3 months) followed by extrahepatic
cholangiocarcinoma (24.8) and intrahepatic cholangio-
carcinoma (30.4) however this did not meet statistical
signiﬁcance (P = 0.971). Only elevated preoperative
CA 19-9 level (> 35 U mL-1) was predictive of poor
median survival by univariate (P = 0.003, ﬁgure)
and multivariate analysis (15.1 months vs. 67.4,
P = 0.047).
Conclusions: While location (i.e. intrahepatic or extra-
hepatic) of Cholangiocarcinoma is often considered
predictive of survival, we did not ﬁnd a difference in
biologic behavior based upon location or histology.
Only high preoperative CA 19-9 levels predicted poor
survival, thus should be routinely measured prior to
resection.
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Identiﬁcation of intraductal papillary mucinous
neoplasm in resected biliary tract lesions
J. G. BARTON, MD, D. BARRETT, MD,
M. MARICEVICH, MD, C. WOOD, MS, T. SMYRK,
MD, D. NAGORNEY, MD, T. BARON, MD and
F. QUE, MD
Mayo Clinic, Rochester, MN, USA
Background: The pathologic similarities between mucin
secreting cholangiocarcinoma and intraductal papillary
mucinous neoplasm (IPMN) of the pancreas have been
reported with increasing frequency. Despite this, bile
duct IPMN (BD–IPMN) is not recognized currently as a
unique medical disease. Our aim was to review the
presence of BD–IPMN in a large series of resected biliary
neoplasms.
Methods: BD–IPMN cases from January 1996 to Octo-
ber 2006 were identiﬁed by reviewing pathology speci-
mens of all resected cholangiocarcinomas, and
additionally by reviewing liver or bile duct lesions other
than cholangiocarcinoma when cystic, papillary, or
mucinous features were cited in pathology reports.
Diagnostic information, presenting symptoms, operative
details, and survival were analyzed via review of medical
records. Follow-up and survival were analyzed by Kap-
lan–Meier techniques.
Results: BD–IPMN was identiﬁed in 23 of 253 specimens
reviewed (48% men; median age = 68 years; range
31–81 years). Symptoms were present for a median of
30 days prior to diagnosis (range 3 days to 7 years).
Presenting symptoms included abdominal discomfort in
15 patients (65%), jaundice in 9 (39%), and weight loss
in 8 (35%). Preoperative biopsies were performed in
14 patients. None of the original preoperative pathology
reports used the term IPMN; 4 (29%) used the terms
cystic, mucinous, and/or papillary. Only one of the
original pathology reports of the surgical resection
specimens used the term IPMN; 13 (57%) used the terms
cystic, mucinous, and/or papillary. BD-IPMN was
located only in the extra-hepatic bile ducts in 12 (52%),
only in the intra-hepatic bile ducts in 6 (26%), and in
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both intra and extra-hepatic bile ducts in 5 (22%). Pan-
creatoduodenectomy was performed in six, combined
major hepatic resection and extra-hepatic duct resection
in six, radical common bile duct resection in four, hepatic
lobectomy in four, segmentectomy in one, cholecystec-
tomy in one, and hepatic duct excision in one. Carcinoma
was found in association with BD-IPMN in 18 patients
(78%) with a median follow-up of 5.5 years (range
1 month to 9.2 years). Of the patients with conﬁrmed
carcinoma, the median survival was 2.8 years; 5-year
survival was 40% (95% CI 21-76%).
Conclusion: BD–IPMN occurs throughout the intra
and extra-hepatic biliary system, and with an under-
standing of recent trends in pathology, is identiﬁed
readily. BD-IPMN is found typically in association
with carcinoma, but like its pancreatic counterpart,
can occur as a benign lesion. Broader acceptance of
BD-IPMN as a unique medical disease may lead to a
better understanding of the pathogenesis of biliary
malignancies.
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Iatrogenic bile ductinjury with loss of conﬂu-
ence: a surgical challenge
M. A. MERCADO, MD, N. SANCHEZ, MD, J. C.
ARRIOLA, MD, M. URENCIO, MD, S. SANCHEZ-
LEENHEER, MD and I. DOMINGUEZ, MD
Instituto Nacional de la Nutricio´n Salvador Zubira´n,
Mexico City, Mexico
Background: One of most feared type of injury is that
that involves the conﬂuence (Bismuth IV, Strasberg E-4).
The injury that produces two separated right and left
ducts is of multifactorial ethiology, and the result of
ischemic or thermal damage, an inﬂammatory reaction,
as well as anatomical variants. The treatment options are
several, mainly surgical. We here in describe our experi-
ence with this type of injury.
Methods: In an 18 year period, among 510 patients
referred to our hospital for surgical treatment of complex
bile duct injuries, 39 presented involvement of the hilar
conﬂuence. Imagenological studies, mainly MRI showed
a loss of conﬂuence. The ﬁles of these patients were
analyzed and general data was recorded, including type
of operation and postoperative outcome with emphasis
on postoperative cholangitis, liver function test and
quality of life.
Results: Patients were divided in ﬁve groups: GI
(n = 16): Construction of neoconﬂuence + Roux en Y
hepatojejunostomy. GII (n = 13): Roux en Y portoent-
erostomy. GIII (n = 6): Double (right and left) Roux en
Y hepatojejunostomy. GIV (n = 2): Major + Roux en
Y hepatojejunostomy. G-V (n = 2): Associated right
posterior injury: portoenterostomy. Postoperative out-
come for each of these groups is as follows: GI: 1 cho-
langitis, treated medically, one lost, 14 asymptomatic.
GII: one cholangitis, one death (40th post-op, month due
to liver failure). GIII: one cholangitis, one liver trans-
plant. GIV: Asymptomatic. GV: one cholangitis, one
asymptomatic. In all patients the outcome was four cases
of cholangitis, one death, two lost to follow-up, one liver
transplant, 32 asymptomatic.
Discussion: Loss of conﬂuence represents a surgical chal-
lenge. There are several treatment options at different
stages. Roux en Y bilioenteric anastomosis (neoconﬂu-
ence, double anastomosis, portoenterostomy, associated
major hepatectomy), is the treatment of choice, but liver
transplantation should also be considered.
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Helicobacter spp. in gallbladder tissue of
patients with symptomatic gallbladder disease
S. SABBAGHIAN, MD, J. RANAUDO, MD,
L. ZENG, MD, A. ALONGI, B.SC., G. PEREZ-
PEREZ, SCD and P. SHAMAMIAN, MD
New York University School of Medicine, New York, NY,
USA
Purpose: Evidence suggests that chronic gallbladder
disease may be associated with gastroesophageal reﬂux
disease and gastritis. Since these processes are chronic
inﬂammatory disorders of the upper gastrointestinal
tract, we questioned if bacteria such as Helicobacter spp
might play a role. We attempted to assess for the pres-
ence of Helicobacter spp. in bile, gallstones, and gall-
bladder tissue from patients with symptomatic
gallbladder disease.
Methods: From February, 2008, to May, 2008, at New
York University Medical Center, twenty nine patients
(mean age = 50 years, 13 female, 16 male) scheduled for
elective cholecystectomy for benign gallbladder disease
were recruited after obtaining written informed consent.
Immediately after gallbladder removal, bile, gallstones if
present, and gallbladder tissue were collected in sterile
manner and stored whole and unprocessed at -80C.
DNA was isolated from bile using the Qiamp DNA
Stool Minikit (Qiagen Valencia, CA, USA); from
gallstones and tissue, the DNeasy Blood and Tissue
Kit (Qiagen) was used. DNA was ampliﬁed via PCR
technique using primers speciﬁc for 16sRNA gene of
Helicobacter spp. Products were analyzed with agarose
gel electrophoresis. Genewiz was used for product
sequencing, and results were aligned using Sequencher
program with Clustal X program. For plasma analysis,
10 mL of blood was collected preoperatively. The resul-
tant plasma was used to assess the immune response to
H. pylori by enzyme linked immunosorbence assay
(ELISA) analysis.
Results: Of 29 patients with benign gallbladder disease
recruited, three did not have gallstones for analysis. Zero
of 29 (0%) bile samples and zero of 26 (0%) gallstone
samples were positive for Helicobacter spp. Five of 29
(17.2%) tissue samples were positive forHelicobacter spp.
Two of these ﬁve samples were sent to Genewiz for
product sequencing and aligned with Sequencher pro-
gram, revealing Helicobacter genus signal. Using Clustal
X program for sequence comparison, the products were
found to be nearly identical. Lastly, ELISA technique
was used to analyze plasma of these two patients for the
presence of Helicobacter pylori, and only one of the two
patients’ plasma demonstrated antibodies reactive to this
single bacterial species.
Conclusions: Helicobacter spp, not necessarily H. pylori,
may play a signiﬁcant role in the development of benign,
symptomatic gallbladder disease. This is clinically
important as people who have colonization/infection of
their gallbladder with this/these organism(s) might ben-
eﬁt from antibiotic treatment instead of surgery.
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What is the beneﬁt of radical resection for T1b
gallbladder cancer: a decision analysis
M. A. ABRAMSON, MD, D. RUAN, MD and
E. E. WHANG, MD
Brigham and Women’s Hospital, Boston, MA, USA
Background: Gallbladder cancer is the ﬁfth most com-
mon gastrointestinal malignancy. Radical surgery
(including liver resection and regional lymphadenectomy)
is applied for some gallbladder cancers, but the beneﬁts
of these procedures are unproven. In particular, for
patients with T1b cancers on cholecystectomy specimens,
the utility of radical surgery remains debated.
Methods: Using published data collected from a sys-
tematic Medline search, we carried out formal decision
analysis in order to compare two management strategies
for patients discovered to have T1b gallbladder cancer at
cholecystectomy: Group 1 underwent no further surgical
therapy while Group 2 underwent additional radical
surgery. The primary outcome of interest for this study
was 5-year survival. Sensitivity analyses were conducted
for variables in which weighted means were calculated
from the literature.
Results: Seventeen studies (114 patients) and eight stud-
ies (28 patients) were included in the analyses for Groups
1 and 2, respectively. Weighted 5-year survival rates were
65% (range: 0–100%) and 93% (range: 0–100%) for
Groups 1 and 2, respectively. Perioperative mortality for
those patients undergoing radical resection was calcu-
lated from 31 studies (981 patients), yielding a weighted
mean of 2.5% (range: 0–10%). Overall decision analysis
favored additional radical resection over no further sur-
gical resection for this patient subset. Sensitivity analysis
demonstrated that this decision is contingent on the
perioperative mortality rate.
Conclusions: Data available for the subset of patients
with T1b gallbladder cancer suggest a potential survival
beneﬁt for further radical resection.
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Epidemiologic differences on presentation of
gallbladder cancer between a high-risk (Temuco,
Chile) and a low-risk population (Georgia,
USA); not all cancers are created equal
H. LOSADA, MD, M. MUNOZ, MD,
G. VELASQUEZ, MD, A. PAGE, MD, J. CARLOS
ROA, MD, D. KOOBY, MD, J. GALLOWAY, MD,
C. STALEY, MD, V. ADSAY, MD and
J. M. SARMIENTO, MD
Universidad de la Frontera, Temuco, Chile; Emory
University, Atlanta, GA, USA
Introduction: The presentation of Gallbladder cancer
(GBCA) differs among world regions; the south of Chile
is likely the location with the highest incidence world-
wide. This being likely enviromentally related, there is no
clear comparison with less prevalent regions, including
USA.
Methods: All patients presenting with the diagnosis of
GBCA in a period between 2000 and 2007 were entered
in the database. Same variables were used and compared
for two academic institutions, one in the south of Chile
(Ch) and one in the Southern region of the USA (US).
Results: Four hundred and sixty patients were identiﬁed;
436 (95%) belong to Ch. The demographic data is shown
in the Table 1. In general, the histologic features were
more favorable in Ch, having an earlier stage at presen-
tation and less invasive tumors. Lithiasis is not always
constant in US.
Conclusions: There are drastic differences in the presen-
tation of GBCA in prevalent (Ch) and low incidence
(US) regions. With a surveillance program, GBCA is
discovered earlier. In addition, the histologic markers for
aggressiveness are less pronounced on tumors with a
higher incidence of GBCA (degree of differentiation,
perivascular -, perineural -, lymphatic invasion). Proba-
bly more sophisticated studies are necessary to elucidate
the different behavior in these two populations.
Table 1. Demographic data.
Variable Ch(n = 436) US(n = 24)
Gender (male) 74 (17%) 7 (29%)
Age (mean–SD) 62 (13) year 64 (11)
Lithiasis (present) 431 (99%) 19 (79%)
Early T (0-1B) 126 (29%) 5 (20%)
Degree of diff. (well-mod) 308 (71%) 11 (46%)
Perivasc invasion (absence) 383 (88%) 10 (42%)
Perineural inﬁlt. (absence) 403 (92%) 4 (17%)
Lymphatic invas (absence) 391 (90%) 10 (42%)
Nodal mets (-) 331 (76%) 12 (50%)
Preop dx unsuspected 402 (92%) 15 (63%)
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The role of pet-ct in patients with incidental
gallbladder cancer
J. M. BUTTE, MD, F. REDONDO, MD, E. WAUGH,
MD, M. MENESES, MD, R. PRUZZO, MD,
H. PARADA, MD, H. AMARAL, MD and
H. A. DE LA FUENTE, MD
Fundacion Arturo Lopez Perez Cancer Center, Santiago,
Chile
Introduction: Incidental gallbladder cancer (IGC) after a
cholecystectomy requires adequate imaging studies to
determine the actual extent of the disease to properly
tailor subsequent treatment. The aim of this study was to
evaluate the utility of PET–CT to provide optimal pre-
treatment staging in patients with ICG.
Material and methods: Between January 2006 and
August 2008, all patients with IGC and at least muscular
layer invasion were studied with 18FDG PET-CT. The
exam was considered positive when the standardized
uptake values (SUV) were ‡ 2.5. In all instances patients
were offered to undergo deﬁnitive exploration and pos-
sible resection. Final pathologic ﬁndings were reported
(ﬁnal pathology report = FPR).
Results: The series included 32 patients, 26 women and 6
men, with a mean age of 58 years (range 30–81 years).
The exam was performed on average 10 weeks after
cholecystectomy (range 2–52 weeks). PET-CT was neg-
ative in 13 patients and positive in 19 patients: nine with
localized potentially resectable disease (PRD) and in 10
with disseminated disease. Of the 13 patients with
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negative exam, nine refused surgery and four underwent
formal exploration: three patients were resected with no
disease identiﬁed in the FPR and one was not resected
due to carcinomatosis. Of the nine with PRD, four
patients refused reoperation and ﬁve underwent explo-
ration: three were resected with residual disease noted in
the FPR and two did not undergo resection due to dis-
semination. Two patients with disseminated disease were
reoperated and in both instances disseminated disease
was conﬁrmed. For the entire group, the median survival
and the 2 years overall survival (OS) was 20.3 months
and 45%, respectively. Fifteen months OS was 90% for
negative ﬁndings, 67% for localized potentially resectable
disease and 0% for disseminated disease found in
CT–PET (P < 0.003).
Conclusions: PET–CT ﬁnding is a useful prognostic
factor in IGC. PET-CT might be a helpful tool for
selection patients for potentially curative treatment.
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HPB NSQIP: potential for quality
improvement, registries, and clinical trials
H. A. PITT, MD, M. KILBANE, RN, BSN,
N. J. ZYROMSKI, MD, T. A. ALOIA, MD,
J. M. HENDERSON, MD and S. J. MULVIHILL, MD
Indiana University, Indianapolis, IN, USA; The Methodist
Hospital, Houston, TX, USA; Cleveland Clinic, Cleveland,
OH, USA; University of Utah, Salt Lake City, UT, USA
Background: The American College of Surgeons –
National Surgical Quality Improvement Program (ACS-
NSQIP) was started in 2004. In the ﬁrst 2 years, 37
hospitals were participating, and data had been accum-
lated on over 30 000 operations. By June, 2008, ACS-
NSQIP had 173 hospitals with reliable data on over
200 000 operations. Presently, 60% of the hospitals
participating in ACS-NSQIP are academic/teaching
hospitals. In addition to general and vascular surgery,
ACS-NSQIP has developed multispecialty, bariatric and
pediatric surgery options. Recently, ACS-NSQIP made
risk-adjusted data available for use by participating
hospitals. Therefore, the aim of this analysis was to
explore the ACS-NSQIP database for utility in hepato-
pancreato-biliary (HPB) surgery.
Methods: The ACS-NSQIP Participant Use File was
queried for patient demographics and outcomes for 18
major HPB operations from January 1 through Decem-
ber 31, 2007. The procedures included four hepatic and
six pancreatic resective as well as eight complex biliary
operations.
Results: During this 12-month period, data were
accumlated on 4204 patients undergoing major HPB
surgery. The operations included 1285 hepatic resections
(31%), 2482 pancreatic resections (59%), and 437 com-
plex biliary procedures (10%) with the majority being
performed at academic/teaching hospitals. Patients
undergoing hepatic resections were more likely to have
metastatic disease (42%) and recent chemotherapy (7%)
whereas those having complex biliary procedures were
most likely to have diabetes (13%), ascites (5%) and
signiﬁcant weight loss (20%). Thirty-day (30d) morbidity
and mortality as well as risk-adjusted morbidity and
mortality (Observed/Expected=Index) are shown in the
Table 1.
Conclusions: These data suggest that major HPB opera-
tions being performed at ACS-NSQIP hospitals have
acceptable morbidity and mortality rates. We conclude
that creation of an HPB NSQIP has the potential to
further improve quality, provide risk-adjusted registries
and facilitate multi-institutional clinical trials.
Table 1. Observed/expected data.
Outcomes Hepatic Pancreatic Biliary HPB
30-day morbidity 24% 35% 30% 34%
Morbidity index 0.69 1.04 0.79 0.91
30-day mortality 1.9% 2.8% 3.0% 2.5%
Mortality index 0.79 1.08 0.75 0.96
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Clinical factors predictive of malignant and
premalignant cystic neoplasms of the pancreas
N. B. JONES, MD, E. C. ELLISON, MD,
W. S. MELVIN, MD, P. MUSCARELLA, MD and
M. BLOOMSTON, MD
The Ohio State University, Columbus, OH, USA
Background: As cystic neoplasms of the pancreas con-
tinue to be more commonly found with advanced imag-
ing techniques, pancreatic surgeons often struggle with
identifying who is at risk of having or developing pan-
creatic cancer. The utility of endoscopic ultrasound
(EUS) with ﬁne needle aspiration and cyst ﬂuid analysis
has been well documented, but preoperative diagnosis of
cystic lesions of the pancreas remains unreliable. As such,
we sought to review our experience with the surgical
management of cystic neoplasms of the pancreas to
determine preoperative clinical indicators of malignancy
or premalignant (i.e. mucinous) lesions.
Methods: Between 1996 and 2007, 114 consecutive
patients with cystic neoplasms of the pancreas underwent
pancreatectomy. Invasive adenocarcinoma was identiﬁed
in 35 while 79 had benign lesions. Mucinous lesions were
considered premalignant and consisted of 29 intraductal
papillary mucinous neoplasms (IPMN) and 17 mucinous
cystic neoplasms (MCN). The remaining 33 benign
lesions were serous microcystic adenomas. Clinicopath-
ologic characteristics were reviewed and compared using
Student’s T and Fisher’s Exact tests.
Results: Patients found to have pancreatic cancer arising
from a cystic neoplasm were signiﬁcantly older than
those with benign cysts but with a similar gender distri-
bution (Table 1). Benign cysts were more commonly
asymptomatic, less likely to have an elevated CA19-9,
more commonly located in the left pancreas, and tended
to be smaller than those with associated malignancy
(Table 1). Premalignant (i.e. mucinous) cysts more
commonly presented with symptoms and elevated
CA19-9 than those without malignant potential (i.e.
serous) (Table 1). At a median follow-up of 33 months,
three (7%) mucinous tumors recurred while no serous
neoplasms recurred (p=NS).
Conclusions: Based upon our modern single institution
experience with resection of cystic neoplasms of the
pancreas, we advocate an aggressive surgical approach to
any patient presenting with a symptomatic cyst or ele-
vated CA19-9, particularly in an older patient and in the
head of the pancreas. Resection for small asymptomatic
cysts located in the left pancreas in younger patients can
be undertaken on a selective basis.
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Escalating computed tomography angiogram
(CTA) grade predicts unresectability and positive
margins for pancreaticobiliary neoplasms
T. S. KENT, MD, A. BROWN, MD, M. P. CALLERY,
MD, V. D. RAPTOPOULOS, MD and
C. M. VOLLMER, MD
Beth Israel Deaconess Medical Center, Boston, MA, USA
Background: The CTA grading system of pancreaticob-
iliary cancers was conceived to predict resectability based
on tumor involvement of critical vasculature. As this has
not yet been rigorously assessed clinically, our goal was
to examine the relationship between CTA grade and
resectability, as well as margin status and other surgical
outcomes, in pancreas resections.
Methods: 370 patients with presumed pancreaticobiliary
malignancyandapancreasprotocolCTAatour institution
underwent attempted curative resection from 10/01 to
08/07. The relationship between radiographic resectability,
according to the 5-point Raptopoulos scale, and actual
resectability,margin status, andothermetricswasassessed.
Results: Overall, 271 patients (73.2%) were resectable.
11% of these had benign ﬁnal pathology. As CT grade
worsened, unresectable cases increased, from 16.6% of
Grade 0 cases, to 79.3% of Grade 3 cases, P < 0.00001
(Figure). Five Grade 4 cases underwent laparotomy for
palliative purposes and were all conﬁrmed to be unresec-
table by vascular invasion, as anticipated preop. Of unre-
sectable Grade 0 cases, 72% were excluded from resection
by peritoneal/ liver metastases/nodes not recognized on
CT, but surprisingly, 28% were due to vascular involve-
ment. For Grade 2 and 3 cases which are potentially
resectable radiographically, 30/48Grade 2 (62.5%) and23/
29 Grade 3 (79.3%) were unresectable – most often due to
vascular involvement (67% and 61%, respectively). The
241 patients with either malignant or premalignant diag-
noses were considered for margin analysis. 72.3%were R0
resections. The positive margin (R1/R2) rate did not differ
appreciably amongGrades 0-2,butwas signiﬁcantly higher
(83%, P = 0.004) for Grade 3 (Fig). The rate of multiple
positive margins differed signiﬁcantly between grades
0–1 and 2–3 (14.3% vs. 50%, p=.01). Among resectable
cases, surrogates of operative difﬁculty (EBL, transfusion,
operative time) did not differ signiﬁcantly by CT grade.
Conclusions: Escalating CTA grade accurately predicts
unresectability. In resectable cases, positive margins are
regularly encountered, even at lower CT grades (20–37%),
and almost always with Grade three lesions. These ﬁnd-
ings suggest that attempted surgical resection has limited
efﬁcacy with advanced presentations as graded by CTA.
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Neoadjuvant therapy may lead to successful
surgical resection and improved survival in
patients with borderline resectable pancreas
cancer
R. J. MCCLAINE, MD, A. M. LOWY, MD,
J. J. SUSSMAN, MD, F. AHMED, MD,
N. SCHMULEWITZ, MD, D. GRISELL, MD,
M. J. EDWARDS, MD and S. A. AHMAD, MD
University of Cincinnati, Cincinnati, OH, USA
Background: Borderline resectable pancreatic cancers are
tumors that are technically amenable to surgical resection
but may be associated with increased risks of locore-
gional recurrence. Patients with borderline resectable
tumors are usually treated with neoadjuvant therapy in
an attempt to improve margin negative resection rates. It
is not clear how effective this strategy is and whether it is
associated with long-term survival.
Objective: This study aims to retrospectively review our
institutional experience with patients demonstrating
borderline resectable pancreatic cancer.
Methods: Pancreas cancer databases from the past
5 years were retrospectively reviewed. The diagnosis of
borderline resectable disease was based upon the pres-
ence of 1 of 4 criteria on abdominal CT or endoscopic
ultrasound: short segment occlusion of the superior
mesenteric vein (SMV) and/or portal vein (PV), short
segment involvement of the hepatic artery (HA), superior
mesenteric artery (SMA) involvement of < 180 degrees,
or SMV involvement of > 180 degrees.
Results: Twenty-eight patients were identiﬁed for inclu-
sion in the study. Of the included patients, 24 underwent
a full course of neoadjuvant therapy. Eleven (46%)
underwent surgical resection, and 13 either had tumor
progression or were deemed unresectable at laparotomy.
The anatomic tumor characteristics did not differ
Table 1 for abstract 42. Characteristics of patients undergoing pancreatectomy for cystic lesions of pancreas.
Benign Malignant
All Serous Mucinous P (vs. serous) P (vs. benign)
N 79 33 46 35
Age 59 (24–84) 59 (38–83) 59 (24–83) NS 68 (36–84) 0.03
Female 68% 79% 61% NS 57% NS
Asymptomatic 25% 42% 6% 0.0002 6% 0.02
Elevated CA 19-9 24% 0% 27% 0.03 67% 0.002
Head of pancreas
location
31% 24% 35% NS 71% < 0.0001
Size 3.5 (0.6-15) 3.5 (1-8.5) 3.6 (0.6-15) NS 4.5 (2-18.5) 0.04
G0
0
20
40
60
80
100
Percentage of unresectable and margin
positive cases, by CT grade
G1 G2 G3 G4
Unresectable
Margin positive
Figure 1.
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between groups. The most common systemic chemo-
therapy regimens were gemcitabine alone (36%), gem-
citabine and Tarceva (27%), and gemcitabine with
Tarceva and oxaliplatin (18%). In addition, 50% of
patients received neoadjuvant chemoradiation, given
only if patients did not respond to the initial chemo-
therapy regimen. Forty-one percent of patients (n = 9)
underwent resection following chemotherapy alone, with
an additional 9% (n = 2) undergoing resection after
subsequent chemoradiation. Of those undergoing surgery
(n = 11), 63% had margin-negative (R0) resection and
45% required venous resection and reconstruction.
Median survival was 14.1 ± 2.6 months for unresected
patients and 23.3 ± 9.0 months for those undergoing
resection.
Conclusion: Patients with borderline resectable pancre-
atic cancer can be successfully treated with neoadjuvant
therapy, resulting in margin negative resection, associ-
ated with long-term survival. Further prospective studies
are needed to further study this subset of patients.
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Multimodal therapy for treatment of hepato-
cellular carcinoma: A ten-year survival analysis.
A. SCHUMACHER, MD, J. POWELL, MD,
A. BUCZKOWSKI, MD, C. SCUDAMORE, MD,
S. HO, MD and S. CHUNG, MD, PHD
University of British Columbia, Vancouver, BC, Canada;
Royal Inﬁrmary of Edinburgh, Edinburgh, UK
Introduction: There are multiple treatment options for
hepatocellular carcinoma (HCC) including resection,
radiofrequency ablation (RFA), ethanol injection (EI),
chemotherapy (CTx), transarterial chemoembolization
(TACE), liver transplantation (OLT) or observation
(obs). This study was performed to evaluate the survival
beneﬁt of multimodal therapy for HCC.
Methods: A retrospective review was conducted on 251
consecutive patients treated for HCC between 1996 and
2006 at Vancouver General Hospital (VGH) and the BC
Cancer Agency (BCCA). There was a complete data set
available on 247/251 patients. Data were retrieved from
clinical charts and Information Systems from VGH and
BCCA. All patients underwent primary treatment by
resection, RFA, EI, CTx, or TACE. A subset of patients
with persistent or recurrent disease underwent salvage
therapy.
Results: Mean overall survival was 76.8 months. Poor
survival was associated with symptoms at diagnosis,
chronic HCV vs. HBV infection, lack of antiviral therapy
in early TNM stage HBV/HCV patients, portal venous
thrombosis, poor Child-Pugh status, and higher TNM
stage (all P < 0.001). Among primary treatment modali-
ties, survival was comparable for resection, RFA, and EI;
with signiﬁcantly shorter survival for CTx, TACE, or
observation.Among salvage treatmentmodalities,RFAof
dominant lesions was associated with improved survival.
Conclusions: These results underscore the value of early
detection of HCC in at-risk patients. The data suggest
that patients may be stratiﬁed based on tumor stage and
underlying liver function to curative intent or disease
control strategies to optimize survival and minimize risk.
Multimodal therapy may also delay or obviate the need
for OLT.
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Results of total pancreatectomy: a single center
experience
J. STAUFFER, MD, C. DAN SMITH, MD,
J. K. MARTIN, MD and J. NGUYEN, MD
Mayo Clinic, Jacksonville, FL, USA
Introduction: Total pancreatectomy (TP) is associated
with major metabolic abnormalities resulting in difﬁcul-
ties in glucose control and malabsorption, leading to
multiple medical problems and decreased quality of life.
However, with the availability of modern pancreatic
enzyme formulations and improvements in control of
diabetes mellitus, the metabolic drawbacks of TP have
diminished. As indications for TP have increased, we
have examined our results of patients undergoing TP.
Methods: A retrospective chart review of 47 patients
undergoing TP from 1/02 to 1/08 was performed. Patient
demographics, perioperative morbidity and mortality,
and long term follow up was obtained.
Results: In this 6-year period, TP was performed on
15 males and 23 females with a mean age of 67.3 years.
Indications were pancreatic adenocarcinoma (18), IPMN
(18), other neoplasm (7), and benign (4). The mean BMI
was 25.5 and most common symptoms were abdominal
pain, weight loss, and new onset diabetes. 23 were per-
formed with pylorus preserving technique and nine in-
volved venous resection. Mean blood loss was 1150 mL
and operative time was 390 mins. Mean units of blood
transfused intraoperatively were 3.3 units and 4.3 units
for the whole hospital stay. Mean ICU stay was
1.68 days and total length of stay was 13 days. Most
patients were maintained on an insulin drip for a mean of
5.1 days postop. Parenteral nutrition was needed in 5.
Medical complications resulting in prolonged hospital-
ization occurred in 14 and surgical complications
occurred in 4. Reoperation within 30 days was needed in
two patients and postoperative inpatient mortality was
0%. Most were discharged with a combination of long
acting and sliding scale insulin and average units of long
acting insulin preparation was 13.7 at discharge. Mean
follow up was 22 months. 14 patients required hospital-
ization within 3 months of discharge resulting in 1 death.
Mean weight loss at 3, 6, and 12 months was 5.0, 7.7, and
9.7 kg respectively from preoperative weight. Mean
HbA1C at 6 months, 12 months, and 24 months was
7.1%, 7.2%, and 7.6% respectively. Survival varied
based on underlying disease process.
Discussion: TP results in signiﬁcant metabolic derange-
ments which require multidisciplinary management for
Table 1 for abstract 45. Survival (months).
Symptoms
PV
thrombosis Child-pugh TNM stage Primary treatment
No Yes No Yes A B + C I + II III + IV Resect RFA EI CTx TACE Obs
92.1 30.7 80.6 20.3 82.8 25.5 76.2 35.4 93.2 66.2 80.1 24.9 47.4 31.4
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improved outcomes. Diabetic control and weight main-
tenance remain a challenge. Intensive diabetic and
nutritional counseling combined with advanced insulin
delivery systems, pancreatic exocrine formulations, and
vitamin supplementations are essential. Readmission
rates are high and a closer look must be taken at pro-
longing hospitalization and providing additional nutri-
tion for these patients. However, the risks of TP appear
acceptable compared to the beneﬁts of resection.
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Predicting poor outcome following hepatectomy:
analysis of 2313 hepatectomies in the NSQIP
database
T. A. ALOIA, MD, B. N. FAHY, C. P. FISCHER, MD,
S. L. JONES, MD, A. DUCHINI, MD, J. GALATI,
MD, A. O. GABER, MD, B. L. BASS, MD and
R. M. GHOBRIAL, MD, PHD
The Methodist Hospital, Houston, TX, USA
Background: For the past two decades multiple series
have documented that liver resection has become safer.
The purpose of this study was to determine the current
status of hepatic resection in the US by analyzing the
multi-institutional experience within the National Surgi-
cal Quality Improvement Program (NSQIP) dataset.
Methods: Of the 363 897 cases in the 2005–2007 NSQIP
Participant Use File, 2313 elective open hepatectomy
cases were identiﬁed (1344 partial, 230 left, 510 right and
229 extended hepatectomies). 36 perioperative risk fac-
tors and 52 postoperative complications were compared.
To determine the applicability of NSQIP general risk
models to hepatic surgery, the prognostic value of stan-
dard multivariate analysis was compared to the novel
NSQIP aggregate risk index (morbprob).
Results: The median age of pts contained in the database
was 60 years, the sex distribution was equivalent, and
78% were Caucasian. With regard to preoperative risk
factors, 65% of pts had an ASA score of 3 or 4. The most
prevalent comorbidity was hypertension (46%). 41% of
pts underwent hepatectomy for disseminated cancer,
19% of whom had received chemotherapy within 30 days
of surgery. The overall 30-day mortality rate was 2.5%
(57/2313) and the 30-day major morbidity (MM) rate
was 19.6% (453/2313). Multivariate analysis identiﬁed
six independent preoperative risk factors for MM
(Table 1). Operative factors associated with MM
included operative time, intraoperative red blood cell
transfusion, and early postoperative transfusion
(Table 1). A 75th percentile morbprob (0.40) was associ-
ated with a major complication PPV of 30.4%, NPV of
85.5%, sensitivity of 49.8% and speciﬁcity of 72.3%. For
those pts who developed MM, the median length of stay
was longer (10 vs. 6 days, P = 0.001) and the mortality
rate was higher (0.3% vs. 11.3%, P = 0.001).
Conclusions: Analysis of the NSQIP experience with
hepatectomy indicates that the current mortality and
major morbidity rate benchmarks are 2.5% and 18%,
respectively. Poor outcomes were not associated with age
or body mass index, and were most dependent on
nutritional status, liver function, and the extent of hep-
atectomy. The NSQIP morbprob value was a relatively
poor predictor of observed morbidity, indicating the need
for specialty-speciﬁc NSQIP modeling.
Table 1. Multivariate analysis-NSQIP hepatectomy.
Strata Risk factor
MV
P-value
Odds
ratio
Preop Elevated alk phos 0.0001 4.9
Low albumin 0.006 2.8
Elevated PTT 0.047 2.0
Extended resection 0.0001 1.8
Smoking 0.0001 1.7
ASA 3/4 0.001 1.4
Periop Intraop transfusion 0.0001 2.2
Prolonged OR time 0.011 1.6
Early postop
transfusion
0.001 1.4
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Validation of the meld based objective scoring
system (moss): unresectable hepatocellular
carcinoma in patients with cirrhosis
S. H. TEH, C. HAMMILL, MD, L. WONG, MD,
B. SHEPPARD, MD, J. SCHWARTZ, MD, K. JOHN,
MD, K. KOLBECK, MD, S. CHA, PHD and
S. ORLOFF, MD
Sacred Heart Medical Center, Eugene, OR, USA;
University of Hawaii, Honolulu, HI, USA; Oregon Health
Sciences University, Portland, OR, USA; Mayo Clinic,
Rochester, MN, USA
Introduction: The novel MELD-based objective scoring
system (MOSS) was recently shown to be accurate in
stratifying survival in patients with hepatocellular carci-
noma (HCC) and cirrhosis undergoing non-liver trans-
plant modalities. The primary aim of this study is to
validate the predictive value of MOSS in patients with
cirrhosis and unresectable HCC.
Methods: A survival analysis of 251 patients with HCC
and cirrhosis diagnosed between 2004 and 2008 at two
university-based institutions was performed. There were
152 patients in the no-therapy group and 99 patients in
the transarterial chemoembolization (TACE) group.
Results: There were 64 females and 187males with amean
age of 59 years. ThemeanMELD score and tumor size for
the no-therapy group and the TACE group were (12.6 vs.
10) and (5.9 cm vs. 5.4 cm), respectively. The median
survival for the no-therapy group was 4.8 months and for
the TACE group 15.7 months (P < 0.0001). In the mul-
tivariable analysis independent prognostic factors that
predict long-term survival were tumor size (P = 0.047,
HR 1.476), vascular invasion (P = 0.021, HR 1.669), T-
stage (P = 0.005, HR 1.331), MOSS Class (P < 0.001,
HR 1.901). The overall median survival according to the
MOSS Class I, II, III and IV were 21, 8.7, 5.2 and
0.2 months respectively (P < 0.0001). Table 1 demon-
strates the median survival for the no-therapy and TACE
groups according to their MOSS Class I, II, III and IV.
Conclusions: MOSS class, an objective clinical scoring
system that combines MELD and tumor characteristics,
accurately stratiﬁes outcomes in cirrhotic patients with
unresectable HCC. Once externally validated, the MOSS
classiﬁcation scheme can be used clinically to guide
decisions regarding non-transplant treatment modalities.
In addition, the objectivity of this scoring system will
afford its use as a common platform for international
data sharing and comparison and to design clinical trials
of novel treatments.
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Interpreting three-dimensional structures from
two-dimensional images: a web-based interactive
3D model of the liver to enhance surgical
residents’ spatial understanding of structural
inter-relationships
J. CROSSINGHAM, B.SC., J. JENKINSON,
N. WOOLRIDGE, S. GALLINGER, MD and
C. -A. MOULTON, MD
Toronto General Hospital, Toronto, ON, Canada;
University of Toronto, Toronto, ON, Canada
Background: Learning intra-hepatic anatomy and
developing an understanding of the relationships that
exist between the key structures is a difﬁcult process that
is required of surgical residents. They need to mentally
reconstruct 3D images from available CT scans and this
may not be an effective way of understanding the liver. A
web-based interactive 3D model of the liver was created
to facilitate understanding of the complex spatial anat-
omy of the liver and to help visualize this anatomy in 3D
when viewing CT scans.
Methods: By importing CT scans into Osirix, 3D surface
renderings of the liver were obtained. Using these images
as reference, anatomical structures were modeled in
Cinema4D. This included the liver surface and the intra-
hepatic structures; portal veins, hepatic veins, hepatic
arteries and the biliary system. Interactivity was created
in Flash.
Implications: Users can view common liver anatomy and
common variations online in interactive 3D rotational
model to observe the complex interactions of the vascular
and biliary systems. This model will be useful for surgical
trainees learn the difﬁcult and complicated intra-hepatic
anatomy and will optimize learning opportunities for all
trainees requiring knowledge of liver structures.
Table 1 for abstract 48: The median survival for patients with cirrhosis and HCC treated with no-therapy or TACE
according to MOSS class
MOSS
Class I
MOSS
Class II
MOSS
Class III
MOSS
Class IV P value
No-therapy (n = 152),
months
21.6 4.1 4.7 0 < 0.0001
TACE (n = 99),
months
21 17.3 7.1 0 0.0004
MELD score (6, 7, 8 = 3 points), (9, 10, 11 = 6 points), (12, 13, 14 = 9 points), (> 15 = 12 points)
Tumor Size (< 5cm = 0 points), (‡ 5 cm = 2 points)
Multiplicity (single lesion = 0 point), (‡ 2 lesions = 1 point), (diffuse HCC =2 points)
Portal Invasion (No= 0 points), (Yes= 1 point)
Class I = Total points= < 5 points
Class II = Total points = 6–9 points
Class III= Total points = 10–14 points
Class IV= Total points = ‡ 15
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Surgery residency training programs greatly
impact outcomes after pancreaticoduoden-
ectomy, greater than hospital volume or surgeon
frequency
A. S. ROSEMURGY, MD, B. A. MCKEON, B.SC.,
A. KAHN, C. A. MORTON, B.SC., P. TOOMEY, MD,
J. M. HERNANDEZ, MD, N. BABEL, MD and
S. B. ROSS, MD
University of South Florida, Tampa, FL, USA
Introduction: Hospital volume of pancreaticoduodenec-
tomy (PD) and the frequency with which surgeons
undertake PD have been shown to impact outcomes.
However, the impact that surgery residency training
programs have on outcomes after PD is not established.
This study was undertaken to determine the impact of
surgery residency training programs on outcomes after
PD as well as their importance relative to hospital vol-
ume and surgeon frequency of PD.
Methods: The State of Florida Agency for Healthcare
Administration database was queried for patients
undergoing PD (ICD-9 code 52.51 [proximal PD] or
52.7 [radical PD]) from 2002 through 2007. Measures
of outcome were compared for patients undergoing
PD at centers with vs. without surgery residency
training programs. Data are presented as median,
mean ± SD.
Results: 1478 (63%) PD were undertaken at centers with
surgery residency training programs and 867 (37%) at
centers without surgery residency training programs.
Relative to centers without surgery training programs,
patients undergoing PD at centers with surgery residency
training programs had shorter lengths of stay, less hos-
pital charges, and lower in-hospital mortality (Table 1).
Relative to the frequency with which surgeons undertook
PD, surgery residency training programs had a greater
favorable impact on hospital length of stay, hospital
charges, and in-hospital mortality (P < 0.001 for each,
ANCOVA). As well, relative to hospital volume of
PD undertaken, surgery residency training programs
had a greater impact on hospital charges (P < 0.001,
ANCOVA).
Table 1. Results.
Length of
stay (days)
Hospital
charges (dollars)
In-hospital
mortality
Training
centers
12 (15 ± 11.8) 87,685
(111,703 ± 98,146)
2.7%
Non-training
centers
17 (20 ± 12.3) 120,367
(150,451 ± 113,557)
11.0%
P-value P < 0.001
(Mann–Whitney)
P < 0.001
(Mann–Whitney)
P < 0.001
(Chi-square)
Conclusions: Most PD in Florida are undertaken at
centers with surgery residency training programs. Rela-
tive to centers without training programs, centers with
training programs have shorter hospital stays, less hos-
pital charges, and less in-hospital mortality. Surgery
residency training programs have a greater impact on
hospital length of stay, hospital charges, and in-hospital
mortality than do the frequency with which surgeons
undertake PD and the hospital volume of PD. Therefore,
surgery residency training programs, and all they entail,
have a favorable impact on outcome after PD, which is
greater than hospital volume of PD or the frequency with
which surgeons undertake PD.
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Pyogenic liver abscess following
pancreaticoduodenectomy: risk factors,
treatment, and long-term outcome
V. C. NJOKU, MS, N. J. ZYROMSKI, MD,
C. M. SCHMIDT, MD, PHD, H. A. PITT, MD,
A. NAKEEB, MD, K. D. LILLEMOE, MD and
T. J. HOWARD, MD
Indiana University School of Medicine, Indianapolis, IN,
USA
Background: Pancreaticoduodenectomy (PD) remains a
challenging operation with a 40% postoperative com-
plication rate. Pyogenic liver abscess (PLA) is an
uncommon complication following PD, and little infor-
mation exists on its incidence and treatment. This study
was performed to examine the incidence, risk factors,
treatment and long-term outcome of PLA after PD.
Methods: We retrospectively reviewed 1189 patients
undergoing PD (n = 839) or distal pancreatectomy (DP)
(n = 350) at a single institution over a 14-year period
(1/1/1994 - 1/1/2008). Two pancreatic databases (PD &
DP) were queried for postop complications and cross-
checked through a hospital wide database using ICD-9
codes 572.0 (PLA) and 006.3 (amebic liver abscess) as
primary or secondary diagnoses. No PLA occurred
following DP. Twenty-four patients (2.9%) developed
PLA following PD. These 24 patients were matched (1:3)
with 72 patients without PLA following PD. Patient
groups were equivalent with respect to age, gender, year
of operation, and indication for surgery. Student’s t-test
and chi square analysis were used with P < 0.05 taken as
signiﬁcant.
Results: There were no differences in eight pre-operative
variables between the groups including: jaundice, pre-
operative biliary stenting, or episodes of cholangitis. In-
tra-operative blood loss (1128 mL vs. 827 mL, P = 0.05)
was signiﬁcantly higher in patients who developed PLA
compared to matched controls. Postoperatively, patients
with anastomotic complications had a signiﬁcantly
higher rate of PLA (33% vs. 7%, P = 0.001) while the
incidence of pancreatic ﬁstula (13% vs. 4%, P = 0.14),
delayed gastric emptying (13% vs. 6%, P = 0.19), and
superior mesenteric\portal venous thrombosis (8% vs.
3%, P = 0.24) were similar between groups. Fifteen
patients (63%) developed a solitary abscess and nine
patients (38%) had multiple abscesses. Treatment
involved antibiotics and percutaneous drainage (n = 16,
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67%), antibiotics alone (n = 6, 25%), or percutaneous
drainage alone (n = 2, 8%) with a mean hospital stay of
12 days. No patient required surgical drainage and all
abscesses resolved. Long-term follow-up showed equiv-
alent 1- (79% vs.74%), 2- (50% vs. 57%), and 3-year
(38% vs. 33%) survival rates and hepatic function (liver
function tests) between patients with PLA and matched
controls.
Conclusions: Intra-operative blood loss and postopera-
tive anastomotic complications are risk factors for the
development of PLA following PD. Treatment utilizing
antibiotics and selective percutaneous drainage is 100%
effective with no adverse effects on long-term hepatic
function or survival.
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Admission volume as a determinant of outcome
for patients with acute pancreatitis
A. SINGLA, B.SC., J. P. SIMONS, MD, S. C. NG,
MS, J. HART, B.SC., J. F. TSENG, MD and
S. A. SHAH, MD
University of Massachusetts, Worcester, MA, USA
The optimal management of acute pancreatitis (AP)
remains controversial with degrees of medical and
surgical management. Our group has previously shown
that high volume (HV) hospitals have lower mortality
after pancreatectomy. We sought to examine if a similar
mortality beneﬁt exists for patients admitted with AP.
Methods: Using the Nationwide Inpatient Sample (NIS),
discharge records for all adult admissions with a primary
diagnosis of AP from 1998 to 2006 were examined.
Unique hospital identiﬁers were used to divide hospital
volume into equal tertiles based on # of admissions
for AP per year (lowest tertile (LV) < 65/year; 64/
year < medium tertile (MV) < 118/year; highest tertile
(HV) > 117/year). Adjusted mortality was the primary
outcome measure while adjusted length of stay (LOS)
was a secondary measure.
Results: There were 416 489 primary admissions for AP
during the study period. In-hospital mortality for the
cohort was 1.6%. The leading causes of AP reported
were alcohol (25.4%) and gallstones (22.6%). Hospital
admissions for AP increased over the study period
(P < 0.0001). HV hospitals tended to be large (82%),
urban (99%), teaching centers (59%) (P < 0.0001)
which cared for patients with greater comorbidities
(35.9% with > 2 comorbidities vs. 29.1% at LV hospi-
tals) (P < 0.0001). Overall, cholecystectomy was the
most commonly performed primary procedure
(n = 45 579) (26.2%). LV centers appeared more likely
to perform pancreatic operations than HV hospitals (OR
1.50; 95% CI 1.32–1.70). There was a lower likelihood of
a prolonged adjusted LOS at HV hospitals compared to
LV (OR 0.75; 95% CI 0.71–0.79) or MV hospitals (OR
0.82; 95% CI 0.79–0.85). After adjusting for patient and
hospital factors, there was an in-hospital mortality ben-
eﬁt for being treated at a HV center (HR 0.68; 95% CI
0.62–0.76). The decision to operate on a given patient did
not alter the mortality beneﬁt of the HV hospital.
Conclusions: The rates of admissions for AP in the US
are increasing. High annual hospital volume of AP con-
fers a shorter LOS and an in-hospital mortality beneﬁt to
patients admitted with AP. Although HV hospitals
performed less pancreatic surgery compared to lower
volume groups, the role of surgery remains unclear.
Further studies should examine other possible reasons
for this mortality beneﬁt such as the availability of
specialists, the quality of critical care and timing of
surgery.
Table 1. Multivariable analysis of factors associated with
mortality.
Variable HR 95% CI
Age 1.04 1.04–1.05
Female gender 1.35 1.27–1.43
Black race 0.79 0.73–0.87
Private insurance 0.83 0.76–0.91
Comorbidity 3.60 3.16–4.12
Teaching hospital 1.46 1.36–1.56
Large bedsize 1.62 1.46–1.80
High volume hospital 0.68 0.62–0.76
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Benign pancreatic islet cell tumors: resect or
enucleate?
S. C. PITT, MD, H. A. PITT, MD, M. S. BAKER, MD,
S. M. WEBER, MD, S. D. WILSON, MD,
T. J. HOWARD, MD, M. S. TALAMONTI, MD and
L. F. RIKKERS, MD
University of Wisconsin, Madison, WI, USA; Indiana
University, Indianapolis, IN, USA; Northwestern
University, Evanston, IL, USA; Medical College of
Wisconsin, Milwaukee, WI, USA; Evanston Northwestern
Healthcare, Evanston, IL, USA
Introduction: The optimal management for benign pan-
creatic islet cell tumors is controversial. Classically, sur-
geons enucleated such lesions; however, more recently,
pancreatic resection has become the standard therapy.
Data comparing these two surgical approaches are
lacking. Therefore, the purpose of this study was to
document the morbidity, mortality, and outcomes of
enucleation versus resection for benign pancreatic islet
cell tumors.
Methods: Multi-institutional retrospective review identi-
ﬁed 113 patients with benign pancreatic islet cell tumors
who were operated on between January 1990 and June
2008. Patients with positive lymph nodes, distant
metastases, or primary tumors greater than 3 cms were
excluded. The enucleation group included patients who
underwent enucleation, duodenal wall excision, or
transduodenal ampullary tumor excision, while the
resection group was comprised of patients treated by
pancreaticoduodenectomy, distal pancreatectomy, or
partial pancreatectomy.
Results: Thirty-three patients underwent enucleation of
their islet cell tumors, and 80 patients were resected.
These groups did not differ with respect to age, gender,
or mean tumor size (1.8 cm vs. 1.7 cm in the enucleated
and resected groups, respectively). Tumors that were
enucleated were a) more likely to be functioning (enu-
cleation vs. resection: 74% vs. 26%, P = 0.0001), b) in
the head, ampulla, or uncinate process of the pancreas
(59% vs. 25%, P = 0.004), and, c) when applicable, less
likely to result in splenectomy (0% vs. 63%, P = 0.005).
The two groups were statistically similar with respect to
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all outcome measures examined: operative (OR) time,
blood loss, morbidity, mortality, hospital stay, and
5-year survival (see Table 1).
Table 1. Outcome measures.
OR
time
(mins)
Blood
loss
(mL)
Morbidity
(%)
Mortality
(%)
Hospital
stay
(days)
5-year
survival
(%)
Resection 251 708 40 1.3 10.2 97.5
Enucleation 228 379 53 0 8.9 100
Conclusion: These data suggest that enucleation of
benign pancreatic islet cell tumors is comparable to
resection in terms of operative time, blood loss,
morbidity, mortality, length of stay, and long-term
survival. However, enucleation has the advantages of
preserving pancreatic and splenic function. Therefore, we
conclude that enucleation of small, benign, pancreatic
islet cell tumors is an acceptable operative option.
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Revision of anastomotic stenosis after
pancreatic head resection for chronic
pancreatitis: is it futile?
K. MORGAN, MD, B. FONTENOT, MD,
S. MICKEY, B.SC. and D. ADAMS, MD
Medical University of South Carolina, Charleston, SC,
USA
Introduction: Because long-term survival after pancrea-
ticoduodenectomy (PD) for cancer is limited, it is difﬁcult
to assess pancreaticojejunal anastomotic patency after
pancreatic head resection. However, in patients with
benign disease pancreaticojejunal anastomotic stenosis
may become problematic post-operatively. What hap-
pens when pancreaticojunal anastomosis revision is
undertaken for anastomotic stenosis?
Methods: Patients undergoing pancreatic anastomotic
revision after pancreatic head resection for chronic pan-
creatitis between 1997 and 2007 at the Medical Univer-
sity of South Carolina were identiﬁed. A retrospective
chart review and analysis was undertaken with the
approval of the Institutional Review Board for the
evaluation of human subjects. Long term follow up was
obtained by patient survey at the time of a clinic visit or
by phone follow-up.
Results: During the study time period, 237 patients
underwent pancreatic head resection. Twenty-seven
patients (17 women, median age 42) were identiﬁed who
underwent revision of their pancreaticojejunal anasto-
mosis. Six patients (22%) had a pancreatic leak or
abscess at the time of their index pancreatic head resec-
tion. Indication for revision of anastomosis was intrac-
table pain. Twenty-four patients underwent preoperative
magnetic resonance cholangiopancreatography (MRCP)
which indicated anastomotic stricture in 15 patients
(63%). Fourteen other patients underwent exploration
based on clinical suspicion due to recurrent pancreatitis
and had stenosis conﬁrmed at the time of surgery. Six
patients (22%) had perioperative complications after
revision and length of stay was median 12 days. There
was no perioperative death; however late mortality
occurred in four patients (15%). Six of 23 survivors
(26%) at time of follow-up (median 56 months) reported
long term pain relief after revision of their pancreat-
icojejunal anatomosis.
Conclusions: Stricture of the pancreaticojejunal anasto-
mosis after pancreatic head resection presents with
recurrent pancreatitis and pancreatic pain. MRCP has
good speciﬁcity in the diagnosis of anastomotic
obstruction but lacks sensitivity. Pancreaticojejunal
revision is safe, but rarely effective as a means of pain
relief in patients with the pain syndrome associated with
chronic pancreatitis.
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Outcome of radical vs. limited pancreatic head
resection for chronic pancreatitis – a meta-
analysis
N. TSIM, MBBS, A. ABULKHIR, MD,
P. LIMONGELLI, MD, M. PAI, MD, O. DAMRAH,
MD, N. JOHNSON, MBBS, A. AYAV, MD,
N. A. HABIB, NONE and L. R. JIAO, MD
Imperial College, London, UK; University Hospital
Nancy-Brabois, Vandoeuvre Les Nancy, France
Aim: A meta-analysis on available published literature to
examine the outcome of surgical management of chronic
pancreatitis (CP) involving the head of pancreas.
Background: There is no consensus in the best surgical
management for intractable pain and other major
complications from CP. Surgical interventions include
pancreatico-duodenectomy (Whipple’s) and pylorus-
preserving pancreatoduodenectomy (PPPD); duodenum-
preserving pancreatic head resection (Beger’s) and
longitudinal pancreaticojejunostomy (Frey’s procedure).
Methods: PubMed was used to search for published
studies in English between 1990 to 2006. ‘MeSH’ search
with ‘chronic pancreatitis’, and above procedural terms
were used. Outcomes of interest included: indication for
surgery, morbidity and mortality, long-term pain control,
and pancreatic function.
Results: Thirty-three published series which fulﬁlled our
inclusion criteria were evaluated. 2215 patients under-
went surgical procedures including Whipple’s (n = 421),
PPPD (n = 383), Beger’s (n = 1172) and Frey’s
(n = 239). There were three randomized controlled
studies comparing pancreatic head resection (PHR) and
Beger’s procedure; three cohort studies, and six reviews.
Between Whipple’s and PPPD, there was no signiﬁcant
difference in morbidity (P = 0.07), mortality
(P = 0.13), postoperative pain (P = 0.15), endocrine
(P = 0.99) or exocrine functions (P = 0.29). Similarly,
postoperative endocrine, exocrine functions were com-
parable in PHR and Beger’s (P = 0.16; P = 0.95), as
was postoperative pain relief (P = 0.18). Importantly,
morbidity rate was signiﬁcantly reduced in Beger’s group
when compared with PHR (P = 0.01), albeit a similar
mortality rate (P = 0.52). Comparing PHR and Frey’s,
there was no signiﬁcant difference for postoperative
morbidity (P = 0.3), mortality (P = 0.18), long-term
pancreatic function (P = 0.77) or pain relief (P = 0.27).
Between Beger’s and Frey’s, there was no difference in
postoperative morbidity (P = 0.49), mortality
(P = 0.28), endocrine or exocrine function (P = 0.92;
P = 0.7 respectively). A signiﬁcantly higher proportion
of patients had better pain control following Frey’s
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compared with Beger’s procedure (89 vs. 85%,
P = 0.009).
Conclusion: There was no signiﬁcant difference in out-
come with Whipple’s procedure compared to PPPD.
Beger’s procedure offered signiﬁcant reduction in post-
operative morbidity rate. Radical or limited resection
had no impact on postoperative mortality or pancreatic
function. Frey’s procedure provided improved long-term
pain relief.
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A simpliﬁed prognostic system for resected
pancreatic neuroendocrine neoplasms
N. BALLIAN, MD, P. NORSTEDT, A. LOEFFLER,
MD, V. RAJAMANICKAM, PHD, S. M. WEBER,
MD and C. S. CHO, MD
University of Wisconsin School of Medicine and Public
Health, Madison, WI, USA
Background: A number of clinicopathological variables
have been proposed for purposes of prognostication for
patients with pancreatic neuroendocrine neoplasms.
Previous analyses have been drawn from heterogeneous
populations that have included patients with metastatic
disease. A consistent and clinically applicable staging
system has yet to be deﬁned for patients undergoing
potentially curative resection of pancreatic neuroendo-
crine neoplasms.
Method: We examined a prospectively maintained single
institution database to identify patients who underwent
potentially curative resection of non-metastatic primary
pancreatic neuroendocrine neoplasms. All pathological
specimens were independently reviewed and histological
grade was deﬁned as low grade or intermediate grade
using previous deﬁned criteria of mitotic activity and
presence of necrosis. Patient, operative, and tumor
characteristics were analyzed to identify factors associ-
ated with disease-speciﬁc and disease-free survival.
Results: Between 1991 and 2007, 43 patients underwent
potentially curative resection of primary pancreatic
neuroendocrine neoplasms. After a median follow-up of
68 months, 5-year disease-speciﬁc survival was 94%, and
5-year disease-free survival was 72%. The only variable
associated with signiﬁcant differences in disease-speciﬁc
survival was tumor size > 5 cm. Tumor size > 5 cm,
presence of nodal metastases, and positive resection
margins were associated with signiﬁcant differences in
disease-free survival. The association between histologic
grade and recurrence neared but did not reach statistical
signiﬁcance (P = 0.091). The onset of disease recurrence
was associated with decreased overall survival; median
survival after disease recurrence was 49 months. A sim-
pliﬁed scoring system consisting of tumor size > 5 cm,
histologic Grade, presence of Nodal metastases and
resection Margin positivity (SGNM) permitted stratiﬁ-
cation of expected disease-speciﬁc (P = 0.047) and dis-
ease-free survival (P = 0.0004) outcomes.
Conclusion: A simpliﬁed scoring system based on tumor
size, histologic grade, presence of nodal metastases and
resection margin status permits accurate prognostication
of outcomes for patients undergoing resection of primary
pancreatic neuroendocrine neoplasms.
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Routine intra-operative biliary cultures during
pancreaticoduodenectomy: a guide to avoid
postoperative complications
V. AUGENSTEIN, MD, N. REUTER, MD,
K. M. MCMASTERS, MD, C. R. SCOGGINS, MD
and R. C. MARTIN
University of Louisville, Louisville, KY, USA
Introduction: Multiple pre-, intra-, and post-operative
factors have been identiﬁed to be potentially predictive of
morbidity and mortality associated with pancreatico-
duodenectomy. Biliary stenting has been demonstrated to
potentially be one of those predictive factors. However,
there have been no reports evaluating the effect of intra-
operative bile culture on preventing post-operative
complications. The aim of this study was to evaluate the
effects of intra-operative bile cultures on the outcome of
patients undergoing pancreaticoduodenectomy.
Methods: A review of our 1430 hepato-pancreatic-biliary
databse from 1/1998 to 8/2008 was performed for
patients who had data on the presence/absence of biliary
stenting, use of intra-operative bile culture, and micro-
biology of the bile culture. All clinico-pathologic data, as
well as all complications 90 days from operation were
recorded and evaluated. Complications were graded
using our established 5-point grading scale. Chi-square
and log rank were used to evaluate the effects of biliary
stents, presence/absence infected bile, and the type of
organism identiﬁed.
Results: We identiﬁed 228 patients who met our data
requirements. There were 55% men, 45% women, med-
ian age of 59 years (range 42–91). Preoperative biliary
stenting was performed in 129 out of 228 patients (57%).
Of this 129 patients, 66 (51%) had bile cultures taken
intraoperative, with 56 (85%) of these patients having
positive bile cultures. Neither Preoperative biliary stent-
ing (incidence complication: 54% w/stent vs. 51% w/o,
P = 0.9) or infected bile (incidence complication: 54%
w/infection vs. 53% w/o, P = 0.9) were predictors of
overall complications. Length of operating time, length
of hospital stay, blood loss, blood transfusion, and
severity of complications were all similar. There were 18
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different organisms identiﬁed with the most common
being Enterococcus (23%), Candida (16%), Escherichia
coli (16%), and Staph (13%). Only a Candida infection
within the bile was a statistically signiﬁcant predictor of
severity of complication and increased length of stay.
Conclusions: Preoperative biliary stenting correlates with
a higher rate of biliary infections, however intra-opera-
tive bile cultures allows for early appropriate antibiotic
use, which maintains a similar morbidity and infectious
incidence as non-stented patients. Treatment of extrahe-
patic biliary obstruction with preoperative stenting
should not be abandoned; however, obtaining intraop-
erative bile cultures is important to further guide treat-
ment of postoperative complications.
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Pancreatic resection: a key component to
reducing racial disparities in pancreatic
adenocarcinoma
M. M. MURPHY, MD, MPH, J. P. SIMONS, MD,
T. P. MC DADE, MD, Z. ZHOU, MD,
L. H. HARRISON JR, MD and
J. F. TSENG, MD, MPH
University of Massachusetts Medical School, Worcester,
MA, USA
Introduction: Pancreatic adenocarcinoma is more com-
mon and outcomes are less favorable among Blacks.
Potential cures require resection. If surgical disparities
exist, theymayprovide insight into outcomediscrepancies.
Methods: Pancreatic adenocarcinoma patients were
identiﬁed using Surveillance, Epidemiology, and End
Results (SEER) 1992–2002. Univariate analyses com-
pared demographics, tumor characteristics, and opera-
tive data; logistic regression was used to determine
independent predictors for recommendation/perfor-
mance of surgery. Kaplan–Meier survival was assessed; a
Cox proportional hazards model examined adjusted
predictors of survival.
Results: A total of 27 828 patients were identiﬁed; 81.4%
were White and 11.5% were Black. Whites and Blacks
presented at equivalent stages, and resection was rec-
ommended at similar rates (34.5% vs. 34.0%, P = 0.93).
However, Blacks underwent fewer resections (10.6% vs.
12.7%, P = 0.0007) and multivariable analysis con-
ﬁrmed they were less likely to undergo resection (adjusted
odds ratio 0.69, P = 0.0002). Overall, Blacks had worse
univariate survival (log rank, P < 0.0001). Resected
Blacks’ survival did not statistically differ from Whites’,
although median survival trended lower (Black median
11 months vs. 13 months for Whites, P = 0.1291). In a
multivariable Cox model, Black race independently pre-
dicted worse survival (HR 1.11, 95% CI 1.07–1.16);
pancreatic resection was independently protective (HR
0.56, 95% CI 0.53–0.59).
Conclusions: In the SEER registry 2002–2006, Blacks
and Whites were recommended for pancreatectomy at
similar rates, yet Blacks were less likely to undergo
resection. Resected Blacks and Whites had crude sur-
vivals that did not differ signiﬁcantly, although in mul-
tivariable analysis a survival disadvantage remained for
Black race despite adjusting for resection. Our results
suggest that pancreatectomy may be underutilized for
Blacks with pancreatic adenocarcinoma. Maximizing
rates of pancreatic resection for appropriate patients may
be an important component in reducing outcome dis-
parities for this disease.
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Perioperative bevacizumab containing chemo-
therapy for colorectal cancer liver metastasis
P. CHAUDHURY, MD, M. HASSANAIN, MBBS,
N. BOUGANIM, MD, P. KAVAN, MD and
P. METRAKOS, MD
McGill University, Montreal, QC, Canada
Background: Colorectal cancer livermetastases (CRCLM)
when treated aggressively have a potential long-term sur-
vival. Liver resection combined with Oxaliplatin based
adjuvant chemotherapy proved to increase disease-free
survival, and neoadjuvant therapy improved progression-
free survival.Bevacizumab (Bev)whenadded toOxaliplatin
based chemotherapy improved median survival in patients
with CRCLM. Our goals are to determine safety and efﬁ-
cacy of adding Bev to the adjuvant therapy following liver
resection for CRCLM and its impact on survival.
Methods: In a single arm feasibility study, all patients with
detectable liver metastasis eligible to receive adjuvant
chemotherapy and Bev were reviewed. Results: Thirty-six
patients were identiﬁed: 26 male, median age 57 years,
ECOG < 2. Thirty-one patients had synchronous liver
metastases and ﬁve metachronous disease. All patients
underwent perioperative Bev containing chemotherapy,
Oxaliplatin based in 29 patients (80%) and CPT-11 in seven
patients (20%). Twenty-eight (78%) had neoadjuvant
therapy, and all had adjuvant chemotherapy. Median
treatment duration pre and postoperatively was 3 and
6 months respectively. Bevwas discontinued 6 weeks before
and restarted 8 weeks after surgery. Seven patients under-
went staged liver resection. Grade 3/4 Bev related compli-
cations were seen in four patients (epistaxis, anaphylactic
reaction, and hypertension), Overall postoperative compli-
cation rate was 48%, grade 3/4 postoperative complications
as per Clavien system was in two patients (5%). Overall
response rate was 70% (22/31): 35% partial and 35%
complete response, with a median follow up of 25 months.
No patients progressed prior to surgery. Overall survival
rates at 12, 24, 36and48 monthswere100%,89%,80%and
77% respectively and 5-year median survival of 55%. Three
patients relapsed, 4, 5 and 12 months post treatment, two
patients died due to sepsis, and disease progression.
Conclusions: Bev containing chemotherapy and hepatec-
tomy iswell toleratedandeffective inpatientswithCRCLM.
Our 70% response rate is one of the highest reported, with
only three patients progressing. Perioperative Bev contain-
ing chemotherapy seems to be justiﬁable in selected patients
and warrants further investigation in phase-III trials.
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Fast track liver resection: single dose intrathecal
morphine with gabapentin vs. continuous
epidural analgesia
J. KOEA, MD, Y. YOUNG, MBBS and K. GUNN,
MBBS
Auckland Hospital, Auckland, New Zealand
Introduction: Historically liver resection has been asso-
ciated with signiﬁcant blood loss requiring large volumes
of intravenous ﬂuid both pre and intraoperatively. With
the advent of low CVP anaesthesia ﬂuid has been re-
stricted preoperatively but patients are volume loaded at
the completion of the resection. While lowering CVP, the
use of epidural anaesthesia may further increase post-
operative ﬂuid requirements to maintain blood pressure.
This may unnecessarily prolong hospital stay delaying
return of gut function, removal of bladder catheter and
full mobility.
Aim: To compare the perioperative course and hospital f
stay in patients managed with continuous epidural infu-
sion of bupivacine 0.125% & fentanyl 2 mcg ml)1 at
0.1 ml kg)1 h)1 or single dose intrathecal morphine
300 mcg in combination with oral gabapentin (1200 mg
preop & 400 mg bd postop) and postoperative diclofenac
SR 75 mg bd. All patients received paracetamol 1 g qid.
Methods: Data on 100 consecutive patients managed
with continuous epidural infusion (n = 50) or single
dose intrathecal morphine (n = 50) were entered on a
computerised database. Intergroup comparisons were
performed using ANOVA.
Results: The epidural and intrathecal morphine groups
were equivalent in terms of patient age, sex, major (‡ 4
segments resected) and minor hepatectomy and intra-
operative blood loss (Table 1). There were no compli-
cations related to either form of analgesia and pain
scores were uniformly low. However patients receiving
intrathecal morphine received less intraoperative intra-
venous ﬂuids [median 1.5 L (range 1.2–2.8 L) vs. 2.2 L
(range 1.5 –3.2 L) P = 0.06], less postoperative ﬂuids
[median 1.2 L (range 0.8–1.5 L) vs. 4.3 L (range 3.5–
5.2 L) P = 0.03] than patients receiving epidural infu-
sion. Patients receiving intrathecal morphine also
established a normal dietary intake earlier (16 h vs. 20h,
P = 0.05) and had shorter hospital stays than those
managed with epidural infusions (4.2 ± 0.6 days vs.
6.8 ± 1.2 days, P = 0.02).
Conclusions: Single dose intrathecal morphine in com-
bination with oral gabapentin is a safe and effective
alternative to epidural analgesia in patients undergoing
hepatectomy. Patients managed with intrathecal
morphine resume an oral diet sooner and have shorter
hospital stays than those managed with continuous
epidural analgesia possibly because of a decreased
requirement for intravenous ﬂuid administration.
Table 1. Results.
Group
Sex
M:F
Age
Median ±
SEM
Hepatectomy
Major:Minor
Intraoperative
blood loss
Median ±
SEM
Epidural
(n = 50)
27:23 61 ± 5 years 21:29 352 ± 73 mL
Intrathecal
(n = 50)
24:26 60 ± 6 yr 20:30 277 ± 88 mL
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Surgical dilemma: liver resection or liver
transplantation for hepatocelular carcinoma and
cirrhosis. intention to treat analysis in patients
within and outside milan criteria
M. FACCIUTO, M. PANDEY, C. ROCHON,
M. RODRIGUEZ-DAVALOS, D. C. WOLF,
L. KIM-SCHLUGER and P. SHEINER
Westchester Medical Center, New York Medical College,
Valhalla, NY, USA
Background: The optimal role of surgery in the man-
agement of hepatocellular carcinoma (HCC) is in con-
tinuous evolution.
Objective: The objective of this study was to analyze the
survival after liver resection (LR) and liver transplanta-
tion (OLT) for HCC within and outside Milan criteria in
an intention to treat analysis.
Methods: From 1997 to 2007, 179 patients with cirrhosis
and HCC underwent either LR (n = 60) or were listed
for OLT (119). After eliminating incidental HCC after
OLT, preoperative macrovascular invasion before LR,
non cirrhotics and Child-Pugh Class C cirrhosis prior to
OLT, 51 patients primarily treated with LR, and 107
patients listed for primary OLT (81 transplanted) were
included in this analysis. Sixty-six patients exceeded
Milan criteria (26 LR; 40 OLT), while 92 patients con-
tinued to meet Milan criteria (25 LR; 57OLT)
Results: The median follow up time was 22 months. The
mean waiting time for OLT was 7 months. During that
time, 21 patients were removed from the waiting list due
to tumor progression. The drop out probability was 2%
and 13% at 6 and 12 months for patients within Milan,
and 34% and 57% at 6 and 12 months for patients
outside Milan (P < 0.01).
Overall survival from time of listing for OLT or LR was
not different between the two groups (p < 0.99); within
Milan criteria, 1 and 4 year survival after LR was 88%
and 67% compared with 92% and 63% for OLT (p 0.84).
Outside Milan criteria, 1 and 4 year survival after LR
was 67% and 54% compared with 67% and 45% for
OLT (p < 0.56).
Conclusion: The survival of patients with HCC is similar
between LR and OLT. Particularly in patients outside
Milan criteria, LR can potentially decrease the dropout
rate and serve as a bridge for future salvage liver trans-
plantation.
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Chemotherapy within 30 days prior to liver
resection does not increase postoperative
morbidity or mortality
B. N. FAHY, MD, T. A. ALOIA, MD, S. L. JONES,
MD, J. PARANILAM, PHD, B. L. BASS, MD and
C. P. FISCHER, MD
The Methodist Hospital, Houston, TX, USA
Introduction: Liver resections (LRsxn) are increasingly
performed for metastatic disease. To minimize the risk of
postoperative complications, six weeks between the
last dose of chemotherapy (CTX) and LRsxn is
recommended. The current study sought to examine
postoperative morbidity and mortality following LRsxn
in patients (pts) who received CTX within 30 days prior
to resection.
Methods: The validated, risk-adjusted, multi-institu-
tional National Surgical Quality Improvement Program
(NSQIP) merged 2005–2007 Participant Use File was
queried for preoperative risk factors, laboratory values,
and postoperative complications in pts who underwent
LRsxn (CPT 47120, 47122, 47125, 47130). Pts were
grouped based upon receipt of CTX within 30 days prior
to LRsxn and the occurrence of major postoperative
complications.
Results: 2331 patients underwent LRsxn; 2147 (92%) did
not receive CTX within 30 days of resection (No Chemo)
and 184 (8%) did receive CTX prior to LRsxn (Chemo).
The groups were similar with regard to preoperative
comorbidities (e.g. diabetes, cardiac disease) and
operative factors (e.g. operative length, intraoperative
transfusion). The median value for the NSQIP statisti-
cally-computed morbidity probability was similar
between the groups (No Chemo 0.32, Chemo 0.34,
P = 0.07) while the median mortality probability was
higher among the Chemo group (0.02) vs. the No Chemo
group (0.014, P = 0.001). Thirty-day survival was simi-
lar between the two groups (No Chemo 97%, Chemo
98%, P = 0.44). The major complication rate did not
differ between the groups (No Chemo 20%, Chemo 18%,
P = 0.51) and there were no differences in the following
major postoperative complication types: infectious com-
plications, thromboembolic events, or pulmonary
complications (Table 1). Factors associated with major
complications in the Chemo group included: extent of
LRsxn, intraoperative transfusion, preoperative ascites,
and preoperative hematocrit (Table).
Table 1.
No chemotherapy vs.
chemotherapy data
No
chemotherapy
n = 2147
Chemotherapy
n = 184 P-value
Major complication 428 (20%) 33 (18%) 0.51
Infectious complications 438 (20%) 36 (20%) 0.79
Thromboembolic
complications
66 (3%) 8 (4%) 0.34
Pulmonary complications 194 (9%) 13 (7%) 0.37
Chemotherapy group
morbidity data
No major
complication
n = 151
Major
complication
n = 33
Extent of hepatectomy
Partial hemihepatectomy
Hemi or extended hepatectomy
94 (62%)
57 (38%)
13 (39%)
20 (61%)
0.02
# packed red blood cells
transfused intraoperatively
(mean ± SD)
Range
0.8 ± 2.1 0–17 3.7 ± 7.5 0–40 <0.001
Preoperative ascites 0 2 (6%) 0.002
Preoperative hematocrit 39.1 ± 3.9 37.1 ± 5.4 0.02
Conclusions: Despite slightly higher predicted risk, major
morbidity was not increased in Chemo pts. The strongest
predictors of major postoperative complications in
Chemo pts were extent of resection and intraoperative
transfusion. These data suggest that LRsxn may be safely
performed within 30 days of CTX, thereby minimizing
the time that pts with liver metastases are off systemic
treatment.
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Pancreaticoduodenectomy for suspected
periampullary cancers: the mimes of malignancy
J. M. HERNANDEZ, MD, C. A. MORTON, B.SC.,
A. R. MARCADIS, S. B. ROSS, MD, N. BABEL, MD,
S. B. GOLDIN, MD and A. S. ROSEMURGY, MD
University of South Florida, Tampa, FL, USA
Introduction: Given the risks and difﬁculty with preop-
erative conﬁrmation of cancer, pancreaticoduodenecto-
my are often undertaken for suspicion of malignancy
without histological diagnosis. We undertook this study
to review preoperative presentations and diagnostics and
ascertain if non-therapeutic resections can be avoided.
Methods: Data from patients undergoing pancreatico-
duodenectomy were prospectively collected and patients
undergoing resections without histological evidence of
premalignant or malignant disease were identiﬁed. Oper-
ative indications, including presenting symptoms, serum
tumor markers, results with ERCP/EUS with or without
biopsy/genetic testing, and radiographic data, were
reviewed. Data are presented as median, mean±SD.
Results: From 1996 through 2007, 729 patients under-
went pancreaticoduodenectomy at our institution.
Malignant lesions were present in 77% of patients; pre-
malignant lesions were identiﬁed in 11% patients.
Chronic pancreatitis was the operative indication in 3%
of patients. 64 (9%) patients underwent pancreatico-
duodenectomy with preoperative constellation of signs
and symptoms mimicking cancer, although they were
without premalignant or malignant disease on ﬁnal re-
port by Pathology; their clinical and radiographic data
are depicted in the table. The most common ﬁnal diag-
noses for patients undergoing pancreaticoduodenectomy
without premalignant or malignant disease were pan-
creatitis (59%) and serous cystadenomas (18%). Of the
64 patients, 17% had preoperative brushings/biopsies
‘‘documenting’’ adenocarcinoma and 41% had a con-
stellation of biliary stricture, jaundice, and pancreatic
head mass, without history of pancreatitis. However,
17% had clinical histories and imaging studies sufﬁcient
to diagnose chronic pancreatitis, 16% had clear misin-
terpretations of their imaging studies, and 6% had
inadequate preoperative evaluations.
Table 1. Clinical and radiographic data.
Patients
(n)
Age
(years)
Weight
loss Jaundice Pain
Symptom
duration
(months)
History
of
pancreatitis
Mass
on
CT
64 58 (59 ± 12.1) 45% 52% 69% 1 (5 ± 11.9) 20% 96%
Conclusion: Only a small minority of patients treated at
a tertiary referral center for suspicion of periampullary
cancer undergo non-therapeutic or inappropriate pan-
creaticoduodenectomy and are, as of now, generally
unidentiﬁable prior to resection. Advances in imaging,
imaging interpretation, and/or evolving molecular diag-
nostics should unmask themimes of periampullary cancer.
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Incidence of benign disease in patients diagnosed
with presumed pancreatic adenocarcinoma by
endoscopic ultrasonography (EUS) and ﬁne-
needle aspiration (FNA)
S. G. DE LA FUENTE, MD, E. P. CEPPA, MD,
S. K. REDDY, DVM, B. M. CLARY, MD,
D. S. TYLER, MD and T. N. PAPPAS, MD
Duke University Medical Center, Durham, NC, USA
Introduction: The lack of accurate markers makes pre-
operative differentiation between pancreatic cancer and
non-malignant head lesions clinically challenging. Several
series have demonstrated the superiority of EUS over CT
scan and MRI in the diagnosis of pancreatic neoplasms;
however, these diagnostic modalities are poor in distin-
guishing malignant from benign disease and in diagnos-
ing superimposed cancer in patients with underlying
pancreatitis. In this study, we investigated the incidence
of benign disease in patients that underwent resection for
presumed pancreatic cancer diagnosed by EUS and EUS-
guided FNA.
Methods: Medical records of consecutive patients who
underwent pylorus-preserving pancreaticoduodenectomy
at Duke University Medical Center from 1992 to 2007
were reviewed. Demographics, clinicopathologic charac-
teristics, preoperative imaging, EUS, EUS-guided FNA,
and postoperative outcomes were analyzed.
Results: A total of 494 patients were operated on for
presumed pancreatic cancer within the study period. Of
these, 37 patients (7.4%) were found to have benign
disease on postoperative pathology. The majority of
these patients were white males with a mean age of
53 years old. The most common presenting symptom was
obstructive jaundice, but 35% of the patients presented
with multiple symptoms. Fifty-nine percent of these pa-
tients (n = 22) with benign disease underwent preoper-
ative EUS. EUS was positive for a head mass in 70%,
demonstrated enlarged lymph nodes in 27% and showed
signs concerning for vascular invasion in 13%. FNA was
suspicious or indeterminate for cancer in 63% of pa-
tients. The mean follow up was 23 months. Early com-
plications occurred in 47% and one patient died after
surgery. The overall pancreatic leak rate was 15%.
Conclusions: In the present series, up to 7% of patients
undergoing pancreaticoduodenectomy for presumed
pancreatic cancer had benign disease on postoperative
pathologic examination. Despite the common use of
endoscopic ultrasonography, most of these patients have
the appearance of malignancy on preoperative assess-
ment. Even with aggressive use of preoperative evalua-
tion there is still a small subset of patients where
malignancy cannot be excluded without pancreatico-
duodenectomy.
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Aetiology and outcome of acute liver failure
R. MARUDANAYAGAM, MS, V. SHANMUGAM,
MS, R. SINGHAL, MS, B. GUNSON,
S. BRAMHALL, MD, MBBS, D. MAYER, MD,
MBBS, J. BUCKELS, MD, MBBS and D. MIRZA, MS
Queen Elizabeth Hospital, Birmingham, UK,
Background: Acute liver failure is a clinical syndrome
characterized by the sudden onset of coagulopathy and
encephalopathy. The outcome is unpredictable and is
associated with high morbidity and mortality. We
reviewed our experience to identify the aetiology and
study the outcome of acute liver failure.
Methods: A total of 1237 patients who presented with
acute liver failure between January 1992 and May 2008
were included in this retrospective study. Liver trans-
plantation was undertaken based on the King’s College
Hospital criteria. Data was obtained from the hospital
liver database. The following parameters were analyzed-
patient demographics, aetiology, operative intervention,
overall outcome, 30-day mortality and regrafts.
Results: There were 558 men and 679 women with a
mean age of 37 years (range: 8–78 years). The most
common aetiology was drug induced liver failure
(68.1%), of which 90% was due to paracetamol over-
dose. Other causes include seronegative hepatitis(15%),
hepatitis B(2.6%), hepatitis A(1.1%), acute Budd-Chiari
syndrome(1.5%), acute Wilson’s disease(0.6%), subacute
necrosis(3.2%) and miscellaneous (7.8%). 327 patients
were listed for liver transplantation, of which 263
patients successfully had the procedure (80.4%). The
current overall survival following transplantation was
70% with a median follow-up of 57 months. The 30-day
mortality was 13.7%. Drug induced hepatic failure
(21.6%) and age over 60 years (21.4%) were associated
with signiﬁcantly higher 30-day mortality. The overall
survival of the 974 patients who were not transplanted
was 71.1% with a median follow-up of 85 months.
Regrafting was performed in 31 patients (11.8%), the
most common indication being hepatic artery thrombosis
(11 patients).
Conclusion: Paracetamol overdose was the most com-
mon cause of acute liver failure. Liver transplantation,
when performed for acute liver failure, has good long-
term survival.
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Overall survival and health-related quality of
life in unresectable hepatocellular carcinoma
(HCC) treated with transarterial chemo-
embolization (TACE) vs. selective internal
radiation therapy (SIRT) with Yttrium-90
microspheres
T. VANOUNOU, MD, J. L. STEEL, PHD,
K. T. NGUYEN, MD, PHD, A. TSUNG, MD,
D. A. GELLER, MD and T. C. GAMBLIN, MD
University of Pittsburgh, Pittsburgh, PA, USA
Background: Locoregional therapies, such as TACE and
SIRT with Yttrium-90 microspheres, are recognized
treatment options for patients with unresectable HCC.
The purpose of this study was to examine the impact of
TACE and SIRT on overall survival (OS), health-related
quality of life (HRQL), and cost-effectiveness.
Methods: A retrospective analysis was performed on 788
patients treated with TACE or SIRT between 1989 and
2008 at a large tertiary care center. A subset of patients
were administered the Functional Assessment of Cancer
Therapy-Hepatobiliary (FACT-Hep) at diagnosis, 3- and
6-months follow-up in a randomized (n = 19) and non-
randomized trial (n = 83) of TACE vs. SIRT. Survival
was assessed with Kaplan–Meier and Cox Regression
analyses. Differences in HRQL were tested using
repeated measures ANOVA. Costs were calculated by
using the mean charged cost and number of treatments
by days of survival.
Results: Using Kaplan–Meier analyses, a signiﬁcant
difference in survival was observed between TACE and
SIRT (P = 0.009) with SIRT patients having a longer
survival (median=466 days, 95% CI=345–587 days]
compared to the TACE patients (median sur-
vival=392 days; 95% CI=353–431 days]. Untreated
patients (n = 14) had a median survival of 137 days.
However, using Cox regression to control for baseline
demographic (i.e. gender, age, ethnicity) and disease-
speciﬁc differences (i.e. cirrhosis, lesion size and number,
PV thrombosis, ascites), a trend toward signiﬁcance was
observed in which treatment with SIRT continued to
contribute to longer survival when compared to TACE
(P = 0.11). Although statistically and clinically mean-
ingful differences in HRQL were not observed, patients
treated with SIRT consistently had improved HRQL
from baseline to 6-months while patients treated with
TACE had decrements in HRQL. The average cost for
SIRT patients was $74 155 (mean # of tx=2) compared
to TACE which was $135 900 (mean # of tx=5). The
cost of SIRT was $9548 per month of life compared to
TACE which was $10 401 per month of life.
Conclusion: After controlling for demographic and
disease-speciﬁc differences, there appears to be a trend
toward signiﬁcance for overall survival and HRQL for
unresectable HCC patients treated by SIRT compared to
TACE. In addition, the average cost per month of
additional life with SIRT was less than that of TACE,
suggesting that SIRT may be a more cost-effective pal-
liative loco-regional therapeutic choice.
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Partial liver resection for HCC in patients
with good liver function can challenge liver
transplantation
J. BELGHITI, MD, A. HERRERO, MD,
C. PULITANO, MD, O. FARGES, MD, PHD,
A. SAUVANET, MD, F. DONDERO, MD and
D. SOMMACALE, MD
Hospital Beaujon, Clichy, France
Introduction: The practice of liver resection for HCC
continues to evolve, but few large, contemporary studies
have speciﬁcally evaluated the impact of these changes.
Methods: From 1990 to 2007, 556 patients underwent
liver resection for HCC in our institution. There were 415
men and 141 women; the mean age was 58 ± 9 years.
Chronic liver disease (CLD) was present in 367 patients,
including 229 with cirrhosis. Etiology of CLD included
HCV (n = 157) HBV (n = 114), alcohol (n = 63),
cryptogenic (n = 182), hemochromatosis (n = 30), and
other (n = 32). Major liver resection was performed in
275 patients and reresection was performed in 53. Mean
tumor size was 7.5 cm and 70 patients had more than one
lesion. Clinical features and outcomes of patients who
underwent liver resection before 2000, n = 329 (59%)
and after 2000, n = 227 (41%) were compared in table.
Results: The incidence of cryptogenic CLD increased
signiﬁcantly after the 2000s (44% vs. 25%, P < 0.001).
After 2000s, use of Pringle maneuver was less frequently
(66 vs. 77%, P < 0.002). Peroperative blood transfusion
decreased signiﬁcantly (20% vs. 30 P < 0.05). Preoper-
ative portal vein embolization (PVE) (n = 36 vs. n = 44,
P < 0.001) as well as the rate of major liver resection
(56% vs. 44%, P < 0.040) and the mean tumor size
(8.6 cm vs. 7 cm, P < 0.003) increased signiﬁcantly.
Before 2000s, 9 patients and 35 after 2000s underwent
liver transplantation following liver resection. The hos-
pital mortality was reduced from 7.9% before 2000s to
3.3% after 2000s (P < 0.05). Overall survival at 1, 3 and
5 years were 79%, 62% and 44% before 2000s and 95%,
89% and 70% after 2000s (P = 0.0001).
Conclusions: Results of the present series showed that
with a better patient selection and preparation, including
PVE, the operative mortality decreased. The 5 years
survival of 70% resulted from operative technical chan-
ges and speciﬁc managements of recurrence.
Table 1. Results.
Before
2000
(n = 329)
After
2000
(n = 227) P
Age 56.5 60 0.023
PVE 4 46 0.0001
Pringle maneuver 256 146 0.002
Blood transfusion 90 46 0.05
Major liver resection 151 124 0.04
Positive margin 55 14 0.0001
LT after resection 9 35 0.001
Disease free 1, 3, 5 yrs 78/39/26 75/76/39 0.0001
Survival free 1, 3, 5 yrs 79/62/44 95/89/70 0.0001
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Reappraisal of pringle maneuver: effect of
ischemic time on late oncological outcomes
following hepatic resection for metastatic
colorectal cancer
H. ITO, MD, M. GONEN, PHD, P. ALLEN, MD,
M. D’ANGELICA, MD, R. P. DEMATTEO, MD,
Y. FONG, MD, L. H. BLUMGART, MD and
W. R. JARNAGIN, MD
Memorial Sloan-Kettering Cancer Center, New York, NY,
USA
Background and aim: Portal pedicle clamping (Pringle
maneuver, PM) is commonly used to reduce bleeding
liver resection. PM is well known to cause ischemia/
reperfusion injury, but its effect on long-term oncological
outcomes is poorly deﬁned. The aim of this study was to
evaluate the effect of ischemic time during liver resection
on late oncological outcomes for metastatic colorectal
cancer (MCRC).
Methods: Medical records of patients who underwent R0
liver resection for MCRC between 1991 and 2002 were
reviewed. Patients without documented Pringle time were
excluded; operative and peri-operative data, including
total occlusion time, number of PM applications, peri-
operative morbidity, mortality, and clinicopathological
variables were analyzed. Long-term progression free (PF)
and disease speciﬁc (DS) survival were analyzed using
Log-Rank test and Cox-regression.
Results: Nine hundred patients were included in the
study, and the median follow-up period was 44 months.
Five hundred and ﬁfty-eight patients (65%) underwent a
hemihepatectomy or greater, 373 patients (41%) had
bilobar resection and 273 patients (30%) had complex
resection. Intermittent PM was used in 781 patients
(87%) (median number of applications = 4 (range =
2–16)), while continuous PM was used in 58 patients
(6%) and 61 patients (7%) had no occlusion at all.
Median of total PM time was 34 min (range = 2–
181 min). The factors associated with prolonged PM time
(> 60 min) included hemihepatecomy or greater resec-
tion, bilobar resection, greater blood loss, longer opera-
tion time, multiple tumors, perioperative transfusion,
preoperative and postoperative chemotherapy. Univari-
ate and multivariate analysis for long-term PFS and DSS
are shown in the Table 1. The total portal pedicle
occlusion time was a signiﬁcant predictor of reduced PFS
[P = 0.028, HR 1.1 (95% CI; 1.0–1.2)], independent of
disease and resection extent.
Conclusions: Prolonged portal pedicle occlusion is an
independent predictor of recurrence and reduced PFS
following hepatic resection for MCRC. The mechanism
by which this occurs is uncertain but appears likely
related to liver ischemia.
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Table 1 for abstract 67. Signiﬁcant predictors for PFS and DSS (only signiﬁcant factors are shown).
Factors PFS UVp PFS MVp HR (95% CI) DSS UVp DSS MVp HR (95% CI)
Pringle time
(as continuous,
increment of 20 min)
<0.0001 0.028 1.1 (1.0–1.2) 0.01 0.30 1.0 (0.96–1.1)
Preoperative chemotherapy 0.0065 0.014 1.3 (1.1–1.6) 0.050 0.18 1.2 (0.93–1.4)
Adjuvant chemotherapy 0.14 0.024 0.04 0.72 (0.57–0.90)
Bilobar resection <0.0001 0.13 1.2 (0.95–1.5) <0.0001 0.005 1.4 (1.1–1.8)
Complex resection <0.0001 0.004 1.3 (1.1–1.7) 0.0018 0.14 1.2 (0.95–1.5)
Primary node (+) <0.0001 <0.001 1.6 (1.3–1.9) <0.0001 <0.001 1.7 (1.4–2.1)
CEA > 200 0.0024 0.035 1.4 (1.0–1.8) 0.0001 0.002 1.6 (1.2–2.3)
Multiple tumors <0.0001 0.095 1.2 (0.97–1.5) <0.0001 0.026 1.3 (1.0–1.6)
Tumor size > 5 cm 0.0001 0.002 1.4 (1.1–1.7) <0.0001 0.017 1.3 (1.1–1.7)
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Two-stage liver resection for colorectal liver
metastases: experience at a single center
N. C. TSIM, MBBS, A. J. HEALEY, MBBS,
N. A. HABIB, MD and L. R. JIAO, MD
Imperial College London, London, UK
Aim: To assess the outcome of patients undergoing two-
stage liver resection (2-SLR) for multiple colorectal liver
metastases (CLM).
Background: Only 10–20% of patients were suitable for
liver resection for CLM. The remainder of patients was
excluded due to extensive bilobar disease, or insufﬁcient
future liver remnant (FLR) which increases the risk of
postoperative liver failure. The technique of 2-SLR with
portal vein embolization (PVE) can increase the number
of patients eligible for resection.
Methods: Between January 2001 and May 2008, patients
with multiple CLM considered suitable for 2-SLR were
prospectively followed up. Stage 1 resection involved
resection of metastasis in the left lobe of liver with or
without radiofrequency ablation (RFA) which was fol-
lowed by right PVE immediately postoperatively. The
ﬁnal stage of liver resection with curative intent ensues
with a right or extended right hepatectomy to remove all
metastases. All patients received neoadjuvant chemo-
therapy prior to initial hepatic resection and 3 patients
received adjuvant chemotherapy following stage 2.
Results: Twenty-nine patients (11 male, 18 female),
median age of 61 (range 36–82; 7 above age 70) under-
went a staged liver resection. The median average num-
ber of metastases after chemotherapy was 4 (range 1–31),
and the median size of the largest metastasis was 30mm
(range 10–87). 25 patients (86%) completed staged 2
resection, 18 (62%) of which were with curative intent.
Seven patients (24%) were found to have disease pro-
gression, but proceeded to undergo resection of tumors.
Stage 2 was abandoned in 4 (14%) patients due to pro-
gressive extra/intrahepatic disease. Overall survival (OS)
after limited stage 2 resection was 67 and 33% at 1 and
2 years. In patients who underwent curative resection,
the OS after hepatectomy was 83, 28 and 6% at 1, 2 and
3 years. The mean OS was 20.4 months (range 2–79) with
2-SLR, with median follow-up of 19 months. Disease
free survival after 2-SLR was 24 and 4% at 1 and 2 years
respectively. There was one major complication of bile
leak requiring repeated percutaneous drainage, and no
perioperative mortality. Four patients later developed
recurrence in the left lobe of the liver and underwent
further RFA.
Conclusion: This study conﬁrms the safety and beneﬁts
of 2-SLR in patients with CLM where previously would
be unsuitable for curative resection. The use of preop-
erative staging modalities, as well as molecular tumor
markers may help in the decision to proceed with 2-SLR.
The role of adjuvant chemotherapy in 2-SLR should also
be considered.
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Predictive factors for outcome after surgery for
colorectal liver metastases: reassessment in a
recent cohort
A. BUGGENHOUT, MD, V. LUCIDI, MD, B.
NEBBOT, MD, J. L. VAN LAETHEM, MD, PHD and
V. DONCKIER, MD, PHD
Hoˆpital Erasme, Universite´ Libre de Bruxelles, Brussels,
Belgium
Aim of the study: Constant progresses in the manage-
ment of patients with colorectal liver metastases (CRLM)
justify to regularly reevaluate the value of predictive
factors for selecting patients for surgery. We reviewed
several established prognostic factors and scores in a
recent series of patients operated for CRLM.
Methods: Sixty-one consecutive patients undergoing a
ﬁrst liver resection for CRLM were reviewed. Classical
factors were analyzed to assess their predictive values on
operative morbidity and mortality and overall (OS) and
disease free survivals (DFS). The accuracy of two prog-
nostic scores was evaluated, Score I: node positive pri-
mary tumor, disease free interval < 12 months, number
of CRLM > 1, largest tumor > 5 cm and CEA
> 200 ng mL-1 (Fong. Ann Surg 1999) and Score II:
inﬂammatory response to tumor and number of CRLM
> 8 (Malik. Ann Surg 2007). Univariate and multivariate
comparisons were made with chi square or Fischer’s
exact tests and Cox model. Predictive values of scores I
and II were analyzed with Wilcoxon-Mann-Withney test.
Results: CRLM were synchronous in 70%, multiple in
63% and bilobar in 30%; 84% of the patients received
preoperative chemotherapy (response rate: 84%). Major
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resections were performed in 48% and 2-steps hepatec-
tomy in 12%. In 12% of the cases, a combined Radio-
frequency was performed on additional non resectable
lesion. Operative mortality and morbidity were 3 and
30% respectively. A largest tumor > 50 mm and a
2-steps hepatectomy were the only signiﬁcant univariate
prognostic factors for operative morbidity. Median
follow-up was 15 months. One and 2-years OS and
DFSwere 92 and 89% and 47 and 30% respectively.
Positive lymph nodes at primary tumor, number of
CRLM, bilobar distribution, increased CEA level and
use of RF were signiﬁcantly associated with tumor
recurrence in univariate but not in multivariate analyses.
Score I was found predictive of tumor recurrence, with a
most discriminative score of 2 (P = 0.001) but no
prognostic value was demonstrated for Score II.
Conclusion: In this recent series of patients operated
for CRLM, none of the classical risk factors used to
predict tumor recurrence after resection were found
signiﬁcant in multivariate analysis. Only clinical score I
(Memorial Sloan-Kettering Cancer Center) was found
predictive. While the large majority of the patients
received active neoadjuvant chemotherapy, a preoper-
ative score > 2 remained associated with high short-
term tumor recurrence rate, questioning the beneﬁt of
surgery and underlying the need to consider other
adjuvant therapies and more sensitive biomarkers in
these cases.
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Increased survival by clip score category after
stereotactic body radiotherapy in patients with
hepatocellular carcinoma
R. SCOTT, MD, H. CARDENES, MD and
M. MALUCCIO, MD
Indiana University School of Medicine, Indianapolis, IN,
USA
Introduction: The absolute impact of cancer therapy is
measured by how long a patient lives compared to their
pre-treatment life expectancy. For patients with hepato-
cellular carcinoma (HCC), life expectancy is often
determined by a combination of liver and tumor related
variables. The Cancer of the Liver Italian Program
(CLIP) score is a validated measure of survival in
patients with HCC and has been used to assess survival in
large cohorts of patients. The objective of this study was
to evaluate the impact of treatment with stereotactic
body radiotherapy (SBRT) on survival of HCC patients
by comparing pretreatment CLIP score estimates of life
expectancy to post therapy survival.
Methods: Records from forty patients treated with
SBRT at Indiana University between March 2005 and
July 2008 were reviewed. Eligible patients had one to
three lesions with a maximum sum of diameters up to
6cm. Patients were treated by receiving either 1200–
1600 cGy per fraction, 3 fractions or 800 cGy, 5 frac-
tions. CLIP scores were calculated for each patient and
patients were stratiﬁed by scores 0–4. Life expectancy
was estimated based on published survival rates for each
CLIP category. Post treatment survival was calculated
using Kaplan Meier methodology. The absolute survival
beneﬁt for each subgroup was evaluated by comparing
the predicted survival of patients based on their CLIP
score to the post treatment survival.
Results: The median follow-up for the entire population
was 10.7 months from the last SBRT treatment date.
Eight patients (20%) have died. No patient died of cancer
progression. Thus far, our population does not include
enough events in the CLIP 0 category to report survival
data. However, survival in the CLIP 1, 2 and 3 groups
has been 90% at 32.4 months follow-up for CLIP 1, 67%
at 19.1 months follow-up for CLIP 2 and 50% at
25.2 months for CLIP 3. The sole CLIP 4 patient sur-
vived 13.9 months. Comparatively, pre-treatment life
expectancies for CLIP 1, 2, 3, and 4 are 32, 16.5, 4.5, and
2.5 months, respectively. This translates to a net survival
beneﬁt of 0.4, 2.6, 20.7, and 11.4 months in CLIP 1–4,
respectively.
Conclusions: SBRT has the potential to prolong survival
in the majority of patients with HCC compared to pre-
treatment survival estimates. This increase may provide
immeasurable beneﬁt for individual patients. Further-
more, as many of these patients may be potential trans-
plant candidates, the additional time may provide a
cushion for patient work-up, health optimization, and
time spent on the wait-list prior to transplant.
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Use of oxaliplatin and irinotecan prior to
hepatic resection of colorectal cancer metastases
is not associated with chemotherapy-associated
steatohepatitis (CASH) in a clinic-based
Canadian population
P. RYAN, MD, S. NANJI, MD, J. GLEICHER, B.SC.,
J. TESSOLINI, B.SC., N. ZWINGERMAN, NONE,
A. POLLETT, MD, M. GUINDI, MD,
C.-A. MOULTON, MD and S. GALLINGER, MD
Mount Sinai Hospital, Toronto, ON, Canada; University
Health Network, Toronto, ON, Canada; University of
Toronto, Toronto, ON, Canada
Background: Newer chemotherapeutic agents have been
linked to liver parenchymal injuries. In particular
chemotherapy-associated steatohepatitis (CASH) and
diffuse sinusoidal injury have been linked to use of iri-
notecan and oxaliplatin, respectively. We assessed the
prevalence of parenchymal liver injury and correlated
ﬁndings with chemotherapy use, tumor response, and
postoperative complications.
Methods: Two hundred and forty-six hepatic resections
for metastatic colorectal carcinoma from 2004 to 2007
were reviewed in a blinded fashion. Each case was scored
for steatohepatitis, vascular injury, and tumor response
using established histological criteria. Chemotherapy and
perioperative complication data were available for ret-
rospective analysis in 206 cases.
Results: In the year prior to hepatic resection 25 patients
received 5-ﬂuorouracil (5FU) alone, 33 irinotecan with
5FU, 24 oxaliplatin with 5FU, 8 all 3 agents, and 116 did
not receive chemotherapy. Signiﬁcant tumor response
was seen only in cases that received newer agents prior to
surgery (15/65, 23%). Steatohepatitis was identiﬁed in
four cases (1.9%) – one case who received irinotecan and
three that did not receive chemotherapy. Vascular injury
was seen in all treatment groups but was signiﬁcantly
associated with oxaliplatin (P < 0.05). Multivariate
analysis of complications using logistic regression
showed a signiﬁcant association with male gender
(P = 0.019) and increased body mass index (P = 0.046),
but not with chemotherapy.
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Conclusions: No signiﬁcant association was demon-
strated in this series between the use of newer chemo-
therapeutic agents and CASH. While the vascular hepatic
injuries identiﬁed were associated with oxaliplatin, the
use of chemotherapy prior to surgery was not associated
with increased post-operative complications.
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National trends in inpatient treatment and
procedure-related mortality for hepatocellular
carcinoma
H. NATHAN, R. D. SCHULICK, M. A. CHOTI and
T. M. PAWLIK
The Johns Hopkins University, Baltimore, MD, USA
Introduction: Although therapeutic options for hepato-
cellular carcinoma (HCC) have evolved over the last
decade, the population-level impact of these changes on
treatment patterns for HCC has not been studied. We
sought to characterize national trends in the application
and procedural mortality of inpatient therapeutic inter-
ventions for HCC.
Methods: The 1998–2006 Nationwide Inpatient Sample
was used to identify all HCC-related hospitalizations.
Population estimates of in-hospital therapy – major
hepatectomy (MH), hepatic wedge resection (WR),
ablation, liver transplantation (LT), and chemotherapy/
transcatheter arterial chemoembolization (TACE) – and
mortality were calculated for each year. Averages over all
years were calculated using inverse variance weighting,
and trends were analyzed using variance-weighted least
squares regression.
Results: The annual number of HCC-related hospital-
izations increased from 17 510 in 1998 to 30 339 in 2006
(P < 0.001). The number of HCC-related procedures
similarly increased from 3905 to 7168 (P < 0.001), and
the number of procedure-related hospitalizations rose
from 3056 to 5694 (P < 0.001). Although the number of
MH remained constant at 489 (P = 0.3), the share of
procedure-related hospitalizations attributable to MH
declined from 16% to 8% (P = 0.01). The number of
WR increased (499 to 697, P = 0.001), as did the num-
ber of TACE (1692 to 2898, P = 0.002), but the share of
procedure-related hospitalizations remained constant for
both (P > 0.05). For ablation, in contrast, both the
number (226–1287, P < 0.001) and share of hospital-
izations (7–23%, P < 0.001) rose dramatically. Simi-
larly, for LT, both the number (212–659, P < 0.001) and
share of hospitalizations (7–12%, P = 0.001) increased.
While mean hospital volume remained constant at 17 for
MH (P = 0.5), it increased for both ablation (13–21,
P = 0.02) and LT (40–81, P < 0.001) and actually de-
clined for WR (44–30, P = 0.009). Teaching hospitals
performed a smaller share of WR over time (91–85%,
P = 0.001) but a larger share of ablations (77–83%,
P < 0.001); there was no change for MH (88%),
LT (100%), or TACE (88%) (all P > 0.05). In-hospital
mortality for MH (9.6%) was higher than for WR
(5.1%), ablation (4.1%), LT (3.7%), and TACE (2.4%)
(all P < 0.05). No changes in procedural mortality rates
occurred over time (all P > 0.05).
Conclusions: The overall increases in HCC-related
hospitalizations and procedures have been characterized
by a shift toward ablation and LT. An increase in WR
has also occurred with a notable decentralization towards
lower-volume and non-teaching hospitals. MH remains
associated with increased in-hospital mortality as com-
pared with other HCC therapies.
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The role hepatic intra-arterial injection of
doxorubicin eluting beads in hepatocellular
cancer: results of multi-institutional study
N. P. REUTER, MD, R. D. TOMALTY,
R. G. O’HARA, MD, B. STRNAD, MD,
K. M. MCMASTERS, MD, PHD, C. R. SCOGGINS,
MD and R. C.G. MARTIN III, MD
University of Louisville, Louisville, KY, USA; Huntsville
Hospital, Huntisville, AL. USA; Memorial Hospital,
Colorado Springs, CO, USA; Covenant Health, Oak
Ridge, TN, USA
Purpose: Hepatic intra-arterial therapy for unresectable
hepatocellular cancer (HCC) has been demonstrated to
improve overall survival, but can have signiﬁcant toxic-
ity. Results from the recent prospective randomized
control trial comparing conventional chemoembolization
to doxorubicin eluting beads (DEB) has demonstrated
superior response rates and signiﬁcantly less morbidity
and less doxorubicin related adverse events. The aim of
this multi-institutional study was to assess the safety and
efﬁcacy of DEB delivered by trans-arterial infusion for
the treatment of unresectable HCC.
Methods: This open-label, multi-center, multi-national
single arm study included 41 HCC patients (Pt’s) who
were not a candidate for transplantation or resection.
Patients received DEB (max 150 mg per infusion) at each
treatment. Complications were graded by the Cancer
Therapy Evaluation Program Common Terminology
Criteria for Adverse Events (CTCAE) version 3.0.
Response rates were graded by the modiﬁed RECIST
criteria.
Results: These 41 pt’s received a total of 88 DEB (range
1–12) treatments. Six patients with portal vein throm-
bosis (PVT) underwent 15 treatments with no complica-
tions. Eight patients while on concurrent sorafenib
underwent 18 treatments and tolerated both therapies
without major complications. Fourteen patients had
prior Yttrium-90 therapy and had failed or progressed
and were treated with 23 treatments with one major
complication. After a median follow up of 12 months we
have seen an overall response of 72% (9CR, 20PR),
Stable Disease: 16% (n = 7), and progression in ﬁve
patients with three in the peritoneum, and two with new
sites of liver disease. Five patients have been downstaged
with additional liver therapy, two transplant and three
patients resection/ablation. There was a non-signiﬁcant
reduction in alpha feto protein levels of 3143 (P = 0.27).
PVT did not affect overall survival (9.3 vs. 6.2 months
with and without respectively, P = 0.83).
Conclusions: Hepatic intra-arterial injection of DEB’s is
safe and effective in the treatment of HCC as demon-
strated by a minimal complication rate and tumor
response. DEB appear safe in patients with PVT, prior
Yttrium therapy, and while receiving concurrent sorafe-
nib treatment, but further larger studies are needed to
conﬁrm this data, and establish where hepatic arterial
precision chemotherapy should be utilized in the
algorithm of the HCC patient.
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Obesity and its impact on cancer-speciﬁc
outcomes following liver resection
A. K. MATHUR, MD, K. SELL, B.SC.,
M. J. ENGLESBE, MD, C. J. SONNENDAY, MD and
T. H. WELLING, MD
University of Michigan, Ann Arbor, MI, USA
While obesity may affect perioperative outcomes follow-
ing hepatectomy, its effect on cancer-speciﬁc outcomes is
unknown. We hypothesized that obesity may impact
recurrence and survival following hepatectomy for
malignancy.
Methods: We retrospectively reviewed 660 patients
undergoing hepatic resection from 1996 to 2006 at our
center. Patient factors including diagnosis, age, resection
type, comorbidities, and obesity (BMI > 30) were eval-
uated. Post-resection recurrence was assessed by CT or
MRI. Mortality was determined using the Social Security
Death Master File. Risk-adjusted models for recurrence
and mortality were constructed using the Cox propor-
tional hazards method.
Results: 359 patients had adequate BMI data.
76 (20.7%) patients had benign disease, 82 (22.3%) had
primary hepatobiliary cancers (HB), 137 (37.2%) had
colorectal metastases (CRM), and 73 (19.8%) had other
resectable liver metastases (OM). 33.3% of patients with
malignant disease (n = 291) were obese. Mean age was
59.1 ± 12.3 years, and was similar by obesity group
(P = 0.99). Obesity was more common in males (61.8%
males vs. 49.8% females, P = 0.04), but was similarly
distributed across diagnoses (37.8% HB vs. 34.3% CRM
vs. 26.3% OM, P = 0.31). The existence of comorbidi-
ties or liver disease was not signiﬁcantly different between
groups. Extent of resection, margin status, and receipt of
adjuvant chemotherapy were similar across the
cohort. Obese patients had more biliary leaks (18.9% vs.
9.0%, P = 0.02), intra-abdominal abscesses (7.2% vs.
1.5% P = 0.01), urinary tract infections (17.5% vs. 7.2%
P = 0.007), and pneumonias (8.2% vs. 3.1% P = 0.05).
Postoperative peak AST, ALT, and total bilirubin were
higher in the obese (P = 0.04, P < 0.001, P = 0.02,
respectively). Median follow-up was 29 months. 53.1%
patients recurred and 51.2% died. Overall, obese patients
had signiﬁcantly longer time to recurrence vs. the non-
obese (14.5 months vs. 12 months, P = 0.01). Overall
survival was not signiﬁcantly different. Independent
predictors of recurrence in the multivariate risk-adjusted
model were CRM diagnosis [HR 0.45, 95% CI
(0.28–0.72)], male sex [HR 2.0, 95% CI (1.34–3.00)], and
post-operative liver failure [HR 15.8, 95% CI (2.03–
123.0)]. Obesity was independently associated with a
decreased recurrence rate (HR 0.58, 95% CI (0.38–0.89).
Conclusions: Our study suggests that while the obese
may have a higher rate of perioperative complications
post hepatectomy, obesity independently confers a re-
duced risk of cancer recurrence. Further study is required
to determine whether the obese have a greater tolerance
for adjuvant therapies or have an inherently different
susceptibility to cancer progression.
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Long-term outcomes after RFA compared to
resection of colorectal liver metastases
A. MCKAY, MD, K. FRADETTE, B.SC. and
J. LIPSCHITZ, MD
University of Manitoba, Winnipeg, MB, Canada;
CancerCare Manitoba, Winnipeg, MB, Canada
Recently some have called for randomized controlled
trials comparing RFA to hepatic resection, particularly
for patients with only a few small metastases. The
objectives of this study were to compare local recurrence
rates and overall survival following open RFA and
hepatic resection for colorectal liver metastases.
Methods: This was a retrospective review of open RFA
and hepatic resection for CRC liver metastases between
January 1999 and May 2007 at two University hospitals
in Winnipeg, Manitoba. All patients who had RFA were
considered to have unresectable disease. A subgroup
analysis comparing outcomes of patients with solitary
metastases who underwent RFA to those who underwent
hepatic resection was planned a priori.
Results: Fifty-eight patients had hepatic resection and 43
had RFA. Mean follow-up was 32 months. The only
operative mortality was seen in a patient who had RFA
alone. OR time, blood loss, and transfusions were higher
for resection. Rates of ICU admission and length of stay
were not different. Complications were not signiﬁcantly
different between groups. OS and DFS were signiﬁcantly
better after resection than RFA. 5-year survival after
resection was 43% compared to 23% after RFA. On
univariate analysis, surgical resection, age under 70,
metastases smaller than 5 cm, less than ﬁve lesions, and
synchronous lesions were positive prognostic factors. See
Table 1 for the results of the multivariate analysis. For
patients with solitary lesions, 5-year survival was 48%
after resection and 15% after RFA. Even when limited to
solitary lesions that were 3 cm or less in diameter, the
survival associated with resection was signiﬁcantly
greater than with RFA. While the proportions of patients
with distant recurrences and recurrences elsewhere in the
liver were not different between groups, the incidence of
local recurrence was dramatically different. Over the
course of the study, 60% of patients who had RFA
suffered local recurrences compared to 7% of patients
who underwent hepatic resection (P < 0.0005). The
local recurrence rate in small (£ 3 cm) solitary lesions
treated by RFA was still 50%.
Conclusions: RFA is not equivalent to hepatic resection.
Although RFA was done in patients with unresectable
disease, the high local recurrence rates and inferior sur-
vival rates raise serious doubt as to the feasibility of
performing a randomized trial at the present time.
Table 1. Multivariate cox proportional hazards regres-
sion model for overall survival.
Variable
Hazard
Ratio*
(95%
Conﬁdence
Intervals) p Value
Procedure
RFA 1.00
Hepatic
Resection
0.36 0.19–0.70 0.0023
Size of Lesion
< 5 cm 1.00
>= 5cm 2.43 1.26–4.67 0.0081
Number of Lesions
< 5 1.00
>= 5 6.08 2.21–16.70 0.0005
Timing of Lesion
Synchronous 1.00
Metachronous 2.92 1.50–5.70 0.0017
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Precision trans-arterial chemotherapy with
doxorubicin-eluting beads (ptace) for hepato-
cellular carcinoma (hcc) in cirrhotics
M. T. SELLERS, MD, K. KEGLEY, MS, PA-C,
R. SHRESTHA, MD, M. W. JOHNSON, MD,
C. BRUNO, MD, M. TAN, MD, H. S. POLLINGER,
DO, D. C. CALDWELL, MD, L. H. JACOBS, MD,
N. B. COOPER, MD, R. A. RUBIN, MD,
M. R. GALAMBOS, MD and S. J. CITRON, MD
Piedmont Hospital, Atlanta, GA, USA
Liver transplantation (LT) is curative for many patients
with HCC and cirrhosis; due to a worsening organ
shortage, LT can’t be utilized immediately upon diagno-
sis, if at all in some patients. Thus, therapy to control
disease while awaiting LT is warranted. Ideally, these
efforts will cure the target lesion(s) to eliminate the risk
of subsequent metastasis or local progression outside
Milan criteria. If consistently curative, the therapy may
eliminate/postpone the need for LT in patients with a low
laboratory-based MELD score, and it would be an
obvious advance in treating non-transplant candidates.
pTACE may provide an advance in this regard.
Methods: This is a retrospective review of 69 LT and
non-LT candidates with cirrhosis/HCC that underwent
pTACE (106 procedures) at our institution, including 11
who subsequently underwent LT.
Results: Fifty patients were male; mean age = 60.4 -
years; mean tumor size = 4.6 cm; 16 had portal vein
thrombosis; 35 were Child’s A, 27 were Child’s B and 7
were Child’s C. 41 of 113 evaluable lesions had a radio-
graphic complete response (CR). Two patients were
downstaged to within Milan criteria and successfully
transplanted. Eight of 11 LT patients had no viable
tumor in their treated lesion(s) on explant histology. Two
patients died following LT (fungal sepsis; recurrent
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hepatitis C in a patient with a laboratory-based MELD
< 15; n = 1 each); there has been no post-LT HCC
recurrence (median follow-up = 612 days;
mean = 604 days). Two patients (2.9%) died within
30 days after pTACE (untreated SBP; pancreatitis;
n = 1 each). 25 pTACE patients have died, the majority
from cirrhotic complications. Non-fatal adverse events
included acute renal failure, gastric ulceration, groin
infection, metabolic acidosis, gallbladder necrosis/perfo-
ration (n = 1 each); and pancreatitis (n = 2).
Conclusions: pTACE is a relatively safe and potentially
curative HCC therapy in cirrhotics. It may be used as a
bridge to LT or as a stand-alone potentially curative
HCC therapy in non-transplant candidates. Radio-
graphic CR may allow watchful waiting in listed trans-
plant candidates with a low laboratory-based MELD.
Underlying cirrhosis often limits survival more than
HCC after pTACE in cirrhotics.
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Impact of obesity on outcomes following hepatic
resections for metastatic colorectal cancer
M. BOWER, MD, N. REUTER, T. METZGER, RN,
M. BENNS, MD, K. MCMASTERS, MD, PHD, C.
SCOGGINS, MD and R. MARTIN, MD
University of Louisville, Louisville, KY, USA
Introduction: Obesity has become an increasingly com-
mon health problem in the United States. The purpose of
this study was to evaluate the surgical and oncologic
outcomes of patients with resections for colorectal liver
metastasis when stratiﬁed by body mass index (BMI).
Methods: Our 1410 patient prospectively maintained
Hepato-Pancreatico-Biliary database from 8/1996 to 12/
2007 was reviewed for patients with colorectal metastasis.
Patient’s weight was recorded at the time of hepatectomy.
Data included resection type, BMI, operative time,
perioperative complication rate, blood loss, length of
stay, recurrence rate, and overall survival. Complications
were graded using our established 5 points grading scale.
Patients with non-anatomic resections, ablations, and
ablations with resections were excluded from the study.
Results: Overall, 148 patients underwent anatomic he-
patic resection for colorectal metastsis with a median
follow up of 26 months. A total of ﬁve central resections,
57 right lobe lobectomies, 19 left lobectomies, 29 left
lateral lobectomies, 15 right posterior sectorectomies,
and 23 trisegmentectomies were performed. Patient
groups where divided based on the National Institutes of
Health BMI class with 46 (31%) of the patients classiﬁed
as obese (BMI ‡ 30 kg m-2). There was no difference in
mean operative times (176 vs. 166 mins, P = 0.5), mean
estimated blood loss (428 mL vs. 421 mL, P = 0.9),
length of stay (8 vs. 10 days, P = 0.2), or major com-
plication rate (22% vs. 30%, P = 0.5). A difference was
not found in the rate of recurrence at last follow up (54%
vs. 51%, P = 0.7), but obese patients did show a longer
median overall survival (63 vs. 39 months, P = 0.01).
Conclusions: Obese patients have similar peri-operative
outcomes as measured by operative time, blood loss, and
complications when compared to non-obese patients.
Interestingly, when compared to non-obese patients,
obese patients have improved overall survival which may
be a reﬂection of worse nutritional status of non-obese
patients.
Table 1. Results.
Patients demographics n = 148
BMI < 30
n = 102
BMI ‡ 30
n = 46 P-values
Mean length of stay 9.9 days 8.1 days 0.2
Mean operative time 166 mins 176 mins 0.5
Mean estimated blood loss 421 428 0.9
Perioperative mortality 4 (4%) 0 0.3
Median overall survival 39 months 63 months 0.01
Major complication
(Grade 3–5)
46 in 31
patients (30%)
11 in 10
patients (22%)
0.5
Minor complication
(Grade 1–2)
67 in 40
patients. (39%)
20 in 17
patients (37%)
0.8
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Single center experience with living donor right
lobe liver resection
A. A. HARAKEH, MD, A. YOSHIDA, MD, D. KIM,
MD, M. KAZIMI, MD, R. SLATER, MD,
A. A. ABBASS, MD, M. ZANINI, RN, CNP and
M. ABOULJOUD, MD
Henry Ford Hospital, Detroit, MI, USA
Background: The ﬁrst living donor right lobe liver
resection (LDLR) was performed in Hong Kong in 1991.
Since then, this procedure has been the subject of debate.
Questions related to indications, safety, outcomes and
donor risks continue to be a major concern for the
transplant community. In this study, we report our
experience with LDLR as it is not included in the A2ALL
registry.
Material and methods: The adult-adult living donor liver
transplant program was initiated at our center in October
2000. Program implementation followed guidelines pub-
lished by the American Society of Transplant Surgeons.
A retrospective review of living liver donors at our center
was done. Patient demographics, procedure details,
complications, and outcomes were reviewed.
Results: Between December 2000 and August 2008, 698
orthotopic liver transplants were performed with 35 from
living donors. Donor mean age was 42 ± 3.2 years, with
11 males (31%) and 24 females (69%) in the group; 33
(94%) were Caucasian and 2 (6%) were African-Ameri-
can. The follow up period was from the date of surgery
until present. Three donors (9%) chose to follow up with
their own doctors and no long-term information is
available but all had no immediate complications. The
mean hospital stay was 6.6 ± 0.7 days. Procedures
consisted of standard open right hepatic lobectomy (31),
extended right hepatic lobectomy (1) and laparoscopic-
assisted right hepatic lobectomy (3). The mean post-
operative peak SGOT, SGPT, and Bilirubin for the
group was 326.1 ± 45.7, 321.8 ± 54.7, and 2.8 ± 0.5
respectively. Smooth uneventful course was seen in 25
donors (71%), while 10 (29%) developed one or more
complications; 6 (17%) of whom required readmissions.
Grading of complications was according to Clavien’s
classiﬁcation post LDLR; CLAV II in 2 (6%), CLAV
IIIa in 5 (14%), and CLAV IIIb in 3 (9%), with
reoperations for bile leak, post-operative bleeding, and
incisional hernia respectively. Interventions included
ERCP, thoracentesis and percutaneous drainage of
perihepatic ﬂuid. All donors resumed their prior
employment. There were no long-term disability
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issues. None of the donors expressed regrets about
donation.
Conclusion: Despite the ongoing debate, we think that
LDLR is a safe procedure if performed in highly spe-
cialized centers with expertise; knowing that this proce-
dure is associated with complications and full disclosure
to donors and education are important. LDLR would
help expand the donor pool and with introduction of the
laparoscopic-assisted procedure, the donors’ acceptance
and sense of well-being have improved. Our experience
was comparable to the A2ALL published report.
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Peri-operative analysis of laparoscopic vs. open
liver resections: are laparoscopic liver resections
cost-effective?
A. J. ROWE, MD, P. A. SCHUMACHER, MD,
A. K. BUCZKOWSKI, MD, A. T. MENEGHETTI,
MD, MPH, O. N. PANTON, MD,
C. H. SCUDAMORE, MD and S. W. CHUNG,
MD, PHD
University of British Columbia, Vancouver, BC, Canada
Introduction: Over the past decade there has been an
increasing trend toward a minimally invasive approach to
liver surgery. While initially limited by technical chal-
lenges, advances in laparoscopic techniques and instru-
mentation have rendered this approach safe and feasible.
However, as health care costs approach 50% of some
provincial budgets, surgical innovation must be justiﬁ-
able in terms of costs and patient outcomes. With
introduction of standardized post-operative liver resec-
tion guidelines (fast-track) to optimize patient length of
stay in hospital, the advantages of laparoscopic liver
resection (LLR) compared to open liver resection (OLR)
measured by peri-operative cliinical outcomes and
resource utilization are not well-deﬁned. It remains to be
established whether LLR is superior to OLR by these
measurements.
Methodology: A prospective analysis of eighteen LLRs
performed at the Vancouver General Hospital from
2005–2007 was performed. These data were compared to
an equivalent group of twelve consecutive OLRs under-
taken immediately prior to and in preparation for the
introduction of the LLR. Outcomes were evaluated for
differences in peri-operative morbidity, hospital length of
stay, and operative costs.
Results: There were no differences between LLRs and
OLRs in demographics, pathology, underlying cirrhosis,
tumour location, or extent of resection. There were no
deaths. LLRs had signiﬁcantly decreased intra-operative
blood loss (287 mL vs. 473 mL, P = 0.03) and post-
operative complications (6% vs. 42%, P = 0.03) com-
pared to OLRs. There was a trend toward reduced hos-
pital length of stay in LLRs (4.3 vs. 5.8 days, P = 0.07).
There were no differences in operating time for LLRs
compared to OLRs (135 vs. 138 min, respectively), total
time in the operating theatre (214 vs. 224 min respec-
tively), or costs related to trocars and stapling devices
($1267 vs. $1007 respectively).
Conclusions: LLR is associated with decreased morbidity
and decreased resource utilization compared to OLR.
Peri-operative patient outcomes and cost-effectiveness
justify LLR despite introduction of standardized post-
operative liver resection guidelines and decreased length
of stay for OLR.
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Evidence of lipid metabolism reprogramming in
hepatitis C associated hepatocellular carcinoma
J. -M. WU, D. RAFTERY, PHD and M. MALUCCIO,
MD, MPH
Indiana University Schoold of Medicine, Indianapolis, IN,
USA; Department of Chemistry, Purdue University, West
Lafayette, IN, USA; Indiana University School of
Medicine, Indianapolis, IN, USA
Background and aim: Under normal physiological con-
ditions, the liver ensures homeostasis of lipid and lipo-
protein metabolism. The relationship between hepatitis
induced alterations in lipid signaling and hepatocellular
carcinoma (HCC) are unclear. The goal of this study was
to systematically explore lipid metabolism and altered
expressions of genes speculatively participating in hepa-
titis C associated HCC.
Methods: Three groups of human samples were used for
microarray experiment: normal, non-hepatitis infected
livers (n = 9), hepatitis C virus related HCC tumor
samples (n = 9) and adjacent non-tumor liver samples
(n = 11). Total RNA was isolated from these three
groups of samples and microarray was performed using
Affymetrix Human Genome HG U133 Plus 2 GeneChip.
GeneSifter software was used to identify differentially
expressed genes according to Gene Ontology and the
Kyoto encyclopedia of genes and genome (KEGG)
pathways.1H and 31P NMR experiments were performed
using a CMX 400 MHz NMR spectrometer.
Results: Using 1.5-fold change cutoff and the adjusted
P-value < 0.001, one way ANOVA analysis showed
3989 genes were differentially expressed. Gene Ontology
analysis showed metabolic process is a major category
with the highest Z-scores (5.75) in biological process
ontology. Genes related with lipid metabolism were
found to be over-represented. KEGG pathways such as
fatty acid metabolism, PPAR signaling pathway and
bile acid biosynthesis were signiﬁcantly enriched in the
differentially expressed genes. Further analysis revealed
genes related to fatty acid synthesis such as fatty acid
synthase were up-regulated, while genes coding the en-
zymes involved in fatty acid oxidation were down-reg-
ulated in HCC tumor samples compare to normal
control. Genes involved in phospholipids synthesis such
as acyltransferase like 2, phosphoinsitide-3-kinase, class
2 beta polypeptide and phosphatidylglycerophosphate
synthase 1 were overexpressed, but genes related to
cholesterol or bile acid biosynthesis were down-regu-
lated in HCC tumor. NMR spectroscopy revealed
detectable and dynamic changes in the lipid metabolome
in HCC tumor specimens compared to adjacent sam-
ples. Speciﬁc ﬂux modulations were detected such as
glycolysis, phospholipid synthesis and fatty acid syn-
thesis.
Conclusion: Whole genome mRNA proﬁle analysis as
well as NMR analysis showed the extensive repro-
gramming of lipid metabolic pathways in HCC. These
results provided further insight into deviations in lipid
metabolism that may contribute to the development of
cancer.
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Comparison of result of hepatic and lung
resection to recurrences after ﬁrst hepatectomy
to liver metastases of colorectal origin
Y. MISE, MD, H. IMAMURA, MD, T. HASHIMOTO,
MD, Y. SEYAMA, MD, T. AOKI, MD,
K. HASEGAWA, Y. BECK, MD, Y. SUGAWARA,
MD, M. MAKUUCHI, MD, J. NAKAJIMA, MD and
N. KOKUDO, MD
Division of Hepato-Biliary-Pancreatic and
Transplantation Surgery, Graduate School of Medicine,
University of Tokyo, Tokyo, Japan; Department of
Hepatobiliary-Pancreatic Surgery, Juntendo School of
Medicine, Tokyo, Japan; Department of Cardiothoracic
Surgery, Graduate School of Medicine, University of
Tokyo, Tokyo, Japan
Introduction and aim: More than 60% of patients
undergoing hepatectomy for colorectal liver metastases
experience recurrence with the liver and lung being the
most frequent site of recurrence. Although repeated
resection provides the only hope for cure, the prognoses
of patients with liver and lung recurrence have not been
correctly compared. We tried to address this question.
Patients: Patients in whom the recurrence was detected
(n = 166) after hepatectomy to colorectal liver metas-
tases conducted in 216 patients.
Methods: We investigated (i) the pattern of recurrences;
(ii) the proportion of patients undergoing repeated
resection and (iii) survival rates of patients after repeated
resection.
Results: (i) Seventy-one had isolated hepatic recurrence
(Liver Rec.), 25 had isolated lung recurrence (Lung Rec.),
13 had isolated hepatic and lung recurrence (Liver &
Lung Rec.), and the remaining 57 had other organ
recurrence. (ii) 60 of 71 (85%) with Liver Rec., 21 of 25
(84%) with Lung Rec., and 9 of 13 (69%) with Liver &
Lung Rec. underwent repeated resection. In these
90 patients, the imbalance between groups was found in
the following variables: disease free interval (DFI) from
the primary tumor resection, DIF from the ﬁrst hepa-
tectomy, CEA values, the size and the number of
metastases at repeated resection. (iii) The 3- and 5-year
survival rates from the repeated liver resection are as
follows: 58 and 39%, 60 and 37%, and 20 and 20%
(Liver Rec., Lung Rec. and Liver & Lung Rec., respec-
tively). Multivariate Cox analysis revealed that four
variables contributed to the poor prognosis (hazard ratio
[95% CI]): the number (1.20 [1.11–1.29]) and the maxi-
mum size (1.26 [1.02–1.48]) of tumor nodules at repeated
resection, the lung recurrence (2.36 [1.41–3.20]), both
lung and liver recurrence (4.01 [2.86–5.17]).
Conclusion: Patients with lung and liver/lung recurrences
portend poorer prognoses than those with hepatic
recurrence. However, the re-resection is the only poten-
tially curative treatment and under the more strict indi-
cation criteria especially regarding the number of tumor
nodules, the comparable long-term outcome to those
with hepatic recurrence can be expected.
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Effect of minimally invasive liver surgery (mils)
on hospital resource utilization
A. MEJIA, MD, C. FOWLER, RN, CNP and
S. CHENG, MD
Liver Institute at Methodist Dallas, Dallas, TX, USA
Introduction: Minimally Invasive Liver Surgery (MILS)
is slowly becoming widely accepted at specialized centers.
There are very few studies analyzing the costs and re-
source utilization of this approach. In order to determine
the ﬁnancial impact of these techniques, we compared the
hospital charges of the open and MILS techniques at our
program.
Methods: A retrospective review of all the charges asso-
ciated with each case was performed. Data was obtained
from the hospital database and under IRB approval.
ANOVA and chi-square tests were used for statistical
analysis. All ﬁgures are reported in US dollars (USD).
Results: A total of 101 liver resections were performed
between 7/05 and 8/08 (open 47%; MILS 53%) at
Methodist Dallas Medical Center. Length of stay (3.2 vs.
5.5 days) and blood loss were signiﬁcantly less for MILS
vs. open (P < 0.001; P = 0.003, respectively).Tumor
size was larger for the open group (6.1 vs. 4.6 cm;
P = 0.04). Results of the charges analysis is shown in
Table 1. The MILS group revealed a signiﬁcantly higher
operative room charge, but a signiﬁcantly lower charge in
all other categories. However, total hospital charges are
not signiﬁcantly different for both techniques
(P = 0.93).
Table 1. Resource utilization in liver surgery in USD.
MILS
(n = 54)
OPEN
(n = 47) P-value
OR Charges 20648 14513 < 0.001
Blood Bank 846 1853 0.005
Laboratory 2232 3150 0.005
Respiratory 756 1519 < 0.001
ICU charges 3042 8528 < 0.001
Pharmacy 3806 5322 0.001
Total Hospitalization 36868 36637 0.93
Discussion: MILS techniques require the use of expen-
sive tools in order to make the procedure safer, causing
an increase in the cost of the actual procedure. However,
all the charges following the surgical procedure are
signiﬁcantly lower than the open cases. From the eco-
nomical standpoint, the higher charges in the operating
room offset the lower charges associated with a shorter
hospital stay resulting in no difference between both
techniques. From the medical standpoint, the patients
spend less time in the hospital, in the ICU and require
less hospital resources when the MILS is used. As tech-
niques are better reﬁned, the goal should be a better
outcome, a safe operation and ideally a less expensive
procedure.
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‘Close shave’ in liver resection for colorectal
liver metastases
J. T. LORDAN, T. R. WORTHINGTON, MD, MBBS
and N. D. KARANJIA, MD, MBBS
Royal Surrey County Hospital, Guildford, UK
Introduction: Metastatic spread to the liver occurs in
about 50% of patients with colorectal cancer. The opti-
mal size of a clear liver resection margin remains con-
troversial. The aim of this study was to investigate the
effect of clear margin width on long-term survival after
liver resection for colorectal liver metastases (CRLM)
with a policy of standard neo-adjuvant chemotherapy.
Methods: Consecutive patients (n = 319) who under-
went exploration with a view to liver resection for CRLM
were included over a 10 year period. All patients with
synchronous or early (< 2 years) metachronous tumours
were treated with neo-adjuvant chemotherapy. Data were
recorded prospectively and analysed retrospectively.
Uni- and multivariate analyses were carried out.
Results: Overall survival of the cohort at 1, 3 and 5 years
were 90.3%, 68.1% and 56.1% respectively. The inci-
dence of cancer involved resection margins (CIRM) was
5.8%. 12 patients who were excluded from the survival
analysis had no residual disease. Patients with macro-
scopically involved resection margins (R2) had a poorer
overall survival than those with microscopically involved
margins (R1) (P = 0.04). Involved resection margins
(R1 and R2) had a poorer overall survival (P = 0.002)
than patients with clear margins. Clear resection margins
of any width did not affect long-term survival.
Conclusion: CIRM is an independent predictor of poor
outcome in patients with CRLM, while the size of clear
margin does not affect survival. A standard policy of
neo-adjuvant chemotherapy may be associated with a
low incidence of CIRM and may improve the long-term
outcome of patients with sub-centimetre clear resection
margin widths to resemble those with > 1 cm clear liver
resection margins.
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The efﬁcacy of anatomical resection for
hepatocellular carcinoma within the
Milan criteria
T. KAMIYAMA, MD, PHD, K. NAKANISHI, MD,
PHD, H. YOKOO, MD, PHD, H. KAMACHI, MD,
PHD, M. TAHARA, MD, PHD, D. FUKUMORI,
MD, PHD, T. SHIMAMURA, MD, PHD,
H. FURUKAWA, MD, PHD, M. MATSUSHITA,
MD, PHD and S. TODO, MD, PHD
Hokkaido University, Sapporo, Japan
Objective: The long patients survival (PS) and disease
free survival (DFS) must be hoped when hepatectomy
was performed for the patients with HCC which was
within Milan criteria and transplantable. We analyzed
the efﬁcacy of anatomical resection for hepatocelluar
carcinoma (HCC) within the Milan criteria.
Methods: Between 1990 and 2006, consecutive 322 pa-
tients within the Milan criteria underwent curative
resection and were classiﬁed to Group A (a tumor 5 cm
or less in diameter in patients with single HCC) and
Group B (no more than three tumor nodules, each 3 cm
or less in diameter, in patients with multiple tumors). PS,
DFS, and risk factors were analyzed.
Results: In Group A and B, PS rates and DFS of patients
who underwent anatomical resection were signiﬁcantly
higher than those of patients who underwent non-ana-
tomical resection (P < 0.01, P < 0.05). While the sig-
niﬁcant factors related with PS of Group A were
ICGR15, T.Bil, HCV, anatomical resection, and non-
cancerous liver, those with DFS were ICGR15, T.Bil,
Alb, anatomical resection, tumor size, portal invasion,
and non-cancerous liver by univariate analysis. In Group
A, anatomical resection was signiﬁcant favorite factor of
PS and DFS by multivariate analysis. Whereas the
signiﬁcant factors related with PS of Group B were
ICGR15, AFP, and anatomical resection, those with
DFS were AFP and anatomical resection by univariate
analysis. Anatomical resection was signiﬁcant favorite
factor of DFS by multivariate analysis. Group A was
classiﬁed to four subgroups according to anatomical /
non-anatomical resection and the value of ICGR15;
Group IA (anatomical resection, ICGR15 < 15%:
n = 109), Group IIA (non-anatomical resection,
ICGR15 < 15%: n=47), Group IIIA (anatomical
resection, ICGR15 ‡ 15%: n = 45), and Group IVA
(non-anatomical resection, ICGR15 ‡ 15%: n = 86).
The PS and DFS curve of Group IVA was signiﬁcantly
worse than other three groups (P < 0.05). The PS curve
of Group IIIA was almost the same as that of Group IIA
until 8 years after LR. The DFS of Group IIIA was
better than that of Group IIA, and the curve of the DFS
up to about 5 years was similar to Group IA. Group B
was also classiﬁed to 4 subgroups; Group IB (n = 9),
Group IIB (n = 6), Group IIIA (n = 6), and Group
IVA (n = 14). The PS and DFS curve of Group IB was
signiﬁcantly better than the other groups.
Conclusion: Anatomical resection should be performed
for the patients with HCC which was within Milan cri-
teria and transplantable.
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Characteristics and frequency of chemotherapy-
associated liver injury following neo-adjuvant
therapy for colorectal metastasis
M. R. POREMBKA, MD, B. R. TAN, MD,
E. M. BRUNT, MD and D. C. LINEHAN, MD
Washington University in Saint Louis, Saint Louis, MO,
USA
Background: Neoadjuvant FOLFOX (folinic acid,
5-ﬂorouracil, and oxaliplatin) chemotherapeutic regi-
mens are used to improve tumor resectability and reduce
recurrence in patients with colorectal liver metastasis
(CLM). However, systemic FOLFOX treatment fre-
quently results in parenchymal injury.
Methods: Clinicopathological data was retrospectively
collected on patients undergoing major liver resection
(‡2 segments) for CLM between January 2003 and
January 2008. Patients who received neoadjuvant
FOLFOX-based chemotherapy were selected; resected
specimens were evaluated for sinusoidal injury, steatosis,
and subcapsular hemorrhage by a single pathologist. The
presence of injury was correlated with the treatment
regimen.
Results: Neoadjuvant FOLFOX was given to 49 patients
and major liver resection was performed in 16 patients
(median age 54.4 years; male 50%; right hepatectomy,
12; left hepatectomy, 1; left lateral sectionectomy, 3).
Bevacizumab (6 patients, 38%) or cetuximab (9 patients,
56%) was commonly used with FOLFOX chemotherapy.
Fourteen patients (88%) were observed to have paren-
chymal injury: sinusoidal obstruction (11 patients, 69%),
steatosis (11 patients, 69%), and subcapsular hemor-
rhage (10 patients, 63%). There was no correlation be-
tween the type of injury and the addition or bevacizumab
or cetuximab. Median time from oxaliplatin adminis-
tration to surgery was 32 days (range 15–70 days). The
presence of sinusoidal injury decreased with increasing
time between ﬁnal oxaliplatin administration and surgery
(< 30 days, 80%; 30–60 days, 67%; > 60 days, 50%);
however, there was no difference in median length of stay
of patients with sinusoidal injury: 10 days, 8 days, or
11 days, respectively (NS).
Conclusion: Neoadjuvant FOLFOX administration for
CLM is associated with combined hepatic injuries
including sinusoidal obstruction, steatosis, and subcap-
sular hemorrhage. Although fewer patients were
observed to have sinusoidal injury with increasing time
between ﬁnal oxaliplatin administration and surgery,
about 50% of patients had persistent injury. Further
studies are needed to investigate the optimum adminis-
tration of FOLFOX chemotherapy.
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Systematic review of combined liver and vena
caval resection for malignancy
J. G. WEAVER, MD, A. W. HEMMING, MD and
E. DIXON, MD
University of Calgary, Calgary, AB, Canada; University
of Florida, Gainesville, FL, USA
Purpose: To perform a systematic review of the existing
literature to identify the best available evidence regarding
combined liver and vena caval resection for malignancy.
Methods: AMedline search was performed to identify all
relevant articles. Search terms used were ‘cava’ and ‘liver
resection’. In addition, the references of those articles
identiﬁed were searched for additional pertinent papers.
Articles up to January 2008 were considered.
Results: A total of 39 articles were identiﬁed, of which 22
were excluded (redundant series, lack of survival data,
case reports). Seventeen articles were identiﬁed for
analysis. All were retrospective case series published
between 1990 and 2007. A total of 185 patients under-
went combined resection, with a median age of 56 years,
and a 56% predominance of males. Colorectal metastases
accounted for 48% of the operative indications, with the
remainder being split amongst cholangiocarcinoma
(20%), hepatocellular carcinoma (17%), leiomyosarcoma
of the cava (7%), and other pathologies (8%). The
median number of tumors resected was 1.9 ± 0.5, and
the median tumor size was 7.5 ± 2.6 cm. Extended
hepatectomy accounted for the majority of resections
(52%). With regards to caval reconstruction, 51% of
patients received a tube graft, 33% were repaired pri-
marily, and 16% were patched. Ex vivo procedures were
performed in 6.5%. Peri-operative mortality ranged from
0 to 50% (median 7.7 ± 2.9%), with an average oper-
ating time of 505 min and an average blood loss of
2599 mL. With regards to outcome, the median survival
of patients undergoing combined resection is
26.3 ± 7.8 months, with a recurrence free survival of
15.8 ± 7.6 month. The 1, 3 and 5 year survivals were
68% ± 10.8, 35% ± 15, and 26% ± 8, respectively.
Conclusions: Combined liver and vena caval resection
can be performed safely in experienced centres with peri-
operative mortalities similar to that of liver resection
alone. In addition, resection appears to provide a survival
advantage. Median survival with no treatment is less
than 12 month, with no 5 year survivors reported even
with chemotherapy. With surgery, the median survival
surpasses 2 years (26 month). Caval involvement should
not preclude resection in those patients who would
otherwise be surgical candidates.
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Myoglobinuria after radiofrequency ablation of
liver tumors
G. TELLIOGLU, MD, J. RODRIGUEZ, MD,
J. MITCHELL, MD, A. SIPERSTEIN, MD and
E. BERBER, MD
Cleveland Clinic Foundation, Cleveland, OH, USA
Background: There is scant data in the literature about
myoglobinuria after radiofrequency ablation (RFA) of
liver tumors. The aim of this study is to analyze the
incidence and identify the risk factors involved in this
complication after RFA.
Patients and methods: An initial case of myoglobinuria
and acute kidney injury (AKI) during laparoscopic liver
RFA after 10 years of the liver ablation program led to
the design of this study. Prospective data were collected
on 41 consecutive patients undergoing laparoscopic RFA
at our institution over a 9-month period. Urine myo-
globin, serum creatinine kinase, and serum creatinine
levels were obtained pre- and post-ablation. Variables
were compared between patients to identify possible risk
factors that might be related to this rare complication.
Data are expressed as mean ± standard error of the
mean (SEM).
Results: Two patients were excluded from the study due
to pre-operative myoglobinuria of unknown etiology. Of
the remaining 39 patients, 3 developed dark urine with
signiﬁcant myoglobinuria on post-operative day 1. Two
of these patients had carcinoid liver metastases; the
remaining patient had a metastatic colorectal lesion. The
number of tumors ablated in these patients was 14,
11 and 3 vs. 2.4 ± 0.4 in the rest of the patients.
Cumulative tumor volume was larger in the group of
patients that developed the complication vs. who did not
(127.9 ± 59.5 cm3 vs. 48 ± 3 cm3). Two grounding
pads were used in the 3 patients that had a complication
vs. 4 pads in the rest of the patients. Dark urine was
identiﬁed promptly intra-operatively and treated
aggressively. All of these patients required intensive care
unit (ICU) admission and had a prolonged hospital
stay. Marked elevation of transaminases and creatinine
kinase as well as a drop in hematocrit and platelet count
was observed in patients with myoglobinuria. In our
retrospective review of 706 patients that underwent liver
RFA in the past 10 years we detected 27 patients (3.8%)
with ten or more lesions (11.9 ± 0.4). None of these
patients had signiﬁcant elevation of serum creatinine
post-operatively. In the whole series of 706 patients, 22
(3.2%) were found to have elevated creatinine after liver
RFA, with return to baseline in all but 7 patients in
follow up.
Conclusion: Myoglobinuria after liver RFA is a rare but
potentially devastating complication that may lead to
AKI with signiﬁcant morbidity and prolonged hospital
stay. Patients with large tumor volumes requiring longer
ablation times need to be monitored closely for the
development of this complication. The fact that this was
not observed in other patients with similar tumor char-
acteristics suggests that individual patient related factors
might play an important role.
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Bipolar radiofrequency ablation: procedure and
outcome in 17 patients with 26 ablations
C. BOUTROS, MD, B. YI, MD, N. J. ESPAT, MD,
P. SOMASUNDAR, MD and R. WILLIAMS
Medical Center, Providence, RI, USA
Introduction: Monopolar radiofrequency ablation
(RFA) is lengthy and cumbersome due to ‘radial energy
deposition’ from ionic friction. Microwave ablation
(MWA) based on electromagnetic energy produced from
rotational friction has been proposed as a superior
method of thermal ablation; however, the relatively
lengthy time to achieve complete ablation remains a
concern; especially for multiple same patient ablations.
In the present study we evaluated the role of laparoscopic
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bipolar RFA(BRFA) using ‘line of sight’ energy deposi-
tion for hepatic tumors; ablation time and efﬁcacy were
compared to known published data for MWA (MWA-
7 min for 3 cm lesions-10 min for larger lesions).
Methods: Using a prospectively maintained hepatobil-
iary database, 17 patients undergoing 26 laparoscopic
BRFA were identiﬁed over the interval (9/07–8/08).
Patient characteristics were studied. Lesion size, time to
complete ablation (initial and conﬁrmatory deployment)
and hepatic associated post-operative complications
were evaluated. For patients subsequently undergoing a
staged hepatic resection, pathological evaluation for
viable tumor in the previously ablated area was per-
formed.
Results: Seventeen patients (9 M : 8 F) mean age of
63 years had 26 laparoscopic BRFA. Patient diagnoses
included: metastatic colorectal cancer (12/17), HCC
(2/17), symptomatic isolated gallbladder cancer (2/17),
and adenoma (1/17). The size of the hepatic lesions were
> 3 cm in 16 ablations and < 3 cm in 10 ablations.
Mean ablation time was 6 min ± 2, and there was no
signiﬁcant difference in time needed for ablation between
lesions < 3 cm and those > 3 < 5 cm larger (mean
ablation time for lesions < 3 cm; 5 min 39 s ± 57 s vs.
6 min 17 s ± 2 min for lesions > 3 cm; P = NS).
There were no peri-operative mortalities and no hepatic
associated morbidities. In 5/17 high risk patients (ASA 3,
age > 65) staged liver resection was performed after a
mean period of 6 months. Pathologically, there was no
evidence of viable tumor the previously ablated areas.
Conclusion: Bipolar RFA achieves the most time efﬁ-
cient ablation to what has been reported in the litera-
ture. Line of sight energy delivery enables a safe means
of energy delivery and rapid ablation for lesions studies
(up to 5 cm). The relative shorter ablation time, the
absence of ablation induced inﬂammatory necrosis-zone
and the pathologic absence of viable tumor in resected
specimens supports BRFA as a potential preferred
ablation method for primary and metastatic hepatic
tumors.
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Transarterial Chemoembolization (TACE) of
Hepatocellular Carcinoma (HCC) using
Doxorubicin Eluting Microspheres (DEB):
initial results
E. EHRENWALD, MD, T. SIELAFF, MD,
S. MACKENZIE, MD, K. KOSARI, MD,
S. INAMPUDI, MD, J. MEHLING, MD, A. REDDY,
MD, G. NAZARIAN, MD and C. SMITH, MD
Virginia Piper Cancer Institute, Minneapolis, MN, USA
Methods: Patients with HCC not amenable to other
therapy were treated using doxorubicin-eluting micro-
spheres (DEB-TACE). Twenty-ﬁve patients, mean age
64.1 year, were treated between 2/27/07 and 12/06/07 for
unresectable HCC. Average number of sessions 1.4.
Average dose 55.0 mg (range 25–130 mg) per session.
DEB-TACE was performed using 1–2 vials of 100–300 l
LC beads mixed with 50 mg of Doxorubicin. The
mixture was injected via a microcatheter positioned as
selectively as possible into arteries supplying each tumor.
Clinical and radiologic data were recorded at 24 h,
1 month, 3 months, 6 months, and 12 months following
each TACE procedure. Response rate (RR) was assessed
using radiologic criteria, including presence of arterial
enhancement during 3-phase CT/MR follow-up studies.
Radiologic responses were categorized as follows: (i)
complete response (CR) if no enhancement in residual
tumor, no tumor growth; (ii) partial response (PR) if
arterial enhancement still present, no tumor growth; (iii)
stable disease (SD) if previous (CR) or (PR) is main-
tained at time of last study; (iv) progressive disease (PD)
if increased, vascular tumor growth or new lesion. The
data was retrospectively evaluated. Response rates were
determined based on change in lesion size and and/or
enhancement.
Results: The procedure was technically successful in
96% of the cases. The mean follow up time was
251 days. The one technical failure was due to hepatic
artery dissection. 30 day mortality was 0%. Major
Complications included one instance of pancreatitis
and one case of ﬂash pulmonary edema occurring
within 30 days of the procedure (8%). Another patient
developed a transient fever treated with antibiotics. Of
the 18 patients with imaging follow up data available,
17 (94%) initially responded favorably with either a
CR or PR. Of all 25 patients treated, two were even-
tually resected (8%), and two received liver transplants
(8%). A partial response was seen in six patients
(33%), complete response in 11 patients (61%), with
stabilizing of disease on follow-up imaginging sixteen
patients (89%), and progressive disease in one (5.6%)
of those with follow up imaging data. Two patients
showed dramatic decreases in alpha fetoprotein levels
after DEB-TACE.
Conclusion: TACE using LC beads is a safe and effective
method for palliation of HCC. The treatment may
downsize tumor to resectability or be used as as a bridge
to liver transplantation. Further study is needed to
determine the effect of DEB-TACE on survival.
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Complications related to radiofrequency
ablation of liver tumors. Review of the current
literature and personnal experience
M. A. F. RIBEIRO JR., MD, PHD,
R. M. MACHADO, L. T. SILVA, E. ACHAR, MD,
PHD, E. CHAIB, MD, PHD, L. D’ALBUQUERQUE,
MD, PHD and W. A. SAAD, MD, PHD
University of Sa˜o Paulo City, Sa˜o Paulo, Brazil
Introduction: The rates of complications in the treatment
of liver tumors by Radiofrequency Ablation (RFA) are
signiﬁcantly lower when compared to the surgical
approach although the recurrence rates are higher.
Methods: We raised and analyzed 11 902 cases per-
formed by percutaneous, laparoscopic, and open surgery
and evaluated the rates of local and systemic complica-
tions reported.
Results: Were found biliary/biloma – 0.75%, vascular
lesions – 1.35%, hepatic abscess – 1.18%, difﬁculty in
removing the needle – 0.03%, hepatic infarct – 0.03%,
aneurysm – 0.03%, pleural effusion – 1.5%, ascites – 1%,
intra-peritoneal hemorrhage – 0.75%, skin and abdomi-
nal wall burn – 0.5%, injuries in extra liver bodies –
0.84%, hemothorax – 0.2%, subscapular hematoma –
0.1%, pneumothorax – 0.15%, intra-peritoneal bleeding
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– 0.62% – tumor seeding along the needle tract – 0.78%,
jaundice – 0.3%, liver failure – 1.49%, decreased blood
pressure – 0.07%, cardiac complications – 0.21%, ar-
rhythmias – 0.41%, acute respiratory failure – 0.41%,
seroma – 4.8%, pneumonia – 2.4%. The overall rate of
mortality among the 11.902 cases evaluated was 0.34%.
Conclusion: The mortality and complication rates are
low when compared to surgery, but the recurrence of the
injuries reach values four times higher than the ﬁgures
obtained in open surgeries. Therefore RFA should be
reserved just for patients in whom surgery does not
represent an option for the treatment.
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Mid duct cholangiocarcinoma: is limited bile
duct resection adequate?
I. A. AZODO, MD, A. SAHAJPAL, MD,
C.D. SCHLECK, B.SC., W. S. HARMSEN, MS,
J. KARLSSON, MD, J. H. DONOHUE, MD,
M. B. FARNELL, MD and D. M. NAGORNEY, MD
Mayo Clinic, Rochester, MN, USA
Purpose: To determine the optimal surgical management
of mid duct cholangiocarcinoma (MC).
Introduction: The overall incidence of MC is low and
few reports speciﬁcally address its treatment. Reports
in hilar cholangiocarcinoma and gallbladder cancer
suggest that aggressive resection may also have
improved survival beneﬁts in MC, based on related
embryology. MC may directly involve the liver,
pancreas, duodenum or regional vasculature. Although
central bile duct resection (CBR) with regional
lymphadenectomy and hepaticojejunostomy for MC may
be appropriate selectively, pancreaticoduodenectomy
(PD) may be superior oncologically and more widely
applicable.
Patients and methods: This retrospective, case–control
study reviewed the medical records of 89 patients with
MC or distal cholangiocarcinoma (DC) who underwent
surgical resection at our institution from 1993–2003.
Demographics, patient and tumor features, operative
morbidity, and mortality were assessed for the primary
outcome, survival, and the secondary outcomes, recur-
rence and adequacy of surgical resection.
Results: MC was resected by CBR in 34 patients, PD in
5 patients and DC by PD in 45 patients. Five patients
were excluded for complex tumors. Demographics, clin-
ical presentation, performance status and tumor grade
were similar between groups. Overall AJCC stage and
T-stage were signiﬁcantly greater for DC. Although
operative mortality and morbidity were similar, duration
of hospitalization was signiﬁcantly shorter for CBR
(P < 0.001). CBR was signiﬁcantly associated with
positive resection margins (P = 0.005) and fewer lymph
nodes harvested than PD (P < 0.001). Overall 5-year
survival after CBR for MC and PD for DC was 21% and
28%, respectively. Five-year survival after R0 resection
for CBR and PD was 29% and 30%, respectively. Local
recurrence was greater for CBR than for PD (P =
0.055). Disease-free survival did not differ signiﬁ-
cantly between CBR and PD (20% and 27%, respec-
tively).
Conclusion: Overall, survival after CBR for MC and
PD for DC is similar. Local disease failure for MC after
CBR likely results from increased margin positivity
and fewer lymph nodes harvested at surgical resection.
PD may address the local failure associated with
these ﬁndings without increased operative morbidity
and mortality and should be employed more widely for
MC.
93
Getting to pure notes transvaginal
cholecystectomy, without laparoscopic
or needleoscopic-assistance
A. A. GUMBS, D. L. FOWLER, MD, MPH,
L. MILONE, MD, J. C. EVANKO, A. UDE, MD and
M. BESSLER, MD
Columbia University College of Physicians and Surgeons,
New York, NY, USA
Introduction: Initial excitement for Natural Oriﬁce
Transluminal Endoscopic Surgery (NOTES) has
been partly tempered by the reality that a NOTES
procedure without laparoscopic or needleoscopic-
assistance has not been performed by most groups.
After safely performing laparoscopically-assisted
transvaginal cholecystectomy in an IACUC-approved
porcine model, we embarked on an IRB-approved
protocol to ultimately perform a pure NOTES chole-
cystectomy.
Materials and methods: We describe our experience with
performing a true NOTES tansvaginal cholecystec-
tomy after safely accomplishing three laparoscopically-
assisted or hybrid procedures in humans. To overcome
the retracting limitations of currently available endo-
scopes, we used a 5 mm curved or articulating retractor
that was placed into the abdomen via a separate colp-
otomy in the second and third patient. In a fourth
patient, pneumoperitoneum to 15 torr was obtained via a
transvaginal trocar placed through a colpotomy made
under direct vision and endoscopically-placed clips were
used for both the cystic duct and artery, thus, obviating
the need for any transabdominally placed instruments
or needles.
Results: This patient was the ﬁrst patient to undergo a
completely NOTES cholecystectomy at our institution
and to our knowledge in the U.S. She was discharged on
the day of surgery and has not suffered any complication
after 1 month of follow-up.
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Conclusion: NOTES Transvaginal Cholecystectomy
without aid of laparoscopic or needleoscopic instruments
is feasible in humans. Additional experience with this
technique will be required before comparative studies
to standard laparoscopy and hybrid techniques are
appropriate.
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Cirrhosis is not a contraindication to laparo-
scopic cholecystectomy: results and practical
recommendations
K. T. NGUYEN, MD, PHD, A. TSUNG, MD,
S. W. CHO, MD, D. A. GELLER, MD and
T. C. GAMBLIN, MD
University of Pittsburgh, Pittsburgh, PA, USA
Background: Gallstones occur more frequently in
patients with cirrhosis compared to the general
population. Open cholecystectomy in cirrhotic patients is
associated with a high morbidity and mortality. Several
studies have suggested that laparoscopic cholecystectomy
(LC) in cirrhotic patients is feasible and safe. We present
a large series of cirrhotic patients who underwent LC and
provide practical recommendations for the practicing
surgeon based on our experience with these cases.
Methods: A retrospective review was performed of all
cirrhotic patients undergoing LC since 1999. Seventy-one
patients with gallbladder disease and Child’s A/B
cirrhosis underwent LC. Pre-operative characteristics,
intra-operative ﬁndings, and post-operative outcomes
were analyzed.
Results: Median age was 54 years (range 23–87) with
37 males. The majority of patients were Child’s A cir-
rhotics (93%). Pre-operative imaging (CT/MRI) was
obtained to evaluate abdominal wall varices for port
placement and to rule out concurrent hepatoma. The
primary indication for LC was symptomatic or chronic
cholelithasis (69%). Median operative time was 120 min
(range 45–300 min) with a median blood loss of 50 mL.
pRBC transfusion was required in 1.4% of patients. Tis-
sueLink cautery or Argon beam coagulation was used in
all patients to ensure hemostasis. An additional ﬁfth port
was used in 11.3% of patients to improve retraction and
exposure. Intra-peritoneal drains were placed in 34% of
patients. Conversion to an open cholecystectomy was
required in 4 patients (5.6%). Post-operatively, there was
no 30-daymortality. Complications occurred infrequently
and included: 2 urinary tract infections, 1 pneumonia, and
1 wound infection. No patients developed acute liver
failure. ICU admission was required in 5.6% of patients,
and median length of stay was 1 day (range 1–13).
Conclusion: With proper planning, LC for gallbladder
disease can be performed safely with minimal morbidity
in patients with Child’s A/B cirrhosis. Pre-operative
imaging, selective drain placement, and use of an addi-
tional port or coagulation devices represent important
elements in the laparoscopic management of biliary dis-
ease for Child’s A/B cirrhotics.
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The changing presentation of choledochal cysts
in adults
R. DHUPAR, MD, B. GULACK, D. A. GELLER,
MD, J. W. MARSH, MD and T. C. GAMBLIN, MD
University of Pittsburgh Medical Center, Pittsbugh, PA,
USA; University of Pittsburgh School of Medicine,
Pittsbugh, PA, USA; University of Pittbsurgh Medical
Center, Pittsbugh, PA, USA
Background: Choledochal cysts are uncommon biliary
lesions associated with an increased lifetime risk of cho-
langiocarcinoma. Recent large series from North Amer-
ica have described the presentation and management of
this disease in adults and children over more than a
30 year period. Due to the evolution of imaging and
laparoscopic surgery, we sought to describe our last
3 years experience with the presentation and manage-
ment of choledochal cysts in adults.
Methods: A retrospective review of a prospectively
established database of adults who were managed for
primary choledochal cyst disease was performed. We
analyzed patient demographics, presentation, type of
cyst, pathology, operation, and complications. The
Todani modiﬁcation of the Alonso-Lej classiﬁcation
system for choledochal cysts was used.
Results: Between 8/2005 and 8/2008, 14 adults were
managed for primary choledochal cyst disease. The
average age was 41 years (range 17–86) and 79% were
female. All three men presented with biliary sepsis, while
women presented with pancreatitis (2), abdominal pain
(3), or painless jaundice (1). Three of the women had the
cyst found during laparoscopic cholecystectomy at an
outside institution. Two women had an incidental ﬁnding
after a CT scan for an unrelated issue. 58% of the
patients had an ERCP, 29% had MRCP only, and no
patients were diagnosed or further evaluated by ultra-
sound. Nine patients had Todani type I cysts and had
excision with a Roux-en-Y hepaticojejunostomy. One
patient had a type III cyst and underwent a Whipple
procedure; one patient had a type IV cyst and one had a
type V cyst and had hepatic lobectomies with or without
Roux-en-Y reconstruction. The one patient with a type II
cyst did not have it removed because of decompensated
liver cirrhosis, and was found after laparoscopic chole-
cystectomy to have HCC. The length of stay for those
who had the cyst removed was 7.8 days (range 5–11).
There were no operative or post-operative complications.
All pathology has revealed benign disease, and all
patients have had an uneventful follow-up.
Conclusions: Over the last 3 years 36% of our patients
with choledochal cysts presented after incidental ﬁnding,
either during a laparoscopic operation or after a CT scan
for an unrelated problem. These patients did not have the
classic ﬁndings of abdominal pain, jaundice, and a pal-
pable mass. Increasing utilization of laparoscopy for
gallbladder disease, CT scan for abdominal complaints,
and less use of ultrasound has lead to a change in the
pattern of presentation and ultimate treatment of
choledochal cysts.
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Gallbladder cancer – still a bad disease
D. E. CURTIS, MD, A. KHITHANI, MD,
A. M. MEJIA, MD, S. CHENG, MD and
D. R. JEYARAJAH, MD
Methodist Dallas Medical Center, Dallas, TX, USA
Background: The aim of this retrospective study is to
review our institutional experience with gallbladder
cancer (GC) in the modern era of sophisticated imaging.
Speciﬁcally, the issue of resectiability and ability to
achieve R0 resection in this condition was examined.
Methods: Patients diagnosed with gallbladder cancer
(GC) from January 2005 to May 2008 were identiﬁed by
diagnosis code in the hospital database and a case review
was performed. Presentation, operative data, and
pathology results were of particular interest in this
review.
Results: Twenty-two cases were reviewed, 16 female
and 6 male, with a mean age or 61 years (range 29–87).
The diagnosis of GC was established pre-operatively in
1 case (palliative procedure), intra-operatively in 11,
incidentally following pathologic examination of cho-
lecystectomy (LC) specimens in 9, and liver explant in 1
(OTL). 9/22 (41%) cases were resected with radical
resection (en-bloc cholecystectomy, bile duct resection,
segment 4b/5 liver resection, and lymphadenectomy)
(7 LC, 2 jaundiced). Palliative surgery was performed in
1 (known metastatic), and 1 was removed incidentally
(OTL). The 11 unresectaible cases were deemed such
due to local invasion in 8 (36%) (liver, duodenum, local
LN), metastatic disease in 2 (9%) (ascites, widespread
peritoneal disease), and both in 1 (5%). Of those
treated with radical resections, 7 achieved negative
margins (R0 resection, 78 %), and 2 were margin
positive (22%). Of note, all of the 9 patients with
incidental GC found after LC had residual cancer
following exploration, and 5/9 (56%) were resected with
negative margins.
Conclusions: Even in the modern era of excellent imag-
ing, 32% (R0) of patients with GC are found to be
resectible in this cohort of patients. In this study, all
patients that have GC diagnosed at LC had residual
disease (9/9). However they can be deemed R0 with
aggressive surgery.
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The incidence of gallbladder carcinoma has not
increased in the laparoscopic cholecystectomy
era
G. MORRIS-STIFF, J. ROCHE, M. H. LEWIS and
M. E. FOSTER
Cwm Taf NHS Trust, Llantrisant, UK
Background: An incidental carcinoma is said to be
identiﬁed in approximately 1–2% of cholecystectomy
specimens. With the advent of the laparoscopic approach
to the gallbladder, many have reported an increase in the
annual number of resections performed and hence it may
be expected that the incidence of gallbladder carcinoma
will have increased.
Aims: To examine longitudinal trends in the incidence of
gallbladder carcinoma and dysplasia.
Patients and methods: All patients undergoing cholecys-
tectomy in the period 1999–2007 were identiﬁed from a
prospectively maintained histopathology database. Data
collected included: gender, age, and presence of carci-
noma or dysplasia in the specimen on histopathological
analysis.
Results: During the period of the study 4000 cholecys-
tectomies were performed. The cohort consisted of
8 males and 21 females with a mean age of 63.6 years.
There was a year-on-year increase increase in the annual
cholecystectomy rate from 214 to 269 cases per annum.
A carcinoma was identiﬁed as an incidental ﬁnding in
21 (0.5%) patients, the histological subtypes consisting
of: adenocarcinoma (n = 16); carcinosarcoma (n = 1);
small cell carcinoma (n = 1); anaplastic carcinoma
(n = 1); papillary carcinoma (n = 1); metastatic
(n = 1). Furthermore, dysplasia was seen in 8 (0.2%)
cases and was classiﬁed as mild (n = 7) or moderate
(n = 1).
Conclusions: During the course of the study there has
been a 26% increase in the number of cholecystectomies
performed, however there has been no increase in the
incidence of gallbladder carcinoma or dysplasia during
this period. Indeed, the incidence of incidental carcinoma
may be signiﬁcantly less than previously believed in
the UK.
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The development of a novel endoscopic bipolar
radiofrequency catheter for the palliation of
malignant biliary obstruction
S. E. KHORSANDI, D. ZACHAROULIS,
D. WESTABY, P. SPYROS, L. JIAO and N. HABIB
Hammersmith Hospital, London, UK; University Hospital
of Larissa, Larissa, Greece; University Hospital of
Larissa, Larissa, Greece
Background: EndoHPB is an endoscopic bipolar radio-
frequency (RF) catheter designed to ablate malignant
tumors within the biliary tree. It is anticipated that
EndoHPB will have a role in conjunction with standard
stent deployment in the palliation of malignant biliary
obstruction and if effective, may compete with photo-
dynamic therapy in the management of unresectable
cholangiocarcinoma. The aim of these in vivo experi-
ments was to determine the ability of the device to heat
and coagulate tissue in the common bile duct (CBD), to
determine the power requirement and time parameter to
achieve coagulation, and to assess its ease of operation
via a side endoscope.
Methods: Three female pigs were anaesthetised and
prepared. A Pentax side viewing endoscope (ED3440T)
was used and the opening of the CBD identiﬁed. The
duct was opened and enlarged using cutting forceps
introduced via the biopsy channel of the endoscope. A
0.035’’ · 260 cm Hydra Jagwire (Boston Scientiﬁc) was
inserted into the duct and the EndoHPB catheter was
inserted over this guidewire into the CBD. The device
was connected to the power source (RITA 1500· RF
generator) and varying wattage and time parameters of
EndoHPB activation were applied at different locations
along the CBD within the same animal. On completion
of the experiment the pig was killed, the abdomen opened
and the CBD resected.
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Results: The EndoHPB catheter is compatible with the
Pentax ED3440T side viewing endoscope which has a
3.2 mm biopsy channel. Given the short length of the pig
CBD, it was only possible to test the catheter’s ability to
coagulate tissue without compromising the lumen at two
levels of the duct. The power setting of 5 W for 2 min
appeared to be ideal, with higher power settings above
10 watts producing heating outside the CBD with com-
plete coagulation of the CBD.
Conclusion: EndoHPB is compatible with any endoscope
with 3.2 mm biopsy channel and a working length of
1500 mm. In the porcine model, the ideal bipolar RF
power setting appears to be 5 W for 2 min Based on this
early data, a pilot clinical study to assess the safety and
effectiveness of EndoHPB in the palliation of malignant
biliary obstruction is to be undertaken, data of which
should be available at the beginning of 2009.
99
Surgical treatment of congenital choledocal cyst
in adults: an 11-year single surgeon experience
J. RACCUIA, MD, J. STEELE, MD,
I. NICHIPORENKO, MD and L. ZANK, MD
Saint Vincent’s Hospital Manhattan, New York, NY, USA
Purpose: A single surgeon experience over an 11-year
period is reviewed with adult patients treated surgically
for congenital choledocal cysts with emphasis on long-
term outcome.
Method: From 1996 to 2007 adult congenital choledo-
cal cysts were completely excised in 7 patients. There
were 6 (85.7%) women and 1 (14.3%) man with mean
age of 46.4 ± 18.3 years (range 18–71 years). Pain was
the most common symptom in all patients and was
associated with pancreatitis in 2 (28.6%) and cholan-
gitis in 3 (42.9%) others. All patients were diagnosed
before operation and none had prior surgery for this
condition or evidence of cancer at the time of diagno-
sis. According to Todoni there were 6 (85.7%) with
type IA and 1 (14.3%) with type II cysts. One patient
(type IA) had a second accessory cystic duct originating
from right hepatic duct that entered the dome of the
gallbladder fundus. Another (type II) had a 12 cm
sacular dilatation emanating from the most distal
portion of the common bile duct just above the con-
ﬂuence of the pancreatic duct well within the pancreas
parenchyma and associated pancreas divisum. Com-
plete cystectomy was performed in all patients and
bilio-enteric bypass was created with 6-0 polypropylene
sutures in an interrupted fashion using the Hepp-
Couinaud technique in 6 (85.7%) patients. The other
(type II) had complete intra-pancreatic enucleation of a
large sacular cyst without biliary anastomosis. No
malignancies were detected on ﬁnal pathology and
there were no post-operative complications or deaths.
Long-term results were evaluated by serial serum liver
function tests and sonogram every 3 months for 2 years
then every 6 months thereafter if no biliary abnormal-
ities existed. Mean follow-up was 53.9 ± 33.9 months
(12.6–107.5 months) and no patient had evidence of
stricture or cancer during this period. Two (28.6%)
patients were considered to have fair results based upon
recurrent symptoms: one with fever from episodic
ascending cholangitis (type IA) and another with pain
from pancreatitis (type II). All symptoms resolved by 4
and 10 months respectively after surgery. Results were
excellent in the other 5 (71.4%) patients (type IA) who
remained asymptomatic during the whole follow-up
period.
Conclusion: Choledocal cysts in adult patients are
exceedingly rare and series representing single surgeon
experience is limited. Once diagnosed cysts must be
completely excised due to their malignant potential
and variations of biliary tract anatomy might alter
operative techniques. Management of post-operative
symptoms can be treated medically as no patient
required operative re-intervention. Type IA lesions
seem to have the best overall long-term symptom-free
prognosis.
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Management of pseudoaneurysms after
hepatobiliary surgery
U. GAWLICK, MD, PHD, A. BURDETTE, MD,
S. J. MULVIHILL, MD and C. L. SCAIFE, MD
University of Utah, Salt Lake City, UT, USA
Background: Life threatening post-surgical hemor-
rhage after hepatobiliary surgery can be caused by a
ruptured pseudoaneurysm. Although a rare complica-
tion with a high mortality rate, there is no standard of
care for the optimal management of post-surgical
pseudoaneurysms.
Purpose: The novel approach of stent placement alone or
in combination with transcatheter arterial embolization
(TAE) has been minimally investigated. In this study
we review management and outcome of patients who
have suffered a gastrointestinal hemorrhage after
hepatobiliary surgery to compare stent placement and/or
TAE and surgery.
Methods: This is a retrospective chart review of 8
patients who suffered a gastrointestinal hemorrhage out
of a total of 125 patients who underwent hepatobiliary
surgery at the University of Utah Huntsman Cancer
Hospital between 2002 and 2008. Data was retrieved
from patient electronic charts in collaboration with
the National Surgical Quality Improvement Program
(NSQIP).
Summary: Six out of the 8 patients underwent a pan-
creaticoduodenectomy. One patient underwent a duo-
denal sparing pancreatic head resection and one patient
underwent a distal pancreatectomy and splenectomy.
All 8 patients suffered a gastrointestinal hemorrhage
within 25 days of their initial surgery involving the
gastroduodenal artery (GDA), the superior mesenteric
artery (SMA), or the left gastric artery. To control
their hemorrhage, 3 patients underwent surgical
exploration, 4 patients underwent TAE of the bleeding
artery and/or stent placement across the bleeding ves-
sel, and 1 patient underwent both TAE and stent
placement followed by surgery. Surgical exploration
controlled hemorrhage in all three cases. Stenting of
the common and proper hepatic arteries alone or in
combination with TAE of the GDA controlled hem-
orrhage without further bleeding complications in two
patients. While TAE and stenting of the SMA in one
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patient failed to control bleeding from multiple
pseudoaneurysms and the patient ultimately required
surgical intervention. TAE alone of the GDA and left
gastric artery controlled bleeding in the remaining 2
cases. No patient developed a delayed liver abscess or
organ ischemia after stenting or TAE. Of the 8 pa-
tients, 7 survived and for one patient, support was
withdrawn per the request of family.
Conclusions: There are no established criteria which
guide treatment of patients with a bleeding pseudoan-
eurysm. We found no survival beneﬁt of interventional
radiology techniques over surgical management. Stent
placement alone or in combination with TAE is a viable
option to control pseudoaneurysm related hemorrhage
after hepatobiliary surgery and less invasive than repeat
surgical exploration.
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Meta-analysis of ischemic pre-conditioning in
liver transplantation
A. M. ALHAWSAWI, MD, M. MOLINARI, M.
ALJIFFRY, MD, M. J. WALSH, MD, I. ALWAYN,
MD and K. PELTEKIAN, MD
Dalhousie University, Halifax, NS, Canada
Background: Hepatic ischemic pre-conditioning (IPC)
during organ procurement is one of the strategies used to
prevent ischemia-reperfusion injury (IRI). IPC has been
shown to protect grafts against ischemic injury in animal
models. The value of this strategy on humans is still
controversial.
Methods: A meta-analysis of six RCTs was performed to
assess the efﬁcacy of IP in cadaveric donor hepatecto-
mies. Included studies were identiﬁed by a systematic
literature search of Medline, EMBASE, PUBMED and
Cochrane databases from 1966 until May 2008. Six RCTs
comparing IPC followed by liver procurement mL liver
procurement alone satisﬁed inclusion criteria (n = 338
patients). Primary outcomes were: mortality, initial poor
function (IPF), primary graft non-function (PGNF) and
re-transplantation. Secondary outcomes were biochemi-
cal markers: AST, ALT, total billirubin and INR.
Results: Peri-operative mortality, IPF, PGNF, rate of
re-transplantation and liver function tests were similar in
the two groups. Among ﬁve studies (n = 285 patients)
the OR for mortality was 0.19 (CI 0.02–1.71). Three
studies (n = 163 patients) showed no difference in IPF
(OR 0.69, CI 0.25–1.92) and among 6 studies (n = 338
patients) the OR of PGNF was 0.50 (CI 0.15–1.69). The
rate of IPF and PGNF were 8.4% (7/83) and 1.8%
(3/167) in IPC compared to 12.5 %( 10/80) and 4.1 %
(7/171) in controls. Re-transplantation rate was 3%
(5/167) in the ischemic pre-conditioning group and 3.5%
(6/171) in the control group with OR of 0.98 (CI 0.28–
2.89) (six studies, n = 338 patients).
Conclusions: The results of this meta-analysis from six
RCTs indicate that the potential beneﬁts of IPC in
cadaveric liver transplantation do not translate in mea-
surable improved peri-operative clinical outcomes.
Table 1. Results.
Outcome
Odds Ratio
(95% conﬁdence interval)
Peri-operative Mortality 0.19 (0.02–1.71)
IPF 0.69 (0.25–1.92)
PGNF 0.50 (0.15–1.69)
Re-transplantation 0.98 (0.28–2.89)
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Early outcomes with laparoscopic-assisted living
donor hepatectomy
A. THENAPPAN, T. FISHBEIN, C. MATSUMOTO,
V. RAOFI, K. SHETTY, J. LAURIN, J. PLOTKIN and
L. JOHNSON
Georgetown University Hospital, Washington, DC, USA
Living donor liver transplantation has become an
increasingly common therapeutic modality. We have
performed 37 living donor liver transplants between 1999
and 2008. While open live donor hepatectomy is well
described and can be performed safely, donor risk and
complications continue to serve as a barrier to its routine
use.
Aims: We describe our experience with laparoscopic-as-
sisted donor hepatectomy and its potential as a safe
alternative in living donor liver transplantation.
Methods and results: We performed a retrospective
review of our last 12 successive living donor liver trans-
plants between 2006 and 2008. Six donors underwent
standard open liver resection (OLR), and six underwent
laparoscopic-assisted liver resection (LALR). We com-
pared donor morbidity, length of surgery, hospital days,
blood transfusions, and need for continuous intravenous
analgesics post-operatively. We then evaluated early graft
function and recipient morbidity/mortality between the
open and laparoscopic groups. Laparoscopic-assisted
liver resection was successfully performed in all six cases.
No speciﬁc complication related to laparoscopy was
observed. Length of surgery in LALR, however, was
longer compared to OLR (5.8 ± 0.76 vs. 4.2 ± 0.75 h,
P < 0.05). Blood loss, length of hospital stay, and
analgesic use was not signiﬁcantly different between
groups. One liver graft in the OLR group failed post-
operatively and required emergent return to the operat-
ing room for revision of the portal vein and hepatic
artery anastomosis, while another developed biliary
stricture requiring ERCP and stent placement. Total
bilirubin was slightly more elevated on post-operative
day 2 in grafts from OLR compared to those from LALR
(6.2 ± 2.1 vs. 2.8 ± 1.1, P < 0.05). No signiﬁcant
complications were observed in LALR recipients.
Conclusions: Given the early outcomes of laparoscopic-
assisted living donor hepatectomy, our experience
demonstrates that it is a safe procedure with minimal
morbidity compared to standard open liver resections
and therefore, can be recommended as a new procedure
in living donor liver transplantation.
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Successful use of super elderly grafts in OLT
B. SAMSTEIN, MD, T. CHRISTOPHIDES, MD, J.
GUARRERA, MD and J. EMOND, MD
Columbia University Medical Center, Department of
Surgery, Center of liver Disease and Transplantation, New
York, NY, USA; Columbia University Medical Center,
Departmnt of Surgery, Center of Liver Diseases and
Trasplantation, New York, NY, USA
Increasing demand for LTX has not been paralleled by
supply, and the extension of donor criteria became more
than necessary to prevent the mortality of patients being
on the waiting list.
Aim: The purpose of our study is to retrospectively
examine the outcomes of patients who were offered a
graft from donors older than 75 years of age.
Materials and methods: We analyzed retrospectively the
clinical data of the patients who received an elderly graft,
including indication for transplantation, MELD score,
cold and warm ischemic times, liver function during the
ﬁrst post-operatively, and survival. During the period
January 2006 to June 2008, and among 297 consecutive
orthotopic liver transplantations that performed for
adults, 23 patients received a graft from a donor who was
over the age of 75.
Results: Twelve males and 11 females from 50 to
71 years of age were offered a graft from donors whose
age ranged between 75 and 86 years (average 78.8 year).
Indications for transplantation included: HCC of various
underlying cause (11 cases), alcoholic cirrhosis (4 cases),
cholangiocarcinoma (2 cases), autoimmune hepatitis (2
cases), steatohepatitis (1 case), cryptogenic cirrhosis (1
case), and antitrypsin deﬁciency (1 case). MELD score of
the recipient ranged between 6 and 35. The cold ischemic
time in all cases was kept below 9 h, with half of them
being under 6 h. The average warm ischemic time was
44 min. Since imported grafts were highly used, donor
biopsy was useful and showed low incidence of steatosis
of the liver. The peak post-operative AST value averaged
1393.48 U/L, and the average AST, bilirubin and INR
values at post-operative day seven were 52.43 U/L,
3.61 mg/dL, and 1.32 respectively. Two deaths occurred
on day 10 and 77 post-operatively. All the other 21 pa-
tients are alive. The 1 month and 1 year graft and patient
survival rates are 95.6% and 87.5% respectively.
Conclusions: Careful selection of elderly grafts for liver
transplantation in patients suffering from hepatic failure,
and by keeping the cold and warm ischemic times as low
as possible, can produce similar results to the trans-
plantation of patients using the standard criteria, espe-
cially in non-hepatitis C induced cirrhotic patients.
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Biliary reconstruction and complications after
living-donor liver transplantation
R. F. SAIDI, N. ELIAS, D. S. KO, T. KAWAI,
H. YEH, J. MARKMANN, A. B. COSIMI and
M. HERTL
Massachusetts General Hospital, Boston, MA, USA
Background: The technique of biliary reconstruction is
remains controversial in LDLT. The objective of this
review was to assess the incidence of biliary complica-
tions after LDLT.
Methods: Thirty patients underwent LDLT between
1997 and 2007. The type of allograft was the right lobe in
14, left lobe in 4, and left lateral sector in 12 patients.
There were 18 adults and 12 pediatric recipients. The
mean follow-up was 48 months (range 6–120 months).
Results: Biliary reconstruction was achieved with Roux-
en-Y choledochojejunostomy in 17 patients (Group I),
and choledochocholedochostomy in 13 patients (Group
II). A external biliary stent was placed in all patients
(expect one) in Group I and reconstruction over a T-tube
was done in 6/13 of patients in Group II. Twenty-ﬁve
(83.3%) patients had one biliary anastomosis and
the remaining 5 (16.7%) had multiple anastomoses (one
in Group I and four in Group II). The overall incidence
of biliary complications was 30%.; 29.4% in Group I and
30.8% in Group II. The incidence of biliary leakage was
23.5% for Roux-en-Y, and 15.4% for Group II
(P > 0.05). However, the incidence of biliary stricture
was signiﬁcantly higher in Group II (15.4%) compared to
Group I (5.9%) (P < 0.01). In Group II, biliary com-
plications occurred equally in patients with and without
T-tube stenting. Overall, 93.3% of the strictures were
managed with endoscopic treatment alone. One patient
in each group needed revision of the biliary anastomosis.
Biliary complications did not affect the graft and patient
survival.
Table 1. Comparison between two biliary reconstruction
methods.
Biliary Anastomosis
Biliary
stent/
t-Tube
Biliary
complications
Biliary
leak
Biliary
stricture
Need
anastomotic
revision
Roux-en-Y
choledocho-
jejunostomy
(n = 17)
94.1%
(n = 16)
29.4%
(n = 5)
23.5%
(n = 4)
5.9%
(n = 1)
5.9%
(n = 1)
duct-to-duct
choledochocholedochostomy
(n = 13)
46.2%
(n = 7)
30.8%
(n = 4)
15.4%
(n = 2)
15.4%*
(n = 2)
7.7%
(n = 1)
*P < 0.01.
Conclusions: Although there was a higher rate of biliary
stricture in the choledochocholedochostomy group, we
feel that because of physiologic bilioenteric continuity,
comparable incidence of leakage, and easy endoscopic
access, duct-to-duct reconstruction represents a feasible
technique in LDLT. The endoscopic approach has been
shown to be a ﬁrst-line therapy for the management of
biliary complications after LDLT. Placement of T-tubes
did not appear to be beneﬁcial.
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Incidence and impact of biliary complications
following pediatric living-donor liver transplan-
tation (LDLT): analysis of 44 consecutive cases
with 5-year follow-up
M. J. GOLDSTEIN, MD, D. C. WOODLAND IV., A.
A. RANA, MD, D. JAN, MD, R. VARADARAJAN,
MD, J. WEINTRAUB, MD, J. RENZ, MD, PHD and
J. C. EMOND, MD
Columbia University College of Physicians and Surgeons,
New York, NY, USA; Arizona Health Sciences Center
Department of Surgery, Tucson, AZ, USA
Purpose: To characterize biliary complications in pedi-
atric patients following LDLT and observe potential
effects on patient and graft survival.
Methods: A single surgical team performed forty-four
consecutive pediatric living-donor liver transplants over a
6-year period. Those patients were followed for occur-
rence, diagnosis and treatment of biliary complications
and for patient and graft survival.
Results: Pediatric patients received mostly left lateral
segment grafts (89%). Biliary reconstruction to a single
duct was performed in 38 of 44 patients (86%). The
overall incidence of biliary complications per ductal
anastomosis was 68%. Fourteen cases were complicated
by persistent biliary leaks (28% per ductal anastomosis).
These were most commonly cut-surface leaks (64%) and
were typically managed with early reoperation (79%).
Eighteen cases were complicated by strictures, which
were managed successfully with primary percutaneous
or endoscopic balloon dilation (PTC or ERCP) in 67%
of occurrences requiring a mean of 2.2 ± 1.1 dilations
for resolution. One, 3 and 5-year graft and patient
survivals were 88, 85, and 83% and 88, 88, and 88%.
There was no signiﬁcant difference in either patient or
graft survival for those with or without biliary compli-
cations (P-values 0.91 and 0.80 respectively) (Figures 1
and 2).
Conclusions: Pediatric living-donor liver transplants
have a signiﬁcant incidence of biliary complications. PTC
has proved to be effective as the ﬁrst line treatment for
biliary stricture. Overall, if identiﬁed and treated
promptly, biliary complications do not portend any
difference in prognosis with respect to graft or patient
survival.
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Steatotic liver graft use does not affect long-
term outcomes, but may require increased
resources following liver transplantation
M. B. M. DOYLE, MD, N. VACHHARAJANI, MD,
C. D. ANDERSON, MD, J. A. LOWELL, MD and
W. C. CHAPMAN, MD
Washington Universtiy, St Louis, MO, USA
With a continuing organ shortage and an ever increasing
recipient population, many centers are using marginal
grafts to avoid deaths on the waiting list. Hepatic
steatosis is encountered in > 30% of potential donors,
and appears to be an increasing problem. Livers with less
than 20% steatosis are routinely used, however livers
with > 30% macrovesicular steatosis are often dis-
carded, for fear of primary non-function and increased
complication rates. The aim of this study was to
determine if the use of moderate to severe steatotic livers
would adversely affect short- and long-term outcome in
liver transplantation.
Methods: From Jan 2002–Dec 2007, 483 liver transplants
were performed at our institution. Pre-transplant donor
biopsies were identiﬁed in 65 patients and classiﬁed into
0% (n = 29), < 30% (n = 26) or ‡30% (n = 10)
macrovesicular steatosis. Patient and graft survival, post-
operative complication rates, transaminase peaks and
pro-thrombin times were assessed in all groups.
Results: One, and 3-year patient survival was similar in
all three groups, (91% and 84% respectively, P = 0.28).
Similarly there was no signiﬁcant difference in 1 and 3-
year graft survival (91% and 82% respectively,
P = 0.24) between groups. Signiﬁcantly increased AST,
ALT, and INR were encountered in the > 30% steatosis
group. No cases of primary non-function were seen
however steatotic graft use was associated with increased
reoperation for hemoperitoneum and longer hospital
stays (P = 0.008).
Conclusion: In our experience, use of liver grafts with
> 30% macrosteatosis was not associated with increased
rates of primary non-function or worsened mid- and
long-term outcomes. However use of such grafts does
appear to be associated with increased resource utiliza-
tion in the peri-operative period.
0 1 2 3
Years
Su
rv
iva
l
4 5
0 1 2 3
Years
4 5
0.00
0.25
0.50
0.75
1.00
Su
rv
iva
l
0.00
0.25
0.50
0.75
1.00
No Complications Complications
Actual Pediatric Graft Survival
No Complications Complications
Actual Pediatric Patient Survival
Figures 1 and 2.
Abstracts58
 2009 The Authors
Journal Compilation  2009 Hepato-Pancreato-Biliary Association, HPB, 11 (Suppl. 1), 1–104
107
Biliary complications in 100 liver transplants.
An old problem in a new era
B. BHATTACHARYA, MD, M. I. RODRIGUEZ-
DAVALOS, MD, C. ROCHON, MD, D. Y. CHO, MD,
P. MARTINS, MD, J. P. ROCCA, MD,
L. KIM-SCHLUGER, MD, E. LEBOVICS, MD,
M. E. FACCIUTO, MD and P. A. SHEINER, MD
New York Medical College, Valhalla, NY, USA
Aim: To review the incidence, clinical outcomes and man-
agement of biliary complications in liver transplantation.
Background: Biliary complications are a major source of
morbidity after liver transplantation. In the current era
of the MELD system and use of extended criteria donors
(ECD) few have addressed the presentation, risk factors
and management of biliary complications, specially in
cases of patients that received ECD in which ischemic
cholangiopathy is becoming a common problem in cen-
ters using donation after cardiac death (DCD).
Methods: We retrospectively reviewed the charts and
electronic database of 100 patients transplanted from
August 2006 to December 2007. Pre-transplant data
included demographics, etiology of liver disease, labora-
tory, and MELD score. Donor factors (use of Extended
Criteria Donors and Ischemia Time) were evaluated in
the group. Post-transplant variables including type of
complications, time of presentation, treatment and out-
comes were studied.
Results: A Total of 100 adults and pediatric patients were
transplanted during the study period. 59 patients were
male, mean age of 55 years of age (4 month–76 yo). HCV
was the most common diagnosis (48%). Avarage MELD
in the study group was 23.3. 35% of the donors were ECD
(6 DCD). Three patients received living donor liver
transplants. Eighteen patients had biliary complications.
Two patients had anastomotic leak, 11 had anastomotic
strictures, 4 had ischemic cholangiopathy (IC) and one
patient had and early leak (duct of Luschka) and later
developed a stricture. All biliary leaks presented within the
ﬁrst 30 days of transplant and were managed with ERCP
stenting. All the extrahepatic strictures (12%) were man-
aged with ERCP interventions. Of the 4 patients with IC, 3
received ECD (2 DCD, 1 HCV+Donor) and one patient
hadpartial thrombosis of her arterial inﬂow.The 2patients
that received DCDwere retransplanted within a year. One
patient has been relisted for transplant and one patient
died of biliary sepsis.
Conclusions: The management of traditional biliary
complications (early leaks and late strictures) has chan-
ged with time. Currently a small number of patients re-
quire surgical intervention. However in this era of ECD
(viz. DCD), we are witnessing a subset of intrahepatic
ischemic complications, that lead to graft loss and require
retransplantation.
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Post-operative liver transplant function score
can predict long-term outcomes
M. HASSANAIN, MBBS, P. METRAKOS, MD,
J. BARKUN, MD, M. FERNANDEZ, RN, P.
CHAUDHURY, MD and J. TCHERVENKOV, MD
McGill University, Montreal, QC, Canada
Introduction: The best predictor of graft survival after
liver transplantation (OLTx) is the Donor Risk Index
(DRI). This however fails to take into account factors
related to recipient characteristics and peri-operative
events. We therefore studied the performance of the
Schindl scoring system, to predict graft survival after
OLTx. This score has been validated after liver resection
to allow for early prediction of subsequent mortality.
Method: All OLTx done at the McGill University Health
Center from 92 to 07 were included (600 patients).
Multiorgan transplants, re-do OLTx, early failures due
to vascular thrombosis, and fulminant liver failure
requiring pre-transplant endotracheal intubation (Cana-
dian list status 4) were excluded, leaving 451 patients for
analysis.
Retrospectively, we calculated the post-transplant liver
function score (PTLF) based on the most elevated results
in the ﬁrst 7 post-operative days, (Table 1). Patients were
labeled as normal if total points were < 4 and as having
liver dysfunction if total points were ‡ 4. Graft survival
analysis using log-rank test was used to test relative
variables. Graft loss was deﬁned as the need for re-
transplant or patients’ death.
Results: Thirty-two percent of patients were male with
mean age 54 years. 34% of patients had Hepatitis C,
24% had Hepatocellular carcinoma, and 46% had either
diagnosis. None of these variables alone was able to
signiﬁcantly predict graft survival. The average MELD
was 20.9, and mean DRI was 1.51. Mean blood loss was
2300 mL, and mean cold ischemia time was 9.8 hours.
DRI was the only pre-operative signiﬁcant predictor of
graft survival (P = 0.034). The median PTLF score was
4 with 42% patients showing a score < 4 (normal), and
58% scoring ‡ 4 (dysfunction). The 1 and 3-year graft
survival were 85% and 74% respectively for the normal
group, and 65% and 58% respectively for the dysfunc-
tion group. The difference was signiﬁcant (P < 0.001).
Survival analysis showed that PTLF alone was a signif-
icant predictor of graft survival. On ﬁnal survival
modeling with both pre-operative and post-operative
co-variates, only PTLF remained signiﬁcant
(P = 0.018).
Table 1. Point system for liver function score calcula-
tions.
Total serum bilirubin < 20 21–60 > 60
INR < 1.8 1.8–2.3 > 2.3
Serum lactate < 1.5 1.6–3.5 > 3.5
Given point 0 1 2
Conclusion: The PTLF scoring system is an easy and
clinically practical tool to help predict long-term graft
survival based on early post-operative events. It may
allow to better tailor aggressive treatment intervention
in selected patient groups.
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Usefulness of 3D-fusion images of MDCT
3D-cholangiography and 3D-angiography for
operative designing of carcinoma in the region
of hepatic hilum
H. KAMACHI, MD, PHD, T. KAMIYAMA, MD,
PHD, M. TAHARA, MD, PHD, D. FUKUMORI,
MD, H. YOKOO, MD, PHD, K. NAKANISHI, MD,
PHD, M. MATSUSHITA, MD, PHD and S. TODO,
MD, PHD
Department of General Surgery, Graduated School of
Medicine Hokkaido University, Sapporo, Japan
Background: Hepatic hilum has a complex anatomical
relation with biliary system, portal system, and hepatic
arteries. To operate the malignancies of hepatic hilum,
precise evaluation of tumor extension and anatomy are
required for operative designing. We evaluated the efﬁ-
cacy of 3D-fusion images of MDCT 3D-cholangiography
and 3D-angiography for operative designing of the
malignancies of hepatic hilum.
Methods: Twenty-two patients of hilar cholangiocarci-
noma, cholangiocellular carcinoma and gall bladder
carcinoma invaded to hepatic hilum were constructed
3D-fusion images of 3D-cholangiography and 3D-angi-
ography using MDCT. Seventeen patients of 22 patients
who underwent the en-block resection with hepatic
resection were evaluated the accordance and accuracy of
bile duct extension of tumor with direct cholangiography
and 3D-cholangiography, and of vascular invasions with
MDCT and 3D-angiography. Anatomical relations with
3D-fusion image were also examined.
Results: Fifteen patients of 17 patients (88.2%) could
obtain the 3D-cholangiography by direct cholangio-
graphy (n = 14) or DIC-CT (n = 1). Two patients
performed EST failed to obtain evaluative 3D-cholangi-
ography. Fourteen patients could be compared the
biliary images with direct cholangiography and
3D-cholangiography. All patients (100%) were obtained
the identical image of tumor extension and 16 in 17
patients (94.1%) were achieved the negative margin of
hepatic bile duct. The expected numbers of bile duct
cutting oriﬁces were accordant with 13 in 15 patients
(86.7%). The sensitivity and speciﬁcity of vascular inva-
sions of 2D-MDCT were 40% and 100% in portal vein
invasion, 66.7% and 100% in arterial invasion, and of
3D-angiography were 50% and 100% in portal vein
invasion and 100% and 92.9% in arterial invasion.
3D-fusion image expressed precise anatomical relations
and variations of biliary system, portal system, and
hepatic arteries and was helpful for pre-operative
designing.
Conclusion: MDCT 3D-cholangiography and 3D-angi-
ography has high accuracy to evaluate tumor extension
to bile ducts and surrounding vessels. Moreover,
3D-fusion images provide useful information of anato-
mical relations and variations for operative designing of
carcinoma in the region of hepatic hilum.
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Pancreatectomy with venous resection and
reconstruction: a single institution 15-year
experience
J. ALLENDORF, MD, J. DINORCIA, MD, M.
DIGIORGI, MPH, B. SCHROPE, MD, PHD, J. LEE,
MD and J. CHABOT, MD
Columbia University College of Physicians and Surgeons,
New York, NY, USA
Purpose: We conducted a retrospective review to assess
outcomes and survival of patients who underwent pan-
createctomy with concomitant venous resection at our
institution.
Methods: We reviewed all patients who underwent pan-
createctomy requiring vascular resection for any pathol-
ogy from 1994 to 2008. Patients who required arterial
resection were excluded. We noted operation, venous
reconstruction, length of stay, morbidity, and mortality.
For patients with adenocarcinoma, oncologic survival
was compared to patients who underwent pancreatec-
tomy without venous resection and to patients who were
explored but not resected.
Results: A total of one hundred and twenty three
patients required vascular resection during pancreatec-
tomy. Thirteen of these patients required resection of the
hepatic and/or superior mesenteric arteries and were
excluded. One hundred and ten patients required supe-
rior mesentericoportal venous resection for varying
pathology. Ninety underwent pancreaticoduodenectomy,
11 total pancreatectomy, 5 distal pancreatectomy, and 4
subtotal pancreatectomy. Resections of the superior
mesentericoportal veins included tangential resection
with primary repair (n = 28), tangential resection with
autologous vein patch (n = 21), segmental resection with
primary anastomosis (n = 19), and segmental resection
with autologous interposition graft (n = 40). Median
length of stay for all venous resection patients was
11 days (95% CI: 1, 58). Peri-operative morbidity and
mortality for all venous resection patients were 31.8%
and 4.5%, respectively. For patients with adenocarci-
noma, median survival was 16.6 months (95% CI: 12.3,
23.7) in those requiring venous resection and
20.1 months (95% CI: 14.1, 24.3) in those not requiring
venous resection (P-value = not signiﬁcant). Median
survival was 6.5 months (95% CI: 12.3, 23.7) in patients
explored but not resected due to vascular invasion, which
was signiﬁcantly shorter than patients requiring venous
resection (P-value < 0.0001).
Conclusion: Median survival of patients with adenocar-
cinoma who undergo pancreatectomy with venous
resection is comparable to those who undergo pancrea-
tectomy without venous resection and is superior to those
who are explored but not resected. Pancreatectomy with
venous resection can be performed with acceptable
morbidity and mortality in select patients.
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Total pancreatectomy: a national study
W. J. KNAUS, B.SC., M. M. MURPHY, MD, MPH,
J. S. HILL, MD and J. F. TSENG, MD, MPH
University of Massachusetts Medical School, Worcester,
MA, USA
Background: Total Pancreatectomy (TP) is performed
for various indications including malignant and non-
malignant pancreatic disease. Historically, morbidity and
mortality associated with TP has been high. No nation-
wide data on TP are currently available. The objective of
this study was to evaluate in-patient mortality, predictors
of mortality, and review national trends for TP.
Methods: The Nationwide Inpatient Sample (NIS) was
queried to identify all TPs performed during 1998–2006.
Univariate analyses and multivariable logistic regression
were performed adjusting for diagnosis, gender, race,
payer, hospital teaching status, and comorbidities to
evaluate in-hospital mortality (SASv9.1, Cary, NC,
USA).
Results: By weighted national estimate, 3241 patient
discharges occurred for TP during 1998–2006. 50.5% of
patients were men; mean age was 61.6 years
[SEM = 0.19]. 49.6% of TPs were for malignant pan-
creatic disease (deﬁned as ICD-9 codes for primary and
secondary malignancies, including carcinoma in situ and
neoplasms of uncertain behavior). 35.2% of TPs were for
non-malignant disease (deﬁned as pancreatic cysts,
pseudocysts, benign neoplasms, and pancreatitis), and
15.2% for other/unknown indications, P < 0.0001.
Mean length of stay (LOS) for all TP was 15.6d; (18.0 d
for non-malignant indications and 14.4 d, malignant).
The overall number of TPs varied over time with 283
performed in 1998 and 432 performed in 2006,
P = 0.4802. Overall, in-hospital mortality was 8.6%,
with a decreasing trend from 1998(17.5%) to 2006
(6.3%), P = 0.3381. Mortality was not inﬂuenced by
gender, race, payer, hospital teaching status, or hospital
size. Increasing age was independently associated with
increased mortality; age 60-79 vs. < 59 (OR 2.58; 95%
CI 1.15–5.79) and > 80 vs. < 59 (OR 4.03; 95% CI
1.10–14.97). The presence of medical co-morbidities
including renal failure, congestive heart failure, and liver
disease were signiﬁcant predictors of increased mortality.
Conclusion: Total pancreatectomy continues to be per-
formed for both malignant and non-malignant pancre-
atic disease. In-hospital mortality remains substantial.
Increasing age and the presence of medical comorbidities
were signiﬁcantly associated with increased mortality.
Additional studies including patient-level data and
overall survival are warranted to provide a better
understanding of the speciﬁc predictors of outcome after
TP.
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Higher expression of RRM2 predicts effect in
pancreatic cancer treated with gemcitabine
S. TAKEDA, MD, PHD, S. NOMOTO, MD, PHD,
N. KANAZUMI, MD, PHD, H. KASUYA, MD, PHD,
H. SUGIMOTO, MD, PHD, T. FUJII, MD, PHD,
S. YAMADA, MD, PHD and A. NAKAO, MD, PHD
Gastroenterological Surgery Nagoya University Graduate
School of Medicine, Nagoya, Japan
Background: Gemcitabine is now considered to be the
standard adjuvant therapy for advanced pancreatic can-
cer worldwide. Randomized controlled studies have
demonstrated that gemcitabine is effective in palliating
symptoms and prolonging survival in patients with ad-
vanced pancreatic cancer. Gemcitabine as adjuvant
therapy brings about a longer survival rate compared to
surgery alone. Although the key enzyme of gemcitabine
sensitivity in vitro is known well, it has not been deﬁned
yet in vivo. The aim of this study is to clarify which
enzyme is the key in gemcitabine as adjuvant therapy for
the resectable pancreatic cancer.
Patients and methods: Patients were given gemcitabine at
100 mg/body weekly for 2 weeks followed by a week rest
and for at least three cycles. RNA was extracted by
microdissection from tumoral and normal surgical fresh-
frozen pancreatic tissue of 32 patients. The expression of
genes such as RRM1, RRM2, dCK and hENT were
determined by real-time quantitative polymerase chain
reaction. The association between clinical outcome and
gene expression levels was estimated by Kaplan–Meier
method.
Results: RRM1, RRM2, dCK and hENT were detect-
able in most tumor specimens. RRM1, dCK and hENT
expression in tumor tissue were lower than in normal,
while RRM2 expression in tumor was so higher than in
normal as to be signiﬁcantly correlated with clinical
outcome. Patients with high levels of RRM2 had a sig-
niﬁcantly shorter overall survival [median, 8.4 months
in the higher expression vs. 14.5 months in the lower
expression]. However, patients with high levels of
RRM2 who were given gemcitabine had a longer overall
survival as well as that of patients with low levels of
RRM2.
Conclusions: This result suggests that tumoral RRM2
expression is a clinically important determinant of
malignant behavior in pancreatic cancer and a major
predictor of disease response to gemcitabine treatment.
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Pancreatic neuroendocrine tumors: a national
survey
E. J. AROUS, B.SC., T. P. MC DADE, MD, J. S. HILL,
MD, G. F. WHALEN, MD and J. F. TSENG, MD,
MPH
University of Massachusetts Medical School, Worcester,
MA, USA
Purpose: Pancreatic neuroendocrine tumors (PNETs)
have a prolonged natural history, and the beneﬁt of
resection remains controversial. As a result, treatment
approaches are not standardized. The purpose of this
study is to assess surgical resection of PNETs on a
national level.
Methods: This is a retrospective observational study
utilizing the Nationwide Inpatient Sample (1998–2006).
The primary outcome measure was in-hospital mortality.
As a secondary outcome, length of stay (LOS) was as-
sessed. Univariate analyses were performed using Rao-
Scott Chi-square and the Cochran-Armitage Trend tests.
Multivariable logistic regression was used to evaluate
predictors of outcomes.
Results: A total of 3306 unweighted observations for
patient admissions associated with PNETs were identi-
ﬁed. Mean age was 58.5; 54.1% were female. Of patients
with race/ethnicity available (83.3%), 81.9% were white.
Most PNET admissions were at teaching and urban
hospitals (59.8 and 91.8%, respectively). Overall, 470
patients (14.2%) underwent resection. Distal pancrea-
tectomy and pancreaticoduodenectomy accounted for
56.4% and 24.5% of resections, respectively. Over the
study time course, the proportion of patients receiving
resection increased (P = 0.0026). Predictors of resection
in multivariable analysis included age < 70 (vs. ‡ 70;
adjusted odds ratio (OR) 1.7 [95% conﬁdence interval
(CI) 1.3–2.3)], hospital teaching status [vs. non-teaching;
OR 2.3 (CI 1.7–3.2)], and urban hospital [vs. rural; OR
2.4 (CI 1.2–4.6)]. Mean LOS for patients undergoing
resection was 12.3 vs. 6.6 days for non-resection admis-
sions (P £0.0001). On univariate analysis, the in-hospital
mortality rate for resected patients was 1.7% compared
to 5.2% for the non-resected group (P = 0.0009). Non-
resection admission status remained a signiﬁcant pre-
dictor of in-hospital mortality by logistic regression [vs.
resection; OR 3.9 (CI 2.0–7.7)], as were age P 70 [vs.
< 70; OR 2.2 (CI 1.6–3.1)] and length-of-stay > 14 days
[vs. 6 2 weeks; OR 3.7 (CI 2.5–5.5)].
Conclusions: More resections for PNETs are being per-
formed over time. In-hospital mortality is higher for the
cohort of patients not undergoing resection, suggesting
disease-related factors such as advanced or recurrent
disease. Peri-operative mortality for patients undergoing
resection is acceptably low, supporting the role of
aggressive treatment for PNETs.
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Laparoscopic distal pancreatectomy for benign
lesions – does splenic preservation effect
outcomes?
K. L. MEKEEL, MD, A. A. MOSS, MD,
K. S. REDDY, MD, D. C. MULLIGAN, MD and
K. L. HAROLD, MD
Mayo Clinic, Phoenix, AZ, USA
Although the spleen is often routinely resected during
both open and laparoscopic distal pancreatectomies, a
splenectomy can increase the risk of post-operative and
life long infectious complications. In the open pancrea-
tectomy literature, spleen preserving or conservative
distal pancreatectomy is advocated if possible for benign
lesions. Spleen preserving laparoscopic pancreatectomies
are technically more difﬁcult because of the delicate
dissection of the splenic vessels. We performed a retro-
spective review of 27 laparoscopic pancreatectomies done
at our institution, all for benign disease. Patient charac-
teristics are listed in Table 1. All procedures were done
laparoscopically without hand assistance. There was only
one conversion to open for a positive proximal margin.
Attempts were made in all patients to conserve the
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spleen, which was successful in seven patients (35%).
Overall, nine patients had complications (33%), includ-
ing four patients with a pancreatic leak (15%) and two
with post-operative hemorrhage requiring re-exploration
(7.4%). Two patients had complications unrelated to the
pancreatectomy (myocardial infarction and pulmonary
embolism). Interestingly the only complication in the
spleen-preserving cohort was a splenic vein thrombosis in
a patient with a hypercoaguable state that was unknown
prior to surgery. The results are listed in Table 1. Patients
with spleen-preserving pancreatectomies had a trend
toward fewer complications, signiﬁcantly less blood loss
and shorter operative time compared to patients who
underwent concomitant splenectomy. Length of stay was
not signiﬁcantly different between the two groups.
Obviously due to anatomic and other intra-operative
factors during distal pancreatectomy, the spleen cannot
always be preserved. However in this small study patients
with spleen-preserving distal pancreatectomies had short-
er operative times, less blood loss and fewer complica-
tions. These ﬁndings support splenic preservation when
possible during laparoscopic distal pancreatectomy.
Table 1. Patient characteristics.
Spleen
preserving (7)
Splenectomy
(20) P-value
Age 30–68 (59) 22–76 (59) 0.9733
Male 57% 40% 0.6618
Diagnosis
Serous
cystadenoma
3 6
Neuroendocrine 0 5
IPMN 1 3
Mucinous cyst 2 2
Stricture 0 2
Other 1 2
Overall
complications
1 (14%) 8 (40%) 0.3632
Surgical
complications
1 (14%) 6 (30%) 0.6334
Operative
time (min)
140–233 (174) 145–515 (276) 0.0076
Estimated
blood loss (mL)
25–150 (59) 50–350 (169) 0.0024
Length of
stay (days)
(3–7) 4.7 3–11 (4.8) 0.9256
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Pancreatic leak as an additional risk factor in
elderly patients undergoing pancreaticoduo-
denectomy
G. D. STARKEY, L. TARICIOTTI, D. F. MIRZA, A.
D. MAYER, J. AC BUCKELS, S. R. BRAMHALL and
C. COLDHAM
University Hospital Birmingham, Birmingham, UK
The aim of this study was to investigate risk factors for
mortality among elderly (greater than 70 years old)
patients who underwent pancreaticoduodenectomy com-
pared to younger (less than seventy) patients. Data
were analysed from our database for all patients who
underwent pancreaticoduodenectomy at a single institu-
tion between January 1997 and May 2008. A total of 706
cases were identiﬁed – 489 in the young group (mean age
58) and 217 in the elderly group (mean age 75). There
were 289 (59%) men in the young group and 108 (50%)
in the elderly group. The prevalence of diabetes, ischemic
heart disease, renal disease and chronic airways disease
were similar between the two groups. Hypertension was
signiﬁcantly more frequent in the elderly (29% vs. 18%).
Both groups had a similar range of pathology in the
resected specimens. Overall 85% of the elderly had a
malignancy compared to 83% of young patients. The
diagnosis of chronic pancreatitis was less frequent in the
elderly group (1.4% vs. 8.2%). Mean post-operative
hospital stay was 14.7 days for the elderly and 13.6 for
younger patients. Both groups had similar rates of
intensive care unit admission (16% vs. 17%). The post-
operative morality rate (30-day or inpatient) was signif-
icantly higher in the elderly group (10.6% vs. 4.3%).
Both the elderly and younger groups experienced a
similar rate of overall morbidity (36% vs. 36%). There
was no signiﬁcant difference in the rate of pancreatic,
biliary or enteric leakage. The rate of pancreatic leak was
10.6% for the elderly group compared to 9.8% for the
young. Elderly patients who did suffer from a pancreatic
anastomotic leak were signiﬁcantly more likely to die
than younger patients (39% vs. 13%). Amongst the
patients who did not suffer from a pancreatic leak the
elderly also had a higher mortality (7.2% vs. 3.4%)
however the difference was less pronounced. Pancreati-
coduodenectomy in elderly patients will become a more
frequent procedure as the population ages. This study
shows that even in those patients judged ﬁt for the
procedure it carries a substantial risk of mortality
(10.6%). Our data suggests that the elderly patients are
particularly at risk if they suffer a leak from the
pancreatic anastomosis.
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Uncinate or body/tail location and node ratio
predict margin positivity and poor outcome in
resected pancreas cancer
B. KUVSHINOFF, MD, S. ASHRAF, MBBS,
C. ANDREWS, PHD, J. GIBBS, MD and
M. JAVLE, MD
Roswell Park Cancer Institute, Buffalo, NY, USA
Pancreatectomy for cancer is associated with a 20–40%
risk of positive surgical margins (PSM). This study
identiﬁes clinicopathologic factors predicting PSM and
poor outcome.
Methods: Clinical data for 86 patients undergoing pan-
cratic cancer resection from 1999–2005 were reviewed.
Data included tumor location and size, grade, morphol-
ogy, node ratio, and the use of neoadjuvant and adjuvant
therapy. Variables were correlated with PSM and sur-
vival using logistic regression, Kaplan–Meier and log
rank analyses.
Results: The 86 patients had a median age of 64.5 years
and median follow-up of 14.3 months. Tumor location
included head only (n = 62), uncinate involvement
(n = 13) or body/tail (n = 10). Neoadjuvant chemora-
diation (CRT) was used in 10 cases and 38 received post-
operative adjuvant therapy including CRT (n = 36) or
chemotherapy only (n = 2). Surgical margins were
positive in 9 (15%) head, 8 (62%) uncinate, and 5 (50%)
body/tail tumors. Tumors in the uncinate or body/tail
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(P < 0.001) and increasing node ratio (P < 0.01) were
strong predictors of a PSM. Patients with PSM had a
7.6 month median survival compared to 18.4 months for
R0 resections (P < 0.005). Median survival was worse
for uncinate (6.4 months) and body/tail (13.9 months),
compared to tumors of the head (18.4 months). Tumors
> 2 cm (P < 0.05), positive nodes (P < 0.05), increas-
ing node ratio (P < 0.005), and poor differentiation
(P < 0.02) were all associated with worse survival.
Median survival with neoadjuvant therapy (14.6 months)
was no different than without (15.6 months). Adjuvant
therapy (18.4 months) was associated with a marginal
(P = 0.05) increase in median survival compared to
surgery alone (9 months).
Conclusions: Surgically resected pancreatic cancers
involving the uncinate process and body/tail have a
higher incidence of positive surgical margins and worse
overall survival compared to isolated head lesions.
Higher node ratio is also associated with positive margins
and poor survival. When identiﬁed pre-operatively,
patients with uncinate or body/tail lesions should be
considered for neoadjuvant protocols.
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An analysis of surgeon volume, predictors of
morbidity, and cost for patients undergoing
pancreaticoduodenectomy at a teaching
community hospital
T. J. KENNEDY, MD, M. A. CASSERA, B.SC.,
R. WOLF, MD, L. L. SWANSTROM, MD and
P. D. HANSEN, MD
Legacy Health System, Portland, OR; Providence
Portland Medical Center, Portland, OR, USA
Background: Most studies in the literature looking at
volume and cost analysis for pancreaticoduodenectomy
(PD) are from large academic centers or state/national
databases, which do not reﬂect the experience of the
individual teaching community hospital. Despite trends
toward regionalization of care, the majority of pancrea-
ticoduodenectomies are performed in community hospi-
tals by surgeons with a variety of experience. Our goal
was to analyze the impact of several peri-operative vari-
ables, including surgeon volume, on morbidity, mortal-
ity, length of stay and cost of PD within a community
based, teaching hospital system.
Methods: Patients who underwent PD at Providence
Medical Center from 2005–2008 were reviewed retro-
spectively. Patient demographics, operative and peri-
operative data were analyzed. Surgeon experience was
categorized as either high volume (HV) or low volume
(LV) based on an average of 10 PD per year. Operative
mortality was deﬁned as death related to the operation,
whenever it occurred. Complications were divided into
minor and major based on the need for signiﬁcant
intervention or prolongation of hospital stay. Hospital
cost data was queried for total cost, total charges and
itemized departmental charges.
Results: Ninety-four patients underwent PD with an
operative mortality rate of 9.6% (HV 2.2%, LV 16.0%),
major complication rate of 32% (HV 18%, LV 44%),
average length of stay of 14.1 days (HV 12.6 days, LV
15.4 days) and average cost of $36 300 (HV $33 680, LV
$39 340). Peri-operative factors predictive of death were
age (P = 0.022), body mass index (P < 0.001), surgeon
volume (P = 0.008) and ASA grade (P = 0.011). Fac-
tors predictive of major complication were surgeon vol-
ume (P = 0.005) and body mass index (P < 0.001).
Factors predictive for increased length of stay for pa-
tients discharged from the hospital were surgeon volume
(P = 0.016), pre-operative albumin (P < 0.001) and
body mass index (P = 0.029). Factors predictive for
higher total cost were body mass index (P = 0.013) and
pre-operative albumin (P = 0.018). The difference in
hospital costs between high and low volume surgeon was
$5660. A detailed analysis of hospital charge data re-
vealed that pharmacy was responsible for most of this
cost difference, speciﬁcally the utilization of antibiotics,
TPN, and octreotide.
Conclusions: Surgeon volume and patient body mass
index are the peri-operative variables that are most
responsible for increased morbidity from PD. This in-
creased morbidity is reﬂected in higher mortality, length
of stay and costs. Increased costs are driven primarily by
pharmacy.
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Figure 1. Overall survival versus tumour location.
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Figure 2. Overall survival versus node ratio.
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Laparoscopic approach to distal pancreat-
ectomy and splenectomy provides less invasive
means for resection of pancreatic pathology
N. BABEL, MD, C. A. MORTON, B.SC., S. LORCH,
B.SC., J. M. HERNANDEZ, MD, S. B. ROSS, MD and
A. S. ROSEMURGY, MD
University of South Florida, Tampa, FL, USA
Introduction: The journey from conventional ‘open’ to
‘minimally invasive’ operations, conferring ‘fast track
care’ in pancreatic surgery, is now a reality. Due to the
complex nature and infrequency of indications for lapa-
roscopic distal pancreatectomy and splenectomy (LDPS),
embracement by the surgical community has been slow
despite technologic advances. This study was undertaken
to evaluate our experience with distal pancreatectomy
and splenectomy undertaken with laparoscopic intent to
compare outcomes with concurrent open distal pancre-
atectomy and splenectomy (ODPS).
Methods: From 2005 to 2008, 30 consecutive patients
undergoing LDPS were compared to the 30 most recent
consecutive patients undergoing ODPS at our institution.
Demographic and post-operative data were compared
utilizing the Mann–Whitney U-test. Data are presented
as median, mean ± SD.
Results: There was no difference in gender, age or BMI
of patients undergoing LDPS or ODPS (Table 1). Time
under anesthesia and estimated intra-operative blood loss
were less in patients undergoing LDPS; length of hospital
stay was 25% shorter (Table 1). 47% of patients under-
going LDPS and 57% undergoing ODPS had malignant
or pre-malignant disease; microscopic negative margins
of resection (R0) were obtained in all patients. 37% of
patients undergoing LDPS underwent conversion to
ODPS; ﬁve were converted due to technical difﬁculties
associated with malignancies. No patients undergoing
LDPS had pancreatic ﬁstula; however, two patients had
extended lengths of hospital stay for myocardial infarc-
tion and atrial ﬁbrillation. No patients died after LDPS.
Table 1. 30 Laparoscopic distal pancreatectomy splenec-
tomy vs. 30 open distal pancreatectomy splenectomy.
LDPS ODPS P-value
Gender 57% Male 60% Male NS
Age 64 years (63 years ± 16.1) 62 years (61 years ± 14.6) NS
BMI 25 kg/m2 (26 kg/m2 ± 4.8) 24 kg/m2 (25 kg/m2 ± 7.6) NS
Anesthesia
time
205 min (210 min ± 41.6) 281 min (289 min ± 78.9) P = 0.001
Blood loss 200 cc (276 cc ± 283.4) 300 cc (433 cc ± 321.9) P = 0.007
Length of stay 6 days (7 days ± 6.1) 8 days (12 days ± 19.8) P = 0.02
Pancreatic leak None None
Conclusions: LDPS is a safe, effective, and technically
feasible operation providing the beneﬁts of minimally
invasive surgery. It can be successfully undertaken in
patients for resection of benign, pre-malignant, or
malignant disease, though conversions to ‘open’ opera-
tions may be required especially for malignant disease.
Application of LDPS is encouraged as it provides less
invasive means for resection of pancreatic pathology.
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Additional organ resection combined with
pancreaticoduodenectomy does not increase
post-operative morbidity and mortality
M. NIKFARJAM, MD, PHD, M. SEHMBEY, B.SC.,
E. KIMCHI, MD, N. GUSANI, MD, S. SHEREEF,
MD, D. AVELLA, MD and K. STAVELEY-
O’CARROLL, MD, PHD
Penn State Milton S. Hershey Medical Center, Hershey,
PA, USA
Background: The mortality associated with pancreatico-
duodenectomy (PD) has decreased substantially in recent
times, but high morbidity continues to be a signiﬁcant
problem. With reductions in mortality there is increasing
willingness to combine organ resections with PD when
indicated. There is however a paucity of information
regarding the morbidity and mortality of multi-visceral
resection (MVR) that involves pancreaticoduodenectomy
(MVR-PD).
Methods: Patients undergoing PD between January 2002
andNovember 2007 by a single surgeonwere reviewed and
peri-operative outcomes determined. Those treated by PD
alone were compared to those undergoing MVR-PD.
Results: There were 105 patients overall who underwent
PD during the study period, with MVR-PD performed in
19 patients. Twelve patients (63%) required PD com-
bined with right colectomy, two (10%) underwent PD
combined with right nephrectomy, two (10%) required
liver resection with PD, and the remaining 3 (11%), had
combinations of liver, kidney. colon, and small bowel
resection in addition to PD. In both groups the main
indication for surgery was pancreatic cancer, however
there were proportionally more patients in the MVR-PD
group with gastrointestinal stromal tumors (2 patients,
11%), sarcomas (2 patients, 11%) and metastases to the
periampullary region (3 patients, 16%). The overall
complication rate in this study was 60%. Delayed gastric
emptying (DGE) (39%) and pancreatic ﬁstula (16%)
were the most common complications. There was no
signiﬁcant difference in complications between the two
groups. A non-pylorus preserving PD was more com-
monly performed in cases of MVR-PD (53% vs. 28%;
P = 0.007), operating times were longer (9.5 h vs. 8 h;
P = 0.002), and surgical intensive care unit stay was
greater (1 day vs. 2 days, P < 0.001). The overall med-
ian length of hospital stay (7 days) and readmission rate
were similar between the groups.
Conclusion: MVR-PD can be performed without signif-
icant added morbidity compared to PD alone. The main
indication for MVR-PD is locally advanced pancreatic
cancer requiring PD combined with right hemicolectomy.
 2009 The Authors
Journal Compilation  2009 Hepato-Pancreato-Biliary Association, HPB, 11 (Suppl. 1), 1–104
120
Inﬂuence of node status, anatomical site and
tumor size on long term outcome of resection for
pancreatic neuroendocrine cancers
N. A. HAMILTON, MD, A. CAVATIAO, B.SC.,
D. C. LINEHAN, MD, S. M. STRASBERG, MD and
W. G. HAWKINS, MD
Washington University, Saint Louis, MO, USA
Purpose: Pancreatic neuroendocrine malignancies are
rare, indolent malignancies for which there is no effective
systemic therapy and from which the mortality is signif-
icant. Here, we identify prognostic factors in pancreatic
neuroendocrine malignancies.
Methods: Demographics, surgical data, pathologic
diagnosis, post-operative course and long term outcome
for patients who underwent pancreas resection for neu-
roendocrine malignancy from 11/1/1997 to 4/1/2008 at
our institution were reviewed.
Results: Sixty-six patients were identiﬁed as having had
surgical resection of a neuroendocrine malignancy, 42
with proximal lesions and 24 with distal lesions. Thirty-
eight percent (12/32) of patients with nodal disease had
recurrent disease in contrast to no disease recurrence in
patients without nodal disease (0/34, P < 0.01). Patients
with node positive disease have a decreased 5-year sur-
vival (37.5% vs. 85.7%, P = 0.03). In patients with node
positive disease, those with a lesion in the distal pancreas
were more likely to have disease recurrence [67% (8/12)]
than those with lesions in the head or neck of the pancreas
[10% (2/20), P < 0.01]. There was no difference in the
percentage of patients with positive lymph nodes based on
location of tumor (proximal lesion 49% positive nodes,
distal lesion 48%, P = 0.95). Recurrence was not related
to the number of positive nodes (2.8 positive nodes for
recurrence vs. 4.3 positive nodes for no recurrence,
P = 0.24), nor was there a recurrence beneﬁt related to
the number of nodes sampled (11.6 nodes sampled in
recurrent disease vs. 18.2 nodes sampled in those without
recurrent disease, P = 0.15). Larger primary tumors
were found in node positive distal lesions than in patients
with distal lesions and negative nodes (5.5 cm ± 0.9 cm
vs.2.9 cm ± 0.6 cm, P = 0.02). This was not true for
patients with proximal disease (3.9 cm ± 0.7 cm, node
positive vs. 3.6 cm ± 0.7 cm, node negative, p
P = 0.78). Patients with recurrent disease had larger tu-
mors (5.4 cm ± 0.9 cm) than did those without disease
recurrence (3.5 cm ± 0.4 cm, P = 0.05).
Discussion: Patients with node positive disease at the time
of surgery are more likely to develop recurrent disease and
have an overall decreased survival. Patients with positive
lymph nodes and a lesion in the distal pancreas have de-
creased disease free survival when compared to patients
with node positive disease in the head or neck of the pan-
creas. Tumors are larger in patients with node positive
disease of the distal pancreas than in those with node
negative disease and are larger in patients who develop
recurrent disease than those who do not have a recurrence.
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Malignant pancreatic cystic neoplasms:
histopathologic subtypes and associated survival
outcomes
R. E. SCHWARZ, A. BIAN, PHD, J. S. MANSOUR,
MD and X. J. XIE, PHD
UT Southwestern Medical Center, Dallas, TX, USA
Background: Cystic neoplasms (CNs) of the pancreas
encompass a spectrum of various tumor types. The low
incidence of malignant CNs represents a challenge to
precise post-operative survival prediction and to appro-
priate choice of post-operative adjuvant therapy.
Methods: A pancreatic CN data set was created from the
SEER 1970-2004 database. Prognostic factors with sur-
vival impact, and relationships between surgical therapy
and overall survival (OS) were analyzed with univariate
and multivariate statistical methods.
Results: Out of a cohort of 109 596 patients with a
primary pancreatic malignancy, 16 CN histologic
subgroups with 815 individuals were identiﬁed. After
exclusion of those with < 15 cases, eight subgroups
with 767 patients remained. These histologic designations
included mucinous cystadenocarcinomas (n = 346),
cystadenocarcinomas NOS (n = 195), intraductal papil-
lary mucinous carcinoma (IPMC), invasive (n = 47),
non-invasive IPMC (n = 45), papillary mucinous cyst-
adenocarcinoma (n = 42), intraductal papillary
adenocarcinoma (n = 36), papillary cystadenocarcino-
ma NOS (n = 30), and non-inﬁltrating intraductal
papillary adenocarcinoma (n = 26). The median age was
69 years (range 24–96), 64% of patients were female, and
the median tumor size was 5 cm (0.1–35). The disease
extent varied by histologic group (P < 0.0001); localized
disease was present in 45% (range 24–100), regional
involvement in 26% (0-39), and distant metastases in
29% (0–46). Resection frequency (mean: 53%, range 15–
100) varied by tumor type (P < 0.0001). At a median
follow up of 12 months (31 for survivors), the median OS
was 17 months (invasive groups range: cystadenocarci-
nomas (6) to intraductal papillary adenoca (34; (IPMC:
not reached); P < 0.0001; see Figure 1). Multivariate OS
variables were: age, disease extent (P < 0.0001), histo-
logic type, grade (P = 0.0002), gender (P = 0.001),
surgical treatment, (P = 0.006), primary site (P = 0.02),
and primary site node involvement (P = 0.03).
Conclusions: When controlled for other established
prognostic parameters, the histopathologic subtype
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Figure 1. Survival of invasive pancreatic cystic neo-
plasma.
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assignment of pancreatic CNs signiﬁcantly affects sur-
vival prediction. Resective local treatment is associated
with superior survival for all tumor types and remains the
standard of care.
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En-bloc pancreatic resection for locally
advanced primary and recurrent sarcoma
J. RACCUIA, MD, I. NICHIPORENKO, MD,
G. ROSEN, MD and J. STEELE, MD
Saint Vincent’s Hospital Manhattan, New York, NY, USA
Purpose: Primary and locally recurrent sarcoma involv-
ing the pancreas is a rare occurrence. The feasibility of
treating these patients surgically with en bloc pancreatic
resection is examined and may provide an opportunity
for signiﬁcant palliation or cure.
Results: Over a 10-year period from 1997 to 2007 a total
of 122 patients were treated surgically for sarcoma
involving the retroperitoneum, abdomen and pelvis at
our institution. Of these 20 (16.4%) had primary or
locally advanced sarcoma involving the pancreas. There
were 8 women and 12 men with a mean age of
49.5 ± 14.9 years (range 25–75 years) and all patients
had been turned down for surgery by other centers. This
included 9 (45%) patients with recurrent disease from a
previously resected tumor of which 6 (30%) had neoad-
juvant chemotherapy prior to surgery. En-bloc resection
of the distal pancreas along with other contiguous organs
for locally advanced disease was performed in 18 (90%)
patients while 2 (10%) others had pancreaticoduoden-
ectomy. The average size of the lesions was
13.4 ± 10.4 cm (range 1–40 cm). En bloc resection most
commonly included the small bowel, stomach, spleen,
colon, diaphragm, liver, adrenal and kidney that varied
with each patient according to organ involvement with
the goal to achieve clear margins. Blood loss averaged
2600 ± 2900 cc (range 400–10 000 cc) with average
blood transfusion of 3.7 ± 4.0 units. There was 1 (5%)
operative death and 5 (25%) non-lethal peri-operative
complications. Pathology included gastrointestinal stro-
mal tumor in 12 (60%) patients, spindle cell sarcoma in 4
(20%), liposarcoma in 2 (10%), malignant hemangiop-
ericytoma in 1 (5%) and Ewing sarcoma in 1 (5%) other.
The tumors were low grade in 7 (35%), intermediate in 4
(20%) and high in 9 (45%) others. All patients received
chemotherapy post-operatively. Presently 7 (35%) pa-
tients remain alive: two (10%) with disease and 5 (25%)
without evidence of recurrence. Nine patients had tumor
recurrence at a mean of 14.5 ± 15.8 months (range 4.0–
54.5 months) after surgery at our institution. Recurrence
occurred in the liver in 5 (25%) patients and locally at the
surgical site in 4 (20%) others. Reoperation for local
recurrence was performed in 2 (10%) patients. The
overall median survival was 27.5 ± 10.8 months with
overall survival at 5 and 10 years of 35.2% and 23.5%
respectively.
Conclusion: En bloc pancreatic resection for locally ad-
vanced sarcoma involving the pancreas is feasible in
properly selected patients. The ability to perform a
complete resection seems to provide worthwhile pallia-
tion or long term survival where the prognosis is other-
wise dismal.
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Updated initial experience with laparoscopic
distal pancreatectomy at an academic institution
J. CHUNG, MD, R. M. THOLEY, B.SC.,
E. P. KENNEDY, MD, E. L. ROSATO, MD,
K. A. CHOJNACKI, MD, F. E. ROSATO JR., MD,
B. C. PROFETA, MD, P. K. SAUTER, RN, CNP
and C. J. YEO, MD
Thomas Jefferson University Hospital, Philadelphia, PA,
USA
Background: Laparoscopic distal pancreatectomy is
increasingly utilized as a mode of resection for diseases
localized to the body and the tail of the pancreas. Here
we report our initial experience with laparoscopic distal
pancreatectomy within the ﬁrst 2 years and compare
outcomes to patients who underwent a traditional open
approach.
Methods: A retrospective review of a prospectively col-
lected database was conducted of 26 patients who
underwent laparoscopic distal pancreatectomy and sple-
nectomy or laparoscopic spleen sparing distal pancrea-
tectomy at a single academic institution from August
2006 to July 2008. Three patients were excluded from the
study because they were converted to open approach.
The remaining 23 patients were compared to 23 consec-
utive patients who underwent open distal pancreatec-
tomy and splenectomy or spleen sparing distal
pancreatectomy in the same time period. Patients who
underwent resection of any additional organs were ex-
cluded from the open group. The charts were analyzed
for demographic information, pathology, operative time,
estimated blood loss (EBL), length of hospital stay, and
pancreatic ﬁstula formation. P-values were determined
using Student’s t-test or Fisher’s exact test as appropri-
ate.
Results: The average age of the study group was 58 years
(range 19–78) vs. 62.9 years in the open group (range 28–
83). The mean BMIs for the study and the open group
were 29.7 (range 20.9–40.6) and 28.4 (range 22.2–46.5),
respectively. The pathology in the open and the study
group included both benign and malignant processes.
The data are summarized in the table below.
Conclusions: Our initial experience indicates that lapa-
roscopic distal pancreatectomy with or without splenec-
tomy can be safely performed, with signiﬁcantly less
blood loss. The laparoscopic approach was associated
with trends toward more splenic preservation, shorter
operative time, and less blood loss. The laparoscopic
technique resulted in higher rate of pancreatic leak. The
different methods of pancreatic transaction and closure
of the pancreatic stump need to be further explored to
decrease the rate of pancreatic ﬁstula formation.
Table 1. Comparison of laparoscopic vs. open distal
pancreatectomy.
Laparoscopic
n = 23
Open
n = 23 P-value
Spleen sparing distal
pancreatectomy
9 (39%) 5 (22%) NS
Pathology
Benign 22 (96%) 18 (82%) NS
Operative time (min) 267 287 NS
EBL (mL) 145 461 0.01
Median LOS (day) 5 6 NS
Pancreatic leak 5 (22%) 0 0.049
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An evaluation of the modiﬁed POSSUM
scoring system for pancreatic resection
T. TANAKA, MD, Y. KAWABATA, MD, S. YANO,
MD and Y. MATSUGU, MD
Shimane University Faculty of Medicine, Izumo, Japan;
Hiroshima Prefectural Hospital, Hiroshima, Japan
Aim: No useful indicator is available for pre-operative
risk evaluation when considering treatment with pan-
creatic surgery. The aim of this study was to clarify a
usefulness of the POSSUM audit system (Physiological
and Operative Severity Score for the Enumeration of
Mortality and Morbidity) in patients with pancreatic
resection. Methods: From June 1996 to December 2006,
256 patients underwent pancreatic resection. The opera-
tive procedure was pancreaticoduodenectomy (PD) in
188 cases and distal pancreatectomy (DP) in 68 cases.
The underlying disease was pancreas cancer in 106 cases,
intrapapillary mucinous tumor (IPMT) in 34 cases, bile
duct cancer in 30 cases, ampullary cancer in 29 cases,
gastric cancer in 35 cases, duodenal cancer in 7 cases and
chronic pancreatitis in 15 cases. There were 10 hospital
deaths (3.9%). Post-operative complications were seen in
90 cases (35.2%). Eighteen pre-operative factors and 5
operative factors, and POSSUM parameters were eval-
uated. Results: In terms of the pre-operative factors,
there was no signiﬁcant difference between the PD group
and the DP group. Observed-to-expected ratio (O/E ra-
tio) of hospital death was 0.27 by original POSSUM and
0.91 by modiﬁed POSSUM (Portsmouth POSSUM). The
O/E ratio of post-operative morbidity was 0.64 by ori-
ginal POSSUM. The subjects were divided into two risk
groups by pre-operative physiological score (high-risk
group is more than 20). Morbidity of the high-risk group
(25/44, 57%) was signiﬁcantly higher than the low-risk
group (65/212, 31%), and the hospital death rate of both
groups were 9.1%, 2.8%. Conclusion: The modiﬁed
POSSUM is useful as a means of risk assessment in
individuals scheduled to undergo pancreatic resection.
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Quality of life after surgical intervention for
chronic pancreatitis
R. E. YOUSSEF, MBBS, B. S. DIGGS,
M. A. DOUTHIT, S. H. TEH, MD and
B. C. SHEPPARD, MD
Oregon Health and Science University, Portland, OR,
USA; Sacred Heart Medical Center, Eugene, OR, USA
Background: Surgical intervention offers durable therapy
for the pain and disability caused by chronic pancreatitis.
Organ resection (either Whipple or distal pancreatic
resection), internal drainage procedures (either by
pseudocyst-enterostomy or pancreaticojejunostomy), or
duodenum-preserving pancreatic head resection may be
used. The quality of life (QOL) of these post-surgical
patients is uncertain. We sought to determine the QOL of
our patients to provide a standard to which emerging
endoscopic and NOTES procedures can be compared.
Methods: We reviewed our hospital database for patients
treated for chronic pancreatitis over a 10 year period and
contacted them to complete a SF-36 questionnaire. 135
patients were identiﬁed. 21 patients had died and 32
responded to the SF-36 survey. Of the responses, 18 had
internal drainage, 12 had organ resection and 2 patients
had external psuedocyst drainage. We analyzed the
patients’ data and then scored the SF-36 responses and
compared these with US Population Norms, patients
reporting long standing illness, and patients with heart
disease.
Results: Our group was signiﬁcantly worse than the US
Population Norms in all 8 SF-36 measures. There was no
signiﬁcant difference in 6 of the SF-36 measures between
the surgical group and a group reporting long standing
illness. There was no signiﬁcant difference in 6 of the SF-
36 measures between the surgical group and a group with
NYHF Class II heart disease. (See Table 1) The internal
drainage and organ resection groups were also compared
to the US Population Norms .Drainage patients were
signiﬁcantly worse than US Population norms on 4 of the
8 SF-36 summary measures while resection patients were
signiﬁcantly worse on only 1 measure.
Conclusions: The quality of life of patients after surgical
intervention for chronic pancreatitis is comparable to
that of patients with common chronic disease. While
indications for each differ, organ resection may provide
an improved QOL than internal drainage procedures for
chronic pancreatitis. This QOL may serve as a standard
for comparison of emerging endoscopic and NOTES
procedures.
Table 1. Comparison of mean SF-36 scores with US
Population Norms, patients reporting long standing
illness, patients with heart disease, and patients having
had surgery for chronic pancreatitis (CP).
SF-36 Measure
CP
patients
US
Norms1 Disease2
NYHA
Class II3
Physical Functioning 73.8 (24.7) 83.2 (23.7)* 78.3 (23.2) 56.7 (21.3)*
Role functioning/
physical
52.2 (42.6) 82.5 (25.5)* 71.9 (38.9)* 28.9 (37.4)*
Role functioning/
emotional
58.9 (45.2) 87.3 (21.4)* 76.3 (36.4)* 55.0 (45.7)
Vitality 48.4 (23.5) 58.3 (20.0)* 54.0 (21.1) 49.5 (19.6)
Mental Health 66.1 (25.7) 74.9 (17.7)* 69.9 (18.7) 66.3 (17.9)
Social Functioning 70.0 (29.3) 84.3 (22.9)* 80.2 (24.8) 75.4 (23.9)
Bodily Pain 63.3 (26.3) 71.3 (23.6)* 69.8 (25.4) 65.7 (28.9)
General Health 52.0 (24.9) 70.8 (20.9)* 60.8 (23.0) 44.5 (17.1)
Values are mean and SD.
11998 US General Population Means.
2Jenkinson C. Short Form 36 (SF 36) Health Survey Questionnaire: Normative data
for adults of working age. BMJ, Vol. 306 (6890)1437–1430. May 29, 1993.
3Juenger J. Health related quality of life in patients with congestive heart failure:
comparison with other chronic diseases and relation to functional variables. Heart
2002;87:235–241.
*P > 0.05 for t-test between group and CP.
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Steatosis in hepatocellular cancer patients
C. HAMMILL, MD, C. FRASER, MD, R. ENOS, MD,
S. KOMURA, MD and L. L. WONG, MD
University of Hawaii, Honolulu, HI; Hawaii Medical
Center – East, Honolulu, HI, USA
Introduction: Non-alcoholic steatohepatitis and steatosis
associated with hepatitis C have been described as risk
factors for hepatocellular cancer (HCC). However little is
known about steatosis, including the prevalence, risk
factors, or impact on outcome in patients with HCC.
Methods: A retrospective review of 106 patients who
underwent liver resection for HCC between 1993 and
2008 was performed. Pathology reports were analyzed
for size of tumor, cirrhosis, ﬁbrosis, vascular invasion,
steatosis, margins and iron deposition. Steatosis was
classiﬁed as none, mild (1–9%), moderate (10–30%) and
severe (> 30%). Binomial logistic regression was per-
formed to identify risk factors associated with steatosis.
Factors associated with survival were determined utiliz-
ing Cox regression analysis.
Results: Of the 106 patients 68.9% had evidence of
steatosis, 13.2% had no steatosis, and in 17.9% of the
reports presence of steatosis was not addressed. In the
patients with steatosis, 8.2% were classiﬁed as severe,
21.9% as moderate, 57.5% as mild, and 12.4% were not
quantiﬁed. Age, sex, ethnicity, body mass index, history
of diabetes, history of alcohol use, and hepatitis status
were not predictive of steatosis. The presence of steatosis
was associated with smaller tumors, mean size 6.0 vs.
9.6 cm in patients without steatosis (P = 0.0045), and a
lower platelet count (192,000/L vs. 262 000/L,
P = 0.0055). In this cohort, lower serum albumin, larger
tumor size, presence of cirrhosis and iron deposition were
predictive of survival, but the presence of steatosis did
not affect survival.
Conclusions: Steatosis was frequently found in the re-
sected HCC specimens, but most patients had mild
steatosis. The usual metabolic factors were not predictive
of the presence or amount of steatosis. Steatosis was
associated with lower platelet count and smaller tumors.
Steatosis did not appear to affect survival or recurrence
in HCC patients who underwent liver resection.
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Combined sorafenib and Yttrium-90
radioembolization in the treatment of advanced
HCC: preliminary results
P. CHAUDHURY, MD, M. HASSANAIN, MBBS,
C. NUDO, MD, J. BOUTEAUD, B.SC., T. CABRERA,
MD, D. VALENTI, MD and P. METRAKOS, MD
McGill University Health Centre, Montreal, QC, Canada
Background: Hepatocellular carcinoma (HCC) is the
most common form of primary liver cancer and the third
leading cause of cancer-related death globally. Curative
treatment (liver transplant and liver resection) can only
be performed in 30% of cases. In the remainder, loco-
regional therapies are employed for palliation. In more
advanced stages, best supportive care is the only option.
Sorafenib has emerged as the treatment of choice in the
treatment of adavnced HCC and has demonstrated an
anti-angiogenic and anti-proliferative effect. Anti-angio-
genic agents have been shown to decrease hypoxia in the
center of tumors, and theoretically would increase sen-
sitivity to radiation. This provides a logical rationale for
the use of combined therapy.
Aim: To evaluate the safety and tolerability of combin-
ing sorafenib with Yttrium-90 TheraSphere radioembol-
isation (Y-90).
Methods: Consecutive eligible patients were enrolled
from the McGill University Health Centre HCC Clinic
from March 2008 to September 2008. Patients with HCC
who were candidates for Y-90 therapy were eligible for
the study. Patients began sorafenib (400 mg po BID) 6–
8 weeks prior to Y-90 treatment. Sorafenib was contin-
ued post-Y-90. The dose was adjusted if toxicity oc-
curred. Follow-up scans and lab work were obtained at
1-month post-Y-90.
Results: Eight patients have completed treatment, and 4
are awaiting Y-90 treatment. All patients are male, mean
age 61.4 years. Seven patients are Child-Pugh A, and all
have ECOG status 0 or 1. The mean AFP pre-treatment
was 1798 ug/L. 6 patients required sorafenib dose
adjustment. The most common toxicities observed were
GI (diarrhea) and hand foot syndrome. Toxicities oc-
curred pre-Y-90, and were generally self-limited and re-
sponded to dose adjustment. No patient required drug
discontinuation or experienced grade 4 toxicity. AFP
levels began to decrease on sorafenib alone in 4 patients.
The mean dose of Y-90 was 150 Gy. 1 patient experi-
enced worsening ascites post-Y-90. 7 patients demon-
strated tumor necrosis, and 4 had 100% necrosis. 5 had
stable disease. 1 patient progressed after treatment
(extrahepatic and contralateral liver). The mean decrease
in AFP post-Y-90 treatment was 1470 ug/L.
Conclusion: These preliminary results demonstrate the
safety and tolerability of combining Y-90 with sorafenib
in the treatment of advanced HCC. 88% of patients
demonstrated radiologic evidence of necrosis. They
continue to be followed to assess progression-free sur-
vival. Based on the encouraging tumor response and
tolerability, a further Phase II study will soon be started.
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A meaning of ischemic pre-conditioning in
patients undergoing major hepatectomy under
total vascular isolation of the liver: a retro-
spective study
J. JEON, MD, PHD and J. C. EMOND, MD
College of Medicine, Hallym University, Hallym
University Sacred Heart Hospital, Anyang-si Kyungki-do,
Republic of Korea; Columbia College of Physicians and
Surgeons, New York, NY, USA
Bleeding and transfusion during major hepatectomy are
the most signiﬁcant risk factors for poor outcome. To
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reduce bleeding and transfusions, major hepatectomy is
performed under Pringle maneuver in combination with
a low central venous pressure in many centers. In
specialized centers which have many experiences in liver
transplantation, Pringle maneuver and concomitant
clamping of inferior vena cava below and above the
liver, i.e. total vascular isolation(TVI), have been popu-
larized. But Pringle maneuver during hepatectomy cause
ischemia reperfusion (IR) injury. Ischemic pre-condition-
ing (IPC) is one of protective strategies that have been
employed to reduce IR injury. Several patient series to
date have argued the merits of IPC for hepatectomy. The
aim of this study is to evaluate whether the ischemic pre-
conditioning has the protective effect on post-operative
outcomes in patients who underwent major hepatectomy
under TVI. The records of 79 patients who underwent
major hepatectomy under TVI were reviewed. They were
divided into TVI alone (group A: n = 46) and TVI with
IPC (group B: n = 33). The IPC group received 10 min
of hepatic pedicle clamping and 3–5 min of reperfusion
prior to hepatectomy under TVI. Operation time, blood
loss, transfusion and clamping time were reviewed. The
serum concentration of aspartate aminotransferase, ala-
nine aminotransferase, total bilirubin, prothrombin time
and creatinine were regularly determined. Hospital stay
and complications including mortality and morbidity
were determined. Post-operative laboratory results of
liver function tests were not signiﬁcantly different
between groups. The concentrations of aspartate amino-
transferse tended to be higher in the group 1 than in the
group 2. The reverse trend was observed for alanine
aminotransferse. The concentration of bilirubin tended
to be higher in the group 1 than in the group 2. The
hyperbilirubinemia developed less in the group 2 than in
the group 1. There were no differences in prothrombin
time, creatinine level between the two groups. The
duration of ischemia was shorter in the group 2. But
IPC had no impact on the duration of operation, intra-
operative blood loss, and hospital stay. Our clinical use
of IPC as a protective strategy against IR injury under
hepatic TVI did not show any beneﬁt of operative,
laboratory parameters and clinical outcomes. More
clinical study will be required to verify or disprove the
merits of IPC far suggested primarily by animal studies.
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Re-evaluation of standard liver volume (SLV) in
patients undergoing living donor liver trans-
plantation (LDLT) and liver resection
H. IMAMURA, MD, T. AOKI, MD, T.
HASHIMOTO, MD, Y. SUGAWARA, MD,
K. HASEGAWA, MD, Y. BECK, MD,
S. KAWASAKI, MD, N. KOKUDO, MD and
M. MAKUUCHI, MD
Department of Hepatobiliary-Pancreatic Surgery,
Juntendo School of Medicine, Tokyo, Japan; Division of
Hepato-Biliary-Pancreatic and Transplantation Surgery,
Graduate School of Medicine, University of Tokyo, Tokyo,
Japan
Introduction: SLV denotes the ideal liver volume of each
patient adjusted for body surface area (BSA). SLV was
ﬁrst applied by us to select the donor and/or the type of
graft in LDLT. This concept has been extended by others
to candidates for liver resection to assess the safe minimal
size of future liver remnant. By contrast, we have been
using total liver volume (TLV) in candidates for liver
resection.
Aim: To re-evaluate the validity of SLV as compared
with TLV.
Methods: (i) In LDLT donors (n = 301; age: 37 ± 12
[17–66] years old), the relationship between BSA and
TLV calculated by CT volumetry was explored. (ii) In
LDLT recipients (n = 362 age: 40 ± 21 [0.6–67] years
old), the relationship between BSA and TLV assessed by
weight of explanted liver was explored. (iii) In LDLT
donors, liver volumetry was conducted on 0.25 post-
operative month (POM) (n = 33), 0.5 POM (n = 33), 1
POM (n = 31), 3 POM (n = 28), 6 POM (n = 25), 12
POM (25), and 57 POM (n = 13).
Results: (i, ii) The relationship between TLV and BSA
was as follows: donor, TLV = )404.8 + 961.3 · BSA
(m2). R2 = 0.58; recipients, TLV = 387.4 + 362.2 ·
BSA (m2). R2 = 0.16. 3) The donor liver volume
regeneration was as follows (mean ± SD/TLV vs. /
SLV): 0 POM, 0.49 ± 0.11 vs. 0.48 ± 0.12; 0.25 POM,
0.57 ± 0.097 vs. 0.56 ± 0.098, 0.5 POM, 0.62 ± 0.087
vs. 0.61 ± 0.095; 1POM, 0.68 ± 0.091 vs. 0.65 ± 0.10;
6; 3 POM, 0.75 ± 0.075 vs. 0.73 ± 0.088; 6 POM,
0.79 ± 0.073 vs. 0.77 ± 0.10; 12 POM, 0.82 ± 0.068 vs.
0.81 ± 0.091; 56 POM, 0.89 ± 0.057 vs. 0.90 ± 0.099.
Conclusion: In normal subjects such as donors of LDLT,
body size (BSA) can explain 58% of interindividual dif-
ference in liver volume. After the extended liver resection,
the liver volume increases irrespective of the extent of
resection until 5 years. However, the model that the
volume regeneration converges to their TLV is more
appropriate than to their SLV as judged by chronological
alteration in SD. In LDLT recipients, the liver size
became abnormally large or small due to the underlying
disease and SLV should be used as a notion of ideal liver
volume. In patients indicated to liver resection, TLV
instead of SLV should be used as reference volume.
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Acute normovolemic hemodilution in major
hepatic resections; risk factors for transfusion
L. B. JOHNSON, MD, J. S. PLOTKIN, MD,
C. MATSUMOTO, MD, R. AMDUR, MD and
T. FISHBEIN, MD
Georgetown University Hospital, Washington, DC, USA
Major hepatic resection carries the risk of intra-operative
hemorrhage and often requires transfusion. Acute Nor-
movolemic hemodilution (NVH) has been shown to be
safe and effective at reducing transfusion requirements
during liver resection. However, risk factors for transfu-
sion in patients undergoing NVH have not been previ-
ously reported.
Methods: Patients were selected for NVH if resection of 4
or more hepatic segments was intended. Patient outcomes
were analyzed to determine risk factors for the need for
transfusion. Variables were analyzed by logistic regression
with forward selection of predictors of transfusion.
Results: A total of 254 patients underwent hepatic
resection during the study period and 134 patients
underwent NVH. Twenty-eight (20.9%) required trans-
fusion. Age, Gender, OR Time, Central Venous Pressure,
BMI, Type of Resection, Estimated Blood Loss (EBL)
and Presence of Cirrhosis were evaluated as risk factors
for transfusion during hospitalization. Only EBL was
signiﬁcantly related to the need for transfusion
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(P < 0.001). The likelihood of transfusion was 0%,
8.33% and 50.0% when EBL was 925cc, respectively. In
a multiple regression model with the dependent variable
EBL, the only predictors that made a signiﬁcant contri-
bution to the regression equation were OR-time
(P < 0.001) and Tumor-size (P < 0.05).
Conclusions: EBL is an independent risk factor for
transfusion in patients undergoing NVH. EBL > 925 cc
has a strong and signiﬁcant relationship to the need for
transfusion in patients undergoing NVH during major
hepatic resection. OR time and Tumor size were inde-
pendent and signiﬁcant predictors of EBL.
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Validating the MELD-based Objective Scoring
System (MOSS) in patients with hepatocellular
cancer treated with radiofrequency ablation
C. HAMMILL, MD and L. L. WONG, MD
University of Hawaii, Honolulu, HI, USA
Introduction: In an attempt to stratify survival in hepa-
tocellular cancer (HCC) patients treated with non-liver
transplant modalities, Oregon Health Sciences University
(OHSU) developed the MELD-based objective scoring
system (MOSS). In addition to MELD score MOSS
incorporates tumor size (< vs. ‡ 5 cm), portal vein inva-
sion, and the number of tumors (single vs.multiple). It was
initially derived from a cohort of patients treated with
transarterial chemoembolization or hepatic resection.
The current study attempts to validate MOSS on HCC
patients treated with radiofrequency ablation (RFA).
Methods: A retrospective analysis of 78 patients with
HCC diagnosed between 1998 and 2008 who underwent
RFA as a ﬁrst treatment was performed. Patients who
subsequently underwent a liver transplant were excluded.
Patients were classiﬁed into MOSS group I, II, or III as
described by OHSU. Survival between the three groups
was compared using Kaplan–Meier and log-rank test.
Variables associated with survival were determined using
a Cox proportionate hazard regression model.
Results: Mean MELD and tumor size were 10 and
3.0 cm respectively. None of the RFA patients had portal
vein invasion, 91% had tumors less than 5 cm in greatest
diameter, and 77% had only one tumor. Similar to the
results of OHSU, multivariate analysis demonstrated
that tumor size and MELD score were associated with
survival. Additionally, in this cohort age and albumin
were also associated with survival. Median survival with
95% conﬁdence intervals categorized by MOSS group is
summarized in Table 1. Log-rank test showed a signiﬁ-
cant difference in survival between MOSS group I and III
(P = 0.003).
Table 1. Median survival of HCC patients treated with
RFA stratiﬁed by MOSS class.
MOSS Group
Median
survival
(months)
95%
Conﬁdence
Interval
MOSS I (n = 34) 59 32–67
MOSS II (n = 23) 29 9.7–42
MOSS III (n = 21) 20 6.1–23
Conclusion: Although MOSS group suggested a trend
toward survival in HCC patients treated with RFA, the
difference was only statistically signiﬁcant between group
I and III. Most of the patients who underwent RFA
(69%) had single tumors less than 5 cm and no portal
vein invasion. In these patients MOSS group is based
entirely on MELD score. Further stratiﬁcation and
heavier weighting of tumor size in the scoring system
might improve its ability to predict survival in HCC
patients treated with RFA.
133
Spontaneous rupture of the non-malignant liver:
our 13 year experience
V. SHANMUGAM, A. LALA, R.
MARUTHANAYAGAM, J. BUCKELS, D. F.
MIRZA, D. MAYER and S. BRAMHALL
Queen Elizabeth Hospital, Birmingham, UK
Background: Spontaneous rupture of the liver is a rare
but potentially fatal condition. The aim of this study was
to review the pathology and management of benign liver
lesions presenting with rupture with particular reference
to the role of delayed surgery.
Methods: Data were collected from a prospectively
maintained database on patients presenting with liver
rupture that were treated at Liver unit, Queen Elizabeth
Hospital, Birmingham, UK between April 1995 and May
2008.
Results: The study included 21 females and 2 males. Nine
patients were operated on during the same admission.
The remainder fourteen were managed conservatively of
these 10 patients had delayed surgical resection. The
surgical treatment included ligation of right hepatic
artery (1), partial hepatectomy (5), hemi-hepatectomy
(8), hemi-hepatectomy with non-anatomical resection (2),
extended hemi-hepatectomy (2) and total hepatectomy
(1). Two patients who bled following eclampsia died after
emergency resection. Surgical resection was facilitated
following resolution of sub capsular haematoma in
elective resection. Histological examination of the 19
lesions showed liver cell adenoma (LCA) in twelve, focal
nodular hyperplasia (FNH) in four, peliosis hepatis in
one, and pregnancy related intra-hepatic haemorrhage/
infarction in two patients.
Conclusion: LCA is the most common benign lesion to
present with spontaneous rupture, however atypical
variants of FNH too can rarely rupture and present with
bleeding. There is a role for conservative management in
a haemodynamically stable patient.
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Hepatic resection for the treatment of common
bile duct injuries
J. A. SALCEDA, MD, C. SALAS, MD, O. MAZZA,
MD, E. DE SANTIBAN˜ES, MD, PHD and J. PEKOLJ,
MD, PHD
Hospital Italiano de Buenos Aires, Buenos Aires,
Argentina
Background: Endoscopic, percutaneous and surgical
procedures are used in the management of common bile
duct injury (CBDI) diagnosticated in late post-operatory.
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Hepatic resections are not indicated frequently. Indica-
tions for resection are: irreversible liver and biliary
pathology generated by a vascular and/or biliary injury.
Objective: To analyse indication, outcome, technical and
tactical aspects of mayor hepatic resections, to treat
CBDI.
Design: Descriptive and retrospective study.
Population: A total of 205 patients with CBDI were trea-
ted between January 1988 and September 2008. Thirteen
patients (6.4%) required mayor hepatic resections.
Methods: Six were men, mean age was 41.8 years old
(range 6–62). Five open surgery and eight laparoscopic
surgery were the causes of the CBDI. Probable mecha-
nism of the injury were: ligatures in three patients,
resection and thermal injury in 4, resection and arterial
injury in 2, section in 2 and 2 unknown mechanism.
Arterial injury was associated in 37.5% and portal injury
in 12.5%, all of them diagnosed with angiography. The
time (median) between the injury and the resection was
24 months (range 2–407). Previous surgeries: 2.4 (range
1–4). Clinical presentation: recurrent cholangitis in 8
patients, abdominal pain and jaundice in 2, biliary leak in
3. The indications to perform the hepatic resection were:
6 patients with intra-hepatic strictures, 5 with unilateral
stricture with bilio-digestive derivation (after failed per-
cutaneous dilatation), 1 with complex CBDI, 1 with right
hepatic artery injury, and 1 with a probable tumor.
Results: We performed nine right hepatectomies and 4
left hepatectomies. Pringle’s Maneuver was used in 7
patients. Mean operative time was 305 min (range 270–
360). Any patient need red blood cell transfusions. Biliary
reconstruction: in 11 cases hepatic-jejunostomy, and 1
case bi-hepatic-jejunostomy. Mortallity was 0% and
morbidity was 37.5%. Mean follow-up 59.9 months
(range 3–129).
Conclusions: Hepatic resection is a good treatment for
complex CBDI (those associated with vascular injury and
biliary conﬂuence injury) followed by intra-hepatic stric-
tures and/or lobar atrophy. Mayor hepatic resections are
complex procedures because of the hepatic pedicle scle-
rosis, adherences and atrophy-hipertrophy phenomenon.
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Tumor neo-angiogenesis is a key factor in the
induction of tumor-speciﬁc t-cell tolerance
D. AVELLA, MD, H. TAGARAM, PHD,
S. SHEREEF, MD, E. KIMCHI, MD and
K. STAVELEY-O’CARROLL, MD, PHD
Penn State University College of Medicine, Hershey, PA,
USA
Introduction: Current literature suggests that tumor
angiogenesis might differ from earlier to later stages of
tumor development. We have developed a murine tumor
model for Hepatocellular cancer (HCC) inoculating
syngeneic tumorigenic cells into the spleen of C57BL/6
mice. Four weeks after inoculation liver tumors reach a
mean diameter of 1mm. At this point endogenous T cells
remain ignorant of tumor associated antigens. However
at 8 weeks post inoculation, when tumors have a diam-
eter of 1 cm, T cells become immunologically tolerant.
To explore the mechanisms of this transition we evalu-
ated the pattern and level of tumor neo-angiogenesis at
different stages of tumor development and the fate of
adoptively transferred naı¨ve tumor antigen speciﬁc
T cells.
Methods: Four cohorts of three C57BL/6 mice were
inoculated with syngeneic HCC cells expressing the
T antigen (T-ag) of the SV40 virus via splenic injections
(ISPL). Four and eight week later tumor growth in the
liver was evaluated with magnetic resonance imaging.
Two cohorts were adoptively transferred with naı¨ve
T cells speciﬁc for the epitope-I of the T-ag: one 4 weeks
and one 8 weeks post-ISPL. The cohorts that did not
receive any adoptive transfer were used as negative con-
trols. C57BL/6 mice adoptively transferred with naı¨ve
T cells and immunized with cells expressing the full-
length T-ag were used as a positive control. Seven days
after transfer, epitope-I speciﬁc T cells proliferation and
c-interferon (c-IFN) production assays were performed.
Immunoﬂuorescent staining for CD105 and VEGF3 was
performed for liver specimens.
Results: All animals injected ISPL developed HCC.
Liver tumors with 1 mm in diameter were negatively
stained for both, VEGF3 and CD105. Normal liver
parenchyma surrounding the tumor showed multiple
vascular structures positively stained for CD105 and
VEGF3. Adoptively transferred cells proliferated and
produced c-IFN in the spleen of these mice. Liver tumors
with 1 cm in diameter showed an intense positive staining
of CD105 and VEGF3. The periphery of tumors was
stained more intensely in comparison with the core of
tumors. The normal liver immediately surrounding the
tumors also showed a marked increase in the level of
expression of these markers. In this group of mice
adoptively transferred cells failed to proliferate and
produce c-IFN.
Conclusion: At early stages of tumor development in the
liver, low levels of neo-angiogenesis are present. As
tumors grow, neo-angiogenesis starts predominantly in
the periphery of tumors and in the surrounding liver
parenchyma. These phenomena are correlated with the
induction of tolerance to naı¨ve tumor antigen speciﬁc
T cells.
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The biliary complications of radiofrequency
assisted hepatectomy
S. E. KHORSANDI, M. PAI, D. SPALDING, R.
CANELO, L. JIAO and H. NAGY
Hammersmith Hospital, London, UK
Introduction: A number of technology reliant techniques
for liver transection have been developed, which has
contributed to a reduction in the morbidity and mortality
of liver surgery. However, the occurrence of biliary
complications has remained essentially static, with an
incidence of 4–10% being reported. The aim of this single
institution study was to document the incidence and
pattern of biliary complications following RF assisted
hepatectomy.
Methods: Data were extracted from a prospectively
maintained database. Bile leak related to hepaticojejun-
ostomy were excluded from this analysis. Univariate
analysis (Fisher exact and Mann–Whitney test.) was
performed using SPSS (Statistical Package for Social
Sciences for Windows 11.0.1, SPSS Inc, Chicago, IL,
USA).
Results: From January 2002 to October 2007, 384 RF
assisted liver resections were performed. There were 150
major and 234 minor resections, of which 36 were per-
formed laparoscopically. The indication for liver resec-
tion were colorectal metastases in 228 (59%),
neuroendocrine metastases in 15 (4%), non-colorectal
non-neuroendocrine metastases in 52 (14%) and primary
hepatobiliary tumors in 58 (15%) (hepatocellular carci-
noma n = 30, intra-hepatic cholangiocarcinoma n = 2,
extrahepatic cholangiocarcinoma n = 21, gallbladder
cancer n = 5). 31 (8%) resections were done for benign
pathologies. There were six bile leaks (incidence 1.6%).
Three were from the hilus, which presented in the
immediate post-operative period with bile in the drain
and were managed by ERCP. The remaining three bile
leaks were parenchymal and presented 2–4 weeks post-
discharge with infection in the ablation zone, after initial
radiological drainage of pus, bile would then follow.
There was one late RF biliary stricture (incidence 0.26%)
at 4 months post-surgery, which had not been preceded
by bile leak. The average length of follow up was 672
(range 4–2427) days. On statistical analysis, the cate-
gorical variables of portal vein embolization
(P = 0.004), major resection (P = 0.003) and intra-
abdominal collection (P = 0.019) were found to have an
association with the occurrence of bile leak.
Conclusion: In this series of RF assisted hepatectomies,
the incidence of bile leak was low (1.6%) and late biliary
strictures (0.26%) were rare. If used appropriately and
paying respect to hepatobiliary anatomy, RF assisted
hepatectomy appears to have equivalent, if not better
biliostasis, compared with other techniques of liver
transection.
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Lysophosphatidic acid biosynthesis in
hepatocellular carcinoma
N. J. SKILL, PHD, R. E. SCOTT, MD and
M. A. MALUCCIO, MD, MPH
Indiana University, Indianapolis, IN, USA
Aim: Lysophosphatidic acid (LPA) is an intercellular li-
pid mediator with growth factor-like activities, and has
frequently been linked to the formation of cancer.
However, to date, its role and biosynthetic pathway has
not been fully investigated in hepatocellular cancer. One
of the main LPA biosynthetic pathways is choline ==>
phosphatidylcholine (PC) ==> lypophosphotidylcho-
line (LPC) ==> LPA. The aim of this study was to
quantify LPA and LPA precursors in order to better
understand hepatic malignancies.
Methods: Liver and bile samples were collected at the
time of hepatic resection for hepatocellular carcinoma
(HCC). All bile specimens were collected from the gall-
bladder at the beginning of the case. Normal bile was
collected from patients undergoing cholecystectomy for
non-neoplastic disease (n = 5 per group). Liver biopsy
samples were taken from both tumor and adjacent nor-
mal tissue. Bile and hepatic lipids were extracted in
chloroform : methanol (2 : 1) and separated from amino
acids, carbohydrates and bile acids by adding KCl.
Choline and LPA were quantiﬁed by ELISA. Lipids were
developed on silica gel G plates with chloro-
form : methanol : H2O (65 : 25 : 4), with phospholipid
standards run in parallel. Phospholipids were detected
with ammonium molybdate/mercury phosphate detec-
tion stain and quantitated by volume densitometry.
Results: Biliary choline and PC levels were similar
between HCC and control patients. In contrast, biliary
LPC and LPA was signiﬁcantly increased 78.8% and
48% in patients with HCC when compared to controls.
In HCC tumor PC and PE were both increased when
compared to adjacent liver control. LPC was below
detectable levels in adjacent liver but was detected in
tumor tissue.
Conclusion: LPA may be of great signiﬁcance in the
induction of hepatobiliary malignancies, including HCC.
Increased PC and LPC biosynthesis would potentially
increase LPA via the phospholipase D autotaxin.
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Hepatic resection for recurrent metastatic
gastrointestinal stromal tumors
G. J. ABOOD, MD, J. BREMS, MD, G. ARANHA,
MD and M. SHOUP, MD
Loyola University Medical Center, Maywood, IL, USA
Introduction: Gastrointestinal stromal tumors (GISTs)
have been associated with a both a high rate of resistance
to standard chemotherapy and radiation as well as a high
recurrence rate following surgical resection. Therapy has
evolved following the discovery that the oncogenic
mutation of the c-kit gene was responsible for much of
the malignant behavior of GISTs – improved survival has
been realized with targeted therapies using imatinib, a
tyrosine kinase inhibitor. Currently, the role of hepatic
resection for non-colorectal, non-neuroendocrine metas-
tases is less deﬁned and at times controversial. Given that
recurrent metastatic GISTs develop resistance and pro-
gression to imatinib, determining the utility of hepatic
resection in recurrent metastatic GISTs remains unan-
swered.
Objective: Demonstrate the effect of hepatic resection on
survival in recurrent metastatic GIST from a single
institution.
Methods: Following IRB approval, consecutive patients
who underwent hepatic resection for non-colorectal,
non-neuroendocrine liver metastases from a single insti-
tution from 1998–2006 were identiﬁed. From this cohort,
patients with a pathologic diagnosis of recurrent meta-
static GIST were identiﬁed. Data were retrospectively
reviewed and abstracted from the medical, surgical and
pathologic records.
Results: Seven patients were identiﬁed with a median
age of 48 (range 21–76 years) with the primary tumor
location in the stomach. All patients considered for
hepatic resection had demonstrated tumor progression
despite imatinib therapy. The median interval between
primary diagnosis and liver resection was 28 months
(range 14–55 months). The types of liver resection per-
formed were: trisegmentectomy-1, right hepatic lobec-
tomy-3, left hepatic lobectomy-3. Six of the patients had
radiofrequency ablation therapy for smaller, intra-
parenchymal tumors identiﬁed intra-operatively. While
there was no peri-operative mortality, 1 patient experi-
enced a post-operative pneumothorax. The overall
median survival was 19 months after hepatic resection-2
patients were dead of disease at 11.5 months and 5
patients were alive with disease at a median follow-up
of 27 months. Following univariate analysis, no prog-
nostic factors for improved overall survival were
identiﬁed.
Conclusion: Hepatic resection for recurrent metastatic
GIST does not result in increased morbidity or mortality.
Furthermore, hepatic resection may allow for sufﬁcient
debulking to permit additional therapy with alter-
native therapies of GISTs that become resistant to
imatinib. Larger cohort analysis may result in the
identiﬁcation of prognostic factors associated with
improved outcomes.
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Colorectal cancer liver metastases resection and
systematic hilar limphadenectomy. Analysis of
lymph nodes micrometastases
P. HERMAN, MD, PHD, E. F. VIANA, MD,
T. A. TAKA, MS, PA-C, P. A. CARVALHO, MS,
F. F. COELHO, MD, S. C. SIQUEIRA, MD,
P. VINCENZO, MD, W. A. SAAD, MD, PHD and
L. C. D’ALBUQUERQUE, MD, PHD
University of Sa˜o Paulo Medical School, Sa˜o Paulo,
Brazil
Hepatectomy is considered the best treatment of meta-
static colorectal cancer. Several prognostic factors have
been investigated, and many studies have shown that
involvement of regional lymph nodes at the hepatic hilum
represents a negative prognostic factor. The present
study evaluated the frequency and characteristics of
microscopic involvement of hilar lymph nodes, through
systematic lymphadenectomy and analysis of microme-
tastases in patients undergoing hepatectomy due to
colorectal metastases. A total of 28 patients underwent
hepatic resection associated to lymphadenectomy of the
hepatic hilum. Lymph nodes considered negative by
conventional hematoxylin and eosin (HE) staining were
analyzed by serial sectioning with 100-micron intervals
and immunohistochemistry (IHC) with the anti-human
pancytokeratin antibody AE1/AE3. In average, 6.18
lymph nodes were dissected per patient. Lymphadenec-
tomy increased surgical time by 48 min in average, but
no morbi-mortality was associated to the procedure. In
two patients, conventional HE analysis showed the
presence of microscopic lymph node metastases. IHC
analysis allowed the identiﬁcation of three other patients
with lymph node micrometastases. The overall frequency
of microscopic metastases, including micrometastases,
was 18%. No statistically signiﬁcant relationship was
observed between other prognostic factors and the
presence of microscopic metastases. Results show that
systematic lymphadenectomy improved the detection of
microscopic lymph node metastases, resulting in more
accurate staging of extrahepatic disease. The inclusion of
IHC for detection of micrometastases increased diagnos-
tic sensitivity of lymph node involvement.
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Pre- and post-chemotherapy computed
tomography ﬁndings in the livers of patients
with colorectal carcinoma undergoing adjuvant
therapy: is steatosis always related to
chemotherapy?
G. MORRIS-STIFF, A. HASSN, L. HEYWOOD,
G. TUDOR and F. BOWYER
Cwm Taf NHS Trust, Llantrisant, UK; Bro Morgannwg
NHS Trust, Bridgend, UK
Background: Recent literature suggests that chemother-
apy-related changes in the livers of patients receiving
adjuvant chemotherapy for colorectal carcinoma, in
particular steatosis/steatohepatitis, may compromise the
results of hepatic resection. However, current studies
have relied on post-resection histopathology and thus it
cannot be certain whether the changes were present prior
to the commencement of chemotherapy.
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Aims: To quantify steatotic changes in the livers of pa-
tients with colorectal carcinoma pre- and post-chemo-
therapy and to relate these to the type of chemotherapy
received.
Methods: The pre- and post-chemotherapy computed
tomography (CT) scans of patients receiving adjuvant
chemotherapy following resection of colorectal carcino-
mas were reviewed independently by two consultant
radiologists. All scans were performed on the same CT
scanner using a standardised protocol. Liver attenuation
was measured in 3 locations in the right and left lobes
and splenic attenuation was measured likewise. A hepa-
tic: splenic ratio < 1 as was indicative of steatosis. All
measurements were made on the workstation. The dis-
tribution of steatosis was also noted.
Results: Forty-ﬁve consecutive patients were studied of
which 25 received 5-ﬂurouracil, 14 oxaliplatin and 6
irrinotecan-based chemotherapy. 16 patients (35%) had
evidence of steatosis as indicated by a hepatic-splenic
ratio < 1 prior to chemotherapy. This was diffuse and
homogenous in 15 cases and with areas of focal sparing
in 1 case. A further 7 (15%) patients developed CT evi-
dence of steatosis following chemotherapy, 4 of which
had received 5-ﬂuorouracil and 1 was treated with oxa-
liplatin-based chemotherapy. In 6 cases this diffuse and
homogenous and in 1 case was geographic.
Conclusions: Although 15% of patients developed stea-
totic changes whilst receiving chemotherapy, one third of
patients already exhibited steatosis prior to commence-
ment of therapy thus suggesting that it is imperative to
consider baseline characteristics in planning adjuvant
treatment.
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Laparoscopic management of segment VII
tumors
B. C. VISSER, MD and C. CORVERA, MD
Palo Alto VA Medical Center, Stanford University,
Stanford, CA, USA; San Francisco VA Medical Center,
University of California San Francisco, CA, USA
Background: While laparoscopic ablation and resection
of liver tumors is rapidly gaining momentum, the ‘safe’
areas for laparoscopy are typically limited to the left lobe
and segments V and VI. However, as experience grows,
the beneﬁts of laparoscopy may be applied to patients
with tumors outside of the ‘safe’ areas. We describe our
early experience with laparoscopic treatment of segment
VII tumors.
Methods: Reviewing our prospectively gathered data-
bases, we identiﬁed 22 patients that underwent laparo-
scopic RFA or resection of segment VII tumors. RFA
was used in patients with contraindications to resection
or as bridge therapy toward transplantation. We ana-
lyzed the indications and operative approach for these
operations. All procedures were done with the patient in
the left lateral decubitus position. The liver is fully
mobilized off of the retroperitoneum and diaphragm as
necessary to fully access segment VII, the IVC, and right
vein. RFA was done with either RITA (Angiodynamics)
monopolar probes or InCircle (RFA-medical) bipolar
probes. During resection, the parenchyma was pre-
coagulated with either the lap Habib (Angiodynamics),
TissueLink hook (Salient) or Monarch (RFA-medical).
In some cases parenchymal division was done using
Gyrus cutting bipolar forceps (Olympus) depending on
nature of the liver parenchyma and surgeon preference.
Results: Fourteen patients underwent laparoscopic RFA
and eight laparoscopic resections. The median age was 61
(range 59–88). The indications for surgery included pri-
mary tumors in 19 cases (HCC = 18; cholangiocarci-
noma = 1) and metastatic tumors in three cases (breast,
neuroendocrine, and colorectal). All hepatomas arose in
the context of chronic HCV and thus some degree of
ﬁbrosis/cirrhosis. Among the RFAs, the average tumor
was 4.2 cm (range 2–8). Eight underwent concomitant
procedures (additional RFA elsewhere in 3; lap resection
of seg 3 tumor in 1; cholecystectomy in 3; placement of
gold ﬁducials in 1). Laparoscopic resections were com-
pleted in 7, while 1 patient required conversion. The
average tumor size was 3.4 (range 2–5). Of these, 5 were
posterior sectorectomies (seg 6 & 7), while 3 were isolated
wedge resections of segment 7 tumors). In one case
(posterior sectorectomy for 5 cm HCC), the case was
converted to open for bleeding from the right hepatic
vein.
Conclusion: Laparoscopic treatment of patients with
tumors in segment VII can be applied to carefully
selected patients. In fact, laparoscopy allows ablation or
resection of these challenging posteriorly situated tumors
in patients that would otherwise not be candidates for
(open) surgery due to comorbidities and/or underlying
chronic liver disease.
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The role of percutaneous biopsy in the
evaluation of liver lesions
P. D. RENFREW, MD, T. D. HAMILTON, MD,
M. MOLINARI, MD and M. J. WALSH, MD
Department of Surgery, Dalhousie University, Halifax,
NS, Canada; Department of Surgery, University of
Calgary, Calgary, AB, Canada
Objective: The objective of this study was to deﬁne the
utilization and timing of diagnostic modalities (serum
tumor markers, ultrasonography (U/S), computerized
tomography (CT), magnetic resonance imaging (MR),
percutaneous biopsy) employed in the evaluation of pa-
tients with liver lesions referred to a hepatopancreatob-
iliary (HPB) surgical practice. Our primary objective was
to determine the role that percutaneous biopsy played in
the assessment of these patients.
Methods: The medical records of a consecutive series of
201 patients presenting to a tertiary care HPB surgical
practice with liver lesions from July 2004 to June 2007
were retrospectively reviewed. Data pertaining to the
utilization, timing and results of serum tumor markers
(CA 19-9, CEA, AFP), diagnostic imaging modalities (U/
S, CT, MR), and liver biopsy were extracted for each
patient. Details of management and the ﬁnal diagnosis,
deﬁned by surgical pathology or serial follow-up, were
recorded. For the patients that underwent percutaneous
biopsy we determined its contribution to the establish-
ment of the ﬁnal diagnosis.
Results: Tumor markers were assayed in 128 of the 201
patients (64%). CT was the most commonly utilized
imaging modality with at least one CT being obtained in
180 of the 201 patients (90%) followed by U/S in 104
(52%) and MR in 56 (28%). Twenty-nine patients in the
series of 201 (14%) had a total of 34 percutaneous
biopsies. Twenty patients (10%) had 24 biopsies prior to
consultation and 10 had biopsy after consultation (one
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patient had two biopsies performed prior to consultation
and one after). Of the 24 biopsies performed prior to
HPB surgical consultation, the results of nine contributed
to establishing the ﬁnal diagnosis (38%). When biopsy
was carried out after HPB surgical consultation the re-
sults contributed to the ﬁnal diagnosis in 8 of the 10
patients (80%). The difference between these two pro-
portions is statistically signiﬁcant (P = 0.024). In the 172
patients that did not have a biopsy performed diagnostic
accuracy was 91% (156 of 172 correct) vs. 86% (25 of 29
correct) when biopsy was utilized (P = 0.455).
Conclusions: The results of this study suggest that, in the
vast majority of cases, the accurate evaluation of liver
lesions can be achieved without percutaneous biopsy. In
this series percutaneous biopsy had a signiﬁcantly greater
utility when it was performed after consultation with a
specialist in HPB surgery. We encourage the involvement
of a specialist in HPB surgery in the evaluation of liver
lesions, particularly if percutaneous biopsy is being
considered.
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Hepatocellular cancer in paciﬁc islanders
L. L. WONG, MD, M. OCHNER, MPH and
K. WIMMER-KUNITOMO, B.SC
University of Hawaii, Honolulu, HI, USA
Purpose: Hepatocellular cancer (HCC) has a high inci-
dence in Asian countries and is increasing in incidence in
the US. The ethnicity broadly described as ‘Asian and
Paciﬁc Islanders’ is known to have an especially high
incidence in the US, but no study has characterized HCC
in the subgroup of Paciﬁc Islanders alone.
Methods: This is a retrospective study of a prospectively
collected database on HCC patients from 1993 to 2008.
Data collected included demographics, risk factors, tu-
mor characteristics, laboratory studies, treatment and
survival. Of 523 patients with HCC, 72 were identiﬁed as
Paciﬁc Islanders and this group was compared to 85
patients in the cohort who were Caucasian. Chi-square
analyses were used to identify differences in the above
characteristics between the groups. Cox proportional
hazards model was used to determine regression analysis
of survival data.
Results: In Paciﬁc Islanders, mean age was 55.6 years
with males : females of 58 : 14 which was not signiﬁ-
cantly different in distribution from Caucasians. Paciﬁc
Islanders were more likely to have hepatitis B (36.1% vs.
5.9%, P < 0.05), symptoms at presentation (59.7% vs.
41.2%, P = 0.003), and larger tumors (P = 0.02).
Caucasians were more likely to have hepatitis C (64.7%
vs. 43.1%, P = 0.012) and encephalopathy (30.9% vs.
12.7%, P = 0.007). Although more HCC was found on
screening in Caucasians (16.7%) compared to Paciﬁc
Islanders (6.9%), this was not statistically signiﬁcant.
Mean survival was not different between Paciﬁc Islanders
(10.9 months, 95% CI 6.77–24.1) and Caucasians
(43.3 months, 95% CI 21.2–75.5). Using backwards
multivariate regression analysis, factors that were asso-
ciated with decreased survival included late stage III/IV
at presentation (Hazard ratio 3.2), female gender (HR
2.58), increased Childs-Turcotte-Pugh score (HR 2.52),
smoking (HR 2.1), and alcohol use (HR 2.0). Ethnicity
did not independently affect survival.
Conclusion: Paciﬁc Islanders were more likely to have
hepatitis B and present with symptoms and larger
tumors, though they were just as likely to have their HCC
found upon screening. Although ethnicity did not inde-
pendently affect survival, efforts should be made to bet-
ter educate the community on the importance of
identifying hepatitis B in Paciﬁc Islanders, vaccinating
against preventable hepatitis B and recognizing the risk
for HCC in this group.
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Liver hanging maneuver improves the outcomes
of complex right upper quadrant resections
Y. S. CHUN, MD, E. K. ABDALLA, MD, D. ZORZI,
MD, J. A. BREAUX, MD and J. N. VAUTHEY, MD
MD Anderson Cancer Center, Houston, TX, USA
Background: While the feasibility and technique of the
liver hanging maneuver (HM) have been reported, its
indications and advantages have not been deﬁned for
resection of hepatic and perihepatic malignancies.
Methods: Medical records of patients who underwent
right or extended right hepatectomy at a single institution
between January 2000 and February 2007 were reviewed.
HM was performed by passing a Penrose drain through
the avascular retrohepatic space to suspend the liver
during parenchymal transection. Patients who underwent
HM were identiﬁed and compared with a group of
matched controls who underwent hepatic resection via a
conventional approach.
Results: Right or extended right hepatectomy was per-
formed by HM in 26 patients and conventional approach
in 127 patients. The two groups were similar with respect
to age, gender, number of tumors, operative time, repeat
liver resection, and post-operative morbidity and mor-
tality. Compared to the conventional group, more pa-
tients in the HM group underwent hepatectomy for
adrenocortical carcinoma (P = 0.002), resection of
contiguous structures (P < 0.001), and had larger tu-
mors (median size 7.5 cm, HM vs. 4 cm, conventional,
P = 0.001). Based on these clinicopathologic variables,
the 26 HM patients were matched with 26 control pa-
tients. Compared to matched controls, HM patients had
less intra-operative tumor rupture, intra-operative blood
loss, and blood transfusions (Table 1). Fewer patients in
the HM group had positive margins and tumor recur-
rence, resulting in a longer disease-free survival (median
23 months, HM vs. 10 months, control, P = 0.019).
Conclusion: Indications for the liver hanging maneuver
during right or extended right hepatectomy include large
tumor size and resection of contiguous structures. For
complex right upper quadrant malignancies, the liver
hanging maneuver results in superior peri-operative and
oncologic outcomes compared to conventional hepat-
ectomy.
Table 1. Results.
Peri-operative and oncologic factors
Hanging
maneuver,
n (%)
Matched
controls,
n (%) P-value
Intra-operative
tumor rupture
0 3 (12%) 0.074
Median blood loss,
mL (range)
475 (150–2500) 770 (200–4000) 0.013
Intra-operative
blood transfusion
8 (31%) 15 (58%) 0.039
Positive margins 2 (8%) 12 (46%) 0.013
Disease recurrence 10 (38%) 18 (69%) 0.008
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Impact factors inﬂuencing the results of radio-
frequency ablation of primary and metastatic
liver tumors – review of 17152 cases of the
literature
M. A. F. RIBEIRO JR., MD, PHD, R. M.
MACHADO, L. T. SILVA, E. CHAIB, MD, PHD, W.
A. SAAD, MD, PHD, L. D’ALBUQUERQUE, MD,
PHD and E. ACHAR, MD, PHD
University of Sa˜o Paulo City, Sa˜o Paulo, Brazil
Introduction: The radiofrequency ablation (RFA) of
primary and metastatic hepatic tumors is a well-known
method used as treatment or palliation.
Methods: Review of 17.152 cases, in which the radio-
frequency ablation (RFA) was performed percutane-
ously, laparoscopically or by laparotomy on the
treatment of focal primary and metastatic hepatic lesions.
The group was composed by 9959 cases of hepatocellular
carcinoma, 4334 cases of colorectal liver metastasis and
2579 cases of other kinds of metastasis, such as neuro-
endocrine carcinoma, metastasis of breast tumor, cho-
langiocarcinoma; pancreatic tumor metastasis; metastasis
of renal cell carcinoma, endometrial tumor metastasis,
leyomiosarcoma hepatic metastasis and others.
Results: The way of approach most commonly used was
the percutaneous route with 86.6%, followed by lapa-
rotomy 48% and laparoscopic with 25.3%. Among the
groups that describe the mean of lesions treated, that
represented 1.40 lesions by case, with a mean size of
2.65 cm per lesion. In the overall average size of the le-
sions was 3.05 cm. The recurrence rate after the proce-
dure was 26% on average.
Conclusion: The RFA is a safe procedure, however, the
size of the lesion less than 3 cm and the means of ap-
proach carry an important factor in the recurrence rates.
Laparotomy is related with the lower recurrency rate due
to the best placement of the electrodes and may be con-
sidered the most appropriate however more invasive way
to approach the lesions when compared to percutaneous
and laparoscopic methods.
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Figure 1. Disease-free survival after hepatectomy.
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The microbiology of secondary and tertiary
pancreatic infections: implications for
antimicrobial therapy
P. V. DICKSON, MD, M. BAHR, MD and
S. W. BEHRMAN, MD
UTHSC, Memphis, TN, USA
Infections within the pancreatic bed following acute
pancreatitis and after elective resection remain common.
Prior data has suggested a shift from enteric to gram-
positive organisms in those receiving antibiotic prophy-
laxis for severe acute pancreatitis (SAP). The ﬂora
responsible for tertiary infections following elective
resection have been ill deﬁned. We retrospectively
reviewed patients developing secondary and tertiary
pancreatic infections at the University of Tennessee,
Memphis afﬁliated hospitals from 1997–2008. Factors
examined relating to secondary pancreatitis included pre-
operative antibiotic use and antecedent extra-pancreatic
infections potentially implicated in seeding the pancreatic
bed. All patients having elective resection received 24–
48 h of antibiotic prophylaxis. All infections were scru-
tinized for the incidence of non-enteric, resistant and
fungal organisms. Twenty patients (8 pancreatic necrosis,
12 pseudocyst) required surgery for secondary infections
with the recovery of 33 isolates. Fourteen patients
received vancomycin prior to surgical intervention either
to treat extra-pancreatic infection or as prophylaxis for
SAP. Six of these 14 had surgical isolates positive for
Enterococcus faecalis – 4 of which were vancomycin
resistant (VRE). Eight patients received antifungal pro-
phylaxis with no fungi recovered from intra-operative
culture. In contrast, 2 patients not receiving empiric
therapy had positive fungal isolates. Four patients with
pseudocysts requiring urgent operation for sepsis had
organisms similar to those recently recovered from
central lines. Tertiary infections occurred in 38 (17.8%)
of 213 patients having elective resection with the recovery
of 73 pathogens. Twenty-one (55.2%) patients had
polymicrobial infections. Thirty-ﬁve (47.9%) and 16
(21.9%) of the isolates obtained were Gram-positive
and fungal organisms respectively. Sixteen (21.9%)
comprised resistant bacteria including methicillin-resis-
tant Staphylococcus aureus, VRE and extended spectrum
b-lactamase producing Gram-negative bacilli. We con-
clude the following: (i) Prolonged vancomycin use in
those with SAP is associated with the development of
VRE. (ii) Empiric antifungal therapy may reduce the
incidence of secondary fungal pancreatic infections. (iii)
Systemic bloodstream infections from extra-pancreatic
sites can lead to the rapid seeding of pancreatic pseud-
ocysts (iv) Tertiary infections of the pancreas frequently
include Gram-positive, fungal and resistant organisms.
(v) Empiric therapy directed at these tertiary pathogens
should be utilized until deﬁnitive cultures are obtained.
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Laparoscopic vs. open distal pancreatectomy for
pancreatic adenocarcinoma of the body or tail
J. E. FISHER, MD, J. H. DONOHUE, MD,
D. M. NAGORNEY, MD, F. G. QUE, MD,
K. M. REID-LOMBARDO, MD, M. B. FARNELL,
MD and M. L. KENDRICK, MD
Mayo School of Graduate Medical Education, Rochester,
MN, USA
Introduction: Utilization of the laparoscopic approach
for distal pancreatectomy in patients with benign or pre-
malignant lesions is increasing. However, the feasibility
and oncologic outcomes of this approach with speciﬁc
regard to pancreatic adenocarcinoma are not known.
The aim of this study is to compare the technical aspects
and outcome of patients undergoing open (ODP) or
laparoscopic (LDP) distal pancreatectomy for pancreatic
adenocarcinoma.
Methods: We conducted a retrospective review of pa-
tients having undergone LDP or ODP for pancreatic
adenocarcinoma at a single institution from May 2005 to
May 2008. Follow up was complete for a mean of
14 months.
Results: A total of 45 patients were identiﬁed having
undergone a distal pancreatectomy and splenectomy for
adenocarcinoma during the study time period. LDP was
performed in 10 patients and ODP in 35 patients, with a
mean age of 66 vs. 65 years respectively. In all patients,
an R0 resection was achieved; adjacent organ resection
was performed when necessary. There were no statistical
differences in operative time (228 vs. 225 min), tumor size
(3.4 vs. 4.5 cm), or number of lymph nodes harvested (14
vs. 11) between the LDP or ODP groups respectively.
Patients undergoing LDP demonstrated reduced opera-
tive blood loss (150 vs. 750 mL; P < 0.001), and shorter
length of hospital stay (7 vs. 8 days; P = 0.05). The
overall incidence of peri-operative complications did not
differ between groups. Peri-operative 30-day or in-hos-
pital mortality occurred in 1 patient in the LDP and no
patients in the ODP group. Median survival was similar
for both groups (14.9 vs. 14.6 months; P = 0.64).
Conclusion: Laparoscopic distal pancreatectomy for
pancreatic adenocarcinoma of the body or tail is feasible
and appears to result in equivalent oncologic resection
and patient outcomes. Advantages of the laparoscopic
approach include reduced operative blood loss and
shorter hospital stay. Further investigation in a large,
controlled trial is warranted.
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Ofﬁce-based, mini-laparoscopy without general
anesthesia for staging of pancreatic carcinoma
R. M. WALSH, MD, W. MAURER, MD and
N. BROWN, RN
Cleveland Clinic, Cleveland, OH, USA
Expeditious diagnosis of patients with metastatic pan-
creatic carcinoma would facilitate patient management
and avoid unnecessary interventions. We studied the use
of mini-laparoscopy for early staging of suspected
pancreatic carcinoma. A prospective trial was initiated
to study the feasibility of low insufﬂation pressure mini-
laparoscopy without general anesthesia. An initial pilot
study was performed in an ambulatory operating room
with an anesthesiologist with the aim of extending this to
an ofﬁce-based setting using nurse-monitored sedation.
Following local anesthetic administration (1% lidocaine
and 0.25% marcaine), Veress needle insufﬂation to
8 mm Hg was achieved. Diagnostic laparoscopy was
performed using a 2 mm laparoscope. General inspection
of the peritoneal cavity, liver and diaphragm were
performed as well as directed biopsies and peritoneal
washings. Intravenous sedation was utilized in two
temporal phases: Phase 1 with meperidine and midazo-
lam, and Phase 2 with dexmedetomidine (Precedex).
Post-operative pain and outcome of laparoscopic ﬁnd-
ings were compared to standard laparoscopy done under
general anesthesia. Twenty-ﬁve patients underwent diag-
nostic mini-laparoscopy with a mean age of 66 years
(range 43–83). The mean pancreatic mass size was
3.03 cm. Four patients had prior abdominal incisions,
and the mean BMI was 24.5. All patients had a supra-
umbilical trocar placed, and 22 patients had a second
trocar in the epigastrum or RUQ. A forceps liver biopsy
was done in 9 (36%) and a peritoneal biopsy in one.
Peritoneal washings were done in 16 (64%) with mean
volume of 73 cc’s aspirated. Metastatic carcinoma was
identiﬁed in 4 (16%) and all ﬁndings from the mini-
laparoscopy were consistent with those at standard
diagnostic laparoscopy. Twelve patients were performed
during Phase 1 anesthesia. A total dose of 117.8 mg of
meperidine or 281.2 mcg of fentanyl, 4.0 mg of midazo-
lam, and 30 mg of ketorolac (Toradol) were used.
Thirteen patients during Phase 2 required a total mean
dose of 157 mcg Precedex and 100 mcg of fentanyl. The
pre-operative pain scale was zero in eleven patients
(44%) and averaged 3.6 in those with pain (range 2–8).
The post-operative pain scale was 0 in 6 (24%) and
averaged 4.5 in those with pain (range 1–9). The mean
time to pre-operative pain level was 1.8 days. There was
no peri-operative morbidity and the mean length of mini-
laparoscopy was 14.2 min (range 7–40). In conclusion,
mini-laparoscopy with biopsy and washings is safe and
accurate. Patient tolerance is suboptimal with meperidine
and midazolam, and only minimally improved with
Precedex administration. Current state of the art does
not foresee use as an ofﬁce based procedure with nurse
managed sedation.
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Analysis of adjuvant gemcitabine chemotherapy
concomitant with gemcitabine-based
chemoradiation therapy for resected pancreatic
cancer: a retrospective study
Y. MATSUGU, MD, PHD, T. KOHASHI, MD, PHD,
H. NAKAHARA, MD, PHD, T. URUSHIHARA, MD,
PHD, T. TANAKA, MD, PHD and Y. FUKUDA, MD,
PHD
Hiroshima Prefectural Hospital, Hiroshima, Japan;
Shimane University, Izumo, Japan
Introduction: Pancreatic cancer has a very poor prog-
nosis. Improving the outcome for patients with pancre-
atic cancer depends on increasing the rate of complete
surgical resection and reducing the rate of local recur-
rence and distant metastasis. After resection of pancre-
atic cancer, we treated patients with gemcitabine
chemotherapy concomitant with gemcitabine-based
chemoradiation therapy since 2001.
Aims and methods: Thirty-six patients (mean age: 60.7,
range: 43–75, pancreatic head tumors: n = 26, body and
tail tumors: n = 10) with stage 3 or 4 cancer (Japan
Pancreatic Society, the ﬁfth edition) treated between
April 2001 and December 2007 were included in this
study. In the group with pancreatic head tumors, patients
were given a single post-operative course of gemcitabine
chemotherapy consisting of gemcitabine 1000 mg/m2 on
Days 1, 8 and 21 after surgery. Then extra beam radio-
therapy at a dose of 41.4Gy/23fr to the tumor bed and
regional node was performed concomitant with the
administration of gemcitabine 250 mg/m2 weekly. After
completion of chemoradiation therapy, patients received
ﬁve more courses of gemcitabine chemotherapy. In the
group with pancreatic body and tail tumors, intra-oper-
ative radiation therapy at a dose of 20Gy was performed
after resection of the tumor then patients received six
courses of gemcitabine chemotherapy after surgery. In
eight cases a combination of systemic and intra-arterial
chemotherapy with gemcitabine was given. Patients were
followed with CT scanning at 3-month intervals for
1 year. We evaluated disease-free survival and an overall
survival determined by the Kaplan-Meier method retro-
spectively.
Results: This regimen was well tolerated and all patients
completed radiation therapy as planned. Local relapse
occurred 23% of patients and Liver metastasis occurred
46% of patients. The median disease-free survival (DFS)
was 15.3 months, median overall survival (OS) was
28.6 months and the overall 5-year survival was 12.1%.
Patients had a DFS of 16.6 months in local relapse group
vs. a DFS of 8.3 months in liver metastasis group.
Conclusion: Although our ﬁndings suggest a survival
beneﬁt for patients with resected pancreatic cancer, it is
necessary to perform a prospective trial of gemcitabine
concomitant with gemcitabine-based chemoradiation vs.
gemcitabine alone following surgery in order to verify
this ﬁnding.
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Malignant potential in intra-ductal papillary
mucinous neoplasm (IPMN): why observe?
A. S. KHITHANI, MBBS, D. E. CURTIS, A. J. SAAD,
MD, P. TARNASKY, MD, J. LINDER, MD and
D. R. JEYARAJAH, MD
Methodist Dallas Medical Center, Dallas, TX, USA
Background: IPMNs are well established as lesions with
an evolving natural history and treatment options in-
clude surgery. IPMNs when present as cystic lesions may
still bear a malignant tumor which may go undetected,
even with endoscopic ultrasound (EUS). Various studies
have cited factors which may suggest a slow progression
and warrant observation of IPMN. IPMN are sub typed
based on their location as main duct type, branch duct
type and mixed type. There are conﬂicting studies as to
which subtype suggests slow progression. The purpose of
this study was to look at the incidence of IPMN, presence
of malignancy in IPMN and incidence of its subtypes
based on location, in our cohort of patients that under-
went pancreaticoduodenectomy (PD).
Methods: A retrospective chart review of 122 patients
that underwent a pancreaticoduodenectomy from Sep-
tember 2005 to August 2008 at a Non University tertiary
training center was performed. Pre-operative workup
included EUS with FNA and ERCP. The demographic
parameters and outcome of this group was studied.
Results: After a pancreaticoduodenectomy, twenty two
patients (18%) were diagnosed with IPMN located in the
pancreatic head. Seven patients had IPMN of main duct
type, 4 had branch type and 11 had a mixed type. The
incidence of cancer with IPMNs was 18% (4 patients), of
which, 2 had the main duct type and two had the mixed
duct type. Two patients had a pre-operative diagnosis of
established. Two of the patients with malignancy were
pre-operatively jaundiced (50%), while only one (6%)
was jaundiced in the non-malignant group. Overall four
patients underwent a total Pancreatectomy for papillary
features on frozen section at the resection margin, of
which one was from the malignant group.
Conclusion: IPMN is an entity that needs to be managed
with a PD. The incidence of malignancy with IPMN was
18% in our series. IPMNs of the pancreatic head should
be managed with low threshold for resection irrespective
of their type or location even with a negative cytology.
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Surgical management of non-functioning
neuroendocrine pancreatic tumours
M. PAI, R. C. N. WILLIAMSON and
D. R. C. SPALDING
HPB Surgery, Hammersmith Hospital, Imperial College,
London, UK.
Introduction: Due to their slow growth and inability to
produce hormone-dependent symptoms, non-functioning
neuroendocrine pancreatic tumours (NFNEPTs) usually
have an indolent natural history. Surgical treatment of
these tumours has become increasingly important for
symptom palliation and survival. The aim of this study
was to assess the role of surgery, adjuvant therapy and
outcomes of NFNEPTs based on the experience of a
single institution.
Methods: Between 1994 and 2007, 21 patients were
treated for NFNEPTs. Their investigations, surgery,
histology and clinical outcome were reviewed retrospec-
tively.
Results: There were 11 men and 10 women of median age
49 (range 26–76) years. Gut hormone proﬁles were nor-
mal in all patients. Contrast-enhanced computed
tomography localised the tumour in 20 patients and
visceral angiography in 15 of 16. The NFNEPTs were
located in the head in 16 patients, body in 2 and tail in 3.
Eleven patients underwent curative resection (pancre-
atoduodenectomy [PD] n = 8, distal pancreatectomy
n = 2 and laparoscopic enucleation n = 1) and 10 pal-
liative resection (PD n = 6, total and distal pancreatec-
tomy two each). Four patients had concomitant liver
resections (curative and palliative two each). There were
no operative deaths. The median tumour size was 4.5 (1–
17) cm. Seventeen tumours were malignant (angioinva-
sion = 14, perineural invasion = 2 and positive lymph
nodes = 10). Ten patients received adjuvant therapy
(chemotherapy n = 2, embolisation n = 2, chemother-
apy and embolisation n = 1, a-interferon n = 2, tar-
geted radionuclide therapy n = 1, targeted radionuclide
therapy and radiation n = 1). Nine patients have died
from disease a median of 43 (range 10–141) months after
operation. The 12 survivors, 7 of whom had curative
resections, have been followed for a median of 46 (range
24–95) months. Ten patients are asymptomatic but only
ﬁve are free from disease.
Conclusions: Although surgical cure is rare in NFN-
EPTs, long-term palliation can be achieved with an
aggressive surgical approach and adjuvant therapy.
Table 1. Immunohistochemical markers.
Marker No (%)
Chromogranin A 14 (66)
Neuron speciﬁc enolase (NSE) 13 (61)
Synaptophysin 9 (42)
Cytokeratin 7 (33)
Protein-gene product (PGP)9.5 6 (28)
VIP 1 (5)
Pancreatic Polypeptide 1 (5)
Somatostatin 1 (5)
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Vascular endothelial growth factor (VEGF) and
placental growth factor (PlGF) in patients with
pancreatic cancer
M. S. SABBAGHIAN, MD, A. P. ALONGI, B.SC.,
J. -P. GAGNER, MD, PHD, C. HAJDU, MD,
D. ZAGZAG, MD, PHD, R. BASCH, MD and
P. SHAMAMIAN, MD
New York University School of Medicine, New York, NY,
USA
Purpose: To determine if pancreatic adenocarcinoma
produces VEGF and/or PlGF and if levels of these fac-
tors are elevated in plasma of patients with this disease.
Methods: From November, 2006, to May, 2008, at New
York University Medical Center, patients with
pancreatic adenocarcinoma undergoing potential tumor
resections were recruited for study. Healthy patients
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‡ 50 years old scheduled for elective hernia repair were
recruited as controls. Immunohistochemistry (IHC) was
performed on cancer specimens using anti-human VEGF
and anti-human PIGF (Santa Cruz Biotechnology Santa
Cruz, CA, USA). A biotin–streptavidin system was used
for visualization. Staining was measured as the overall
percent of cells staining within one high-power ﬁeld, and
the scale used was 0 = no staining, 1+ = < 1%,
2+ = 1–10%, 3+ = 11–50%, and 4+ = > 50%. For
plasma, 8 mL of venous blood was collected pre-opera-
tively in K2-EDTA containing Vacutainer tubes (Becton,
Dickinson and Company Franklin Lakes, NJ, USA) with
platelet depletion via high-speed centrifugation. Human
Quantikine Kits (R&D Systems Minneapolis, MN, USA)
targeting VEGF or PlGF were used. Mann–Whitney test
was used for comparison of pancreatic cancer patients vs.
controls. Two-sided tests were performed and run at a
signiﬁcance level of 0.05.
Results: IHC of normal pancreas demonstrated VEGF
staining in ductular and acinar cells and PlGF staining in
Islets of Langerhans. Tumor cells in all cancers (n = 8)
stained for VEGF and PlGF. Five of eight tumors had
‡ 11% of cancer cells positive for these factors. Inﬂam-
matory cells associated with tumor did not stain for
VEGF (between 0 and < 1%), although they did stain
for PlGF (between 1 and 50%). Plasma samples dem-
onstrated no differences in VEGF levels between the
cancer group (n = 10) and the control group (n = 9),
but cancer patients demonstrated elevated levels of PlGF.
Median VEGF plasma levels were 37.85 pg/mL for the
cancer group and 42.93 pg/mL for controls. The median
PlGF plasma level was elevated to 12.74 pg/mL for the
cancer group compared to 8.71 pg/mL for controls
(P = 0.053).
Conclusions: (i) Pancreatic cancer is a source of pro-
angiogenic VEGF and PlGF. (ii) Tumor-associated
inﬂammatory cells may contribute to neovascularization
via PlGF production. (iii) PlGF, which is thought to act
synergistically with VEGF, is elevated in the plasma of
pancreatic cancer patients. (iv) Realizing that bev-
acizumab, which targets only VEGF, does not affect
patients with pancreatic cancer, targeting both VEGF
and PlGF and/or their receptors may be important for
successful anti-angiogenic therapy in patients with this
disease.
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Laparoscopic pancreatectomy under the
scrutiny
H. M. ALGHAMDI, MD, MBBS
Vancouver general hospital, Vancouver, BC, Canada
Aim: A systematic review carried out to assess the pub-
lished evidence for safety, feasibility and reproducibility
of laparoscopic pancreatectomy.
Material and methods: Literature search used Medline,
EMbase and Pre-medline databases. A total of 397 pa-
tients (22 series) of laparoscopic distal pancreatectomy
and Laparoscopic Enucleation (LEn) and 50 patients (5
series) of laparoscopic pancreaticoduodenectomy (LPD)
were included.
Result: In over 90% of cases the disease was benign (45
% are neuroendocrine lesions). The mean tumor size
ranged from 1.8–5.8 cm. Spleen preservation was re-
ported in around 37% of the LDP. The mean blood loss
and average operative time was 278 mL (100–1800) and
192 min (104–354) respectively. Approximately 16% (0–
40%) of the procedures were converted to open. LEn was
feasible in around 22% of the cases. When compared
with LDP, LEn incurred signiﬁcantly less operative
blood loss [10 vs. 38 mL; (P < 0.001)], shorter mean
operative time [152 vs. 251 min (P < 0.001)] and shorter
mean post-operative hospital stay [4.7 vs. 0.4 days
(P < 0.001)]. Post-operative complications, pancreatic
ﬁstula and Re-operation were 26%, 13% (0–33%) and
8% respectively. The ﬁrst 30-days mortality rate was
around 0.5%. Mean post-operative hospital stay ranged
between 4.1 and 11.8 days. Recurrence of the original
pathology was observed in only 8 patients. In LPD
cancer was the indication in over a third of patients. The
mean operative time and blood loss were 410 min and
222 mL respectively. In 14% the procedure was con-
verted to open. The recovery was uncomplicated in 76%
of the patients, only 4 patients (8%) requiring re-opera-
tion. The operative mortality and mean post-operative
hospital stay was 6% and 16.5 days respectively. The
disease recurred in six patients (12%).
Conclusion: LDP is a feasible primary approach. The
procedure requires a very skillful surgeon and advanced
laparoscopic setting. In LPD it is still experimental in
approach and need to be investigated further.
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Post-operative complications in live liver donors
afterpartialhepatectomyfor liver transplantation
R. F. SAIDI, N. ELIAS, D. SC KO, T. KAWAI,
H. YEH, J. MARKMANN, A. B. COSIMI and
M. HERTL
Massachusetts General Hospital, Boston, MA, USA
Introduction: Donor safety is the ﬁrst priority in living
donor liver transplantation (LDLT). We evaluated the
post-operative morbidity after partial hepatectomy for
LDLT in our unit.
Method: Thirty patients underwent LDLT between 1997
and 2007 at our institution. This represented approxi-
mately 8% of the total liver transplant experience during
that period. The type of graft was the right lobe (seg-
ments 5–8) in 14, left lobe (segments 1–4) in 4, and left
lateral sector (segments 2 and 3) in 12 patients. There
were 18 adults and 12 pediatric recipients. Mean donor
age was 36 years (26–57). The mean follow-up was
48 months (range 6–120 months). Complications were
classiﬁed according to Clavien’s system: grade I, devia-
tion from the normal post-operative course but without
the need for therapy; grade II, complication requiring
pharmacologic treatment; grade III, complication with
the need for surgical, endoscopic or radiological inter-
vention (IIIa/b: without/with the need for general anes-
thesia); grade IV, life-threatening complication requiring
intensive care; grade V, death.
Results: No deaths occurred. Overall 8 (26.6%) patients
experienced a total of 14 post-operative complications.
Mean length of hospitalization was 7.5 days (5–12 days).
Donor complications based on graft type were as follows:
left lateral sector (16.7%), left lobe (25%), and right
lobe (35.7%). Type of and grade of complications are
summarized in the Table 1. The experience was divided
into two periods 1997–2001 (15 patients) and 2002–2007
(15 patients). Overall complications during two periods
were 40% and 13.3%, respectively (P < 0.001). The
incidence of grade III complication also decreased sig-
niﬁcantly, 63.6% vs. 33.3 (P < 0.01).
Table 1. Complications.
Grade of
complications: n (%)
Complications
(1997–2001) (n)
Complications
(2002–2007)
I: 4 (28.6%) atelectasis (2),
superﬁcial phlebitis (1)
a
II: 1 (7.1%) Ileus (1) 0
IIIa: 7 (50%) Biloma (3), perihepatic ﬂuid
collection (1), pleural
effusion (1), GI bleeding (1)
peripancreatic
ﬂuid collection (1)
IIIb: 2 (14.3%) wound dehiscence (1) ventral hernia (1)
IV: 0 0 0
V: 0 0 0
Conclusion: Partial hepatectomy in living donors has a
learning curve which appears to approximate is about 15
cases. This learning curve is not restricted to the surgeons
performing theprocedure but involves all areasof peri- and
post-operative patient care. Our experience emphasizes
thatLDLTcanbe safely providedbyactive liver transplant
programs performing only modest number of LDLT.
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Retransplantation of the liver: the Columbia
University experience
B. SAMSTEIN, MD, T. CHRISTOPHIDES, MD,
J. GUARRERA, MD and J. EMOND, MD
Columbia University Medical Center, Department of
Surgery, Center of Liver Disease and Transplantation,
New York, NY, USA
Primary graft failure, recurrence disease and technical
complications contribute signiﬁcantly to decreased graft
and patient survival after liver transplantation. Re-trans-
plant is only option for patient with end-stage liver disease
after transplantation. Retransplantation is historical asso-
ciated with worse outcomes then primary transplant.
Aim: The purpose of our study is to present our experi-
ence of re-OLT for patients with graft failure after pri-
mary transplantation.
Materials and methods: We analyzed retrospectively the
clinical data of 54 patients who were offered re-OLT for
liver failure, including the indications, timing, causes of
death and survival rates. Between the period June 1998
and June 2008, 817 adult patients were treated with liver
transplantation, and 54 (6.6%) underwent re-transplan-
tation. One of them needed a second re-OLT.
Results: The indications for re-OLT included: recurrence
of viral induced hepatitis C (24 cases), primary non-
function (15 cases), biliary cast syndrome (5 cases), bili-
ary obstruction (4 cases), hepatic artery thrombosis (3
cases), outﬂow obstruction (1 case), chronic rejection (1
case), acute graft failure following portal vein thrombosis
reconstruct tion (1 case), and refractory ITP (1 case). The
timing of re- OLT was between 2 days and 6 years. The
most common cause of death was sepsis (65%), usually
associated with multi-organ failure. The 1-month, 1-year,
and 3-year survival rates were 86.9%, 64.4% and 56%
respectively. How common was recurrent hepatitis C as
cause of retransplant failure/death?
Conclusions: Retransplantation remains a challenging
clinical entity but sepsis rather than recurrent disease is
the primary cause of death. Efforts in the future should
focus on novel and reduced immunosuppression for
patients undergoing retransplantation.
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Approach to management of excluded bile ducts
in pediatric orthotopic liver transplantation
K. D. CONZEN, MD, J. A. LOWELL, MD,
W. C. CHAPMAN, MD, M. D. DARCY, MD,
M. NADLER, RN, Y. P. TURMELLE, MD,
R. W. SHEPHERD, MD and C. D. ANDERSON, MD
Washington University in St. Louis, St. Louis, MO; St.
Louis Children’s Hospital, St. Louis, MO, USA
Wider application of orthotopic liver transplantation
(OLT) with living donor, cadaveric reduced and split
allografts has reduced pediatric waiting list mortality.
Segmental grafts have increased risk of biliary
complications. A complication which can lead to graft
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loss is exclusion of a major segmental bile duct. We
present three cases and describe an algorithm to correct
these complications.
Case 1: A 6-month-old girl underwent OLT for biliary
atresia with a segment 2/3 graft from an in situ cadaveric
split liver. She became jaundiced 1 month later. Hepatic
ultrasonography revealed a dilated biliary tree and per-
cutaneous transhepatic cholangiography (PTC) demon-
strated complete obstruction of the segment two bile duct
system. Following external biliary decompression, she
was explored and the excluded duct was anastomosed to
the existing Roux limb using the indwelling PTC catheter
as a guide.
Case 2: A 5-month-old boy with biliary atresia received a
segment 2/3 graft from a living donor. Reexploration for
fevers and leukocytosis revealed a biloma, but no iden-
tiﬁable leak. An area of bile staining on the cut surface
was oversewn and drained. Persistent drainage prompted
a PTC which demonstrated an aberrant biliary tree
draining a large portion of segment 3. This was not evi-
dent on the donor MRCP. It was managed with external
biliary drainage followed by exploration and hepati-
cojejunostomy using the PTC catheter as a guide.
Case 3: A 4 year-old girl with OTC deﬁciency received a
segment 2/3 graft from an in situ cadaveric split liver.
Two bile ducts were identiﬁed during procurement and
Roux-en-Y hepaticojejunostomy was performed for
each. She required percutaneous drainage of a biloma
post-operatively. An abdominal CT scan revealed an
isolated dilated biliary tract. The excluded system
drained the medial graft; the other two systems appeared
normal. This was again managed with PTC for external
drainage and interval revision hepaticojejunostomy. The
patient developed a post-operative anastomotic stricture
requiring PTC and dilation. Segmental allografts have an
increased incidence of biliary complications. Although
unusual, suspicion should remain high for an excluded
bile duct if the patient develops jaundice or increased
liver enzymes. Aggressive diagnosis, percutaneous
decompression, and interval revision hepaticojejuno-
stomy are the main tenets of management. Careful revi-
sion hepaticojejunostomy over a percutaneous biliary
stent can result in restoration of biliary continuity and
allograft survival.
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Right-sided diaphragmatic hernias after
orthotopic liver transplant in children: an under-
reported problem after reduced size grafts
J. R. WELLEN, MD, C. D. ANDERSON, MD,
M. B. DOYLE, MD, M. NADLER, RN, CNP,
S. SHENOY, MD, PHD, W. C. CHAPMAN, MD and
J. A. LOWELL, MD
Washington University in St. Louis, St. Louis, MO;
St. Louis Childrens Hospital, St. Louis, MO, USA
Liver transplantation in children is being performed at
increasing rates and at earlier ages. Between 1996 and
2007 there were 6863 liver transplants performed in
children under the age of 17. Of these, 4333 were whole
organ grafts and 2492 were reduced size grafts (living
donor, in situ, ex situ split and cut-down). In general,
partial grafts are associated with slightly increased
complication rates such as bile leaks, vascular thrombotic
events and bowel obstructions. Because most pediatric
liver transplants are re-operative procedures, diaphrag-
matic complications such as paralysis or the development
of a diaphragmatic hernia can occur. However, the
incidence of diaphragmatic hernia (DH) remains un-
known. We present three patients with this complication
and a review of the literature. Our center has performed
122 liver transplants in children < 17 years of age
between 1996 and 2007. Of these, 59 were whole organ
grafts and 63 were reduced size grafts (16 were ex situ
split or cut-down grafts, 18 were in situ split grafts and 29
were living grafts). Patient 1 is a 10 y/o girl who received
an OLT with (left lateral segment) from an in situ split
graft for Alagille’s syndrome. A CT scan was unreveal-
ing. After failure to improve she was explored and a right
sided DH was identiﬁed and repaired primarily. Patient 2
is an 18-month-old girl with a history of biliary atresia s/
p Kasai procedure who received an OLT with a left lobe
reduced size graft obtained from an ex situ split. Her DH
was repaired with a bridge of Alloderm to prevent
tension on the repair. Patient 3 is a 5-year-old girl who
underwent an OLT for an unresectable 15 · 10 cm
embryonal sarcoma with a left lateral segment obtained
from an in situ split. Her DH was performed primarily.
To date there are only seven reported cases of children
developing right sided diaphragmatic hernias following
partial liver transplantation. The treatment of this
complication can include: primary closure, with or
without pledgets, to reapproximate the edges and bridge
the gap with either an artiﬁcial mesh (gortex, prolene) or
a biological mesh (i.e. Alloderm). Right sided DH
acquired after a partial liver transplant within the
pediatric population remains uncommon. This diagnosis
should be considered in pediatric recipients of partial
liver grafts who develop pulmonary complications or
abdominal symptoms of bowel obstruction. Expeditious
exploration and repair should be performed to prevent
bowel infarction.
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Piggy back technique with three suprahepatic
veins: systematic use in adult orthotopic liver
transplantation
O. C. IMVENTARZA, MD, P.H. B. SCHELOTTO,
MD, MPH, C. M. QUARIN, MD, F. S. DUEK, MD,
G. A. RAFFIN, MD, V. B. GARAY, MD, L. GIL, MD
and J. C. LENDOIRE, MD, PHD
Hospital Dr Cosme Argerich, Buenos Aires, Argentina
Piggy Back technique (PBT), a procedure that preserves
the recipient inferior cava vein, could be performed
selectively with 1, 2 or 3 suprahepatic veins (SHV).
Advantages of PBT are haemodynamics stability, pre-
served kidney function, shorter operation time and
reduction of blood loss. However, PBT is not used
routinely in all liver transplant centers and some authors
advocate more complications in using three SHV. The
aim of this study was to describe and analyze a single
center experience with PBT with three SHV.
Methods: PBT was used in adults with acute or chronic
hepatic failure. Technique was as follows: after the
common bile duct and hepatic artery were dissected and
divided, accessory hepatic veins were approach from the
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right side of the cava. According to the size of segment I,
portal vein section was intended to be performed at the
end of IVC dissection. A german clamp was applied
proximally across the conﬂuence of the three recipient
SHV without occluding the ﬂow. Intra-parenchyma vein
section allowed appropriate cuffs for the upper side of
the anastomoses. It was performed with the suprahepatic
donor IVC and the joined cuff of the three recipient’s
SHV. There was no requirement of venous-venous by-
pass. Graft revascularization was performed via portal
vein reperfusion and subsequent reconstruction of he-
patic artery inﬂow. Variables of recipient, surgical pro-
cedure and post-operative outcome were analyzed.
Results: A total of 161 consecutive adult OLT with PBT
were performed from May 2002 to June 2008. Eleven
were second transplants, ﬁve combined liver-kidney and
one liver-heart transplant. Average operating time was
373 ± 89 min, cross clamp time 73 ± 23 min. Red
blood cell requirement 6.2 ± 3 U and fresh frozen
plasma 9.5 ± 8.5 U. There were no intra-operative
complications related to the recipient vena cava outﬂow.
In the post-operative period there was arterial throm-
bosis in 3.1%, portal thrombosis in 0.6% and no caval
thrombosis was detected. Three cases developed severe
post-operative ascites but none showed caval obstruction
in the hemodynamic studies.
Conclusion: OLT with PBT with three SHV is a safe
procedure and can be used routinely in adults.
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A novel mouse model of mucinous cystic
neoplasms
M. D. JOHNSON, R. MACKEY, MD, L. LU, MD,
C. BISCOTTI, MD, N. BROWN, RN and
R. M. WALSH, MD
Cleveland Clinic, Cleveland, OH, USA
We sought to create a reproducible animal model of
human mucinous cystic neoplasms to study cyst injection
ablation techniques which may serve as alternatives to
surgical resection. A mucinous cystic neoplasm cell line
(MCC1) was developed at the University of Verona from
a patient with a 7 cm non-invasive mucinous tumor. The
MCC1 cell suspension was grown in tissue culture using
RPMI 1640 media with fetal bovine serum and other
additives. Once conﬂuent, cells were trypsinized, counted,
and resuspended in 200 microliter aliquots of PBS buffer
and centrifuged in ﬂexible capillary tubing in preparation
for implantation. Five-week-old female Swiss nude mice
were used as the hosts. Samples of 0.25, 0.5, or
1.0 · 106 cells were implanted under the renal capsule
via the capillary tube centrifuged aliquot under general
anesthesia. Animals were sacriﬁced at a mean of 27 days
(range 22–41 days). Cysts, if present, were aspirated and
samples analyzed for cytology and mucin content. The
entire kidney was explanted, ﬁxed in 10% formalin,
sectioned, and stained with H&E. A single staff pathol-
ogist (CB) reviewed each pathology specimen. A total of
eight renal subcapsular implantations were performed in
four mice. Four cysts formed in two mice. In the other
two mice there was either minimal growth or grossly solid
tumors formed. Among the four cysts, maximum cyst
diameter was 0.8–1.2 cm. Alcian blue/PAS staining of
cyst contents revealed abundant mucin. Histology
revealed columnar epithelium with varying degrees of
dysplasia. In two cysts there was no component of
carcinoma whereas in the other two there were small foci
of invasive carcinoma. We have demonstrated that
mucinous cystic neoplasms can be reproduced in a renal
capsule model of nude mice. In the future this model can
be used to study cyst injection ablation techniques.
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Adipokines and cytokines in human pancreatic
juice: unraveling the local pancreatic
inﬂammatory milieu
N. J. ZYROMSKI, MD, C. M. SCHMIDT, MD,
A. MATHUR, MD, S. WANG, MD, T. E. WADE,
MD, D. A. SWARTZ-BASILE, PHD, H. A. PITT, MD
and K. D. LILLEMOE, MD
Indiana University, Indianapolis, IN, USA
Background: Obesity is an independent risk factor both
for increased severity of pancreatitis as well as for
development and progression of pancreatic cancer. The
mechanisms underlying this association are incompletely
understood; however, the generalized proinﬂammatory
state of obesity appears to play an important role. Precise
evaluation of human pancreatic physiology is challeng-
ing, and current understanding of the altered pancreatic
inﬂammatory milieu in obesity is based exclusively on
experimental animal data. Evaluation of adipokines and
cytokines in pancreatic juice offers a relatively non-
invasive method to assess the pancreatic inﬂammatory
Figure 1.
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proﬁle. However, to date there has been no study of
adipokines or cytokines in human pancreatic juice. This
proof of concept study was therefore designed to deter-
mine the presence of adipokines and cytokines in human
pancreatic juice.
Methods: With institutional review board approval,
pancreatic juice was obtained from nine patients at the
time of endoscopic retrograde cholangiopancreatogra-
phy. Clinical diagnoses included: intra-ductal papillary
mucinous neoplasm (n = 3), normal (n = 2), sphincter
of Oddi dysfunction (n = 2), chronic pancreatitis
(n = 1), and adenocarcinoma (n = 1). Pancreatic juice
was assayed by ELISA for the proinﬂammatory adipo-
kine leptin, anti-inﬂammatory adipokine adiponectin,
proinﬂammatory cytokines interleukin-6 (IL-6) and tu-
mor necrosis factor alpha (TNF-a), and the chemoattr-
actant molecule monocyte chemoattractant protein-1
(MCP-1). Correlation of adipokine, chemokine, and
cytokine concentration was performed by regression
analysis. Data are presented as mean ± SEM; P < 0.05
was considered statistically signiﬁcant.
Results: Leptin was expressed in pg/mL and adiponectin
in lg/mL concentrations (leptin 11.0 ± 0.6 pg/mL,
adiponectin 61.3 ± 1.1 lg/mL). IL-6 (112.6 ± 28.1 pg/
mL), TNF-a (49.0 ± 18.8 pg/mL), and MCP-1
(32.2 ± 0.9 pg/mL) were all detected. Paradoxically, the
anti-inﬂammatory adipokine adiponectin had a strong
positive correlation with the proinﬂammatory cytokine
IL-6 (r2=0.977, P < 0.001).
Conclusion: This is the ﬁrst report of adipokine and
cytokine levels in human pancreatic juice. Leptin and
adiponectin are expressed in pancreatic juice in concen-
trations similar to those observed in serum. Pancreatic
juice IL-6 expression paradoxically showed a strong
positive correlation with adiponectin. Adipokine and
cytokine concentration in pancreatic juice likely provides
an important reﬂection of the local pancreatic inﬂam-
matory milieu.
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Analysis of genomic abnormal area concerning
biological malignant potential and prognosis of
hepatocellular carcinoma by high sensitivity
array CGH
N. KAZUAKI, MD, PHD, N. TOMIOKA, MD, PHD,
T. KAMIYAMA, T. NAKAGAWA, MD, PHD, H.
YOKOO, MD, PHD, K. MORITA, PHD, M. TADA,
MD, PHD, S. TODO, MD, PHD and T. HIRANO,
PHD
Hokkaido University Sapporo, Japan; National institute of
advanced industrial science and technology, Tukuba, Japan
Background and purpose: Array Comparative Genomic
Hybridization method (aCGH) is a genomic analysis
technology that measures minute abnormalities (loss: ),
gain:+) of the number of copies of chromosomes. It is
covered by BAC (bacterial artiﬁcial chromosome) clones
that make the fragment of all genomes (some hundreds of
kb). Hepatocellular carcinoma (HCC) has a poor prog-
nosis. Though there were a lot of clinical pathologic
analysis of prognostic factor, the result had not been still
enough. The aim in this research is that genomic
abnormal areas concerning about biological malignancy
and the prognostic factor were analyzed by aCGH, and
there made comparative study with the result of a clini-
copathologic examination.
Objective and method: Fifty-eight HCC samples were
analyzed by using aCGH of 4000 clones that had the
resolution of about 1Mb. These samples were collected
from liver resections carried out at Hokkaido university
hospital from 1999 to 2001, and DNA was obtained from
frozen tumor tissues.
Result: There were 48 males and 10 females, and average
age was 59.9 years old. 28 samples were obtained from
patients with HBV infection, and 22 samples from pa-
tients with HCV infection. Using Japanese TNM staging
system for primary liver cancer (Ref: Ann Surg. 245: 909–
22, 2007), the number of Stage1, 2, 3, 4A were 3, 28, 17,
and 1 respectively. The average observation period was
1808 days, and the accumulation survival rate for 3 or
5 years was 80.3, and 70% respectively. The univariate
and multivariate analysis revealed that serum concen-
tration of albumin (< 4.0 mg/dL), and positive patho-
logical portal invasion (vp) were independent poor
prognostic factors. The areas of 40% or more in the
frequency of gain or loss of the number of copies were
+1q, )4q, 8p and +)8q, )13q, )16p, )16q, )17p, and
)19p. Speciﬁc BAC clones correlated with vp, intra-he-
patic metastasis, and the degree of histological differen-
tiation was shown respectively, but there was little
common BAC clones among them. In addition, the areas
that signiﬁcantly related to the prognosis were +2q+3q,
)4q, )6q, )12p, )16p, )16q and )19q. E-cadherin and
P27, etc. that were the already-known cancer related
genes were included in these BAC clones.
Conclusion: It was suggested that aCGH was a promis-
ing method of getting more information about biological
malignant potential and prognostic factor, included a
new prognostic marker genes.
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Microwave ablation – the state of the art
I. WIELAND, P. CLEGG, PHD and N. CRONIN,
PHD
University of Bath, Bath, UK
Although many techniques for soft tissue ablation have
been extensively investigated, by far the most dominant
modality over the last decade has been radio frequency
ablation (RFA). Whilst being reasonably efﬁcacious in
the treatment of small hepatocellular carcinoma (HCC),
RFA has serious limitations in large tumour ablations
and in coping with the different environments encoun-
tered in various soft tissue types. This paper demon-
strates theoretical, computational, experimental, and
clinical evidence in support of the hypothesis that
microwave ablation (MWA) successfully addresses the
major problems experienced with RFA. The physical
principles of radio frequency and microwave tissue
heating are presented, indicating expected differences in
heating performance. Finite element modelling (FEM) is
used to conﬁrm the theoretical expectations and is
compared with microwave bench experimentation and
published literature for RFA. Finally, clinical compari-
son of MWA and RFA in an interventional radiology
(IR) setting indicates that for any given ablation volume
the time required for MWA is approximately 33% of that
for RFA. In addition, the maximum achievable ablation
volume for MWA is approximately 290% of that for
RFA. The study therefore indicates that MWA is capable
of larger and faster ablations.
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Identiﬁcation of candidate genes in familial
pancreatic cancer with analysis of germline
genomic copy number variation
W AL-SUKHNI, MD, S. JOE, B.SC., A. GROPPER,
B.SC., S. MOORE, B.SC., G. ZOGOPOULOS, MD,
PHD, H. ROTHENMUND, MS, A. E. BORGIDA, MS
and S. GALLINGER, MD, FRCP
University of Toronto, Toronto, ON, Canada
The genetic basis of Familial Pancreatic Cancer (FPC) is
largely unknown. Germline genomic copy number var-
iation (CNV) is a widespread form of human genetic
variation, and may inﬂuence cancer risk. High-resolution
SNP-based DNA arrays can be used for genome-wide
detection of CNVs in germline DNA. We hypothesize
that one or more FPC genes are altered in the germline
by large genomic deletions (affecting tumor suppressor
genes) or gains (impacting dose-sensitive oncogenes),
both detectable using CNV analysis of SNP platforms.
Lymphocyte DNA was extracted from 128 Pancreas
Cancer Genetic Epidemiology (PACGENE) Consortium
FPC patients and assayed on the Affymetrix 500K SNP
microarray, consisting of two chips. Raw intensity data
were analyzed with two algorithms using a Hidden
Markov Model to estimate copy numbers. Only deletions
were examined in the present analysis, and only regions
at least 1000 base pairs in size were included. Results
were compared to deletions previously identiﬁed in 1200
healthy controls. Genomic regions exclusively deleted in
FPC cases were annotated using bioinformatic tools,
identifying genes with potential involvement in cancer.
Interesting deletions were biologically conﬁrmed with
qPCR. A total of 425 non-overlapping deletions were
detected, of which 131 were detected by two algorithms
and/or on both SNP chips. Thirteen percent of deletions
(55/425) were detected in more than one FPC case.
Importantly, 166/425 (39%) deletions were not present in
any control samples, of which 74 contained 101 known
genes. At least 13 deletions affect known or putative
tumor suppressor genes, two of which have been
validated biologically with qPCR. Validation of the
other interesting regions is ongoing. Unique or rare
germline copy number losses in FPC patients may lead to
the discovery of putative tumor suppressor genes predis-
posing to FPC. Further annotation and characterization
of these CNVs is in progress.
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Pancreatic necrosectomy: North American
mortality is much lower than expected
P. Y. PARIKH, MD, M. KILBANE, RN, BSN, H. A.
PITT, MD, T. J. HOWARD, MD, A. NAKEEB, MD,
K. D. LILLEMOE, MD and N. J. ZYROMSKI, MD
Indiana University, Indianapolis, IN, USA
Background: Necrotizing pancreatitis is a highly lethal
disease. Single institution series suggest that the mortality
of patients undergoing pancreatic necrosectomy has im-
proved, but remains at 15–20%. No national data cur-
rently exist regarding the outcome of patients requiring
pancreatic necrosectomy. The American College of Sur-
geons National Surgical Quality Improvement Program
(ACS-NSQIP) currently accrues demographic and out-
come data from 171 United States and two Canadian
hospitals. In 2007 a CPT code speciﬁc for debridement of
pancreatic and peripancreatic necrosis became available.
Therefore, the aim of this analysis was to explore the
ACS-NSQIP database to determine contemporary out-
comes of a North American sample of patients under-
going debridement for pancreatic and peripancreatic
necrosis.
Methods: The ACS-NSQIP Participant Use File was
queried for all patients who had debridement of pan-
creatic and peripancreatic necrosis (CPT code 48105)
from January 1, 2007 through December 31, 2007. Pa-
tient demographics, observed (O) and expected (E)
morbidity and mortality as well as indices (O/E) were
evaluated. An O/E ratio of less than 1.0 suggests that
outcomes were better than expected.
Results: During this 12-month period, data were accu-
mulated on 161 patients. The mean age was 54 years;
71% were male; and 75% were Caucasian. The mean
Body Mass Index was 30.3; 29% had diabetes; and 10%
abused alcohol. Forty-two percent were transferred to
NSQIP hospitals from other facilities. Systemic Inﬂam-
matory Response Syndrome (SIRS), sepsis or septic
shock were present pre-operatively in 14%, 30% and
23% of patients, respectively. Overall morbidity was
62%, and 30-day mortality was 6.8%. However, mor-
bidity and mortality indices were 0.86 and 0.33, respec-
tively.
Conclusions: These data suggest that patients undergoing
debridement for pancreatic and peripancreatic necrosis at
ACS-NSQIP hospitals (i) provide a new North American
sample and (ii) have better than expected outcomes,
especially with respect to 30-day mortality. We conclude
that ACS-NSQIP is a powerful tool to assess contem-
porary outcomes of uncommon, high-risk procedures.
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Reducing ICU admissions in higher ASA class
patients after pancreaticoduodenectomy: impact
of a team based approach
A. S. KHITHANI, MBBS, D. E. CURTIS, MD,
M. WHITE, RN and D. R. JEYARAJAH, MD
Methodist Dallas Medical Center, Dallas, TX, USA
Background: Peri-operative outcome of a pancreatico-
duodenectomy (PD) may be impacted by several factors,
such as co-morbidities, operative technique, and post-
operative care. The purpose of this study is to evaluate
whether the development of a dedicated multidisciplinary
team can increase direct admission to the ﬂoor and
reduce the ICU admission after PD.
Methods: Medical records of 122 patients, who under-
went PD by a single surgeon between September 2005
and August 2008 at a high volume non-university tertiary
training center (NUTTC), were analyzed. The records
were reviewed with respect to number of patients who
were transferred to the ﬂoor directly, bypassing the ICU.
During the ﬁrst year 45 PD were performed and this data
was compared with the 31 PD cases performed during the
second year and 46 cases in the third year. The multi-
disciplinary team consists of a gastroenterologist, sur-
geon, hepatobiliary fellow, general surgery residents,
ICU nursing staff, operating room team, and a surgery
ﬂoor nursing staff. Standardized algorithms and a dedi-
cated ﬂoor nursing staff were developed during this time
period.
Results: A total of 122 patients underwent PD. The total
of 55 (45%) patients transferred directly to the ﬂoor
managed by a dedicated team, without being admitted to
the ICU. The yearly distribution of patients was 10
(22%), 16 (52%), 29 (63%) in years I, II and III
respectively. Hence the ICU admission rate has sequen-
tially dropped from 78% in Year I to 48% in year II and
37% in year III. Overall 12% of these patients were ASA
class II, 75% were ASA class III, and 13% were ASA
class IV respectively. Every subsequent year a higher
number of patients of ASA III (Year I – 25%, Year II –
60%, Year III – 75%) and ASA IV (Year I – 0, Year II –
33%, Year III – 70%) were transferred to the ﬂoor
directly when compared to the previous year.
Conclusions: This study demonstrates that a multidisci-
plinary team can be developed in a NUTTC for patients
with pancreatic disease. This process results in improved
peri-operative outcomes. This outcome can be achieved
with decreased use of the ICU if a dedicated ﬂoor nursing
team is developed, even in patients with signiﬁcant
comorbidities and poor ASA status. This will translate to
decreased hospital charges, earlier mobilization, and a
more streamlined pathway for patients after PD.
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Routine nasogastric decompression is
unnecessary after pancreatic resections
C. L. ROLAND, MD, S. P. DINEEN, MD and
R. E. SCHWARZ, MD
UT Southwestern Medical Center, Dallas, TX, USA
Introduction: Many major operative procedures in the
upper abdomen are routinely accompanied by nasogas-
tric tube (NGT) decompression intra- and post-opera-
tively, although the beneﬁt of prolonged post-operative
NGT decompression is unproven.
Methods: Clinical information of all operative procedures
involving the pancreas in a single-surgeon oncologic
practice were collected in a prospective database. NGTs
wereplaced routinely intra-operatively throughout theﬁrst
part of the study interval, and removed based on clinical
recovery progress; orogastric tubes (OGTs) were used in-
tra-operatively whenever possible since April 2006, and
removed prior to endotracheal extubation. Post-operative
NGT duration and reinsertion rate, morbidity, length-of-
stay, and later outcomes were analyzed between groups.
Results: The analysis includes 189 operations between
1997 and 2008, including 138 pancreatoduodenectomies
(PD), 39 distal pancreatectomies (DP), two total pan-
createctomies (TP), and 10 other procedures. The mean
age was 65 years, there were 60% females, and 73% of
patients had a cancer diagnosis. Forty patients (21%) re-
ceived no NGT, compared to 149 who did; there were no
differences between resection types. The median post-
operative NGT duration was 1 day (range 0–79, no group
differences), themedian length of stay 9 days (4-100, group
differences: P < 0.0001). The mean proportion of in-
hospital time with NGTwas 19% (PD: 18.5, DP: 17.5, TP:
35, others: 29;P = NS).NGT reinsertionwas necessary in
30 patients (16%), andmore common after PD (20%) than
after DP (3%, P = 0.04). NGT reinsertion needs did not
differ between patients after routine NGT and OGT use
(17 vs. 13%). The complication rate was 38% (major: 12,
minor: 26), with lethal outcomes in 3%. NGTs were rein-
serted in 73% of major vs. 24% of minor complications
(P < 0.0001). Pyloric preservation (PP) duringPDdidnot
affectOGTuse (18 vs. 26%),medianNGTduration (2 day
vs. 1 day), or NGT reinsertion rate (21% vs. 19%).
Delayed gastric emptying (DGE) was observed in two
patients after PPPD (2.9%), and in three patients past
classic PD (4.3%).
Conclusion: This experience demonstrates that NGTs can
be safely avoided in patients undergoing pancreatic
resective procedures, since post-operative NGT reinser-
tion need, DGE rate, total NGT duration and length of
stay are not negatively affected. Based on the results, we
prefer to place OGTs intra-operatively, and attempt to
routinely avoidpost-operative nasogastric decompression.
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Dissecting the role of cancer-directed surgery in
pancreatic cancer – a case-controlled population
based analysis using propensity-score matching
P. SCHNEIDER, B.SC., E. T. KIMCHI, MD, K. F.
STAVELEY-O’CARROLL, MD, PHD, C. S.
HOLLENBEAK, PHD and N. J. GUSANI, MD
Penn State College of Medicine, Hershey, PA, USA
Background: Cancer-directed surgery (CDS) improves
survival in pancreatic cancer (PaCa). Those who present
with localized tumors are thought to derive the greatest
beneﬁt from CDS. The use of population-based datasets
allows estimation of the effect of CDS among large
cohorts, but these analyses are confounded by non-
uniformity in patient proﬁles among the groups com-
pared. Using data from the SEER registry, we per-
formed a retrospective, matched study to mitigate the
effects of baseline heterogeneity in the study population
and to examine the true effect of CDS on survival in
PaCa.
Methods: A total of 2856 patients with localized PaCa
were identiﬁed over a 12-year period. 34% received
CDS. The patient, tumor, and treatment proﬁles, as well
as survival, of these two cohorts were compared. Then,
using propensity score matching (PSM), we performed a
case-controlled analysis to delineate the effect of CDS
on survival. Matching 1 : 1 produced a ﬁnal cohort of
715 patients (358 no CDS and 357 CDS). The matched
groups were once again compared to ensure equality
between the groups. After matching, survival functions
were plotted for the CDS and no CDS groups and
compared. Chi square tests were used for comparison of
groups. Survival functions were derived using the
Kaplan–Meier method and compared by the log-rank
test.
Results: At baseline, there were signiﬁcant differences
between the CDS and no CDS groups in terms of
patient demographics, year of diagnosis, tumor size
and grade, and receipt of radiation. This heterogeneity
among the groups makes direct comparison between
CDS and no CDS prone to bias, calling into question
the improved median survival in patients receiving
CDS (27 months vs. 6 months, P < 0.001). When
matched 1 : 1 (no CDS: CDS), no statistically signiﬁ-
cant differences remained between the two populations
for any of the baseline variables. In this well-matched
cohort, the survival advantage in the CDS group was
maintained (median 26 months vs. 7 months,
P < 0.001) (Figure 1).
Conclusion: Through PSM, a large cohort of well-mat-
ched patients with localized PaCa from the SEER data-
base was examined to show that CDS results in a
signiﬁcantly improved survival compared to patients not
receiving CDS. This study provides further evidence for
the critical role of CDS in the treatment of early-stage
PaCa.
Figure 1.
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Novel economic model of observation vs.
immediate laparoscopic resection of hepatic
adenomas
T. VANOUNOU, MD, T. NGUYEN, MD,
D. GELLER, MD and T. C. GAMBLIN, MD
University of Pittsburgh Medical Center, Pittsburgh, PA,
USA
Background: Elective surgical resection of hepatic ade-
nomas (HA) is well-accepted in the context of uncertain
diagnosis, presence of symptoms, large or increasing size,
and occurrence of major complications. However, in the
absence of such criteria, the management of HAs is
controversial with a wide variation in clinical practice
concerning the use of elective surgery. Given the absence
of randomized data and the inability of existing case
series to support or refute elective surgery for patients
with small asymptomatic HAs, we sought to investigate
whether the cost-effectiveness of observation vs. imme-
diate surgery could be used to further clarify the pre-
ferred management of asymptomatic HAs.
Objective: Compare the societal costs of immediate sur-
gery vs. routine screening in a theoretical cohort of
patients with hepatic adenomas amenable to limited
laparoscopic hepatic resection using evidence-based and
institutional-speciﬁc assumptions.
Methods: Economic model comparing the net present
value (NPV) of either observing a theoretical cohort of
100 patients with hepatic adenomas using a variety of
imaging modalities vs. immediately operating on a com-
parable theoretical cohort of 100 patients whose lesions
are amenable to limited laparoscopic hepatic resection.
The assumptions underpinning the model are based on
Deviation-Based Cost Modeling of our large institutional
experience with minimally invasive liver surgery and in-
clude a major deviation rate of 2% and a 0% mortality
rate.
Results: Assuming an initial progression rate of 5%
followed by a rate of 2% after year 3, the NPV of
observation using yearly computed tomography and
magnetic resonance imaging is $1 537 711 and
$1 644 922 respectively after 5 years of follow-up and
$2 448 960 and $2 630 514 respectively at 10 years of
follow-up. The NPV of immediate surgery is
$1 717 021. The break-even point at which point the
present costs of yearly observation and immediate sur-
gery intersect is after 6 years of follow-up for CT and
5 years for MRI.
Conclusion: There is considerable controversy regarding
the management of asymptomatic hepatic adenomas.
The risks of spontaneous rupture, malignant transfor-
mation, and elective surgery must be weighted against the
societal economic burden of frequent monitoring and
public health issue surrounding long-term exposure to
radiation from screening. In light of the young age of
patients afﬂicted with hepatic adenomas and the need for
long-term serial follow up, immediate surgery in a highly
selective cohort of patients is cost-beneﬁcial assuming the
operation can be performed laparoscopically and with
minimal morbidity and no mortality.
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Impact of intra-operative blood transfusion on
survival following pancreaticoduodenectomy for
cancer
N. TSIM, MBBS, M. PAI, MD, R. WILLIAMSON,
MD, N. HABIB, MD and L. JIAO, MD
Imperial College, London, UK
Aim: To compare the outcomes of patients with and
without intra-operative blood transfusion (BT) following
pancreaticoduodenectomy (PD) for cancer in a single
tertiary referral centre.
Background: Peri-operative blood transfusion (BT) has
been implicated in reduced disease free (DF) and overall
survival (OS) in patients with colorectal malignancies.
Increased threshold for transfusion and the use of
autologous blood aims to prevent complications of
immunosuppression, cancer recurrence and infective
complications of BT. Few studies to date have investigated
whether allogenic peri-operative BT is an independent risk
factor for reduced survival in patients with pancreatic
carcinoma undergoing pancreaticoduodenectomy (PD).
Methods: A total of 64 patients (43 male, 21 female) who
underwent PD in our institution between 2002 and 2007
were prospectively followed up. Those received BT were
compared with those who did not have transfusion of
blood or blood products (NBT). The two groups were
case-matched for all clinicopathological data including
age, histology (pancreatic vs. ampullary carcinoma), type
of surgical procedures (pylorus-preserving PD vs.
Whipples); tumour and nodal stage, bilirubin, albumin
and pre-operative haemoglobin level. Outcome measures
were post-operative morbidity, mortality, DF and OS.
Data were analyzed using a multivariate linear regression
model (SPSS).
Results: There was no statistically signiﬁcant difference
in demographics data. The median age was 67.5 years
(range 40–82) in BT, 68 years (range 36–81) in NBT
group. There was no signiﬁcant difference in the early
complication rates in wound infection, abscess and col-
lection, relaparotomy, morbidity or mortality rate. Intra-
operative blood loss (P < 0.001) and operative time
(P < 0.0001) were signiﬁcantly higher in the BT group.
However, there was no difference in intensive care
(P = 0.08) or hospital stay (P = 0.4). The median DF
survival was 13 vs. 8 months in NBT vs. BT groups post-
surgery for pancreatic adenocarcinoma (P = 0.61); and
22 vs. 10.5 months in NBT vs. BT groups in ampullary
carcinoma (P = 0.04). The median OS is 19 vs.
18.5 months in NBT vs. BT groups in patients with
pancreatic adenocarcinoma (P = 0.78); compared to 28
vs. 24 months in NBT vs. BT groups in patients with
ampullary carcinoma (P = 0.21). Multivariate analysis
revealed BT signiﬁcantly reduces DF survival in ampul-
lary carcinoma, but has no signiﬁcant impact on DF or
OS in pancreatic adenocarcinoma.
Conclusion: This study shows BT signiﬁcantly reduces
DF survival after PD for ampullary carcinoma. Meticu-
lous dissection and care in haemostasis reduce blood loss
and prevents the need for BT; this in turn prolongs DF
survival.
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Early nutrition support after pancreaticoduo-
denectomy can improve patient status.
H. BABA, K. NAKAJIMA, MD, N. GOSEKI, MD,
PHD and S. ARII, MD, PHD
Shuwa General Hospital, Kasukabe, Japan; Tokyo
Medical and Dental University, Tokyo, Japan
Background: Various post-operative complications occur
after pancreaticoduodenectomy (PD). Although surgical
techniques mainly contribute to its outcome, nutrition
factor cannot be neglected. Onodera’s Prognostic
Nutrition Index (PNI) is a convenient nutritional
assessment index which predicts post-operative modality
by calculating pre-operative albumin level and lympho-
cyte counts.
Aim: We aimed to clarify whether early nutrition sup-
port after PD can improve post-operative patient status
whose pre-operative PNI were poor.
Patients and method: Eighteen consecutive patients who
underwent PD (conventional or pylorus preserving) were
evaluated. Duct-to-mucosa anastomosis was carried out
in all patients. Enteral feeding was started within 2 days
after operation. PNI, post-operative hospital stay,
modality (delayed gastric emptying, failure of anasto-
mosis, abdominal abcess) were investigated. Onodera’s
PNI is calculated as 10 · alb (g/dL) + 0.005 ·peripheral
lymphocyte count (/mm3). PNI is originally described as
a pre-operative modality prediction factor for advanced
colorectal cancer patients. Values under 40 are consid-
ered dangerous and 45 or above are considered safe.
Results: There were eight conventional PD and ten
pylorus preserving. Ten patients were pancreatic cancer.
There were three patients whose PNI was less than 40.
On the other hand, eight patients were above 45. Average
PNI of pancreatic cancer patients were 40.9, whereas 45.1
in other diseases. Delayed gastric emptying occurred in
seven patients (average PNI; 44.9), pancreatojejunal
anastomosis failure in three patients (average PNI; 44.5),
abdominal abcess in three patients (average PNI; 42.3).
Every patient with PNI below 40 experienced post-
operative complication. Even with good PNI (above 45),
modality rate was 37%. Hospital stay of patients with
PNI less than 40, between 40 and 45, and above 45 were
40 days, 37 days, and 43 days, respectively.
Conclusion: PNI below 40 can also be classiﬁed as dan-
gerous range, as in original deﬁnition, for performing
PD. However, patients with PNI above 45 cannot be
classiﬁed as safety range for relatively high modality rate.
Interestingly, length of hospital stay with PNI below 40
patients is shorter than PNI above 45 patients. Early
nutrition support may contribute to early recovery from
adverse events even with PNI below 40.
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Results of liver surgery at a low-volume center
M. STELLA, MD, S. BERTOGLIO, MD, N. SOLARI,
MD, P. PERCIVALE, MD, C. SONAGLIO, MD,
A. CASSATA, MD, C. MUROLO, MD,
D. MARENCO, MD, F. CARDINALE, MD,
F. CAFIERO, MD and C. DI SOMMA, MD
IST National Cancer Institute, Genoa, Italy
The paper reports results from a series of 52 patients,
which were prospectively collected between January 2003
and December 2007, in order to determine whether liver
resection might be a safe procedure at a low-volume
hospital. The mean age was 62.5 years; in 34 patients
there was comorbid disease, mainly cardiovascular. Pre-
operative impairment of liver function related to chronic
liver disease or to steatohepatitis induced by pre-opera-
tive chemotherapy was present in 12 patients. Pre-
operative right portal vein embolization was employed
in six patients. Twenty-eight patients (53%) underwent
major liver resections. A two-stage hepatectomy was
necessary in two patients, while in 19 patients, liver
resection was synchronous with other abdominal oper-
ations. Intra-operative radiofrequency thermal ablation
was used with resection in ﬁve patients. Mean intra-
operative blood loss was 334.8 mL, twelve patients
required peri-operative blood transfusions. There was
one post-operative death (1.9%), of a cirrhotic patient
due to a biliopleural ﬁstula, resulting in a lung abscess
and sepsis. Overall complications, most of which were
minor, occurred in 17 patients (32.7%) (Table 1) and they
were always managed conservatively. Pre-operative
impairment of liver function was the only factor affecting
operative morbidity by univariate analysis (P = 0.03;
odds ratio [OR]: 4.2; 95% conﬁdence interval [CI]: 0.9–
20.2). The mean hospital stay was 9.7 days. A stay of
more than 7 days was associated with the presence of
post-operative complications (P < 0.001) and to pre-
operative impairment of liver function (P < 0.001).
According to the studies with the largest numbers of
patients to date, the overall mortality and morbidity rates
following hepatectomy range from 0–4.9% and 32.4–
39%, respectively; our results are similar to those
reported in major series. Liver resection may be safely
performed at low-volume hospitals, provided that there is
an ICU available, and trained surgeons, anesthesiolo-
gists, and nursing staff experienced in managing patients
with complex conditions. Mortality and morbidity rates
are acceptable and comparable with those of high-
volume hospitals, even in cases of major hepatectomy
or associated procedures.
Table 1. Post-operative complications.
Complication n
Wound infection 4
Pleural effusion 4
Biliary ﬁstula 4
Abdominal collection 2
Persistent ascites 2
Gastric ulcer bleeding 1
Central venous catheter infection 1
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Outcomes of hepatic resection for metabolic
disorders related to hepatocellular carcinoma
S. ZALINSKI, MD, Y. S. CHUN, MD,
E. K. ABDALLA, MD, S. A. CURLEY, MD and
J. N. VAUTHEY, MD
MD Anderson Cancer Center, Houston, TX, USA
Purpose: The incidence of hepatocellular carcinoma
(HCC) is increasing dramatically in Western countries
because of the hepatitis C virus epidemic and screening
policy of high risk populations. Recently, metabolic dis-
orders such as obesity and insulin resistance have been
identiﬁed as contributing to the increase in HCC inci-
dence. We assessed the outcome of liver resection for
HCC among patients with metabolic disorders but
without other HCC risk factors.
Patients and methods: The records of all patients who
underwent liver resection for HCC at our institution
between 1998 and 2008 were reviewed. Patients with
known HCC risk factors (alcohol use, hepatitis, immu-
nologic factors, and estrogen use), as well as patients with
ﬁbrolamellar HCC were excluded. The remaining
patients were included if they were overweight (body
mass index [BMI] > 25 kg/m2) and had at least one of
the following: type II diabetes, hypertension, or dyslipi-
demia.
Results: Among 36 patients meeting inclusion criteria, 26
(72%) were male and 24 (67%) were Caucasian. Sixteen
patients (44%) were obese (BMI > 30 kg/m2), 15 (42%)
had diabetes mellitus, 30 (83%) had hypertension, and 19
(53%) had dyslipidemia. Alpha-fetoprotein values were
within normal range in 20 patients (56%). Pre-operative
right portal vein embolization was performed in twelve
patients (33%), transarterial chemoembolization in 6
(17%), and sequential arterio-portal embolization in 3
(8%). Twenty-four patients (67%) underwent major liver
resection (‡ 3 segments). On pathological examination of
the resected specimen, only 4 patients (11%) had cir-
rhosis, and mean tumor size was 81 ± 8 mm. Seven
patients (19%) had satellite nodules, and 12 (33%) had
vascular invasion. Post-operative morbidity and 90-day
mortality rates were 50% and 11%, respectively. After
median follow-up of 25 months, median overall (OS) and
disease-free survival (DFS) had not been reached. OS
rates at 1, 3, and 5 years were 82%, 78%, and 70%,
respectively. Satellite nodules (P = 0.06) and vascular
invasion (P = 0.05) were associated with worse DFS.
Conclusion: Owing to lack of screening, HCC in patients
with metabolic disorders is diagnosed at an advanced
stage and often requires major resection. However, the
long-term prognosis is good, and aggressive surgical
strategies are justiﬁed.
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Operative mortality after resection of biliary
tract cancer in the United States
J. E. CARROLL JR., MD, Z. M. HURWITZ, MD,
J. P. SIMONS, MD, J. T. MCPHEE, MD, S. CHAU
NG, MS, S. A. SHAH, MD, W. B. AL REFAIE, MD
and J. F. TSENG, MD
University of Massachusetts Medical School, Worcester,
MA, USA; University of Minnesota Department of
Surgery and Minneapolis Veterans Affairs Medical
Center, Minneapolis, MN, USA
Objective: To assess peri-operative mortality following
resection of biliary tract cancer within the US.
Background: Resection remains the only curative treat-
ment for biliary tract cancer [BTC]. Early detection to
offer operative intervention may contribute to improved
survival. However, current data on operative mortality
after surgical resections for BTC are limited to small and
single-center studies.
Methods: Using the Nationwide Inpatient Sample 1998–
2006, a cohort of patient-discharges was assembled with
a diagnosis of BTC, including intra-hepatic bile duct,
extrahepatic bile duct, and gallbladder cancers. Patients
undergoing resection, including hepatic resection, bile
duct resection, pancreaticoduodenectomy, and cholecys-
tectomy, were retained. The primary outcome measure
was in-hospital mortality. Continuous variables were
analyzed by t-test; categorical variables were analyzed by
chi-square. Multivariable logistic regression was per-
formed to identify independent predictors of in-hospital
mortality following resection.
Results: A total of 31 870 patient-discharges occurred
for the diagnosis of BTC, including 31.1% intra-hepatic
ductal, 36.2% extrahepatic ductal, and 26.7% gallblad-
der. Of the total, 18.6% underwent resection: mean age
was 69.3 years; 60.9% were female; 73.7% were white.
Overall inpatient surgical mortality was 5.62%. Inde-
pendently predictive factors of increased peri-operative
mortality included patient age ‡ 70 (vs. < 50; odds ratio
[OR] 8.99, 95% conﬁdence interval [CI] 2.84–28.48), the
presence of identiﬁed comorbidities (congestive heart
failure, OR 3.66, 95% CI 2.58–5.18; acute renal failure,
OR 4.68, 95% CI 2.93–7.43), and admission designated
as emergent (vs. elective; OR 1.84, 95% CI 1.40–2.41).
Conclusion: Increased in-hospital mortality for patients
undergoing BTC resection corresponded to age, comor-
bidity, and emergent admission. Further study is war-
ranted to utilize these observations in promoting early
detection, diagnosis, and elective resection.
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Outcomes of liver resection for HCC in patients
with metabolic disorders
S. ZALINSKI, MD, V. PARADIS, MD, S. DOKMAK,
MD, V. VILGRAIN, MD and J. BELGHITI, MD
Hopital Beaujon, Clichy, France
Background: Although, it is well established that HCC
can be discovered in patients with metabolic disorders
(MD), including type 2 diabetes, obesity and dyslipide-
mia, homogeneous series of patients of this group are
lacking. Moreover the outcome of surgical series is not
known.
Aim: To assess outcome of liver resection among a
stringently selected population of patients with MD
related HCC.
Patients and methods: From 2000 to 2008, among 240
patients who underwent partial liver resection for HCC,
31 patients fulﬁlling the criteria of MD were resected. A
single pathologist reviewed pathological features of HCC
and non-tumoral liver. Post-operative morbidity was
stratiﬁed with the Dindo’s classiﬁcation. To study the
survival, all patients were reviewed every 6 months for a
mean duration of 3 years and there were no lost of fol-
low-up.
Results: These 31 patients were characterized by 97%
(n = 30) men, a mean age of 67.4 ± 1.7 years old
(ranging from 50 to 81 mm), including 19 > 65 years, a
BMI > 25 kg/m2 in 77% (n = 24) of cases. Diabetes,
High blood pressure and dyslipidemia were found in 24
(77%), 26 (84%) and 20 (65%), respectively. AFP was
elevated in 23% (n = 7) of cases including, 3 > 500 ng.
Mean tumor size was 85 ± 6 mm (ranging from 20 to
350 mm) and 15 required (48%) major resection (more
than three segments). Post-operative morbidity was 52%
(Dindo I, II, III, IV in 6 (19%), 2 (7%), 1 (3%) and
4(13%) cases respectively) and 4 patients died within 90
post-operative days (13%). Pathological examination
showed that the tumor was well differentiated in 20
(64%) cases, with macro/micro vascular invasion in 6
(19%)/4 (45%) and satellite nodules in 11(35%). Non-
tumoral liver showed that chronic liver parenchyma
disease was present in 11 cases (35%), while steatosis
> 30% was present in 5 (16%). After a mean follow-up
of 33 months, three patients died from recurrence.
Overall survival at one, 3 and 5 years was 87%, 79%,
70% whereas disease free survival (DFS) was 84%, 53%,
and 35% respectively. DFS was negatively inﬂuenced by
the presence of satellite nodules (P = 0.004). Size of the
tumor, differentiation, vascular invasion and the status
of non-tumorous parenchyma were not correlated to
DFS. OS was impaired in patients with absence of cap-
sule (P = 0.02), multinodular disease (P = 0.059), vas-
cular invasion (P = 0.053) and satellite nodules
(P = 0.077).
Conclusion: According to the results of this ﬁrst surgical
series of HCC resected in patients with MD, surgical risk
is important but long term outcome is favourable.
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Resection of tumors of the Ampulla of Vater:
retrospective review of a single institution’s
experience
P. O. SIMON JR., MD, M. YOUNKIN, N. A.
HAMILTON, MD, R. AZAR, MD, S.
EDMUNDOWICZ, MD, D. C. LINEHAN, MD,
S. M. STRASBERG, MD and W. G. HAWKINS, MD
Washington University School of Medicine, St. Louis,
MO, USA
Purpose: Tumors of the Ampulla of Vater are amenable
to treatment by both endoscopic techniques as well as
conventional surgical management. This study evaluates
a single tertiary referral center’s recent experience with
tumors of the Ampulla of Vater and presents a strategy
for optimal treatment choice to guide therapy.
Methods: Demographics, treatment course, and out-
comes for all patients presenting with a diagnosis of tu-
mor of the Ampulla of Vater during a 64 month period
(January 1, 2003–April 1, 2008) were analyzed
(n = 108).
Results: Benign adenomas and dysplastic / atypical
adenomas were treated by endoscopic papillectomy
(n = 29, 27%). Ampullary adenocarcinomas were trea-
ted with pancreaticoduodenectomy (n = 79, 73%). No
single demographic factors favored either treatment
group (age, gender, or race). Signs that were predictive of
pancreaticoduodenctomy included jaundice (80% vs.
3%, P < 0.01) and steatorrhea (33% vs. 3%, P < 0.01).
Patients that presented with GI bleed trended toward
treatment with endoscopic papillectomy (14% vs. 6% for
pancreaticoduodenectomy, P = 0.25). Symptoms that
favored malignancy and treatment by pancreaticodeuo-
denectomy included pruritis (37% vs. 3% for endoscopic
papillectomy, P < 0.01) and fever (19% vs. 0% for
endoscopic papillectomy, P < 0.01). Length of stay and
complication rates were higher in the pancreaticoduo-
denectomy group. No 30-day mortalities occurred in the
endoscopic group (0/22) vs. a single 30-day mortality in
the pancreaticoduodenectomy group (1/79, 1.2%).
Conclusions: Endoscopic papillectomy is a safe and
effective treatment of benign and dysplastic/atypical
adenomas. Pancreaticoduodenectomy can be effectively
performed for adenocarcinoma of the ampulla and
should be considered the treatment of choice for can-
cerous lesions. Jaundice, steatorrhea, pruritis, and fever
are statistically signiﬁcant predictors of malignancy as
treated by pancreaticoduodenectomy compared to
adenomatous lesions.
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Maternal abdominal surgery during gestation
outcomes relate to emergent nature and imply
cytokine inﬂuence
J. L. ALMEDA, MD, C. TOKIN, B.SC., J. FIEBER,
B.SC. and R. SELBY, MD
Keck-USC School of Medicine, Los Angeles, CA; USC,
Los Angeles, CA, USA
Introduction: Major non-obstetric abdominal operations
during pregnancy impose inherent risks upon mother and
fetus. This Gestational Surgical Risk Assessment
(GSRA) has been correlated with gestational age during
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pregnancy, but other factors may play important roles.
Based on a hypothesis that inﬂammatory states may
induce cytokines with abortifacient and other properties,
we propose that emergency operations for inﬂammatory
conditions may carry risks not shared by elective opera-
tions for conditions of non-inﬂammatory states, regard-
less of trimester.
Methods: We combined our experience (n = 32
patients.) with a literature meta-analysis (n > 2000
patients) to evaluate outcomes as a function of maternal
surgical indication. All patients had major non-obstetric
procedures during gestation and were divided into
inﬂammatory and non-inﬂammatory cohorts. Maternal
death as well as fetal prematurity and spontaneous
abortion were endpoints.
Results: Inﬂammatory etiologies included appendicitis,
cholecystitis, intestinal obstruction, inﬂammatory bowel
disease, and spontaneous hepatic rupture. There was a
signiﬁcantly higher risk of pre-term labor and sponta-
neous abortion for those patients with inﬂammatory and
infectious indications for surgery, as compared to major
oncologic procedures. Peritonitis proved to be an even
more signiﬁcant risk factor for not only fetal complica-
tions, but maternal death (Table 1).
Table 1. Procedures for inﬂammatory processes.
Indication Number
Fetal
death (%)
Maternal
death (%)
Appendicitis –
perforated
1653 67 (4.0) 0 (0)
Appendicitis –
non-perforated
182 18 (9.9) 0 (0)
Biliary stone disease 279 12 (4.3) 1 (0.36)
Volvulus 16 4 (25) 2 (12.5)
Adhesions 39 11 (28) 2 (5.1)
Toxic obstruction 16 10 (62.5) 5 (31.2)
Obstruction (other) 21 6 (28.5) 0 (0)
Inﬂammatory
bowel disease
12 2 (16.7) 0 (0)
Hepatic rupture 35 7 (20) 7 (20)
Conclusions: While major hepatobiliary operations can
be tolerated well by mother and fetus, operations for
perforated appendicits and bowel obstruction prove to be
extremely high risk for mother and fetus. We believe that
the inﬂammatory cytokines and proinﬂammatory medi-
ators associated with peritonitis are responsible for many
of the complications experienced during emergent oper-
ations in gravid patients. Cytokines, speciﬁcally TNG-
alpha, IL-1beta, and IL-6, have long been implicated as
factors contributing to the common signs of infection
and inﬂammation in cases of sepsis, shock, and trauma.
Cytokines have also recently been suspected to play a
crucial role in pre-term labor and delivery. We believe
that it is important to consider not only the underlying
condition, but the association with physiologic stress and
inﬂammation when assessing the risk maternal and fetal
risk of a procedure.
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Major hepatobiliary surgery without blood
transfusion in Jehovah witness patients
J. RACCUIA, MD, J. STEELE, MD and
I. NICHIPORENKO, MD
Saint Vincent’s Hospital Manhattan, New York, NY, USA
Major life-threatening conditions that require extensive
hepatobiliary and oncologic procedures in the Jehovah
Witness patient can be safely performed with a low
operative risk. Over a 2.5-year period 12 Jehovah
Witness patients had 14 major hepatobiliary surgeries.
All of these patients were considered high risk for surgery
by any standard regardless of their religious beliefs.
Accordingly all of these patients were refused surgery at
other major centers in the United States due to their
reluctance to respect their religious belief of not accepting
blood transfusions and due to the size and locations of
their lesions. During the initial evaluation patients were
considered for surgery depending upon the ability to
technically perform the extensive surgeries based upon
imaging criteria and clinical data at the time of presen-
tation. All patients were pre-treated with epoetin alfa
(Epogen) according to our protocol to optimize the
hemoglobin level above 12.0 g/dl prior to any surgical
intervention. The pre-operative goals were to maximize
red blood cell mass, delineate tumor extension and
develop a plan to incorporate blood conservation strat-
egies and minimize blood loss. There were 5 (29%)
patients that had prior unsuccessful surgery before
presentation. The patients had various diagnoses that
included 2 benign biliary strictures, 3 liver neoplasms, 5
pancreas tumors, and 4 with retroperitoneal tumors
associated with the liver and pancreas. A total of 12
Jehovah Witness patients underwent 14 major hepatob-
iliary and oncologic surgeries for various diagnoses. The
primary surgical procedures consisted of three complex
biliary reconstructions, three hepatectomies, three distal
pancreatectomies, one pancreaticoduodenectomy and
three retroperitoneal tumor resections associated with
the liver or pancreas. The mean blood loss was
641 ± 550 cc and cell saver transfusion was necessary
in only 7 (50%) patients with a mean transfusion of
111 ± 150 cc of salvaged blood. Pre-operative and post-
operative hemoglobin levels averaged 13.1 ± 1.5 and
11.0 ± 1.6 respectively. The mean decrease in hemoglo-
bin was 1.7 ± 1.9 after surgery. Post-operative compli-
cations occurred in 4 (24%) and there was one death
within 30 days of surgery. Multiple blood conservation
techniques were employed for these procedures that were
denied at other institutions. Complex hepatobiliary
surgery can be successfully performed in these patients
while respecting the right to refuse allogeneic blood
products. These results demonstrate that these complex
procedures can be performed with acceptable morbidity
and morality when compared to other individuals with
similar diagnoses when the use of blood transfusion is
not an option.
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Digital 3D anatomical images of the liver – a
didatic tool
A. C. DE A MARTINS, MD, PHD and C. MARTINS
IMIP – Instituto de Medicina Integral Prof. Fernando
Figueira and Medical School of Pernambuco – FBV/
IMIP, Recife – Pe, Brazil
Three-dimensional images of complex anatomical sites
aid with correct understanding of depth during surgical
procedures. This paper describes a simple method to
obtain stereoscopic anatomical images for teaching
purposes using common photographic equipament. The
stereoscopic pairs were produced using a simple sliding
tray with an adapted millimeter scale to control the
distance between the pictures. The initial still image was
captured and the tray shifted laterally to capture the
second image. Frozen isolated cadaveric livers and liver
corrosion casts were used to obtain the 3D images.
Binocular vision is the result of adding two slightly
different images of the same object, produced by the
alignment of eyes and orbits, which ‘see’ the same object
from slightly different points of view. The distance
between pictures must approximate the interpupillary
distance in normal conditions. The distance between
pictures is variable and depends on the distance between
the lens and the object to be depicted. The resulted
images can be projected or printed.
Abstracts94
 2009 The Authors
Journal Compilation  2009 Hepato-Pancreato-Biliary Association, HPB, 11 (Suppl. 1), 1–104
Abstracts 180 to 187
Oral Posters – Imaging/Outcomes/Other
Saturday, March 14, 2009 7:00–8:00 am
180
3D operative planning for liver surgery from
your laptop
B. C. VISSER, MD, S. WREN, MD, M. SUGIMOTO,
MD and R. SOETIKNO, MD
Stanford University, Stanford, CA, USA
Background: The unique surgical anatomy of the liver
has led to efforts to perform 3D rendering for operative
planning and volumetrics. Typically, these 3D recon-
structions require specialized computer equipment and
training. The authors report early experience with a novel
technology to allow high quality 3D operative planning
performed by the surgeon using consumer-grade com-
puters.
Methods: Standard thin-cut triphasic liver CT scans were
obtained in 21 consecutive patients before resection
(n = 13: 7 open; 6 laparoscopic) or laparoscopic radio-
frequency ablation (8). The DICOM images, whether ‘in-
house’ and on CD from elsewhere, were imported into
OsiriX software on Apple computers (iMac and Mac-
Book). 3D reconstructions were produced to characterize
the anatomy of the liver and location of tumor(s) (Fig. 1).
In ﬁve cases, PET images were also fused into contrast-
enhanced CT. In three cases, volumetrics of the future
liver remnant were performed pre- and post-portal vein
embolization (Fig. 2), and the results compared to the
Department of Radiology 3D lab. All reconstructions
and volumetrics were performed by the operating
surgeon himself.
Results: The OsiriX software proved very easy to learn
with little (< 2 h) training. 3D rendering accurately de-
picted anatomic details and the relationship between the
tumor(s) and vasculature in all cases. The 3D recon-
structions can be rotated 360 to facilitate planning of the
operative approach, particularly in lap RFA and resec-
tion. Surgeon-measured volumetrics matched those of
the 3D lab (< 5% difference). 3D reconstructions
greatly assisted in teaching residents the relevant anat-
omy.
Conclusion: In early experience, OsiriX software allows
accurate 3D rendering of liver/tumor anatomy and
accurate volumetrics. These reconstructions are simple to
perform and offer evident utility for both operative
planning and teaching.
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Pre-liminary clinical data on the use of a novel
endovascular radiofrequency catheter in the
management of unresectable primary and
secondary cancers of the liver
S. E. KHORSANDI, P. KYSELA, V. VALEK,
O. OLUFEMI, I. LA´ZAR and N. HABIB
Hammersmith Hospital, London, UK; Department of
Radiology, Brno, Czech Republic; Borsod County
Teaching Hospital, Miskolc, Hungary
Introduction: A number of different transarterial tech-
niques have been developed for the locoregional control
of liver tumors. Presently available endovascular tech-
niques rely on the delivery of embolic material which has
the risk of collateral damage to non-tumoral liver or
other non-target organs. This study reports our initial
assessment of the endovascular use of a novel radiofre-
quency catheter (VesCoag) in the management of pri-
mary and secondary cancers of the liver.
Methods: Multicentre pilot study to assess the technical
feasibility of manipulating VesCoag into the target vessel
and to determine the parameters of activation to produce
the angiographic endpoint of target vessel occlusion.
Patients considered for inclusion in the study had pri-
mary or secondary cancer of the liver, which were not
suitable for surgical resection.
Results: In this series VesCoag was used to occlude the
tumor arterial blood supply (n = 13). The average age of
the patient was 68.5 years (range 48–80), ﬁve patients
were female and eight were male. The indications for
treatment were metastatic disease in 4, hepatocellular
carcinoma in 7 and intra-hepatic cholangiocarcinoma in
2. In all cases, VesCoag was able to be manipulated into
the target vessel for probe activation. There were no
technical problems such as vessel dissection or rupture.
The average ﬂuoroscopic time was 12.86 min and the
Figure 1. 3D reconstruction showing segment V HCC
prior to laparoscopic resection.
Figure 2. Volume of left lateral segment in patient
requiring right triseg. Volume is only 191 cc, prompting
left and seg. IV PVE.
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mean duration of probe activation was 240 (range 20–
600) seconds. The lowest wattage used was 2W and the
highest 120 W. In no cases was bipolar radiofrequency
activation sufﬁcient to produce vessel sealing, so in all
patients (n = 13), VesCoag was used in monopolar
mode. There were four minor complications of pain. The
angiographic endpoint of occlusion of the targeted vessel
after VesCoag activation was achieved in 11 patients. In
12 out of 13 cases an additional endovascular therapeutic
manoeuvre was performed after VesCoag activation.
These additional therapies were chemoembolization
n = 10, chemotherapy n = 1 and lipiodol n = 1.
Conclusion: This initial assessment of VesCoag shows it
to be safe and fulﬁl its design remit of being able to
produce precise occlusion of the target vessel.
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Intra-operative ultrasonographic characteristics
determine its sensitivity in detecting colorectal
liver metastases
M. G. VAN VLEDDER, B.SC., T. M. PAWLIK, MD,
MPH, S. MUNIREDDY, MD, M. C. DE JONG, B.SC.
and M. A. CHOTI, MD
Johns Hopkins Hospital, Baltimore, MD, USA
Background: In an era of improved pre-operative cross-
sectional imaging, the clinical value of intra-operative
ultrasonography (IOUS) in the treatment of patients
undergoing liver resection for colorectal liver metastases
(CRLM) is unclear. Whether IOUS allows for the iden-
tiﬁcation of additional lesions, as well as the relationship
between lesion-speciﬁc ultrasonographic features and
IOUS sensitivity also remain ill-deﬁned. The purpose of
the current study was to determine the association of
tumor echogenicity with the ability of IOUS to detect
occult CRLM.
Methods: Prospective data, including IOUS images and
clinicopathological information, were collected on 149
patients who underwent liver surgery for CRLM between
1998 and 2007.In each instance, IOUS images were dig-
itally recorded at the time of surgery; the images were
subsequently blindly reviewed and scored for echoge-
nicity (hypo-, iso-, or hyperechoic). Patients with
isoechoic lesions were compared with patients who had
non-isoechoic (hyper- plus hypo-) lesions with regard to
the overall IOUS yield of detecting additional metastases
intra-operatively. Routine CT scans were obtained on all
patients, and early (< 6 months) intra-hepatic recur-
rence was used as a surrogate for residual disease (e.g.
small metastases that were undetected on initial IOUS).
The rate of early intra-hepatic were then compared
among the iso- and non-isoechoic groups.
Results: Compared with pre-operative cross-sectional
imaging, the detection of additional metastases by IOUS
was signiﬁcantly less in the isoechoic group (n = 67;
4.6%) compared with patients who had non-isoechoic
lesions group (n = 82; 14.6%) (P = 0.05). While late
recurrence, extrahepatic recurrence and overall survival
were not different among the groups, early intra-hepatic
recurrences were signiﬁcantly more common in patients
following resection of isoechoic tumors (22.6%) com-
pared with patients who had non-isoechoic lesions
(8.3%) (P = 0.03).
Conclusions: The sensitivity of IOUS to detect otherwise
occult intra-hepatic CRLM lesions is dependent on
tumor echogenicity. The use of IOUS in patients with
isoechoic tumors is not reliable in the detection of addi-
tional CRLM metastases compared with pre-operative
cross-sectional imaging. These data suggest that early
intra-hepatic recurrence following resection of CRLM in
patients with isoechoic lesions compared with non-iso-
echoic lesions is due to differences in lesion detection
rather than tumor biology.
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Advanced imaging guidance system improves
accuracy of needle placement for hepatic tumors
S. M. SMEATON, MD, J. B. MARTINIE, MD,
M. C. MEADOWS, MD, P. H. NGUYEN, MD,
J. J. HEATH, B.SC., S. RAZZAQUE, PHD, C. GREEN,
H. J. NORTON, PHD and D. A. IANNITTI, MD
Carolinas Medical Center, Charlotte, NC, USA;
InnerOptic Technology Inc, Chapel Hill, NC, USA
This study measures the effectiveness of a novel guidance
system which fuses virtual reality, ultrasound and real
time position location. Ultrasound guided procedures
such as hepatic tumor ablation or biopsy can be limited
by the user’s ability to accurately place the needle into the
target. Three users with various levels of experience in
ultrasound guidance made microwave needle antenna
placements into a target both with and without advanced
guidance. We hypothesized increased accuracy with the
guidance system for needle placement at all angles of
approach regardless of experience.
Methods: Seven millimetre targets 3 cm deep to the
surface were created in agar gel. An InVision guidance
system (InnerOptic, Chapel Hill, NC, USA) was attached
to the ultrasound probe and microwave needle antenna
of a B-K Pro Focus 2202 (B-K Medical, Denmark) with
surgical T probe (#8659). Real time guidance was viewed
on a stereoscopic monitor. A 13 gauge 22 cm surgical
microwave needle antenna (Valley Lab, Boulder, CO,
USA) was used for all procedures. Three users, a novice,
amateur, and expert in experience with ultrasound
guidance were selected. Placements were randomized
between use of enhanced image guidance vs. standard
ultrasound and three angles of approach relative to the
ultrasound plane: 0, 45 and 90 degrees. Users could not
alter the needle course once an angle of approach was
chosen. Accuracy data was collected by ultrasound con-
ﬁrmation in two planes. Descriptive statistics comparing
guided vs. non-guided were calculated using chi-square
test.
Results: Users made 10 placements each for the three
angles with and without advanced image guidance. For
all users at all angles the accuracy improved signiﬁcantly
when using the guidance system: 40% to 90%
(P < 0.0001) at 0 degrees, 40% to 97% (P < 0.0001) at
45 degrees, and 27–77% (P = 0.0001) at 90 degrees. In
addition, the accuracy of the novice and amateur using
the system was better than that of the expert not using the
system.
Conclusions: This advanced needle guidance system sig-
niﬁcantly improved accuracy of microwave needle
placement regardless of the angle of approach or the
surgeon’s level of experience. Clinical trials are needed to
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assess the usefulness of improved accuracy for both
surgeons and interventionalists.
Table 1. Results.
Angle
0
degrees
45
degrees
90
degrees
Novice non-guided 30% 30% 0%
Novice guided 90% 100% 60%
Amateur non-guided 40% 20% 20%
Amateur guided 80% 90% 70%
Expert non-guided 50% 70% 60%
Expert guided 100% 100% 100%
Totals
Non-guided 40% 40% 27%
Guided 90% 97% 77%
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Accuracy of pre-operative automatic
measurement of the liver volume by CT-scan
with a 3D surgical planiﬁcation software
F. VANDENBROUCKE, MD, L. SIMARD, MD,
C. FOUTE-NELONG, MD, L. SOLER, PHD,
J. MARESCAUX, MD and R. LAPOINTE, MD
Hopital Saint Luc – CHUM, Montreal, QC, Canada;
IRCAD, Strasbourg, France
Introduction: The evaluation of the volume of remnant
liver is very important in the case of major hepatectomy.
We used a software developed for the 3D visualisation and
analysis of the liver, vessels and tumors from a contrast
CT-Scan. Therefore, pre-operative hepatectomy simula-
tion can be done and different volumes of the liver are
automatically calculated before surgery. The aim of this
study were ﬁrst, to compare different hepatic volumes
between automatic (AC) and manual (MC) calculation
techniques, and secondly operative or post-operative data.
Material and methods: This prospective study included
34 patients (16 females and 18 men; mean age:
55 years ± 13). Pre-operative total, resected, remnant
liver and tumor volumes were calculated by both tech-
niques and compared. The volume of resected liver was
obtained by its weight at surgery. A Ct scan was per-
formed on the 2nd post-operative day in order to eval-
uate the real remnant liver volume. Wilcoxon’s test and
Pearson’s correlation were used for statistical analysis.
Results: Resected AC liver volume was signiﬁcantly cor-
related to the resected MC volume (943 cm3 vs. 1010 cm3,
difference of 4%, r = 0.971) and to the weight of the liver
specimen (943 cm3 vs. 748 cm3, r = 0.734). Resected AC
and MC volumes were signiﬁcantly more important than
the weight of the liver specimen (748 cm3) (P < 0.0001).
The mean of percentage of remnant AC and MC liver
volume was not signiﬁcantly different (54.6% vs. 52.8%,
P = 0.5, r = 0.926). The difference between pre-opera-
tiveACandMC tumor volumes (194 cm3 vs. 189 cm3)was
2.6% (P = 0.395). These volumes were not signiﬁcantly
different from the pathological tumor volume (217 cm3)
(P = 0.381). Pre- and post-operative AC remnant volume
were not signiﬁcantly different (971 cm3 vs. 1047 cm3;
P = 0.182; r = 0.854), but the post-operative AC width
of the remnant liver was 2.6 cm more than the pre-oper-
ative AC width (P = 0.005).
Conclusions: The automatic calculation of liver volume
by this software is accurate and reliable with a good
correlation to the manual technique of liver volume
measurement. It allows an easy and fast calculation of
different liver volumes and a 3D visualisation of the
foreseen liver resection. This software appears to be very
useful for a better planning of hepatic surgery. The full
potential of this tool is still under assessment.
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Color Doppler ultrasound provides real time
measurement of microwave ﬁeld in ablation
therapy
S. M. SMEATON, MD, P. H. NGUYEN, MD,
J. B. MARTINIE, MD, J. J. HEATH, MD and
D. A. IANNITTI, MD
Carolinas Medical Center, Charlotte, NC, USA
Microwave generators create an energy ﬁeld around the
active tip of an antenna via pulsed electromagnetic
waves. Tissue thermocoagulation is achieved as water
molecules within the ﬁeld oscillate according to the
frequency and energy delivered. This differs from
RadioFrequency ablation where electric current passing
through the tissue results in tissue heating. Through
clinical experience with hepatic microwave ablation
(MWA) it was suspected that color Doppler ultrasound
(US) demonstrated the active microwave ﬁeld in real
time. This study tests the hypothesis that the visualized
ﬁeld seen in color Doppler US during MWA correlates
with measured zone of thermocoagulation.
Figure 1.
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Methods: Microwave ablations with a single needle 915
MHz surgical antenna (ValleyLab, Boulder, CO, USA)
at 45W for 6 min were performed in ex vivo bovine liver.
Ultrasound (BK Pro Focus 2202, BK Medical, Den-
mark) was used to monitor the ablation using color
Doppler mode. A clear demarcation was observed at the
edge of the microwave ﬁeld (A in Fig. 1). This edge was
marked circumferentially in the tissue with methylene
blue soaked probes with US guidance. The tissue was
then transected along the plane of needle placement and
the distance between each mark and the edge of ther-
mocoagulation zone was measured with digital calipers
(B in Fig. 1).
Results: Twenty MW ablations were performed with an
average of ﬁve markings per ablation. Measured distance
from the markings to the edge of the thermocoagulation
zone averaged 1.62 mm (range 0.00–5.5, SD 1.34).
Additionally the ﬁeld seen on Doppler US was measured
at its widest point to be 2.94 cm. The width of the ther-
mocoagulation zone seen in the beef liver was 3 cm at its
widest point.
Conclusions: The visualized ﬁeld observed in the color
Doppler mode of US during MWA correlates with the
MW ﬁeld as well as the zone of thermocoagulation. To
date this has not been described. Live feedback of the
treatment area during microwave ablation can be used to
create target speciﬁc probes, generator modulated abla-
tions, and more efﬁcient methods for shielding. In-vitro
studies with active bloodﬂow may further delineate this
observed effect.
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Comparison of radiologic and pathologic
response following 90Y microspheres therapy
for hepatocellular carcinoma
D. -S. KIM, MD, PHD, J. WANG, MD, T. C. DOTY,
RN, BSN, A. D. TEVAR, MD, J. F. BUELL, MD, R. L.
RISTAGNO, MD and S. M. RUDICH, MD, PHD
University of Cincinnati, Cincinnati, OH, USA; University
Hospital of Cincinnati, Cincinnati, OH, USA; University
of Louisville, Louisville, KY, USA
Background: Selective internal radiation therapy (SIRT)
with intra-hepatic arterial administration of radioactive
Yttrium-90 (90Y) labeled microspheres has been evalu-
ated and used as an alternative treatment modality for
advanced primary or metastatic hepatic tumors. Favor-
able outcomes following SIRT for inoperable hepatic
tumors have been reported, but there has been difﬁculty
regarding evaluation of response after treatment.
Purpose: We compared radiologic and pathologic re-
sponse after microsphere (90Y) therapy for hepatocellu-
lar carcinoma (HCC) to evaluate accuracy and reliability
of imaging modalities assessing therapeutic response.
Methods: Four patients were identiﬁed from database,
who received hepatic arterial delivery of 90Y micro-
spheres for HCC and subsequent orthotopic liver trans-
plantation (OLT). Three patients received SIRT for
downstaging of advanced HCC before OLT. One patient
received SIRT due to recurrence of HCC after initial
resection, and subsequently underwent OLT. All imaging
studies including computed tomography (CT) and F18-2-
ﬂuoro-2-deoxy-D-glucose (FDG) positron emission
tomography (PET) were reviewed. All four patients had
pre- and post-SIRT CTs and two patients had FDG PET
scan available. Complete pathologic evaluation of the
explanted liver was performed.
Results: Two patients showed good correlation between
imaging and pathologic ﬁndings following SIRT. How-
ever, Two patients showed new-onset enhancement le-
sions surrounding tumor after SIRT, which was
concerning for progressive disease. One patient under-
went laparoscopic exploration and multiple biopsy of
lesion to conﬁrm the tumor status, which was negative
for malignancy. Pathologic ﬁndings of explanted liver of
those two patients showed almost complete necrosis of
tumor with numerous neoangiogenesis at the periphery
of tumor and ﬁbrosis at the same time.
Conclusion: Radiologic response after SIRT can be
confusing and can mislead clinical judgment. If SIRT was
administered for downstaging modality, histologic con-
ﬁrmation of non-responder is recommended before
changing treatment plan. Larger number of case study is
recommended to deﬁne response to SIRT better.
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Margin status with a standardized protocol for
the sectioning of pancreaticoduodenectomy
specimens
D. E. CURTIS, MD, A. S. KHITHANI, MD,
A. J. SAAD, MD and D. R. JEYARAJAH, MD
Methodist Dallas Medical Center, Dallas, TX, USA
Background: Margin positivity is associated with poor
prognosis in periampullary cancer. Every effort should
me made by the surgeon to attain a margin negative
status. Ensuring microscopic margin negativity is how-
ever challenging due to anatomical limitations and
proximity to major vessels. Various centers have reported
on their experience with a standardized protocol for the
sectioning of PD specimens. We report our experience
and the impact on Superior mesenteric margin (SMA)
status.
Methods: Medical records of Patients who underwent
pancreaticoduodenectomy (PD) by a single surgeon be-
tween September 2005 and August 2008 were retrospec-
tively reviewed. Pathologic data including tumor type,
and margin status was collected. After the resection of
the specimen, the circumferential soft tissue margins and
surfaces were stained according to a ﬁxed color protocol.
The superior mesenteric artery margin was speciﬁcally
inked.
Results: Seventy-eight PDs were performed for periam-
pullary carcinoma. Thirty-two percent (25) patients with
periampullary carcinoma had positive margins. Positive
margins were more frequent with carcinoma of the pan-
creatic head. Of the patients with positive margins 21
patients had a diagnosis of carcinoma of the head of
pancreas, 3 had duodenal carcinoma and 1 had carci-
noma of the Ampulla of Vater. Overall 13/25 patients
had a positive SMA margin, 12 of whom had a carci-
noma of the pancreatic head. SMA positivity in the ﬁrst
2 years was associated with a one and 2 year survival of
70% and 0% respectively which portends a poor out-
come.
Conclusion: The use of a standardized inking and sam-
pling protocol of resected PD specimens which includes
speciﬁcally inking the SMA margin leads to a high inci-
dence of margin positivity. The use of a standardized
protocol, including speciﬁcally inking the SMA margin
should be routinely performed on PD specimens.
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Radical distal pancreatectomy with en bloc
celiac axis resection for locally advanced cancer
of the pancreatic body
E. VICENTE, MD, PHD, Y. QUIJANO, MD, PHD,
M. MARCELLO, MD, E. ESTEBAN, MD,
P. GALINDO, MD, C. LOINAZ, MD, R. CONRADI,
MD, H. DURAN, MD, PHD, U. L. DE LA
GUARDIA, MD, F. MACHES, MD, A. CARBAJO,
MD and B. WAEZ, MD
Hospital Madrid Norte Sanchinarro, Universidad San
Pablo CEU, Facultad de Medicina, Madrid, Spain
Despite the development of surgical technique, locally
advanced cancer of the pancreatic body is still associated
with a low resectability and dismal prognosis. The main
reason for unresectability is the invasion of major vessels
such as the common hepatic artery (CHA) and celiac axis
(CA). Resection of the involved arteries can increase
respectability and thus might improve prognosis and
quality of life (excellent pain control) in such patients. A
49-year-old woman was admitted to our hospital because
of persistent epigastric and back pain, as well as weight
loss. Contrast-enhanced computed tomography showed a
tumor, 4 cm in diameter, in the body of the pancreas with
encasement of the CA and CHA. An en bloc subtotal
pancreatectomy with splenectomy and resection of the
CA was performed. The stomach was preserved. Surgical
margins were free of tumor. Intra-operative Doppler
ultrasonography measurement of the hepatic arterial ﬂow
was obtained before and after clamping of the CA. No
signiﬁcant change in the color and tension of the liver
was observed. The hepatic arterial ﬂow via the pancreatic
arcade from the SMA was sufﬁcient and no re-arterial-
ization of the liver was performed. The patient had an
uneventful post-operative course and was discharged on
post-operative day 12. 34 months after the operation, the
patient is free from epigastric and back pain, without
evidence of tumoral recurrence.
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Laparoscopic robot-assisted Whipple procedure
S. MACKENZIE, MD, E. JOHNSON, MD, D. DUNN,
MD and T. SIELAFF, MD, PHD
Virginia Piper Cancer Institute, Minneapolis, MN, USA
Purpose: Advances in robotic surgery have allowed the
frontiers of minimally invasive surgery to expand. We
present a video demonstrating the key technical maneu-
vers during a Laparoscopic Robot-assisted Whipple
procedure (da Vinci S System, Intuitive Surgical, Sun-
nyvale, CA, USA). The video demonstrates utilization of
the robot assistance for pancreaticoduodenectomy, as
well as the reconstruction, including the pancreatic duct
to small bowel mucosa anastomosis.
Case presentation: The Robotic Whipple is performed on
a 69-year-old male with a pre-operative diagnosis of a
main duct intraductal papillary muscinous neoplasm
(IPMN) with ominous features, including pancreatic duct
obstruction. Pre-operative symptoms included steator-
rhea and 15 lbs weight loss over the proceeding
4 months. Endoscopic ultrasound and pre-operative
imaging revealed a 6.2 · 3.3 cm nodular cystic structure
in the head of the pancreas. Cyst ﬂuid aspiration dem-
onstrated an elevated CEA level. Relevant past medical
history also includes a right hemicolectomy for colon
cancer 6 years prior to the Whipple.
Results: The Robotic Whipple utilized 9 h and 47 min of
robotic time, 6 min Robotic docking time, and blood loss
was approximately 200 cc. Pathology assessment
revealed a main duct IPMN without evidence of malig-
nancy and widely negative margins. The patient had an
uneventful hospital stay, used no pain medication after
post-operative day 2, and was discharged home post-
operative day 6 with no post-operative complications.
Conclusions: The video demonstrates that, with robotic
assistance, the minimally invasive Whipple procedure can
be completed safely and effectively, incurring all of the
advantages of laparoscopic pancreas resections.
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Pancreatic head resection with segmental
duodenectomy (PHRSD) for intraductal
papillary mucinous neoplasms (IPMN) of the
pancreatic head
A. NAKAO, MD, PHD, S. TAKEDA, MD, PHD,
S. NOMOTO, MD, PHD, N. KANAZUMI, MD, PHD,
H. KASUYA, MD, PHD, H. SUGIMOTO, MD, PHD,
T. FUJII, MD, PHD, S. YAMADA, MD, PHD and
Y. KODERA, MD, PHD
Gastroenterological Surgery, Nagoya University,
Graduate School of Medicine, Nagoya, Japan
We proposed pancreatic head resection with segmental
duodenectomy (PHRSD) for benign or low grade malig-
nancy tumor of the pancreatic head region as a function-
preserving operation instead of pylorus preserving
pancreatoduodenectomy (PpPD). This operation is sim-
ple, easy and safe procedure compared with duodenum
preserving pancreatic head resection (DpPHR). Lapa-
rotomy is done by upper midline skins incision. The
gastrocolic and duodenocolic ligament is divided. Intra-
operative US study is done. By conserving the right
gastric artery and gastroduodenal artery, 5–7 cm of the
ﬁrst portion of the duodenum is preserved with good
arterial circulation. The anterior superior pancreatodu-
odenal artery and post-erior superior pancreatoduodenal
artery are ligated and divided. In addition, by conserving
the anterior inferior pancreatoduodenal artery, the third
portion and anal side of the second portion of the
duodenum are preserved with good arterial circulation.
Resection of the pancreatic head with 3–4 cm of
segmental duodenectomy including minor and major
papilla completes PHRSD. The distal pancreas is exam-
ined by ultrathin pancreatoscope. Reconstruction of the
alimentary tract is then performed with pancreatoga-
strostomy, end to end duodenoduodenostomy and end to
side choledochoduodenostomy. PHRSD is simple, easy,
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safe and function-preserving operations for benign or
low grade malignancy tumor of the pancreas. In this
video, PHRSD for the branch type of IPMN of the
pancreatic head is presented.
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Laparoscopic middle pancreatectomy
K. K. LEE, MD, J. WEY, MD, S. HUGHES, MD,
A. J. MOSER, MD and H. ZEH
University of Pittsburgh, Pittsburgh, PA, USA
A middle pancreatectomy provides a pancreas-sparing
treatment for low grade neoplasms arising in the body
and neck of the pancreas. We demonstrate a middle
pancreatectomy performed laparoscopically for treat-
ment of a pancreatic endocrine tumor arising in the neck
of the pancreas. A 40-year-old woman undergoing
evaluation of left-sided abdominal pain was found to
have a hypervascular mass in the neck of her pancreas
causing upstream pancreatic ductal dilatation. Endo-
scopic ultrasound conﬁrmed obstruction of the pancre-
atic duct by the mass, and biopsy of the mass conﬁrmed
the diagnosis of a pancreatic endocrine tumor. The
patient was positioned supine and using ﬁve ports placed
in standard positions for a laparoscopic distal pancrea-
tectomy, the neck of the pancreas was elevated and
separated from the splenoportal conﬂuence. The pancre-
atic endocrine tumor was localized using a laparoscopic
ultrasound probe, and the pancreas was then divided to
the left and right of the mass using a laparoscopic stapler,
allowing the neck of the pancreas containing the mass to
be passed off of the operative ﬁeld. After further
mobilizing the body of the pancreas, a Roux limb was
created using additional applications of the stapler and
was passed in retrocolic fashion to the pancreas. The
staple line was excised from the end of the pancreas, and
a two layer interrupted hand sewn end to side pancre-
aticojejunostomy was then completed in duct to mucosal
fashion. The procedure was completed without compli-
cation and with minimal blood loss. The patient’s post-
operative course was uneventful and she was discharged
home on post-operative day 4. She has since shown no
signs of pancreatic endocrine or exocrine insufﬁciency,
and a follow-up CT scan obtained 6 months post-
operatively has shown marked improvement in the
pancreatic ductal dilatation consistent with a patent
pancreaticojejunostomy. A middle pancreatectomy pre-
serves pancreatic parenchyma and thereby reduces the
likelihood of subsequent pancreatic endocrine or exo-
crine insufﬁciency. Performing this operation laparo-
scopically confers the additional beneﬁts associated with
minimally invasive surgery. Moreover, the magniﬁcation
provided by laparoscopy facilitates completion of a
precise pancreaticojejunostomy and may decrease the
risk of leakage from this anastomosis.
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Totally laparoscopic pancreatoduodenectomy
N. P. JARUFE, MD, A. ESCALONA, MD,
R. FUNKE, MD, J. F. GUERRA, MD,
I. FERNA´NDEZ, MD and C. BOZA, MD
Pontiﬁcia Universidad Cato´lica de Chile, Santiago, Chile
The development of laparoscopic surgery has allowed
incorporating this technology to the surgical treatment of
diverse pathologies. The use of laparoscopic approach
for pancreatic resections has remained limited for
selected patients with left-sided (body and tail) lesions.
Pancreatoduodenectomy (PD) is a high demanding
operation with multiple anastomoses which require
advance experience in laparoscopic as well as pancreatic
an hepatobiliary surgery. Most of literature reports in
laparoscopic PD include hand assisted support especially
for reconstruction step (pancreas, biliar and gastro-
anastomoses). This video shows a totally laparoscopic
PD in a 16-years-old woman with a 5 cm pseudopapillary
tumour of the head of the pancreas. Her history was
abdominal pain and gastric oulet obstruction. After
surgery she had full recovery with no post-operative
complications. So far we have performed 4 totally
laparoscopic PD for both benign and malignant disease
of the head of pancreas.
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Robotic-assisted laparoscopic spleen-preserving
distal pancreatectomy for solid pseudopapillary
neoplasm
S. PADMA, MD, M. MEADOWS, MD, C. A. HILL,
MD, S. M. SMEATON, MD, D. A. IANNITTI, MD
and J. B. MARTINIE, MD
Carolinas Medical Center, Charlotte, NC, USA
Objective: An 8-min video will be presented to demon-
strate a robotic-assisted laparoscopic spleen-preserving
distal pancreatectomy (LSPDP) using the daVinci robot
(Intuitive Surgical, Inc, Sunnyvale, CA, USA) for a case
of solid pseudopapillary neoplasm (SPN) of distal body
of pancreas.
Background: SPN is a rare tumor accounting for less
than 1–2% of primary pancreatic neoplasms. The etiol-
ogy and biologic behavior are still not completely
understood. With latest advances in minimally invasive
surgery, laparoscopic pancreatic surgery (LPS) is now
established as a safe and feasible operative procedure.
Laparoscopic distal pancreatectomy is an appropriate
treatment option for benign or low-grade malignant
pancreatic lesions. In addition, there has been an
increasing trend towards adopting LSPDP due to the
importance of spleen for its immunologic functions.
Robotic-assisted LPS is the latest development in this
ﬁeld of pancreatic surgery.
Materials and methods: The patient, a 22-year-old
woman was evaluated for intermittent left upper quad-
rant abdominal pain, hot ﬂashes and diarrhea of
3 months duration. She was in otherwise good health
with no past medical history. CT scan of the abdomen
revealed a 4 cm solid mass in the distal body of pancreas,
hypointense in the delayed venous phase, with no
lymphadenopathy, free ﬂuid or hepatic metastases.
Endoscopic ultrasound (EUS)-guided ﬁne needle aspira-
tion cytology (FNAC) conﬁrmed SPN, staining strong-
positive for vimentin, CD10, alpha-1-antitrypsin and
CD56, and focal-positive for synaptophysin and chro-
mogranin. To help with the complexity of the dissection
involved, the daVinci robot was utilized. Dissection was
performed using three robotic instrument arms via 8 mm
ports, as well as a single assistant port for suction/
irrigation device, laparoscopic ultrasound probe and
endostaplers. The spleen was carefully preserved follow-
ing Warshaw’s procedure with division of splenic vessels.
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Discussion: To our knowledge, this case represents the
ﬁrst report of robotic-assisted LSPDP in an adult female
patient for SPN. The entire procedure was completed
laparoscopically, with no complications, and the patient
was discharged home 4 days later. Surgical pathology
conﬁrmed a 4 cm sized SPN with no lympho-vascular
invasion and all ten lymph nodes negative for metastasis.
She remains symptom-free during the follow-up.
Robotic-assisted LSPDP is a safe and feasible option for
pancreatic neoplasms of benign or low-grade malignant
potential.
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Transduodenal ampullectomy and exploration
of the common bile duct for treatment of an
ampullary adenoma and impacted common bile
stone
J. A. BREAUX, MD, G. JEYABALAN, MD and
K. K. LEE, MD
University of Pittsburgh, Pittsburgh, PA, USA
A transduodenal ampullectomy is an effective and
potentially less morbid alternative to a pancreaticoduo-
denectomy for treatment of a benign ampullary ade-
noma. We demonstrate the technique of a transduodenal
ampullectomy performed together with exploration of
the common bile duct for treatment of a benign ampul-
lary adenoma and a concurrent impacted common bile
duct stone. A 75-year-old woman presented with jaundice
and was found on CT scan to have a large common bile
duct stone. An ERCP conﬁrmed the presence of the stone
but also identiﬁed a large ampullary mass that was
unsuitable for endoscopic removal. Biopsies, however,
showed only benign adenomatous changes. After place-
ment of a stent across the obstructing stone, an
endoscopic ultrasound was performed. This showed the
ampullary abnormality to be conﬁned to the mucosa of
the duodenum without extension into the deeper wall
layers. Extension up the bile duct could not be deter-
mined. In light of these ﬁndings, a transduodenal
ampullectomy and transduodenal exploration of the
common bile duct were performed for treatment of the
ampullary mass and common duct stone. After perform-
ing a Kocher maneuver, the duodenum was opened
transversely over the palpable ampullary abnormality.
The mass was delivered out through the duodenotomy,
and the mucosa around the mass was incised circumfer-
entially where it appeared normal. The bile and pancre-
atic ducts were transected and the mass was removed.
Frozen section evaluation of the deep margin did not
show adenomatous changes, but some frond-like changes
were visible extending up the bile duct. A short segment
of the bile duct was excised to remove these changes. The
bile duct was then explored and the large stone was
removed using stone forceps, a biliary catheter, and a
mechanical lithotripsy catheter. Duct clearance was
conﬁrmed by choledochoscopy. Next, the septum
between the bile and pancreatic duct openings was
incised to create a single common opening to which the
surrounding duodenal mucosa was then sewn, thereby
completing reconstruction of the two ducts. Finally, the
anterior duodenotomy was closed transversely in two
layers. The patient recovered uneventfully from the
procedure, and ﬁnal pathologic evaluation showed a
benign ampullary adenoma with negative margins of
resection. This patient illustrates the usefulness of a
transduodenal ampullectomy for treatment of a benign
ampullary adenoma unsuitable for endoscopic resection.
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Laparoscopic treatment of todani type 1
choledochal cyst
J. A. SALCEDA, MD, C. SALAS, MD,
D. FERNANDEZ, MD, R. S. CLARIA, MD,
E. DE SANTIBAN˜ES, MD, PHD and
J. PEKOLJ, MD, PHD
Hospital Italiano de Buenos Aires, Buenos Aires,
Argentina
The choledochal cyst are uncommon congenital disorder
characterized by a globular or fusiform dilatation of the
common bile duct just below the site of entry of the cystic
duct. It is detected with an incidence of 0.2–0.5% per
1 000 000 population. There is a 3 : 1 female predomi-
nance. The diameter of the dilatation varies between 2
and several centimeters. The etiology is unknown but
may be related to a mal-junction of the pancreatico-
biliary channel. Total excision of the cyst in types I, II,
and IV followed by reconstruction of the biliary tree with
hepaticojejunostomy in a Roux-en-Y fashion has been
widely accepted as the procedure of choice in treating
choledochal cysts and has been found to be superior to
hepaticoduodenostomy In selected patients with a favor-
able anatomy we will consider a laparoscopic approach
for removal of the cyst. We present two cases of
choledochal cyst type I (according to Todani’s classiﬁca-
tion) that were successfully excised by laparoscopy
including hepaticojejunostomy. The patient´s had an
uneventful recovery. The laparoscopic management of
the choledochal cyst is feasible. Surgeon may reproduce
every single step of the open technique with all the
beneﬁts of the laparoscopic approach.
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Bilobar totally laparoscopic anatomic segmental
resection of hepatocellular carcinoma in cirrho-
tics
H. AOKI, MD and C. U. CORVERA
UCSF Department of Surgery, San Francisco, CA, USA
Hepatic resection remains the gold standard for curative
resection for hepatocellular carcinoma (HCC) in non-
transplant candidate patients. Data is emerging showing
that radiofrequency ablation (RFA) is competitive with
resection in the treatment of small HCC (< 5 cm).
Laparoscopic hepatic resections are gaining popularity as
laparoscopic techniques and vessel sealing instruments
improve. Anatomic and non-anatomic resections as well
as major lobectomies can now be done safely laparo-
scopically for both benign and malignant disease.
Because HCC often presents as multifocal disease, we
combine laparoscopic resection and RFA in patients with
preserved liver function. In a subset of patients with
limited bilobar disease, laparoscopic resection is our
preferred treatment choice.
Methods: We present two cases of patients with bilobar
HCC that were treated by laparoscopic hepatic resection.
Position: Patients were placed on a bean-bag in a partial
left lateral position (70) with the bed slightly ﬂexed.
With the bed rotated fully to the right, the patient
assumes a near supine position.
Procedure: A 4–5 cm vertical incision is made at the
umbilicus and gel hand port device is inserted. Although
the surgeons hand is not inserted, we prefer the gel port
because we can use up three working ports at this loca-
tion. Moreover, the intact specimens are extracted
through our periumbilical port site. When appropriate,
anatomic segmental resections are done with the primary
goal of achieving complete histological negative margins.
Intra-operative ultrasonography is done and the disease
distribution veriﬁed. Lines of transection are marked on
the surface of the liver using electrocautery. Inﬂow
occlusion is not required and the liver parenchyma is
transected using a bipolar cautery device (Gyrus) to
expose portal structures. Segmental portal pedicles are
then divided with a vascular stapler. Division of the liver
parenchyma is continued and the hepatic veins are
identiﬁed and divide with a vascular stapler. Specimens
are individually placed into a nylon bag and extracted
through the wound protected umbilical incision.
Conclusion: Bilobar laparoscopic hepatic resection is an
aggressive treatment modality for patients with multifo-
cal HCC who generally have a poor prognosis. These
procedures are still high-risk and should only be done on
highly selected patients with preserved liver function. In
these carefully selected patients, laparoscopic resection
often combined with RFA offers an extended disease free
interval and possible extend overall survival.
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Right hepatectomy extended to segment 4a for
hepatocellular carcinoma
D. CHERQUI, MD, L. VIGANO, MD, A. LAURENT,
MD and C. TAYAR, MD
Henri Mondor Hospital, Creteil, France
The video shows a right hepatectomy extended to
segment 4a for hepatocellular carcinoma in a 50-year-
old woman with HBV+ chronic hepatitis A2F1. In
March 2008, screening abdominal US and MRI showed
a 4 cm HCC in segment 8 in contact with the right and
the middle hepatic veins. AFP was 26.9 ng/mL and liver
function tests were normal. Liver resection was planned.
A J-shaped incision was performed. The conﬂuence of
the hepatic veins and the space between the right and the
middle hepatic veins were dissected. A tape was passed
between the liver and the IVC in order to perform a
hanging maneuver. Right portal branch and right hepatic
artery were taped and divided. Ischemic demarcation
along the Cantlie’s line was obtained. Cautery incision of
Glisson’s capsule was performed along the right side of
the upper part of falciform ligament. The middle hepatic
vein was exposed along its ﬁnal 4 cm up to its conﬂuence
into the inferior vena cava. Transection line was then
conducted along the Cantlie’s line between segments 5
and 4b, and then transversally between segment 4a and
4b to reach transection line along falciform ligament
previously marked. Parenchymal transection was per-
formed with bipolar coagulation and ultrasonic dissector.
Encountered structures were treated with the application
of clips or sutures according to their size. In the
horizontal part of transection plane, the middle hepatic
vein was identiﬁed and divided between ligatures. The
right hepatic duct and the portal pedicles of segment 4a
were intra-parenchymally divided. The scissural vein was
exposed along transection line and preserved. At the end
of parenchymal transection the middle and the right
hepatic veins were divided by linear stapler. The hepato-
caval ligament was divided between clips. Right hepa-
tectomy was completed by mobilisation of the specimen.
Operative time was 210 min. A single session of pedicle
clamping (20 min) was needed during the ﬁnal part of
parenchymal transection. Blood loss was 250 mL and no
transfusions were required. Post-operative course was
uneventful and the patient was discharged on post-
operative day 10. Final pathology conﬁrmed diagnosis of
hepatocellular carcinoma inﬁltrating the right hepatic
vein. Surgical margin was 2 mm.
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Hepatic resection in polycystic liver disease
J. A. SALCEDA, MD, M. NICOLAS, MD, D. L.
FERNANDEZ, MD, E. DE SANTIBAN˜ES, MD, PHD
and J. PEKOLJ, MD, PHD
Hospital Italiano de Buenos Aires, Buenos Aires,
Argentina
Surgical treatment of Adult Polycystic Liver Disease
(APLD) may includes differents procedures such as
percutaneous drainage, laparoscopic or open fenestra-
tion, liver resections and also transplant. Surgeons must
have many different skills in order to achieve the best
outcomes. Patient selection and Gigot classiﬁcation may
be the key for the best results. We present a single case of
a 42-year-old female with APLD associated with kidney
polycystic disease. Patient presented mass effect symp-
toms, right upper cuadrant pain, tenderness and fever
episodes. US and MRI were performed and patiente
underwent open surgery combining fenestration and
central hepatic resection. Total surgery time was
220 min, pringle maneuver was done twice (7 and
9 min). Post-operative course with no further complica-
tions. Discharged at 5th day. In the follow-up patient was
asympthomatic.
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Two-stage laparoscopic liver resection for
bilobar colorectal liver metastasis
M. A. MACHADO, MD, F. F. MAKDISSI, MD,
R. C. SURJAN, MD, G. KAPPAZ, MD and
N. YAMAGUCHI, MD
University of Sa˜o Paulo, Sa˜o Paulo, Brazil
Background: Hepatectomy may prolong survival time of
colorectal cancer patients with liver metastases. Two-
stage liver surgery is a valid option for the treatment of
advanced or synchronous colorectal liver metastasis. Its
goal is to achieve a complete tumor clearance in those
cases in which a complete resection with a single hepa-
tectomy would have left a remnant post-resection liver
too small for patient survival.
Aim: To present a video of two-stage laparoscopic liver
resection for bilobar liver metastasis.
Patient and method: A 54-year-old male suffering from
right colon cancer and synchronous bilobar colorectal
liver metastasis underwent laparoscopic right colon
resection followed by oxaliplatin-based chemotherapy.
The patient was then referred for surgical treatment of
liver metastasis. Liver volumetry showed a small left liver
remnant and CT scan disclosed moderate liver steatosis.
Surgical decision was to perform a totally laparoscopic
two-stage liver resection. The ﬁrst stage: laparoscopic
resection of segment 3 and ligature of right portal vein.
Post-operative pathology conﬁrmed high-grade liver
steatosis. After 4 weeks the patient was re-evaluated and
the left liver has regenerated. Volumetry of the future
liver remnant was 43%. Second stage: Laparoscopic right
hepatectomy using intra-hepatic Glissonian approach
without Pringle maneuver and without hilar dissection.
Intra-hepatic access to the main right Glissonian pedicle
was achieved with two small incisions and an endoscopic
vascular stapling device is inserted between these inci-
sions, and the stapler is ﬁred. Line of liver transection is
marked along the liver surface following ischemic area.
Liver transection is accomplished with harmonic scalpel
and endoscopic stapling device as appropriate. The
specimen is extracted through a suprapubic incision.
Falciform ligament is then ﬁxed to maintain the left liver
in its original anatomical position, avoiding hepatic vein
kinking.
Results: Operative time was 90 and 240 min, respec-
tively. The recovery after the ﬁrst and the second oper-
ations were uneventful and the patient was discharged on
the 2nd and 7th post-operative day, respectively.
Conclusion: Two stage liver resections can safely be done
by laparoscopy. Intra-hepatic Glissonian approach is a
useful tool for pedicle control of the right liver, especially
after previous dissection of the hilar plate.
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En-bloc right nephrectomy/right hepatectomy
with hanging liver technique
D. A. KOOBY, MD and V. MASTER, MD, PHD
Emory University, Atlanta, GA, USA
The patient is a 60-year-old man with a biopsy-proven
renal cell carcinoma extending from the upper pole of the
right kidney into the right liver. The hanging liver
technique is employed, as the mass precludes mobiliza-
tion of the right liver prior to parenchymal transection.
Surgical technique is highlighted.
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Transabdominal and intra-pericardial surgical
approach without the use of cardiopulmonary
bypass in the management of retrohepatic and
supraphrenic inferior vena cava thrombus
extending into right atrium
E. VICENTE, MD, PHD, Y. QUIJANO, MD, PHD,
E. ESTEBAN, MD, P. GALINDO, MD,
M. MARCELLO, MD, R. CONRADI, MD,
C. LOINAZ, MD, PHD, H. DURAN, MD, PHD,
J. A. ROMAN, MD, B. MORATO, MD and
E. GARCIA, MD, PHD
Hospital Madrid Norte Sanchinarro, Universidad San
Pablo, CEU, Facultad de Medicina, Madrid, Spain
Management of thrombus of the inferior vena cava
represents a serious challenge for the surgeons. Operative
strategy is determinated by the proximal and distal
extension of the thrombus. When the thrombus extend
into the suprahepatic inferior vena cava and right atrium,
it is widely accepted that cardiopulmonary bypass is
essential to safely and completely thrombectomy. How-
ever, the use of cardiopulmonary bypass in this proce-
dure, is associated with high morbidity and mortality.
The video show the pre-operative diagnostic procedures
to evaluate the location of the hidatid cyst, the vascular
invasion and extent of thrombus as well as the surgical
procedure. Ultrasonography, CT and MRI demonstrated
a thrombus extending into retrohepatic, supraphrenic-
intrapericardial IVC and right atrium. Through a bilat-
eral subcostal laparotomy, total cystoperiystectomy and
resection of retrohepatic IVC was performed with total
liver vascular exclusion. The transabdominal and
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transpericardial approach to the intrapericardial IVC
and right atrium avoided median sternotomy. Total
trombectomy with intra-operative transesophageal echo-
cardiogram control was performed. The post-operative
course was uneventful and he was discharged on the 15th
day after the surgery. Three years after the operation, the
patient remains alive without evidence of hydatid disease
recurrence.
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Totally laparoscopic right trisectionectomy
using intra-hepatic glissonian approach
M. A. MACHADO, MD, F. F. MAKDISSI, MD, R. C.
SURJAN, MD, A. C. OLIVEIRA, MD, V. F. PILLA,
MD and A. R. TEIXEIRA, MD
University of Sa˜o Paulo, Sa˜o Paulo, Brazil
Background: Laparoscopic right liver trisectionectomy is
a very complex procedure with few technical descriptions
so far in the English literature. To facilitate pedicle
control and to reduce operating time, we have previously
described a technique for laparoscopic right liver resec-
tions using intra-hepatic Glissonian approach. This video
demonstrates technical aspects of a totally laparoscopic
right trisectionectomy. Our technique uses intra-hepatic
Glissonian approach and total control of venous outﬂow.
Method: This technique uses ﬁve trocars. Round and
falciform ligaments are taken down close to the abdom-
inal wall in order to facilitate left liver ﬁxation at the end
of the procedure. Due to previous right portal vein
embolization, hepatic pedicle is not fully dissected. Main
right hepatic vein is divided with vascular endoscopic
stapler. Main trunk is encircled and its traction or tem-
porary clamping permits complete outﬂow control of the
liver, minimizing bleeding during liver transection. Intra-
hepatic access to the main right Glissonian pedicle is
achieved with two small incisions and an endoscopic
vascular stapling device is inserted between these inci-
sions, and the stapler is ﬁred. Line of liver transection is
marked along the liver surface and to avoid possible
damage to pedicles from segments 2 and 3, the line of
transection should be placed at 1 cm right from falciform
ligament. Glissonian pedicle from segment 4 is divided
within liver substance. Liver transection is accomplished
with harmonic scalpel and endoscopic stapling device
as appropriate. The specimen is extracted through a
suprapubic incision. Falciform ligament is then ﬁxed to
the abdominal wall in order to prevent remnant liver to
rotate spontaneously into the right subphrenic space
and cause left hepatic vein kinking. Right hepatic
trisectionectomy is then completed.
Results: Operative time was 360 min and hospital
stay was 7 days. Apart from self-limited biliary leakage,
post-operative recovery was uneventful.
Conclusion: A totally laparoscopic right trisectionectomy
is safe and feasible in selected patients and should be
considered for patients with benign or malignant liver
neoplasms. The described technique with the use of intra-
hepatic Glissonian approach and control of venous out-
ﬂow may facilitate laparoscopic extended liver resections
by reducing the technical difﬁculties in pedicle control
and may diminish bleeding during liver transection.
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Robotic resection of colon cancer metastasis to
the caudate lobe
S. CELINSKI, MD, D. BARTLETT, MD and
S. CHALIKONDA, MD
Division of Surgical Oncology, Department of Surgery,
University of Pittsburgh, Pittsburgh, PA, USA
Purpose: To present our experience with laparoscopic
robotic assisted resection of a colorectal metastasis to the
caudate lobe of the liver.
Patient: The patient is a 44-year-old man with a history
of stage III colon cancer, status post-transverse colecto-
my 2 years prior. He received adjuvant FOLFOX and on
follow up at 15 months was found to have multiple liver
metastases. He underwent laparoscopic radiofrequency
ablation of the lesions. One year later he developed
metastases to the caudate lobe and segment VI. We
present only the resection of the caudate lobe metastasis.
Results: Four 12 mm ports were used. The lesser sac was
entered through the lesser omentum. A stay suture was
placed for traction and a bipolar radiofrequency device
was used to circumferentially coagulate the surrounding
parenchyma. The parenchyma was then divided using a
combination of cautery, Ligasure and clips. Hemostasis
and ablation of the resection margin was achieved using
the bipolar radiofrequency device.
Conclusion: Laparoscopic resection of masses located in
the caudate lobe may be achieved with robotic assistance.
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